0001201800-12-000026.txt : 20121120 0001201800-12-000026.hdr.sgml : 20121120 20121120091607 ACCESSION NUMBER: 0001201800-12-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121120 DATE AS OF CHANGE: 20121120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL, INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 121216618 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10q-sept2012.htm vaso10q-sept2012.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 10-Q


[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2012

[   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _______________ to ______________

Commission File Number: 0-18105


VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware
11-2871434
(State or other jurisdiction of
(IRS Employer Identification Number)
incorporation or organization)
  

180 Linden Ave., Westbury, New York 11590
(Address of principal executive offices)

Registrant’s Telephone Number     (516) 997-4600
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days       .Yes [X]      No  [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
Large Accelerated Filer [  ] Accelerated Filer [  ] Non-Accelerated Filer [  ] Smaller Reporting Company [X]
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes [   ] No  [X]

Number of Shares Outstanding of Common Stock, $.001 Par Value, at November 15, 2012 – 162,917,996
 
 
Page 1
 
Vasomedical, Inc. and Subsidiaries

 
INDEX
 
 
 
Page 2
 
Vasomedical, Inc. and Subsidiaries
(in thousands, except share data)
   
September 30, 2012
    
December 31, 2011 (a)
  
ASSETS
  
(unaudited)
    
(audited)
  
CURRENT ASSETS
            
Cash and cash equivalents
   $ 9,691     $ 2,294  
Short-term investments
     110       110  
Accounts and other receivables, net of an allowance for doubtful
                
accounts and commission adjustments of $2,086 at September 30,
                
2012 and $2,163 at December 31, 2011
     8,388       20,695  
Receivables due from related parties
     41       196  
Inventories, net
     2,461       2,421  
Financing receivables, net
     21       19  
Deferred commission expense
     2,577       2,053  
Deferred related party consulting expense - current portion
     213       510  
Other current assets
     354       202  
 Total current assets
     23,856       28,500  
                 
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
                
$1,564 at September 30, 2012 and $1,774 at December 31, 2011
     628       429  
GOODWILL
     3,200       3,168  
FINANCING RECEIVABLES, net
     -       16  
DEFERRED RELATED PARTY CONSULTING EXPENSE
     -       85  
OTHER ASSETS, net
     1,825       2,137  
    $ 29,509     $ 34,335  
LIABILITIES AND STOCKHOLDERS' EQUITY
                
CURRENT LIABILITIES
                
Accounts payable
   $ 312     $ 273  
Accrued commissions
     1,944       3,889  
Accrued expenses and other liabilities
     3,334       2,560  
Sales tax payable
     355       355  
Income taxes payable
     (37 )     278  
Deferred revenue - current portion
     10,102       9,484  
Deferred gain on sale-leaseback of building - current portion
     -       31  
Deferred tax liability, net
     112       112  
Notes payable due to related party
     3       193  
Total current liabilities
     16,125       17,175  
                 
LONG-TERM LIABILITIES
                
Deferred revenue
     4,896       5,743  
Other long-term liabilities
     127       141  
Total long-term liabilities
     5,023       5,884  
                 
COMMITMENTS AND CONTINGENCIES (NOTE N)
                
                 
STOCKHOLDERS' EQUITY
                
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
                
 issued and outstanding at September 30, 2012, and December 31, 2011
     -       -  
Common stock, $.001 par value; 250,000,000 shares authorized;
                
162,917,996 and 153,186,295 shares issued and outstanding
                
 at September 30, 2012 and December 31, 2011
     163       153  
Additional paid-in capital
     60,993       60,188  
Accumulated deficit
     (52,823 )     (49,065 )
Accumulated other comprehensive income
     28       -  
Total stockholders’ equity
     8,361       11,276  
     $ 29,509     $ 34,335  
(a) Retroactively adjusted to give effect to measurement period adjustment (see Note I)
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 3
 

Vasomedical, Inc. and Subsidiaries
 
(Unaudited)
(in thousands, except per share data)

    Three months ended September 30,     Nine months ended September 30,  
   
2012
    
2011
    
2012
    
2011
  
Revenues
                        
Equipment sales
   $ 688     $ 410     $ 3,197     $ 1,495  
Equipment rentals and services
     375       390       1,407       1,509  
Commissions
     4,659       5,730       14,858       13,545  
Total revenues
     5,722       6,530       19,462       16,549  
                                 
Cost of revenues
                                
Cost of sales, equipment
     282       200       1,304       949  
Cost of equipment rentals and services
     148       157       699       635  
Cost of commissions
     1,229       1,454       3,685       3,503  
Total cost of revenues
     1,659       1,811       5,688       5,087  
Gross profit
     4,063       4,719       13,774       11,462  
                                 
Operating expenses
                                
Selling, general and administrative
     6,591       4,553       17,256       12,497  
Research and development
     131       140       403       382  
Total operating expenses
     6,722       4,693       17,659       12,879  
Operating (loss) income
     (2,659 )     26       (3,885 )     (1,417 )
                                 
Other income (expenses)
                                
Interest and financing costs
     -       (3 )     (3 )     (28 )
Interest and other income, net
     93       33       123       51  
Amortization of deferred gain on
                                
sale-leaseback of building
     4       13       31       40  
Total other income (expenses), net
     97       43       151       63  
                                 
(Loss) income before income taxes
     (2,562 )     69       (3,734 )     (1,354 )
Income tax (expense) benefit
     44       (5 )     (72 )     (4 )
Net (loss) income
     (2,518 )     64       (3,806 )     (1,358 )
                                 
Preferred stock dividends
     -       (1,180 )     -       (1,459 )
Net (loss) income applicable to common stockholders
     (2,518 )     (1,116 )     (3,806 )     (2,817 )
                                 
Other comprehensive income (loss)
                                
Foreign currency translation gain
    30       2       29       2  
Comprehensive loss
   $ (2,488 )   $ (1,114 )   $ (3,777 )   $ (2,815 )
                                 
Loss per common share
                                
- basic and diluted
   $ (0.02 )   $ (0.01 )   $ (0.02 )   $ (0.02 )
                                 
Weighted average common shares outstanding
                          
- basic and diluted
     159,018       149,524       157,162       126,023  
 
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
 
Page 4
 
Vasomedical, Inc. and Subsidiaries

(Unaudited)
(in thousands)
    Nine months ended  
   
September 30, 2012
    
September 30, 2011
  
Cash flows from operating activities
            
Net  loss
   $ (3,806 )   $ (1,358 )
Adjustments to reconcile net loss to net cash
                
  provided by operating activities
                
Depreciation and amortization
     296       118  
Amortization of deferred gain on sale-leaseback of building
     (31 )     (40 )
Provision for doubtful accounts and commission adjustments
     (7 )     15  
Amortization of deferred distributor costs
     -       177  
Share-based compensation
     559       295  
Amortization of deferred consulting expense
     416       367  
Changes in operating assets and liabilities:
                
Accounts and other receivables
     12,212       3,516  
Receivables due from related parties
     159       -  
Inventories, net
     (47 )     (804 )
Finance receivables
     14       13  
Deferred commission expense
     (525 )     (719 )
Other current assets
     (170 )     55  
Other assets
     172       96  
Accounts payable
     39       (368 )
Accrued commissions
     (1,945 )     840  
Accrued expenses and other  liabilities
     813       (73 )
Sales tax payable
     (1 )     45  
Income taxes payable
     (315 )     4  
Deferred revenue
     (229 )     838  
Trade payable due to related party
     -       (243 )
Other long-term liabilities
     (26 )     (589 )
Net cash provided by operating activities
     7,578       2,185  
                 
Cash flows from investing activities
                
Purchases of property and equipment
     (344 )     (21 )
Purchases of short-term investments
     -       (41 )
Acquisition of Fast Growth Enterprises
     -       (1,000 )
Cash acquired through purchase of Fast Growth Enterprises
     -       442  
Net cash used in investing activities
     (344 )     (620 )
                 
Cash flows from financing activities
                
Proceeds from exercise of warrant
     343       -  
Repayment of note payable
     -       (294 )
Repayment of notes payable due to related party
     (190 )     -  
Proceeds from issuance of preferred stock
     -       150  
Net cash provided by (used in) financing activities
     153       (144 )
Effect of exchange rate differences on cash
     10       -  
                 
NET INCREASE IN CASH AND CASH EQUIVALENTS
     7,397       1,421  
Cash and cash equivalents - beginning of period
     2,294       3,101  
Cash and cash equivalents - end of period
   $ 9,691     $ 4,522  
                 
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
                
Interest paid
   $ 5     $ 30  
Income taxes paid
   $ 411     $ 9  
                 
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
          
Inventories transferred to property and equipment,
                
attributable to operating leases, net
   $ 8     $ 93  
Accrued preferred stock dividends
   $ -     $ 1,459  
Common shares, warrants and contingent shares issued for acquisition
   $ -     $ 2,979  
Fair value of assets acquired
   $ 291     $ 4,469  
Liabilities assumed through acquisition
   $ (291 )   $ (931 )
Issuance of preferred stock in satisfaction of accrued dividend
   $ -     $ 224  
Conversion of preferred stock to common stock
   $ -     $ 32  
Common shares issued for consulting agreements
   $ -     $ 1,070  
 
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
 
Page 5
 
Vasomedical, Inc. and Subsidiaries
 
 
 
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company’s recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Transition Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

 
Page 6
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.
 
Revenue and Expense Recognition for VasoHealthcare

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.  These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the Consolidated Balance Sheets.  Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.  Commission expense is recognized when the corresponding commission revenue is recognized.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company’s responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:
 
     (in thousands)  
      As of or for the three months ended September 30, 2012  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 1,063     $ 4,659     $ -     $ 5,722  
Operating loss
   $ (838 )   $ (1,358 )   $ (463 )   $ (2,659 )
Total assets
   $ 8,595     $ 11,319     $ 9,595     $ 29,509  
Accounts and other receivables, net
   $ 1,059     $ 7,329     $ -     $ 8,388  
Deferred commission expense
   $ -     $ 3,635     $ -     $ 3,635  
                                 
                                 
        As of or for the three months ended September 30, 2011  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 800     $ 5,730     $ -     $ 6,530  
Operating income/(loss)
   $ (640 )   $ 1,047     $ (381 )   $ 26  
Total assets
   $ 8,810     $ 12,405     $ 4,318     $ 25,533  
Accounts and other receivables, net
   $ 763     $ 9,260     $ -     $ 10,023  
Deferred commission expense
   $ -     $ 3,124     $ -     $ 3,124  
                                 


 
Page 7
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
 
     (in thousands)  
    As of or for the nine months ended September 30, 2012  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 4,604     $ 14,858     $ -     $ 19,462  
Operating loss
   $ (1,191 )   $ (1,473 )   $ (1,221 )   $ (3,885 )
Total assets
   $ 8,595     $ 11,319     $ 9,595     $ 29,509  
Accounts and other receivables, net
   $ 1,059     $ 7,329     $ -     $ 8,388  
Deferred commission expense
   $ -     $ 3,635     $ -     $ 3,635  
                                 
                     
    As of or for the nine months ended September 30, 2011  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 3,005     $ 13,545     $ -     $ 16,550  
Operating income/(loss)
   $ (1,382 )   $ 628     $ (663 )   $ (1,417 )
Total assets
   $ 8,810     $ 12,405     $ 4,318     $ 25,533  
Accounts and other receivables, net
   $ 763     $ 9,260     $ -     $ 10,023  
Deferred commission expense
   $ -     $ 3,124     $ -     $ 3,124  
                                 

 
For the three months ended September 30, 2012 and 2011, GE Healthcare accounted for 81% and 88% of revenue, respectively.  For the nine months ended September 30, 2012 and 2011, GE Healthcare accounted for 76% and 82% of revenue, respectively.   Also, GE Healthcare accounted for $7.2 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at September 30, 2012 and December 31, 2011, respectively.

NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the three and nine-month periods ended September 30, 2012, the Company granted 0 and 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter.  During the three months ended September 30, 2011, 100,000 shares of restricted common stock valued at $35,000 were granted to officers and directors, and 466,279 shares of restricted common stock valued at $170,500 were granted to officers and directors during the nine months ended September 30, 2011.

During the nine-month periods ended September 30, 2012 and 2011, the Company did not grant any stock options.

For the three and nine months ended September 30, 2012, the Company granted 500,000 and 2,690,000 shares of restricted common stock valued at $130,000 and $678,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012.  For the three and nine months ended September 30, 2011, the Company granted 0 and 10,000 shares of restricted common stock, respectively, valued at $6,800 to other non-officer employees.
 
 
 
Page 8
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

Share-based compensation expense recognized for the three and nine months ended September 30, 2012 was $328,000 and $559,000, respectively,  and $92,000 and $295,000 for the three and nine months ended September 30, 2011, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively, and $159,000 and $367,000 for the three and nine months ended September 30, 2011, respectively.  Unrecognized expense related to existing share-based compensation and arrangements is approximately $806,000 at September 30, 2012 and will be recognized through July 2013.

NOTE E – LOSS PER COMMON SHARE

 Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

  The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
 
     (in thousands)  
    For the three months ended     For the nine months ended  
   
September 30, 2012
    
September 30, 2011
    
September 30, 2012
    
September 30, 2011
  
Stock options
     1,810       1,810       1,810       1,810  
Warrants
     1,500       5,786       1,500       5,786  
Contingently issuable shares
     -       2,000       -       2,000  
Common stock grants
     3,260       2,903       3,260       2,903  
      6,570       12,499       6,570       12,499  
        
 
NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
 
 
Page 9
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
The following tables present information about the Company’s assets and liabilities measured at fair value as of September 30, 2012 and December 31, 2011:
          
    (in thousands)  
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
    
Significant
Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
    
Balance
as of
September 30, 2012
  
Assets
                    
(unaudited)
  
Cash equivalents invested in money market funds (included in cash and cash equivalents)
   $ 8,604     $ -     $ -     $ 8,604  
Investment in certificates of deposit (included in short-term investments)
     110                       110  
    $ 8,714     $ -     $ -     $ 8,714  
                                 
                                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
  
Significant
Other
Observable
Inputs
(Level 2)
   Significant
Unobservable
Inputs
(Level 3)
    
Balance
as of
December 31,
2011
  
Assets                                
Cash equivalents invested in money market funds (included in cash and cash equivalents)
   $ 1,313     $ -     $ -     $ 1,313  
Investment in certificates of deposit (included in short-term investments)
     110                       110  
    $ 1,423     $ -     $ -     $ 1,423  
                                 

The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2012 and December 31, 2011:
 
    (in thousands)  
   
September 30, 2012
    
December 31, 2011
  
   
(unaudited)
        
Trade receivables
   $ 10,349     $ 22,737  
Due from employees
     125       121  
Allowance for doubtful accounts and
                
commission adjustments
     (2,086 )     (2,163 )
Accounts and other receivables, net
   $ 8,388     $ 20,695  
 
Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
 
Page 10
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees is primarily commission advances made to sales personnel.

NOTE H – INVENTORIES, NET
 
Inventories, net of reserves, consist of the following:    
    (in thousands)  
   
September 30, 2012
    
December 31, 2011
  
   
(unaudited)
        
Raw materials
   $ 1,087     $ 842  
Work in process
     521       528  
Finished goods
     853       1,051  
    $ 2,461     $ 2,421  
                 

At September 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $540,000 and $606,000, respectively.

NOTE I– BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd (“LET”) and Biox Instruments Co. Ltd. (“Biox”), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition included a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company’s common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.  The Company completed its evaluation of FGE’s calendar year 2011 performance targets and determined that the targets were met, resulting in the issuance of 2.4 million shares to the prior owners in September 2012.

LET, based in Foshan, Guangdong, China, is Vasomedical’s supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices, is located in Wuxi, Jiangsu, China, and is Vasomedical’s supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.

The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the three and nine months ended September 30, 2012.    The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
 
 
 
Page 11
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
    
    (in thousands)  
Cash
   $ 1,000  
Vasomedical, Inc. common stock ($0.42 per share)
     2,100  
Vasomedical, Inc. warrants to purchase common stock
     304  
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
     575  
Total purchase price
   $ 3,979  

In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information  available as of the acquisition date, and subsequently adjusted (measurement period adjustments) after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The measurement period adjustments were completed during the quarter ended September 30, 2012 (within a year of the acquisition date).  The accompanying Consolidated Condensed Balance Sheet as of December 31, 2011 has been retroactively adjusted to include the effect of the measurement period adjustment.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
 
      (in thousands)  
 
  
 
 As initially reported
    
Measurement period adjustments
    
 
As adjusted
  
Cash and cash equivalents
   $ 442     $ -     $ 442  
Accounts receivable and other current assets
     591       (308 )     283  
Inventories
     670       (194 )     476  
Property and equipment
     32       -       32  
Goodwill
     3,175       (7 )     3,168  
Customer lists
     -       800       800  
Accounts payable and other current liabilites
     (931 )     (291 )     (1,222 )
Net assets acquired
   $ 3,979     $ -     $ 3,979  
 
The goodwill is attributable to the synergies expected to arise after the Company’s acquisition of FGE as well as FGE’s projected growth and profitability.  The goodwill is not expected to be deductible for tax purposes.  Customer lists were valued based on sales history of certain recurring customers and the timing of expected future revenues.

After elimination of intercompany transactions, which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company’s Consolidated Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2012 was $271,000 and $189,000, respectively, and $1,181,000 and $299,000, respectively, for the nine months ended September 30, 2012.  For the three and nine months ended September 30, 2011, the amounts of revenue and net loss of FGE included in the Company’s Consolidated Condensed Statement of Operations and Comprehensive Income (Loss) were $96,000 and $24,000, respectively.  The effect of FGE’s loss on earnings per share for the three and nine months ended September 30, 2012 and September 30, 2011 was $0.00.

The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):
 
     (in thousands except per share data)  
   
Three months ended September 30,
       Nine months ended September 30,  
   
2012
    
2011
    
2012
    
2011
  
Revenue
   $ 5,722     $ 6,605     $ 19,462     $ 17,225  
                                 
Net (loss) income
     (2,515 )     19       (3,620 )     (937 )
                                 
Basic and diluted (loss) earnings per share
   $ (0.02 )   $ (0.01 )   $ (0.02 )   $ (0.02 )
 
Page 12
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
NOTE J – GOODWILL AND OTHER INTANGIBLES
 
Goodwill aggregating $3,200,000 and $3,168,000 (retroactively adjusted to give effect to measurement period adjustment) was recorded on the Company’s Consolidated Condensed Balance Sheets at September 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011.  All of the goodwill was allocated to the Company’s Equipment segment.  The components of the change in goodwill are as follows:
   
   
Carrying Amount
  
       
Balance at December 31, 2011
   $ 3,168  
Foreign currency translation
     32  
Balance at September 30, 2012
   $ 3,200  
 
The Company’s other intangible assets consist of capitalized customer lists and patent costs, as follows:
                                                                                                                                            
     (in thousands)  
   
September 30, 2012
    
December 31, 2011 (a)
  
Other intangibles, net
  
(unaudited)
        
Customer lists, net
   $ 676     $ 800  
Patents, net
     37       56  
    $ 713     $ 856  
(a)  
Retroactively adjusted to give effect to measurement period adjustment.

Patents and customer lists are included in other assets in the accompanying Consolidated Condensed Balance Sheets and customer lists are amortized on a straight line basis over their estimated useful life of seven years.  The useful life was estimated based on the length of time the customer is expected to remain active.  Amortization expense amounted to $130,000 and $9,000 for the three months ended September 30, 2012 and 2011, respectively, and $143,000 and $28,000 for the nine months ended September 30, 2012 and 2011, respectively.
 
Page 13
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

NOTE K - DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:
 
    (in thousands)  
    For the three months ended September 30,       For the nine months ended September 30,  
   
2012
    
2011
    
2012
    
2011
  
   
(unaudited)
    
(unaudited)
    
(unaudited)
    
(unaudited)
  
Deferred revenue at the beginning of the period
   $ 15,198     $ 11,360     $ 15,228     $ 12,637  
Additions:
                                
Deferred extended service contracts
     288       240       987       968  
Deferred in-service and training
     13       10       33       28  
Deferred service arrangements
     20       20       75       65  
Deferred commission revenues
     2,037       4,941       6,116       9,085  
Recognized as revenue:
                                
Deferred extended service contracts
     (283 )     (269 )     (840 )     (872 )
Deferred in-service and training
     (10 )     (8 )     (25 )     (23 )
Deferred service arrangements
     (22 )     (21 )     (64 )     (55 )
Deferred commission revenues
     (2,243 )     (2,798 )     (6,512 )     (8,358 )
Deferred revenue at end of period
     14,998       13,475       14,998       13,475  
Less: current portion
     10,102       10,042       10,102       10,042  
Long-term deferred revenue at end of period
   $ 4,896     $ 3,433     $ 4,896     $ 3,433  
 
 NOTE L – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”).  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $30,000 and $102,000 were billed by the firm through the three and nine months ended September 30, 2011, respectively, and approximately $60,000 and $194,000 were billed by the firm through the three and nine months ended September 30, 2012, respectively, at which date no amounts were outstanding.
 
Mr. Rios is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement (the “Agreement”) with Edgary Consultants, LLC (“Consultant”).  The Agreement commenced on March 1, 2011 and runs for a two year term.  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  More specifically, Consultant will be assisting the Company in the following areas:
 
 
Page 14
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 
1.  
Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2.  
Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3.  
Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of September 30, 2012 and December 31, 2011.

During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company’s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $159,000 were collected during the nine months ended September 30, 2012.

NOTE M – STOCKHOLDERS’ EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

As of September 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company.  As of September 30, 2012, 840,000 shares have been forfeited.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period.  In June 2012, 2,190,000 additional shares, vesting at various times through July 1, 2013, of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 185,500 shares had been forfeited as of September 30, 2012.  In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest in June 2013 and the remainder in June 2014.
 
 
Page 15
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

No options were issued under the 2010 Plan during the nine months ended September 30, 2012 and 2011.
 
In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE.  In addition, 2,400,000 shares of common stock were issued, under the terms of the purchase agreement, in September 2012 to former owners of FGE for attaining certain operating targets for the twelve months ending December 31, 2011.    The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition, recorded as of the September 2, 2011 acquisition date, was $2,979,000 (see Note I).
 
Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder’s option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company’s common stock for the 30 consecutive trading days exceeds 250,000 shares.

Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of September 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.

For the three and nine months ended September 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $1,180,000 and $1,459,000, respectively.  Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,180,000 and $1,336,000 for the three and nine months ended September 30, 2011, respectively.  These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.

NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year.  The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013.  A condition of the incentives is that the employees remain continuously employed through the vesting dates.  As of September 30, 2012, approximately $1.3 million and 1.3 million shares remain unvested.
 
 
Page 16
 
Vasomedical, Inc. and Subsidiaries
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS


NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The adoption of this guidance did not have a material impact on the Company’s consolidated condensed financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company’s consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.
 
 
 
Page 17
 
Vasomedical, Inc. and Subsidiaries

 

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent transition report on Form 10-K.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987.  Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries.  Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® Enhanced External Counterpulsation systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets.

In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (see Note C).

The Company will seek to improve profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio.  In addition, the Company plans to actively pursue other accretive acquisitions.
 

 
 
Page 18
 
Vasomedical, Inc. and Subsidiaries
Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Transition Report on Form 10-K for the seven months ended December 31, 2011.

On June 15, 2011, the Board of Directors approved a change of the Company’s fiscal year end from May 31st to December 31st.  As a result of this change, the Company filed a Transition Report on Form 10-K for the seven-month transition period ended December 31, 2011.  Going forward, references to our 2012 and 2011 fiscal years herein mean the fiscal years ended December 31, 2012 and December 31, 2011, respectively.

New Accounting Pronouncements - Adoption of New Standards
 
Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company’s consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.

Consolidated Results of Operations

Three months ended September 30, 2012 and September 30, 2011

Total revenue for the three months ended September 30, 2012 and September 30, 2011, was $5,722,000 and $6,530,000, respectively, a decrease of $808,000, or 12%. Net loss for the three months ended September 30, 2012 was $2,518,000 compared to net income of $64,000 for the three months ended September 30, 2011.  We a reported net loss applicable to common stockholders of $2,518,000 for the third quarter of fiscal year 2012 compared to a net loss applicable to common stockholders of $1,116,000 for the third quarter of fiscal year 2011. The increase in net loss applicable to common stockholders was primarily attributable to a $2,038,000 increase in selling, general and administrative (“SG&A”) costs (of which $1,557,000 was attributable to the Sales Representation segment), partially offset by a $1,180,000 decrease in preferred stock dividends.  Our total net loss was ($0.02) and ($0.01) per basic and diluted common share for the three months ended September 30, 2012 and 2011, respectively.
 
 
Page 19
 
Vasomedical, Inc. and Subsidiaries

Revenues

Revenue in our Equipment segment increased by $263,000, or 33%, to $1,063,000 for the three-month period ended September 30, 2012 from $800,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $278,000, or 68%, to $688,000 for the three-month period ended September 30, 2012 as compared to $410,000 for the same period in the prior year. The increase in equipment sales is due to an increase of $175,000 in equipment sales generated by our Chinese subsidiaries acquired in September 2011 and an increase in the sales price per EECP® unit , partially offset by decreases in the number of EECP® and other medical equipment units shipped.
 
Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note L, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 4% to $375,000 in the third quarter of 2012 from $390,000 in the third quarter of 2011. Revenue from equipment rental and services represented 35% and 49% of total Equipment segment revenue in the third quarters of fiscal 2012 and fiscal 2011, respectively.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased accessory part revenue.

Commission revenues in the Sales Representation segment were $4,659,000 in the third quarter of 2012, as compared to $5,730,000 in the third quarter of 2011, a decrease of 19%.  The decrease in commission revenue in the third quarter of 2012 is due to a 15% decrease in volume of equipment delivered by GEHC.  In addition, third quarter 2011 revenue also exceeded third quarter 2012 revenue because a retroactive commission rate adjustment recorded in the third quarter of 2011 was, due to a change in contract terms which allowed us to recognize a higher commission rate earlier, recorded in the second quarter in 2012.  The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the Consolidated Condensed Balance Sheet.  Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues earned in the first and fourth quarters typically reflect a higher blended commission rate than revenues earned in the second and third quarters.  As of September 30, 2012, $13,689,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $4,378,000 is long-term.  At September 30, 2011, $12,417,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $3,106,000 was long-term.
 
Gross Profit
 
The Company had a gross profit of $4,063,000 in the third quarter of 2012 compared to $4,719,000 in the third quarter of the prior year, a decrease of 14%.  The decrease is principally due to the decrease in commission revenue discussed below.  Equipment segment gross profit increased to $633,000, or 60% of Equipment segment revenues, for the third quarter of 2012 compared to $443,000 or 55% of Equipment segment revenues, for the same quarter of 2011.  Equipment segment gross profit was favorably impacted both in absolute dollars and gross profit percentage by the $271,000 in sales of other medical equipment sold through our Chinese subsidiaries in the third quarter of 2012.  In addition, gross profit on EECP® equipment improved due to lower costs arising from the acquisition of LET, our primary supplier of certain EECP® systems.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.
 
Sales Representation segment gross profit was $3,430,000, or 74%, for the three months ended September 30, 2012 as compared to $4,276,000, or 75%, for the three months ended September 30, 2011.  The decrease was due to lower revenue in this segment, as explained above.  Cost of commissions of $1,229,000 and $1,454,000, for the three months ended September 30, 2012 and 2011, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
 
 
Page 20
 
Vasomedical, Inc. and Subsidiaries
Operating Income (Loss)

Operating income (loss) was $(2,659,000) for the three months ended September 30, 2012 as compared to operating income (loss) of $26,000 for the three months ended September 30, 2011, a decrease of $2,685,000.  The increase in operating loss was primarily attributable to lower operating performance in the Sales Representation segment, where operating loss was $1,358,000 for the third quarter of 2012 compared to operating income of $1,047,000 in the same quarter of the prior year.

Selling, general and administrative (“SG&A”) expenses for the third quarter of 2012 and 2011 were $6,591,000, or 115% of revenues, and $4,553,000, or 70% of revenues, respectively, reflecting an increase of $2,038,000 or approximately 45%. The increase in SG&A expenditures in the third quarter of 2012 resulted primarily from increased sales costs in the Sales Representation segment associated with the extension of the GEHC contract (see Note N), as well as increased sales, marketing and amortization costs in the Equipment segment which now includes SG&A costs - including a one-time charge of $300,000 in incentive compensation for certain key employees - of the recently acquired Chinese entities, and higher corporate compensation costs.

Research and development (“R&D”) expenses of $131,000, or 2% of revenues (12% of Equipment segment revenues), for the third quarter of 2012 decreased by $9,000, or 6%, from $140,000, or 2% of revenues (18% of Equipment segment revenues), for the third quarter of 2011. The decrease is primarily attributable to a decrease in clinical research expenses.
 
Interest and Financing Costs

No interest and financing costs were incurred in the third quarter of 2012, as compared to $3,000 incurred in the third quarter of 2011.  Interest and financing costs for the third quarter of 2011 consisted mainly of interest on related party trade payables.

Interest and Other Income, Net

Interest and other income for the third quarters of 2012 and 2011, was $93,000 and $33,000, respectively. The increase of $60,000 in the third quarter of 2012 is due primarily to value-added tax refunds recognized by our Chinese subsidiaries, as well as to higher interest earned on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of the deferred gain on the sale-leaseback of our Westbury, NY facility for the third quarters of 2012 and 2011 was $4,000 and $13,000, respectively.  The deferred gain was fully amortized in the third quarter of 2012.

Income Tax Expense, Net

During the third quarter of year 2012 we recorded an income tax benefit of $44,000 as compared to a provision of $5,000 for the third quarter of 2011.  The benefit arose from pre-tax losses at our Chinese subsidiaries.

Nine months ended September 30, 2012 and September 30, 2011

Total revenue for the nine months ended September 30, 2012 and September 30, 2011, was $19,462,000 and $16,549,000, respectively, an increase of $2,913,000, or 18%.  Net loss for the nine months ended September 30, 2012 was $3,806,000 compared to a net loss of $1,358,000 for the nine months ended September 30, 2011.  We reported net loss applicable to common stockholders of $3,806,000 for the first three quarters of 2012 compared to a net loss applicable to common stockholders of $2,817,000 for the first three quarters of 2011. The increase in net loss applicable to common stockholders was primarily attributable to a $4,759,000 increase in selling, general and administrative (“SG&A”) costs (of which $3,231,000 was attributable to the Sales Representation segment), partially offset by $2,312,000 increase in gross profit and $1,459,000 reduction in preferred stock dividends.  Our total net loss was $0.02 per basic and diluted common share for the nine months ended September 30, 2012 and 2011.
 
 
Page 21
 
Vasomedical, Inc. and Subsidiaries
Revenues

Revenue in our Equipment segment increased by $1,600,000, or 53%, to $4,604,000 for the nine-month period ended September 30, 2012 from $3,004,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $1,702,000, or 114%, to $3,197,000 for the nine-month period ended September 30, 2012 as compared to $1,495,000 for the same period in the prior year. The increase in equipment sales is due primarily to an increase of $1,085,000 in equipment sales generated by our Chinese subsidiaries and an increase in the number of EECP® units shipped as well as an increase in the sales price per EECP® unit, partially offset by a decrease in sales of other medical equipment.

Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note L, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 7% to $1,407,000 in the first nine months of 2012 from $1,509,000 in the first nine months of 2011. Revenue from equipment rental and services represented 31% and 50% of total Equipment segment revenue in the first nine months of 2012 and 2011, respectively.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased service revenue and lower accessory shipments.

Commission revenues in the Sales Representation segment were $14,858,000 in the first nine months of 2012, as compared to $13,545,000 in the first nine months of 2011, an increase of 10%.  The increase in commission revenue in the first nine months of 2012 is due to increased volume of equipment delivered.  The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the Consolidated Condensed Balance Sheet.  Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues earned in the first and fourth fiscal quarters typically reflect a higher blended commission rate than revenues earned in the second and third fiscal quarters.  As of September 30, 2012, $13,689,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $4,378,000 is long-term.  At September 30, 2011, $12,417,000 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $3,106,000 was long-term.

Gross Profit

The Company had a gross profit of $13,774,000 in the first nine months of 2012 compared to $11,462,000 in the first nine months of the prior year, an increase of 20%.  Equipment segment gross profit increased to $2,601,000, or 56% of Equipment segment revenues, for the first nine months of 2012 compared to $1,420,000 or 47% of Equipment segment revenues, for the first nine months of 2011.  Equipment segment gross profit was favorably impacted both in absolute dollars and gross profit percentage by the $1,181,000 in sales of other medical equipment sold through our Chinese subsidiaries in the first nine months of 2012.  In addition, gross profit on EECP® equipment improved due to lower costs arising from the acquisition of LET, our primary supplier of certain EECP® systems.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $11,173,000 for the nine months ended September 30, 2012 as compared to $10,042,000 for the nine months ended September 30, 2011.  Cost of commissions of $3,685,000 and $3,503,000, for the nine months ended September 30, 2012 and 2011, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
 
 
Page 22
 
Vasomedical, Inc. and Subsidiaries
 
Operating Loss

Operating loss increased by $2,468,000, or 174%, to $3,885,000 for the nine months ended September 30, 2012 as compared to an operating loss of $1,417,000 for the nine months ended September 30, 2011.  The increase in operating loss was primarily attributable to lower operating performance in the Sales Representation segment, where operating loss was $1,473,000 for the first nine months of 2012 compared to operating income of $628,000 in the same period of 2011.  The decreased operating performance in the Sales Representation segment was driven mainly by $3,231,000 higher SG&A costs, partially offset by $1,131,000 higher gross profit.
 
Selling, general and administrative (“SG&A”) expenses for the first nine months of 2012 and 2011 were $17,256,000, or 89% of revenues, and $12,497,000, or 76% of revenues, respectively, reflecting an increase of $4,759,000 or approximately 38%.  The increase in SG&A expenditures in the first nine months of 2012 resulted primarily from increased sales costs in the Sales Representation segment associated with the extension of the GEHC contract, as well as increased sales, marketing and amortization costs in the Equipment segment which now includes SG&A costs - including a one-time charge of $300,000 in incentive compensation for certain key employees - of the recently acquired Chinese entities, and higher corporate compensation costs.

Research and development (“R&D”) expenses of $403,000, or 2% of revenues (9% of Equipment segment revenues), for the first nine months of 2012 increased by $21,000, or 5%, from $382,000, or 2% of revenues (13% of Equipment segment revenues), for the first nine months of 2011. The increase is primarily attributable to an increase in regulatory costs.
 
Interest and Financing Costs
 
Interest and financing costs for the first nine months of 2012 and 2011 were $3,000 and $28,000, respectively.  Interest and financing costs for the first nine months of 2012 consisted primarily of interest on the notes payable to a related party in one of the China subsidiaries.  Interest and financing costs for the first nine months of 2011 consisted of interest on related party trade payables and a short-term note to finance the Company’s insurance premiums.
 
Interest and Other Income, Net

Interest and other income for the first nine months of 2012 and 2011, was $123,000 and $51,000, respectively. The increase of $72,000 in the first nine months of 2012 is due primarily to value-added tax refunds recognized by our Chinese subsidiaries, as well as to higher interest earned on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of the deferred gain on the sale-leaseback of our Westbury, NY facility for the first nine months of 2012 and 2011 was $31,000 and $40,000, respectively.
 
Income Tax Expense, Net

During the first nine months of 2012 we recorded a provision for income taxes of $72,000 as compared to the first nine months of 2011 when we recorded a provision for income taxes of $4,000.  The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.
 
 
Page 23
 
Vasomedical, Inc. and Subsidiaries
 
 
Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations primarily from working capital, and, in the first nine months of 2011, from the issuance of the Company’s Series E Preferred Stock. At September 30, 2012, we had cash and cash equivalents of $9,691,000, short-term investments of $110,000 and working capital of $7,731,000 compared to cash and cash equivalents of $2,294,000, short-term investments of $110,000 and working capital of $11,354,000 at December 31, 2011.

Cash provided by operating activities was $7,578,000 during the first nine months of 2012, which consisted of a net loss after adjustments to reconcile net loss to net cash of $2,573,000, offset by cash provided by operating assets and liabilities of $10,151,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $12,212,000, offset by a decrease in accrued commissions of $1,945,000 and an increase in deferred commission expense of $525,000.  As noted above, under the GEHC Agreement the Company earns progressively higher commission rates as calendar year targets are met, which also has a significant impact on our cash flows. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore, the significantly higher commission billings and recognized revenue generated in the fourth quarter of 2011 resulted in significant cash inflows in the first quarter of 2012.

Cash used in investing activities during the nine-month period ended September 30, 2012 was $344,000 for the purchase of property and equipment.

Financing activities during the nine-month period ended September 30, 2012 provided cash of $153,000, consisting of $343,000 provided from the exercise of warrants, offset by $190,000 for the repayment of notes payable to a related party.
 
Liquidity

The Company will seek to improve profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio.  In addition, the Company plans to actively pursue other accretive acquisitions.
 
While we expect to generate positive operating cash flows for 2012, the progressive nature of the commission rates under the GEHC Agreement can cause related cash inflows to vary widely during the year.
 
 
Page 24
 
Vasomedical, Inc. and Subsidiaries
 
 
 

Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.  Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2012 and have concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2012 due to insufficient controls and management review over the recording of certain transactions, and to lack of accounting personnel with appropriate level of knowledge and experience in accounting principles generally accepted in the United States of America and related accounting systems and the closing process at our China subsidiaries.  The Company has engaged additional accounting personnel, including an accounting controller, and is in the process of strengthening its internal controls with regard to its closing process, related disclosures, and the approval of certain transactions.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
 
 
Page 25
 
Vasomedical, Inc. and Subsidiaries




 

 
Exhibits

31
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



 
Page 26
 
Vasomedical, Inc. and Subsidiaries


In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


VASOMEDICAL, INC.

By:           /s/ Jun Ma                                           
Jun Ma
 
President and Chief Executive Officer
 
(Principal Executive Officer)

/s/ Michael J. Beecher   .
Michael J. Beecher
 
Chief Financial Officer and Principal Accounting Officer

Date:  November 19, 2012
 
 
Page 27
 
 
 GRAPHIC 2 vasologo2.jpg begin 644 vasologo2.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"L! M$`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^**_FM_X+3?\`!4[]J7_@G[\9_AKX3^$EEX'N/"7CKP3>^(U? MQ'HLVI7AN["_@TVXC25;B!(D68RN`!*7!`(3;D]I_P`$2_\`@J+^T!_P4!\8 M?&7P[\:K+P?;V_@3PUH^M:+-X8TR3397GO\`5([2:&YC>:?>B0OE)`Z[FS^[ M&*_1*GAAQ/3X,CQVUE\LAE0AB%*&-C+%J$\7]2L\-R74XU[QG'FTBN;8_/X> M)7#<^,)<#IX^.>1KSP[C+!M85SAA/KMXXCGLX2H:QERZO2U]OZ'JHZCJFFZ1 M:R7VK:A9:99PJSRW5_=06EO&B`LS/-(XO@!\0--URW\+>'K>^EM;6?4/"NJ6VE:I?7,5ML\_P"W MS/YT<,C,HCW*Z.#Q^/\`%>;8GAGAK%\3?V9B+QRJO# M0K5Y*2ASJC4=HPG*R^%73/ZO^CAX.4OI!^,&1^$E/B[+>$L?G&59SG<,7CL- M6Q^(K8#(:-*OCZ>7X"A.D\5C'3JITH5<1AJ/NSXL?$_QS\(/JUN7232=*N9-1O1)'D,F((S#G*D9$I''N*^+?%O\`P7B_8X\. MRR0:78^/O%$JLRQOIVE6T%M*1T*W-S`_B5\1K];?POX M:\4>*;^>98FCT;2=2U.?S9`"%E^QV\@0D$-F9T4`Y+`&OOCX:_\`!(_]M[XD MI9WMC\*-2TG2[E8Y#?\`B2]L]'2-'SC]S/<-<%Q_%&T2<=&R<5^%KQ0XZSB; MCDF34.6]DL+@,7CY+;XJLI*E?S<8Q[KM_K;6_9Z_1`\+<)"MXM>+.;*O&,95 M9<0<8\-<&4JDK)OV&6TJ%7,N23ORQAB,1/5+G;U?[A:Q_P`'"7P93=_8/PF\ M57)`R/[0U#3(AR>.8+L@G&O'^KN#^ M)XKY<\&?\&^G[0NK1V\WB3XB^`_"H?!N()8=1U.>(-C*J;6?RV9>%W*A5SQ9]6I74OJ.<>(. M=*JM[E6W5:,J+_P<):C(^(O@3HI7N7\1W(YSQTE/YX]/6NFT MO_@OXEPR_P!H_!.QA4XW?9==FD89]/,F"GCU(]`2>OI^D?\`!`/X%6RK_:?Q M1\9SO@;S:6.CH"V.2HEM#WY'L:[NR_X(/_LO6P7[1XV^)%R5ZE;C3;:<3_LLZ2G3PO"7%>(TLJF# MPO&Z;VUC+%YU2\]91_R.5T#_`(+M?"R[V_VW\+?$5L2,G^S]0T^49XR%\^Z7 MGTSCT([U[CX:_P""SW[+^NE$O=&\>:)*Q4-]ITVUN8%SU/GV]QM(!XX!/?IS M7/6W_!#W]E2W`'_"0_$:0C`W-JMIG`X_Y]C_`)]3DG6A_P""*O[+]NH$/B+X MC(0W_D(!_GVXKJI4O'VA_R_X7Q2O\.(]BM/\5&G2?X[GY;G6,_9NYAS M?V?EWB[E$G\,\#]=E&-^U/'XO&Q:7FKGTQX:_P""D7[(_B)(F?XG6&B/*0!' MK,,UNRLW16*)(`>N1VQ7T+X;_:+^!OB_RQX;^*/A'53*`4$&IHA(.,<3K%CK MT./T-?GC%_P1O_9[M_\`CU\9?$.+C@27EC<`'CD+-"R@X&.`./>M*V_X)+?" MK3\?V;\1?&L)4D@O#I).<="PM"Q'8@D\5[.&S7QIP[BL;PMPGCXJW-+"YQ5P ME1][>T=6"^<.NETC\=SWAGZ'&,YY<-^)?BID\VWR4\XX3PV94(;6YGAJ>%K. MW;VE]]=%?]4[76M'OD62RU73;M'^X]M>VTZMGT,4K`]:T@P)V9QTZUZ;I/[.?[1_AV96 MT?\`:4U">U7&++5;.>X@.WINVQEC[\\^W2OH\+Q)Q>K+,N`<;2?6>79WE&.C MTUY:U7!2[Z:O3K<_*,TX'\-DY/(/&#+<9%*\89SPKQ%E%26ND>;#T,TIIVZR M<5Z'W=17SUH6C_M%:*BQ:KXG\$>)HU(4R_V=?6MR5Y^8LS+EOKQSSP*]9T:] M\4L`FMZ7;HW`,EG,#&.<$A7._'!(!YP17U&$S5XCE57+Q^>YADD<$Y.AG&39G33TJ8#%SO)=U2Q=#"UEZ.G?NCK**!GN,?K1 M7JGAA1110`45\^?M5?&^S_9Q_9Z^*_QJO3;@>`?".IZS:+=_\>TFI)%Y6FQS M#(W1/>R0B11RR;@.37\D7[)?_!=__@H!^TO^TC\)_@M8:)\+Y+;QSXWTG2M4 M%IX:N8;BUT&:[1]5F2X%Y*4>TT_SF24Q,&D1-R1*2R?><+>'7$?%^5YOG65K M`T\NR12>.KXW%QPR7L\//%5/9)PE[3V=&'-/:W-!:N1\1Q-X@\/<*9IE.3YI M+&3S#.7%8*A@\++$M\^(IX:G[5J453]I5J';+4=8^'7B#5;J_P!4LX$75KQ;VW"1 M2VQNRZ6ZH"-J;E?YL#^B3]@SXE_&;XQ?LK_"KXG?'W3+'1OB=XRT>36=;TG3 M["?3+>PBGN)%L(38W&9;>8VJI++&Q;:9``S8W&.(/#WB#AG(= M>P>"HTL;"MC;8C#?6XNMAHQ4J7)2Y?::2YI=%=] M#CS#'8;+,#C,QQDW3PN!PU;%XB:7,XT:%.52HU'[4N6+Y8KXG9=3[6HK^/#_ M`()U?\%JOV[OVR/VMOA9\$=4TKX;?\(?KFM2R>-;[3/#=U:7ECX:M;>5[J[A MG%W<".43>0BAEVD2'YU(57_K`T?XM^$];\;:A\/[4ZDOB+39)UFCFTZYCM'B M@BFE:>.\9!"R,L+A/FR6VCJ0*^FXOX#S_@K,(99G$<)/%2P*S&<$9+B[_9K\:B/]W9:1XF\/O+CO/?/? M+'G'JN['X_3Q+_@UMU;ROV@OV@=()(-U\,-'N-N>HBUX\D9R?]4,9'T)QQ^E MO_!RY\.=0\6?LI_#'Q#I-FMS=Z#\3([2X6>EZ#X=^"%Y-!#-,BR:EJT>HRR:;I\0+[W:ZN%6' M"!F7S-V,#!_IGAK"8[/_`*-N-PN!P>(Q5:E];R^E"A2G4E4Q"SW#5:5**BG[ M\Y8B"4=_>3ZW/YJXES+*^'_I&X*MF&88/!1K+"9A5>(KPI1XB%:M)3:M M",,-4RN#'>Z-X M*W+);6!,;;E;7RLT4J$H?LZENH`;X/\`^"=_@[]G3XC_`/!.VW^+/[:-QKWA MCX1?LM^//$7_``CTEHTUK-\1)/$EW-JEUX=T5U*OJ4XOU@T][*$,Q,N"-B.X M_*9?AG^T=_P5,_;HNKV^MKBY\0?%GQK)>7$?#NDV=SI7PY7 M3X-5USQ3K5G`!J/B1=,)11=7=X9KC[1(W$7C]P7QU1X%P_"F4YQPWPYQ1+'+"X?!?VM@YX#V7UI3A[*53#X MF6)Q;H3ABO;8FA1HN,^5P_GB'_!<;XB:;XIB^&W_``3T_9)\!>`-.CEGT[0H MX/"+^+/&/B"S@/_!,PZW\0==@;36US68GE*QI<+)%Y#Z2EVFCRRS^4 M[".6&=ES&Q=!)7Y%_P#!6'XZ?MU?M*_$?PIH/[4WPTT;X7:CX4T[^T=`\"V- MO`MWI5MK8<+]MO!)-*ACQ]UPSX>Y&\WP7#L/!K(>'\HC@9 MU9T?L$?L^QZM'9/4NU6)E#*?$_V7_P#@G-\;OBK_ M`,$6_BI:_"VQN9?B;\3_`(K:?XI_X16.1H)?%'AGP'?_`+JQMOF7SKB]B"]?\`>*=2TUM!\06WB/PDUW M;7NEK.MTUE7OA35_AXVB:G M>::\O^ML)X!<2/!,JLJ3V_FB,D;MK8`_IU_9X_X*0?"+XJ_L7VO[8WQ*$OP? M\+Z7%>V/C/3_`!$&ADT[Q%I:HMWIVD"X\F35/MDKA=*5`'NB<#`5F'\UGPI_ MX+K?%K4O&FAG]J/]EGX)?$^VBEM]-U/QC=>'[2?QAI&EB=#<'3EO;":V<1J9 M)5MVD"EP%1CZ):P:% M::GXG\3QRRR-JNF:<+>SDN-)2U$<8DB8QRN)%^;FN?.O"/'\19OP[PYBO#+# M\%8BK.KB\PXCR#&O%X#$X+!4X_7<+0P2I?N\16G5PZPOUJ2JTI2E+][34T;9 M-XQY+P_E/$7$.%\4O]5"G&EB'B? MJT94JBC&*]E4<&_IS]H[_@Y<^)/B#Q?>^%?V0OA/91:9#?/:Z/XB\6V,VN:O MK\(;"7"^'8K9S:!NJPDF4<[P%PS?,_@O_@Y)_;B\#^,(K7XN^#_`?B'2[2]7 M^UO#I\+'PMJPB+*9+=;E4:>V8ICRRZ)@,&Q@@U^J_P#P;Y?\$^OAOX)_9Z/[ M2OQ&\(:'XG^)?Q%U74;30)M>TVTU./PUX:TN:6T5;&WO(IX$GU-F6X>XV^:A M1A&5!!K\K_\`@XZ^'W@JY_:T\$0?"SPSX=TK5[;X>HGCP:':6FGBXUF?4`^G M->6]FD,8NTL<*S%=[(5+9+"NCAW*_#',^.L=X899X=T\>LLH8VEC,\Q%2MB, M:\7ET;8MS=U6ITXU7*@J].K2_?6<*,:=D\^(\Y\1,JX#P/B?FGB+_9T,SKX" MM@\GHPP^&P/U3,9)X-4Y-.C4G.C;$.C4I5?W'-SU934F?THM_P`%4_ACXM_X M)V>,?VYOA];*?^$8T62UO_"NI.K2Z)XZ;R8$T&[?Y5N%2XN8620!%FB)P.#G M\)/V>/\`@Y1^*FM_$FTA^/.A^#]&^&MAIFJ:EK,OA_1S)K-]-9HKV6F:>@5) M#<7SL85,6YE*Y"GDU^;8N?B?\+/^"3,?PR-K/:Q_';XZW.HRV$K%%ET+PQIE MG<0:DB%AO@N;FU:.-P-KX7DD`5]*?\$"?^"=7A/]H7XV>+OB?\<_"]IXD\$? M"6PLY=/\.:BGF:7JOB?5'D-A)=QG*W*:8+=;DV[9C?S/FZ4UX7<#\(<+%674 MJ.*]E2G!RA5E3C)*:DNN^.G_```O!<5W*NFV?B+1X MO$VKW%I%*RP37=S*(5BEN(0DDL<6](W'?"_A:V:S\/>+HI+*.==6O;I1Y>@6UO'/!\GAOP3:6_C6'P[9VVF6-]K&H2V]U82 MFSM4A@BEALQ)$X5>2Q)QTK]/?^"`_P#P37^$L7P.US]I+X]?#[0_%WBOQ3J5 M[IWA2#Q/:1:GHVE>$K."(W%]%972R6YNKJY24O.4.R--N6VJ5.(^'/"[!>&. M1\9YAP)B.>75\!A,)6E1S7&U*\I^RPE?,Y/,'FF.P"S&EF%?$TH5LNP-.@J4:V+HY9#E="OA:] M6%"E14U35>].K*I!._YMZK_P$;K3 M;J/7;.]E22X;Q'I;FUO=*T2$NCZC<7=W&XL;>$EG!QNPN:_@8_;U^&>FZI^V MA\>8O@]X4L])\#3?$S6[3POI&F!?LR6\=X;58K**/$:QR7`80QQJ$`*X`SS] M%_\`!0#5_B7X=^&?[.7[&OAT7%I\/O@]\/M-\4:CIZ3O%#JGC7QU;V^LZE/? MPJZK-/I;--#;M,C%%N#@[AQ[O$O@MPYQ-1X*PV3<-2X9K9E*.:8Z>$H3CBZ> M14\!2KXNC5A*4Z=;%?6,5@L/2K33<*M:'?&_-N&ZO&F)SGBS#\2 M4,KOE>$CBL52>$EGE7'5*&%J4Y14)T'?VAOAGX51K:2&[U+PIK/@F?P9K4UC,V0 M(IWA-Q$CH&"3*C@'T^[7G7_!*_\`:=\9_L'>`=?U71OV+=0^*GC?QIJ:7VO[*.O_``XO?"_AYM'O;BWT+6)[S5U-Q+,KW<[VH>40&4K&TC%E154< M5M@O#C(%J3 MITW&JVW4I2C^[!_`_AZWO+7QKI M>I2QR:AHOB;3@J7&@6B;D;4+B[N&$6EE`#=Y)7(1FK^:?]HK_@YC_:!\0^-+ MVR_9F\"^%_!_@ZVNY+;3Y_%FE)XDUO5K:.1EAO9[>1(TLI+I0'^RQ.[1A@C# M=N%?D1\2O#O[0OPL_90\"_`?69-3\/:5XM\6ZYXS\2>!KX36#_`()T?#V]\#^+OVG?C5X)T?Q7XCGUQ_#G MP\L])\->!/#3)>(> M-^(#\3>,?$K/,@X(X=SO#9!F4,GH8[B'&X91^M^UCAZ5?$UW27[W#T(PK8 M>,,/3=&<\37<*E2%-1BOSF_:F_X+J?$7]K+]BGQ=^SM\4O!MEI7Q*\1ZY8KJ MOB?P]"=/T?4_#]H\=PUE+I8P+2']OA'2?^$XL=`@MK"Q'BJ66X:9_L%HL5O;3-;-!YL<:* MN[!VKD`>J_!+P=K7[,'_``1+^-OC"WA_LCXH?M1_$33O`^E`MY4UWX-TNY6. M[E0G:TD+PF20;205)/3`K[:668"/AGEM#A?A_$Y!0\3,RRO"X?+;5*CI3S^M M1IX_V4GJZ4,JPF)G3Y;1C2M.,8)\J^+CG=9^)>9U.)N)<%GE?PSRS-,7B\>Y MTJ=Z>0TJD\%+$0O:-5YIC,-"HY^\ZUX2E*6K]%^$7_!>']H3X]_'SP5\,M%^ M!?P9O+SXC^/],\/6#77A.SN-4>#5M1CA5KBXDA_>745L6GFE9V.49OFQ@_NG M_P`%"O\`@L5\#OV`-+L?``L;/XB?'C^R+*2?X=^'[F.VTCPY))`HD_MV_MA* MFFJLVY[>Q6/SI(`"OS';7\C/_!)WX:ZWX(^-GCC]I#Q%H4=S8?L[?"OQC\2= M%:4!K=_&5E:QQ^'(=QROF&0W3`<'N.E>$?!_X)_%C]O']M[PQH_CR^O+S5/C M1\4Y+KQ-JUU)K3J5)TL/A,MPT:]54G"I4>(A M"$HJ3D=^2^,_$.$X>P=*EQ#ALUXGXUSIX'(ZF*GA)QP>$P]6E@IU,)1A"$*] M?%YEB)8>G[55*=/V$YRC-I1?Z?:__P`'$7_!1/Q;_:OB3X?^"?!NE>#M/N'E MD>W\!S:]#80`EA#>ZJ85C&Q/ON[*<#+**^M?V%O^#D#QWXU^*OA3X;?M5>$/ M#9T;QAK%CH,7CGPG:_V0=!OM2N8+*QFO=+6,PS63W,ZKOA1\)].^$'ACX5^![+P5I_A_^P;JVG\/Z3<37]L]F;6\N=1OKFT> MXN+FY5I))+B:0LC/E-FT`?`GAK_@B)_P3<\.^(KKQQ_PK)=4NX=4F\01->^* M[W^R-*=)S>!HK:"Y2WAM[67,B'*)&JKP`BX_&Y<<>#&9X+-L!C/#BIE4%&5' M*,;E"A5S";DI0IUZ]6=;#^PK0E&G4Y)3Q<*G-*G-2LW+]FAP7XPY9C,JQN$\ M0Z6:2YU5S7!YMSTL#%1<)5*%&C&AB%7I3BZE-3C'"SIM*<7&Z4(O@+:?M'^.= M/MK3PU^%_V(/\`@GAHOPL^#_AC0]1\KQ7J-O$` MR2&ZD:XFF#*66<,9=B:GA'+%9ABY498C/?$',\)D^4UH5K2 M3P%"O7I5TFI0C0HPPLZTU+GE4J2<8+Y7B7CJGF?$^886CXO4*&"P<:T:&0^' M^`Q.<9M1G1?+-8ZOAZ-:CHX5'7K3Q,*5-QY5"FDYGR?\#/\`@Y0_:C\/_$O2 M=`_:*\!^#]?\-G6K71_$-MH^B'PMKFE)+>Q6=[=;%C8FXT]7>8VTFWS#$8R, ML,_7_P#PWFTPW,0.=K MRWVW:<@2@@C%?R^_#WX5_%;]IK]JGPK'XEL8+KQ!\5?BOHK^('L8$@B#:[X@ MM)=4EBM[?]W#%';23N%4;55/7K^BW_!=._U_QK^UUIGPM\*2IJ/@?X"?#GPC M\,?#ZB7>(KO3-.A.M`8.%_TF&,$+SN5L]./U"MX79'@O$O@>>3\.0RK'8/+< MUS[-<%@:=9X5QP:PN%P-6-.>D91S+%N-.HH0]K3HMR@Y1LOS*EXL9CC/#7C9 MYMQ53S3+\3F>59!E>.QM>@L2IXQ8C%XVE.K"S?/EN%4YTY3J>RG45I.,_>^U MO^#7OX%2:M\3?C5\?;VV$MCX5T.W\#:9)+&"(M5UC[)J<\L3$'Y_L8V<8*E< MYR,5_:2MC9)=/>I:6Z7CIY;W*PQB=DSG:TH7>1GL37XP?\$%_P!GM_@7^P;X M1U+4;`Z?XC^*FJWWC/6H73;-L$LUEIAE[[OLB\`G@$`<8K]JJ_D_QASN6=^( MG$==2DZ.#Q2RF@KO2EEL8X62WM9UZ=6>FCYK[ZG]6^$63PR?P^X7=Z7K.GVFJ M:==)_)X:JYTJF;5\RHUX9A#"PIJ MO2P\?92IRPU9MQJ4'/G4E\2LDXW/R#QH^C=6\5N+0E;KPSX1DC\VRLU251-:WVH&:22_0A&VJB%=I7'\\/_!6VR^- M6K?MG_%&_P#B#HVOK##J5O9^'7:TU!]+?P[#;QC2_P"S9Q$;5HGB4/,+=L^< M#Y@)"FO[W(HHX(XX88TAAB18XHHD6...-`%1(T0!415`"JH"J```!7G_`(U^ M$?PH^)+P2?$7X8?#SQ]):KLM7\:^"O#?BI[9#_#`VNZ;?M"O^S&5'M7E<&>/ M>.R+Q)X@\0L_RB.>5\_PE7!.A3Q'L*N5X9UJ-3#8?+JM2G5A&A1I4*>&E2<8 M^TIWESJ3ES^MQQ]'?`<0>%_#GAMPYG+R##\.XNACO;U,,\11S;%*A6I8O$9E M2IU*4Y5\16KU,5&JI2]E4:@HN"CR_P`OW["7_!2BP^#W[.W@?X$_"#]CSQCX ML^-<2S:5_P`)!I&GVHT/7M?NGN);;7-:N4M6U&&)=Z).))52..+(`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`L?)]Q_X*R_\`!/+Q MQ^SYX^\*^)?AQX9USQ#\)9O!WA[0;/6=/LKO49;/7-'AG74H=46SCG:T2X>= M);:615B*@J6!Q7]K>@^&_#OA73X])\+Z!HOAO2H3F+3-!TJQT?3XC@#,=EIT M%O;(<`#Y8QP`.U6-7T?2-?T^YTG7=*TW6]*O$\N[TS5[&UU+3[J/.?+N;*\B MFMITR`=LL;+D9Q7O?\32Y]0XIR/,(<5B^+>(, MSHYS7XHA@,/AJ&%QE"=>JL+A_MXH\W4 M5O*28%5"Q&$==N17G'P-_8T_:T_X*6_M":G\2_B+I^NZ/H^O^(8]4\<^/O$N MF7NF6-EI[2IFUT:VNU@FNVCMHUMK"*U22*$@.6)!4_V@1_LM_LR0W0OH?V=/ M@3%?!_-%Y'\(OA^ET),Y\P7"^'A-OSSOW[L\YKVC3=,TW1K*WTW1].L=*TZT M01VNGZ;:6]C96T8Z1V]K:QQ00H.RQQJOM5XSZ1>0934SW-O#_P`.L%P[Q7Q) M[1YCQ%C<8\=6A4K3]K5JX?#*"I*2,%G@OHS<1YQ3 MX>R?Q'\3&XN9"(MTZL/WW_P"")'P>;X._L7IXQ\2:9<:/KOCC7=<\ M1:HMU;2072Z+IY)TUI(Y%64XMFD*C;_"0`2:_5G5_@W\(?$&H76KZ_\`"KX; MZWJM\Y>]U/5_`WAC4M0O'889[J]O=+FN;AV`P6FEWKXFK."H4W"IB\PQ-3&3(KA=;\=ZGIU@Z:3J3L] MGIMV='L-F+9E_>+:*T85L%75N]?V7:+9VG[&O_!-NTLOL=P;CP'\$WB\BRMI M9KR36=0S6DL:%5*I)$RK@8`P*T\0O&O`<;Y;P+D-#ANM ME>0<(8G"UL3@?K\*T\QHX.AA<)1I0G'#TH4''"T<1!2<*EI8ERM:-GGX;>!. M8:'X4UK4OAGXO MTS2KCPUJ^FV-Y?V=FVGV$-K>Z5>O:PR+9RVLBL8?.")+&#M(VJ&_LVT/X1?" M?PQJ4&L^&_AA\//#VL6JNEMJNA^"O#>DZE;K(,.L%]8:9;W42N``ZQRJ&`Y! MKJ/$/AGPWXMTR;1?%?A_1/$VCW!!GTGQ#I-AK6F3E<[3-8:E;W-K(5R<%XFQ MDXZU]OC?I48RIQQDO$V"X9]AD^79)B\DQ61U/P6!^B+@:7`.>\*X_BEXC.LSS_!9]A<^I9;R0PU3 M`8.MA*>%Q&$GB9SQ%&NL7C)UG&O3DIU*4X>]2M/^1K]DK_@LK)^S_P#LX^%O M@MXB_9WO/%OBGP1I-QH_AOQ!9QV-K:7,1EGFMI-3:5H>A>'Y)T M-PT.L7!MI+V>*T^6%88+AYIV4N(@Q8?O^G[*O[+\4PN8_P!F_P"`L=P&W"=/ M@_\`#U)@P.0PE7PZ'#9YR&SGFO8]$T#0?#.GQ:3X;T32/#^E0$F#3-$TVSTK M3X20`3%96$-O;1DA0#LC&0`.PKY#/O%CPTQ,,\Q>2>$>">>Y]6KXBMF'$6;8 MK,\-@L5B)2J5<3@L#!TXTYNK.=54XU*5-U&G-2IKV1]KP[X/>*6%GD&#S[QD MQW]@G?M'Z!\5/["OM1\*>*/`/A_2UU31]-N6T>VU?P]"+?4;9(RQ9FKR#]@#]O#]MOX/^![C]G;X#_#B'QT?$>I74GAR7 M4=`U:]N/#6H7\#/!_CK2GT+ MQOX4\->,M$EUO+1W&>&:$D=C7/>"_@]\(_AO- M/OEGTA,G7A MQEG`W$O`&"XFJ9+0HT<#/&8R5/+*E3!2F\OQ.)PU.FL0JF'A-TZD*-:,:\%* M+E"-6:/%S/Z-V=?\10S7Q`X6\1<=PK3SS$5JV80P6"C5S6G3QL:2S'"87%5: MCPSI8B=)5*4Z]"<\/-PDHSE1A)_YVWQF\'?'GQK\>?%4GQ'@\0^*/B#K/B[R MM>UEK#4+F.[UNZDMHGCBE6W\LPV\LB6<04J@2#`/!:OU+_X*L66M^`O@Y^Q[ M^R3X?T#699_A;\*=,\5>)_L&FWK)YHNS=G23.;H2_O!<>9YHD^ MUF_%M",16XO-1TZYN! M!$`!'")/+0#"J*]S%_2?P6,S?@G'5.#9T\%P?3Q]6&7X?,*5"CB,RQ.6PRO" MXFC"&%5/"X?!8>>,]CAE"HHNO34)15*[\#`_10QV`R;CO+Z?&\:N/XUJY=1J M9GB,MK5Z^'RO"YI/-L9AJ\YXSVN+Q./Q-/!>VQ4IP:WNK M68O;JES:3QNRB:%Y$92DR[@NT_Z-&@>&_#OA/38M&\+:!HOAK2(&=X=*T#2K M'1M-A>0YD:*QTZ"VM8V<\NR1`L>6)-^(5T+WQ]\*/AKXXO0JH+O MQAX$\+^);H(@PBBXUK2KV7:HX5=^`.`!7!D?TFZN#SOCFOG?"\,XX>XTQOUF M>5O&\E?`T5@*65?4G6E1E2Q6&K8"C2IU8.%%J<93IM>TDCT,^^BI2QF0<`8? M(.+*F2<2\"X+ZM#-XX#GPV/KRS&IF[QJH0KQJX7$T77@6;78(;;Q!K'A2PUG4?$=T`4$UII M;VL,S6EM=L661EC,VTA`.04[KX.?LJ?\%`-#_9&^+_QR\7>/OBEI/E^";^U\ M)_"E]2O9]6U_1]0B=-4UB[L7:2ZMS9PD&QM5"W3,LCYYV1?U,^&_V?/@)X,O MXM4\'_!#X0^%-3@=7AU'PW\-?!FA7\+JBVMQ&ZD`JR2`@C(->N.B2 M(\RO+&C7A25"5=5:E6E1E*-!4FW)^Y@/H^ M<29KFN)S_P`1O%+/N)(H5*5/%U,-AJ].GBI8>I5>( MAAG2I4JM91EB)5E%17^;E^SCXIA^#/[0_P`/_B'\3OAIK'Q`T'PCXKM]5USP M??6=PEQK$<,CDP2)?PJGG^:PE(N!AFSO#$XK]Y?VRO\`@HI^T!^TQ^S?X[T' M]G']FOQS\*_A!;VMCIGC_P`9:W8+:7UQIUTUN;?3O#L>G0VL7V21S&ES+;1R MM'"IB*$,0O\`1W>?LR_LVZCJ,NKZA^SY\$+_`%:>8W$VJ7GPG\!W6HS3LVYI MI;V?0'N9)F;YC(\IE2PU;&J7-]6Q.)BXTY*E.K1K*E""\#@_P"C9QGP MGP]Q)PK@_$ZC@9XBO4POU6E'$9IB*U3%4,"X*/UK"X22 ME4BZL*->@ZTZC_AZ_P""/WPWO;/]K*W^(WC7P_JL>C?"OP3XN\?O'>:7>*MQ MJ&BZ7,]A&AG@0-*'4O'&NYG;9@9Q7QOXR\.?$7]I/]IO6]9A\.^)'N?BG\3; MVXM9+G2]2#+#XAUZ5;?)>`*GDV,\;!=V$5/FZ&O]#32/A'\*/#TES+H'PQ^' MNARWEM)9W"_#>FR75G,GERVER]EIL+3VTJ?))!*6B=/E92.*IV'P4^#6 ME7MKJ>E_"3X8Z;J-C,MQ9:A8>`O"MG>V=PA)6>UNK?2HY[>9225EBD1P2<-7 MJ4_I3X6EQ-GW$ZX0Q,L9F619;DF74YYM3<,MI8&>.Q-2;?U/]\L3CL73KU$H MTWRT(PN])1\FK]$?%5>%.'>$Y<9X:."RKB'-,_S.I#)ZBGFE7,(9?A:=.SQG M[IX7`8.KAZ;E*HN:O*:4=8NQ\(/!EI\._A;\/_!%C;K;0>&O".@Z4854*%N+ M;3K=+HD``!FN?-8^YKT:BBOY`Q%>IBL17Q-:3G5Q%:I7JR;; EX-31 3 vaso10q-sept2012ex31.htm vaso10q-sept2012ex31.htm
EXHIBIT 31.1
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jun Ma                         .
Jun Ma
President and Chief Executive Officer

Date: November 19, 2012
 
 
 
 

EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael J. Beecher           .
Michael J. Beecher
Chief Financial Officer

Date: November 19, 2012
 EX-32 4 vaso10q-sept2012ex32.htm vaso10q-sept2012ex32.htm

 


EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Jun Ma                          .
Jun Ma
President and Chief Executive Officer

Dated: November 19, 2012



 
 
 


EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Michael J. Beecher             .
                 Michael J. Beecher
Dated: November 19, 2012                                                                                   Chief Financial Officer

 EX-101.INS 5 vaso-20120930.xml XBRL INSTANCE DOCUMENT 0000839087 2012-01-01 2012-09-30 0000839087 2012-11-15 0000839087 2012-09-30 0000839087 2011-12-31 0000839087 2012-07-01 2012-09-30 0000839087 2011-07-01 2011-09-30 0000839087 2011-01-01 2011-09-30 0000839087 2010-12-31 0000839087 2011-09-30 0000839087 us-gaap:PreferredStockMember 2012-09-30 0000839087 us-gaap:PreferredStockMember 2011-09-30 0000839087 vaso:EquipmentSegmentMember 2012-07-01 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-07-01 2012-09-30 0000839087 us-gaap:CorporateMember 2012-07-01 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2011-07-01 2011-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-07-01 2011-09-30 0000839087 us-gaap:CorporateMember 2011-07-01 2011-09-30 0000839087 vaso:EquipmentSegmentMember 2012-01-01 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-01-01 2012-09-30 0000839087 us-gaap:CorporateMember 2012-01-01 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2011-01-01 2011-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-01-01 2011-09-30 0000839087 us-gaap:CorporateMember 2011-01-01 2011-09-30 0000839087 vaso:EquipmentSegmentMember 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-09-30 0000839087 us-gaap:CorporateMember 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2011-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2011-09-30 0000839087 us-gaap:CorporateMember 2011-09-30 0000839087 vaso:GeHealthcareMember 2012-07-01 2012-09-30 0000839087 vaso:GeHealthcareMember 2011-07-01 2011-09-30 0000839087 vaso:GeHealthcareMember 2012-01-01 2012-09-30 0000839087 vaso:GeHealthcareMember 2011-01-01 2011-09-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember vaso:GeHealthcareMember 2012-09-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember vaso:GeHealthcareMember 2011-12-31 0000839087 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember vaso:GeHealthcareMember 2012-01-01 2012-09-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember vaso:GeHealthcareMember 2011-01-01 2011-12-31 0000839087 us-gaap:RestrictedStockMember 2011-01-01 2011-09-30 0000839087 us-gaap:RestrictedStockMember 2011-07-01 2011-09-30 0000839087 us-gaap:RestrictedStockMember us-gaap:OfficerMember 2012-07-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember us-gaap:OfficerMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2011-07-01 2011-09-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2011-01-01 2011-09-30 0000839087 us-gaap:RestrictedStockMember 2012-07-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2012-01-01 2012-09-30 0000839087 us-gaap:StockCompensationPlanMember 2012-07-01 2012-09-30 0000839087 us-gaap:StockCompensationPlanMember 2012-01-01 2012-09-30 0000839087 us-gaap:StockCompensationPlanMember 2011-07-01 2011-09-30 0000839087 us-gaap:StockCompensationPlanMember 2011-01-01 2011-09-30 0000839087 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0000839087 us-gaap:StockOptionsMember 2011-07-01 2011-09-30 0000839087 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000839087 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000839087 us-gaap:WarrantMember 2012-07-01 2012-09-30 0000839087 us-gaap:WarrantMember 2011-07-01 2011-09-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000839087 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2012-07-01 2012-09-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2011-07-01 2011-09-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2012-01-01 2012-09-30 0000839087 us-gaap:ContingentlyIssuableSharesMember 2011-01-01 2011-09-30 0000839087 us-gaap:CommonStockMember 2012-07-01 2012-09-30 0000839087 us-gaap:CommonStockMember 2011-07-01 2011-09-30 0000839087 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:CommonStockMember 2011-01-01 2011-09-30 0000839087 us-gaap:FairValueInputsLevel1Member 2012-09-30 0000839087 us-gaap:FairValueInputsLevel2Member 2012-09-30 0000839087 us-gaap:FairValueInputsLevel3Member 2012-09-30 0000839087 us-gaap:FairValueInputsLevel1Member 2011-12-31 0000839087 us-gaap:FairValueInputsLevel2Member 2011-12-31 0000839087 us-gaap:FairValueInputsLevel3Member 2011-12-31 0000839087 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember us-gaap:CommonStockMember 2012-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember us-gaap:WarrantMember 2012-09-30 0000839087 us-gaap:ContingentConsiderationClassifiedAsEquityMember vaso:FastGrowthEnterprisesLimitedFgeMember 2012-09-30 0000839087 us-gaap:CommonStockMember 2012-09-30 0000839087 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2012-09-30 0000839087 vaso:AsInitiallyReportedMember 2011-09-02 0000839087 vaso:MeasurementPeriodAdjustmentsMember 2011-09-02 0000839087 vaso:AsAdjustedMember 2011-09-02 0000839087 2011-09-02 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-07-01 2012-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2012-01-01 2012-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2011-07-01 2011-09-30 0000839087 vaso:FastGrowthEnterprisesLimitedFgeMember 2011-01-01 2011-09-30 0000839087 us-gaap:CustomerListsMember 2012-09-30 0000839087 us-gaap:CustomerListsMember 2011-12-31 0000839087 us-gaap:PatentsMember 2012-09-30 0000839087 us-gaap:PatentsMember 2011-12-31 0000839087 us-gaap:CustomerListsMember 2012-07-01 2012-09-30 0000839087 us-gaap:CustomerListsMember 2011-07-01 2011-09-30 0000839087 us-gaap:CustomerListsMember 2012-01-01 2012-09-30 0000839087 us-gaap:CustomerListsMember 2011-01-01 2011-09-30 0000839087 2012-06-30 0000839087 2011-06-30 0000839087 vaso:ExtendedServiceContractsMember 2012-07-01 2012-09-30 0000839087 vaso:ExtendedServiceContractsMember 2011-07-01 2011-09-30 0000839087 vaso:ExtendedServiceContractsMember 2012-01-01 2012-09-30 0000839087 vaso:ExtendedServiceContractsMember 2011-01-01 2011-09-30 0000839087 vaso:In-ServiceAndTrainingMember 2012-07-01 2012-09-30 0000839087 vaso:In-ServiceAndTrainingMember 2011-07-01 2011-09-30 0000839087 vaso:In-ServiceAndTrainingMember 2012-01-01 2012-09-30 0000839087 vaso:In-ServiceAndTrainingMember 2011-01-01 2011-09-30 0000839087 vaso:ServiceArrangementsMember 2012-07-01 2012-09-30 0000839087 vaso:ServiceArrangementsMember 2011-07-01 2011-09-30 0000839087 vaso:ServiceArrangementsMember 2012-01-01 2012-09-30 0000839087 vaso:ServiceArrangementsMember 2011-01-01 2011-09-30 0000839087 vaso:CommissionRevenuesMember 2012-07-01 2012-09-30 0000839087 vaso:CommissionRevenuesMember 2011-07-01 2011-09-30 0000839087 vaso:CommissionRevenuesMember 2012-01-01 2012-09-30 0000839087 vaso:CommissionRevenuesMember 2011-01-01 2011-09-30 0000839087 us-gaap:DirectorMember 2011-07-01 2011-09-30 0000839087 us-gaap:DirectorMember 2011-01-01 2011-09-30 0000839087 us-gaap:DirectorMember 2012-07-01 2012-09-30 0000839087 us-gaap:DirectorMember 2012-01-01 2012-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2012-01-01 2012-09-30 0000839087 vaso:ConsultantMember 2012-09-30 0000839087 vaso:ConsultantMember 2012-01-01 2012-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-10-01 2011-12-31 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-01-01 2012-03-31 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-03-31 0000839087 vaso:Plan2010Member 2010-06-30 0000839087 vaso:Plan2010Member 2012-09-30 0000839087 vaso:Plan2010Member 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-09-30 0000839087 vaso:Non-OfficerEmployeeMember us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-01-01 2012-09-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2011-07-01 2011-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2011-01-01 2011-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2010-06-30 0000839087 us-gaap:PreferredStockMember 2010-06-30 0000839087 us-gaap:SeriesEPreferredStockMember 2012-07-01 2012-09-30 0000839087 us-gaap:PreferredStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:PreferredStockMember 2011-01-01 2011-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2012-09-30 0000839087 us-gaap:SeriesEPreferredStockMember 2012-01-01 2012-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure false --12-31 2012-09-30 No No Yes Smaller Reporting Company VASOMEDICAL, INC 0000839087 162917996 2012 Q3 10-Q 8388000 20695000 1059000 7329000 0 763000 9260000 0 10023000 7200000 19700000 10349000 22737000 312000 273000 41000 196000 1944000 3889000 3334000 2560000 1564000 1774000 28000 0 0 800000 800000 800000 60993000 60188000 128000 416000 159000 367000 2086000 2163000 130000 9000 143000 28000 1810000 1810000 1810000 1810000 1500000 5786000 1500000 5786000 0 2000000 0 2000000 3260000 2903000 3260000 2903000 6570000 12499000 6570000 12499000 8714000 0 0 8714000 1423000 0 0 1423000 23856000 28500000 29509000 34335000 8595000 11319000 9595000 8810000 12405000 4318000 25533000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation and Use of Estimates</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Transition Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant Accounting Policies</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue and Expense Recognition for VasoHealthcare</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the Consolidated Balance Sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.</div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Reclassifications</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Certain reclassifications have been made to prior period amounts to conform with the current period presentation.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div></div></div> 931000 291000 1222000 1222000 2400000 1000000 3175000 -7000 3168000 5722000 6605000 19462000 17225000 <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;"><font style="font-style: italic; display: inline;">(in thousands except per share data)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">Nine months ended September 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,605</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">17,225</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net (loss) income</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,515)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,620)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(937)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted (loss) earnings per share</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.01)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr></table></div></div> 3979000 3979000 0 3979000 442000 0 442000 442000 -2515000 19000 -3620000 -937000 0.42 0.42 5000000 1500000 2400000 670000 -194000 476000 476000 2979000 2100000 304000 575000 591000 -308000 283000 283000 3979000 288000 32000 0 32000 32000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE I&#8211; BUSINESS COMBINATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition included a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock. The Company completed its evaluation of FGE's calendar year 2011 performance targets and determined that the targets were met, resulting in the issuance of 2.4 million shares to the prior owners in September 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">LET, based in Foshan, Guangdong, China, is Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>) systems, including certain Lumenair systems and all AngioNew<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>systems. Biox, a developer and manufacturer of ambulatory monitoring devices, is located in Wuxi, Jiangsu, China, and is Vasomedical's supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States. The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems. The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the three and nine months ended September 30, 2012. The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div></div><div style="text-indent: 0pt; display: block;"><div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td align="right" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,100</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. warrants to purchase common stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">304</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total purchase price</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date). The purchase price was allocated based on the information available as of the acquisition date, and subsequently adjusted (measurement period adjustments) after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The measurement period adjustments were completed during the quarter ended September 30, 2012 (within a year of the acquisition date). The accompanying Consolidated Condensed Balance Sheet as of December 31, 2011 has been retroactively adjusted to include the effect of the measurement period adjustment. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td align="left" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td colspan="10" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: normal;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><font style="font-weight: normal;">As initially reported</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: normal; margin-right: 0pt;">Measurement period adjustments</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: normal; margin-right: 0pt;">As adjusted</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable and other current assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">591</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(308)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">670</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(194)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">476</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Property and equipment</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,175</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(7)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,168</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and other current liabilites</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(931)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(291)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,222)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 64%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net assets acquired</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div></div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability. The goodwill is not expected to be deductible for tax purposes. Customer lists were valued based on sales history of certain recurring customers and the timing of expected future revenues.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">After elimination of intercompany transactions, which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2012 was $271,000 and $189,000, respectively, and $1,181,000 and $299,000, respectively, for the nine months ended September 30, 2012. For the three and nine months ended September 30, 2011, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Income (Loss) were $96,000 and $24,000, respectively. The effect of FGE's loss on earnings per share for the three and nine months ended September 30, 2012 and September 30, 2011 was $0.00.</div></div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;"><font style="font-style: italic; display: inline;">(in thousands except per share data)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Three months ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">Nine months ended September 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,605</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">17,225</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net (loss) income</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,515)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,620)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(937)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted (loss) earnings per share</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.01)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(0.02)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr></table></div></div><div style="text-indent: 0pt; display: block;">&#160;</div></div><div style="text-indent: 0pt; display: block;"><br /></div></div> 9691000 2294000 3101000 4522000 0 442000 7397000 1421000 8604000 0 0 8604000 1313000 0 0 1313000 0.08 4285714 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE N &#8211; COMMITMENTS AND CONTINGENCIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales representation agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year. The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013. A condition of the incentives is that the employees remain continuously employed through the vesting dates. As of September 30, 2012, approximately $1.3 million and 1.3 million shares remain unvested.</div><br /></div></div> 162917996 153186295 163000 153000 162917996 153186295 30668500 0.001 0.001 250000000 250000000 -2488000 -1114000 -3777000 -2815000 0.86 0.95 306685 0 32000 100 282000 200000 1304000 949000 1659000 1811000 5688000 5087000 148000 157000 699000 635000 0.06 2577000 2053000 15198000 11360000 15228000 12637000 14998000 13475000 <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The changes in the Company's deferred revenues are as follows:</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">For the three months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the nine months ended September 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at the beginning of the period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,198</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,360</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,637</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Additions:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">288</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">240</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">987</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">968</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">33</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">28</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">75</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">65</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,037</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,941</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,116</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,085</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(269</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(840</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(872</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(23</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(22</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(21</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(64</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(55</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,243</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,798</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(6,512</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at end of period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,475</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,475</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Less: current portion</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,102</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,042</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,102</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,042</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Long-term deferred revenue at end of period</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,896</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,433</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,896</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,433</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE K - DEFERRED REVENUE</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-indent: 0pt; display: block;"><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The changes in the Company's deferred revenues are as follows:</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">For the three months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the nine months ended September 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at the beginning of the period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,198</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,360</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,637</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Additions:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">288</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">240</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">987</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">968</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">33</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">28</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">75</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">65</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,037</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,941</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,116</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,085</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(269</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(840</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(872</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(23</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(22</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(21</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(64</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(55</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,243</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,798</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(6,512</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at end of period</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,475</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,475</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 52%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Less: current portion</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,102</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,042</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,102</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,042</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Long-term deferred revenue at end of period</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,896</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,433</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,896</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,433</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><br /></div></div></div> 288000 240000 987000 968000 13000 10000 33000 28000 20000 20000 75000 65000 2037000 4941000 6116000 9085000 4896000 5743000 3433000 10102000 9484000 10042000 -840000 -872000 -10000 -8000 -25000 -23000 -22000 -21000 -64000 -55000 -2243000 -2798000 -6512000 -8358000 -283000 -269000 112000 112000 296000 118000 <div><div style="text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt;">NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other Comprehensive Income: Presentation of Comprehensive Income</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated condensed financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.</div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE D &#8211; SHARE-BASED COMPENSATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with ASC Topic 718 "Compensation &#8211; Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three and nine-month periods ended September 30, 2012, the Company granted 0 and 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter. During the three months ended September 30, 2011, 100,000 shares of restricted common stock valued at $35,000 were granted to officers and directors, and 466,279 shares of restricted common stock valued at $170,500 were granted to officers and directors during the nine months ended September 30, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the nine-month periods ended September 30, 2012 and 2011, the Company did not grant any stock options.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three and nine months ended September 30, 2012, the Company granted 500,000 and 2,690,000 shares of restricted common stock valued at $130,000 and $678,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012. For the three and nine months ended September 30, 2011, the Company granted 0 and 10,000 shares of restricted common stock, respectively, valued at $6,800 to other non-officer employees.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Share-based compensation expense recognized for the three and nine months ended September 30, 2012 was $328,000 and $559,000, respectively, and $92,000 and $295,000 for the three and nine months ended September 30, 2011, respectively. These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations. Expense for share-based arrangements was $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively, and $159,000 and $367,000 for the three and nine months ended September 30, 2011, respectively. Unrecognized expense related to existing share-based compensation and arrangements is approximately $806,000 at September 30, 2012 and will be recognized through July 2013.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div></div></div> 0 1459000 1180000 1459000 125000 121000 -0.02 -0.01 -0.02 -0.02 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE E &#8211; LOSS PER COMMON SHARE</div><div style="text-indent: 0pt; display: block;"><br /><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">three </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">months ended</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">nine </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">months ended</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,903</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,903</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,499</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,499</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 180pt; font-size: 10pt; margin-right: 0pt;"></div></div></div> 10000 0 806000 0.81 0.88 0.76 0.82 4469000 291000 <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">September 30, 2012 and December 31, 2011:</font></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">in Active</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Identical Assets</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level I)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Inputs</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level 2)</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Significant</div><div style="text-align: center;">Unobservable</div><div style="text-align: center;">Inputs</div><div style="text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Balance</div><div style="text-align: center;">as of</div><div style="text-align: center;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,714</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,714</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">i</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">n Active</font></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level I)</div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Inputs</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level 2)</div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant </font><div style="display: inline; font-family: times new roman; font-size: 10pt;">Unobservable</div><div style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</div><div style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Balance</div><div style="text-align: center;">as of</div><div style="text-align: center;">December 31,</div><div style="text-align: center;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Assets</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE F &#8211; FAIR VALUE MEASUREMENTS</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820"). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">September 30, 2012 and December 31, 2011:</font></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">in Active</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Identical Assets</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level I)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Inputs</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level 2)</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Significant</div><div style="text-align: center;">Unobservable</div><div style="text-align: center;">Inputs</div><div style="text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Balance</div><div style="text-align: center;">as of</div><div style="text-align: center;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,714</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,714</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">i</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">n Active</font></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level I)</div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Other</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Observable</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Inputs</div><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">(Level 2)</div></div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant </font><div style="display: inline; font-family: times new roman; font-size: 10pt;">Unobservable</div><div style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</div><div style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><div style="text-align: center; font-family: times new roman; font-size: 10pt;">Balance</div><div style="text-align: center;">as of</div><div style="text-align: center;">December 31,</div><div style="text-align: center;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Assets</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,313</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,423</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</div><br /></div></div> 676000 800000 37000 56000 713000 856000 3200000 3168000 32000 <div><div style="text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt;">NOTE J &#8211; GOODWILL AND OTHER INTANGIBLES</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill aggregating $3,200,000 and $3,168,000 (retroactively adjusted to give effect to measurement period adjustment) was recorded on the Company's Consolidated Condensed Balance Sheets at September 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company's Equipment segment. The components of the change in goodwill are as follows:</div><font style="letter-spacing: 9pt;">&#160; </font></div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying Amount</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at December 31, 2011</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,168</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Foreign currency translation</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at September 30, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,200</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company's other intangible assets consist of capitalized customer lists and patent costs, as follows:</div><div style="text-align: justify; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011 (a)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other intangibles, net</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">676</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents, net</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">37</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">56</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">713</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">856</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="text-align: left; width: 29px;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(a) </div></td><td style="width: 1302px;"><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Retroactively adjusted to give effect to measurement period adjustment.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents and customer lists are included in other assets in the accompanying Consolidated Condensed Balance Sheets and customer lists are amortized on a straight line basis over their estimated useful life of seven years. The useful life was estimated based on the length of time the customer is expected to remain active. Amortization expense amounted to $130,000 and $9,000 for the three months ended September 30, 2012 and 2011, respectively, and $143,000 and $28,000 for the nine months ended September 30, 2012 and 2011, respectively.</div></div><br /></div></div> 4063000 4719000 13774000 11462000 -2562000 69000 -3734000 -1354000 -44000 5000 72000 4000 411000 9000 525000 719000 -315000 4000 813000 -73000 0 -243000 -159000 0 170000 -55000 39000 -368000 -26000 -589000 -229000 838000 -12212000 -3516000 -172000 -96000 47000 804000 -14000 -13000 -1000 45000 -1945000 840000 0 3000 3000 28000 93000 33000 123000 51000 5000 30000 540000 606000 853000 1051000 1087000 842000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE H &#8211; INVENTORIES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:<font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,087</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">842</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">521</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">528</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">853</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,051</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,461</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,421</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At September 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $540,000 and $606,000, respectively.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div></div></div> 2461000 2421000 521000 528000 110000 110000 110000 110000 30000 102000 60000 194000 16125000 17175000 -291000 -931000 5023000 5884000 29509000 34335000 <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE G &#8211; ACCOUNTS AND OTHER RECEIVABLES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company's accounts and other receivables as of September 30, 2012 and December 31, 2011:</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,349</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,737</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">125</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,086</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,163</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20,695</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 36pt; display: block; font-family: Times New Roman; font-size: 10pt;">Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><br />&#160;</div></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE A - ORGANIZATION AND PLAN OF OPERATIONS</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC's exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement ("GEHC Agreement") extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively &#8211; to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174; </font>therapy business as well as other medical equipment operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment. VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><br /></div></div> -2518000 -1116000 -3806000 -2817000 -344000 -620000 153000 -144000 -2518000 64000 -3806000 -1358000 189000 299000 24000 7578000 2185000 97000 43000 151000 63000 0 16000 21000 19000 3000 193000 48 2 6722000 4693000 17659000 12879000 -1417000 -3885000 26000 -2659000 -838000 -1358000 -463000 -640000 1047000 -381000 -1191000 -1473000 -1221000 -1382000 628000 -663000 354000 202000 0 177000 1825000 2137000 30000 2000 29000 2000 0 3635000 0 3635000 0 3124000 0 3124000 127000 141000 344000 21000 0 1000000 0 41000 0 0 1000000 1000000 350000 1000000 0 0 0.01 0.01 0 1180000 0 1459000 0 0 343000 0 0 150000 10000 628000 429000 -7000 15000 <div><div style="text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt;">NOTE L &#8211; RELATED-PARTY TRANSACTIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns. In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock. Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns. Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012. Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> system. Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company. Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board. He is currently a senior partner at the law firm of Beckman, Lieberman &amp; Barandes, LLP, which firm performs certain legal services for the Company. Fees of approximately $30,000 and $102,000 were billed by the firm through the three and nine months ended September 30, 2011, respectively, and approximately $60,000 and $194,000 were billed by the firm through the three and nine months ended September 30, 2012, respectively, at which date no amounts were outstanding.</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Mr. Rios is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement (the "Agreement") with Edgary Consultants, LLC ("Consultant"). The Agreement commenced on March 1, 2011 and runs for a two year term. The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>therapy. More specifically, Consultant will be assisting the Company in the following areas:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">1. </font>&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging the adoption of EECP&#174; therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">2. </font>&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP&#174; therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">3. </font>&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP&#174; therapy as a first line treatment for CCS Class III/IV angina.</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">4. </font>&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for CCS Class II angina; and</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">5. </font>&#160;</div></td><td><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for NYHA Class II/III heart failure.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011. In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares. The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement. The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of September 30, 2012 and December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012. In addition, receivables due from FGE management aggregating $159,000 were collected during the nine months ended September 30, 2012.</div><br /></div></div> 190000 0 95000 190000 0 294000 131000 140000 403000 382000 -52823000 -49065000 1063000 4659000 0 5722000 800000 5730000 0 6530000 4604000 14858000 0 19462000 3005000 13545000 0 16550000 1 150000 4000 13000 31000 40000 688000 410000 3197000 1495000 5722000 6530000 19462000 16549000 271000 1181000 96000 355000 355000 375000 390000 1407000 1509000 <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the three and nine months ended September 30, 2012. The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td align="right" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,100</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. warrants to purchase common stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">304</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total purchase price</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:<font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,087</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">842</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">521</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">528</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">853</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,051</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,461</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,421</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">three </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">months ended</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">nine </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">months ended</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Contingently issuable shares</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,903</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,903</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,499</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,499</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date). The purchase price was allocated based on the information available as of the acquisition date, and subsequently adjusted (measurement period adjustments) after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The measurement period adjustments were completed during the quarter ended September 30, 2012 (within a year of the acquisition date). The accompanying Consolidated Condensed Balance Sheet as of December 31, 2011 has been retroactively adjusted to include the effect of the measurement period adjustment. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td align="left" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td colspan="10" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: normal;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"><font style="font-weight: normal;">As initially reported</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: normal; margin-right: 0pt;">Measurement period adjustments</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: normal;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: normal; margin-right: 0pt;">As adjusted</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none; font-weight: bold;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts receivable and other current assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">591</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(308)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">670</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(194)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">476</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Property and equipment</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,175</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(7)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,168</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 64%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts payable and other current liabilites</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(931)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(291)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,222)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; text-indent: 9pt; width: 64%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Net assets acquired</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,979</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div></div> <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company's other intangible assets consist of capitalized customer lists and patent costs, as follows:</div><div style="text-align: justify; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"></div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011 (a)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other intangibles, net</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">676</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents, net</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">37</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">56</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">713</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">856</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="text-align: left; width: 29px;"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt;">(a) </div></td><td style="width: 1302px;"><div style="text-align: justify; text-indent: 0pt; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Retroactively adjusted to give effect to measurement period adjustment.</div></td></tr></table></div></div> <div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill aggregating $3,200,000 and $3,168,000 (retroactively adjusted to give effect to measurement period adjustment) was recorded on the Company's Consolidated Condensed Balance Sheets at September 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company's Equipment segment. The components of the change in goodwill are as follows:</div><font style="letter-spacing: 9pt;">&#160; </font></div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying Amount</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at December 31, 2011</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,168</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 88%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Foreign currency translation</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">32</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at September 30, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,200</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments &#8211; the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets &#8211; primarily cash balances &#8211; are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-indent: 0pt; display: block;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;"><font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended September 30, 2012</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,063</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(838</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(463</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,329</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended September 30, 2011</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,730</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,530</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(640</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,047</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(381</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">26</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,405</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,318</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">763</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,023</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><br /></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 18pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;"><font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">As of or for the nine months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,858</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,191)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,473)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,221)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,885)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,329</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="7" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">As of or for the nine months ended September 30, 2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,005</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,545</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">16,550</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,382)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">628</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(663)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,417)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,405</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,318</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">763</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,023</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company's accounts and other receivables as of September 30, 2012 and December 31, 2011:</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-style: italic; font-family: times new roman; font-size: 10pt; border-top: medium none;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,349</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,737</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">125</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; text-indent: 9pt; width: 76%;"><div style="text-align: left; text-indent: 9pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,086</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,163</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20,695</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE C &#8211; SEGMENT REPORTING AND CONCENTRATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments &#8211; the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets &#8211; primarily cash balances &#8211; are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-indent: 0pt; display: block;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: medium none;"><font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended September 30, 2012</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: medium none;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,063</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(838</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(463</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,329</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended September 30, 2011</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,730</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,530</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(640</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,047</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(381</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">26</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,405</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,318</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">763</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,023</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><br /></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 18pt; display: block;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td><td valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td><td colspan="14" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;"><font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: black 0.75pt solid;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">As of or for the nine months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,858</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,191)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,473)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,221)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,885)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,329</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,388</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="7" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="text-align: center; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt;">As of or for the nine months ended September 30, 2011</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,005</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,545</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">16,550</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating income/(loss)</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,382)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">628</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(663)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,417)</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,405</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,318</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">763</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,023</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div><div style="text-indent: 18pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; font-size: 10pt;">For the three months ended September 30, 2012 and 2011, GE Healthcare accounted for 81% and 88% of revenue, respectively. For the nine months ended September 30, 2012 and 2011, GE Healthcare accounted for 76% and 82% of revenue, respectively. Also, GE Healthcare accounted for $7.2 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at September 30, 2012 and December 31, 2011, respectively.</div></div></div></div> 6591000 4553000 17256000 12497000 559000 295000 328000 559000 92000 295000 840000 185500 P1Y P1Y 10000 0 0 500000 100000 466279 500000 2690000 1300000 250000 0.50 0.16 2190000 500000 5000000 5000000 1500000 0 9375 0 9375 5Y 110000 110000 3000000 600000 6800 120000 35000 170500 130000 678000 1020000 0 2979000 8361000 11276000 <div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE M &#8211; STOCKHOLDERS' EQUITY</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of September 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of September 30, 2012, 840,000 shares have been forfeited. In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period. In June 2012, 2,190,000 additional shares, vesting at various times through July 1, 2013, of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 185,500 shares had been forfeited as of September 30, 2012. In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest in June 2013 and the remainder in June 2014.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">No options were issued under the 2010 Plan during the nine months ended September 30, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE. In addition, 2,400,000 shares of common stock were issued, under the terms of the purchase agreement, in September 2012 to former owners of FGE for attaining certain operating targets for the twelve months ending December 31, 2011. The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition, recorded as of the September 2, 2011 acquisition date, was $2,979,000 (see Note I).</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Preferred Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below. Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011. As of September 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three and nine months ended September 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $1,180,000 and $1,459,000, respectively. Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,180,000 and $1,336,000 for the three and nine months ended September 30, 2011, respectively. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.</div><br /></div></div> -37000 278000 159018000 149524000 157162000 126023000 213000 510000 0 85000 0 31000 4659000 5730000 14858000 13545000 1229000 1454000 3685000 3503000 -416000 -367000 8000 93000 0 224000 0 1070000 2 3 1300000 -0.02 -0.01 -0.02 -0.02 P5Y 4285714 P2Y 0.1 0.82 2 0.1 1.1 3790000 P12M Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares. 1180000 1336000 P3Y P5Y 2200000 2200000 Retroactively adjusted to give effect to measurement period adjustment (see Note I) Retroactively adjusted to give effect to measurement period adjustment. EX-101.SCH 6 vaso-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - BUSINESS COMBINATION (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vaso-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vaso-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vaso-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] Accounts and other receivables, net Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,086 at September 30, 2012 and $2,163 at December 31, 2011 Accounts and other receivables, net Accounts and other receivables Trade receivables Accounts payable Accounts Payable, Current Receivables due from related parties Accounts Receivable, Related Parties Accounts and Other Receivables [Member] Accrued commissions Accrued Sales Commission, Current Accrued expenses and other liabilities Accrued Liabilities, Current PROPERTY AND EQUIPMENT, accumulated depreciation Accumulated other comprehensive income (loss) Customer lists Additional paid-in capital Adjustments to reconcile net loss to net cash provided by operating activities Allocated share-based arrangements Allowance for doubtful accounts and commission adjustments Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization expense Antidilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Assets Assets, Fair Value Disclosure CURRENT ASSETS ASSETS Total current assets Assets, Current Total Assets Total assets BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Accounts payable and other current liabilities Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable Common stock contingently issuable Business Acquisition, Contingent Consideration, Shares Issuable Business Acquisition [Axis] Cash Supplemental pro forma information [Abstract] Goodwill Fair values of assets acquired and liabilities assumed [Abstract] Revenue Business Acquisition, Pro Forma Revenue Business Acquisition, Acquiree [Domain] Acquisition date fair value of total consideration transferred [Abstract] Supplemental pro forma information Net assets acquired Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net Cash and cash equivalents Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents Net (loss) income Share price (in dollars per share) Business Acquisition, Share Price Number of shares of common stock issued relating to acquisition (in shares) Number of shares of common stock contingently issuable (in shares) BUSINESS COMBINATION [Abstract] Inventories Aggregate value relative to the acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Equity interests issued and issuable Accounts receivable and other current assets Business Acquisition [Line Items] Total purchase price Unsecured notes payable assumed Business Acquisition, Purchase Price Allocation, Notes Payable and Long-term Debt Property and equipment BUSINESS COMBINATION Business Combination Disclosure [Text Block] Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Cash acquired through purchase of Fast Growth Enterprises NET INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Cash equivalents invested in money market funds (included in cash and cash equivalents) Class of Stock [Line Items] Exercise price of warrants (in dollars per share) Class of Stock [Domain] Number of shares of common stock called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES (NOTE N) Common Stock [Member] Common Stock Grants [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $.001 par value; 250,000,000 shares authorized; 162,917,996 and 153,186,295 shares issued and outstanding at September 30, 2012 and December 31, 2011 Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock issued upon conversion of Series E preferred shares (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk Type [Domain] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Percentage of accounts and other receivables (in hundredths) Contingent Issuance of Common Stock [Member] Contingently Issuable Shares [Member] Shares issued (in shares) Conversion of preferred stock to common stock Shares Issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Corporate [Member] Cost of sales, equipment Total cost of revenues Cost of Goods and Services Sold Cost of equipment rentals and services Cost of revenues Customer Lists, Net [Member] Customer Concentration Risk [Member] Interest rate (in hundredths) Debt Instrument, Interest Rate, Stated Percentage Title of Individual [Axis] Deferred commission expense Deferred Costs, Current DEFERRED REVENUE [Abstract] Deferred revenue at the beginning of the period Deferred revenue at end of period Deferred Revenue Changes in deferred revenues DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred Revenue Arrangement, by Type [Table] Additions: Deferred Revenue Arrangement Type [Domain] Deferred Revenue Arrangement [Line Items] Deferred revenue Long-term deferred revenue at end of period Deferred Revenue, Noncurrent Deferred Revenue Arrangement Type [Axis] Deferred revenue - current portion Less: current portion Recognized as revenue: Deferred tax liability, net Deferred Tax Liabilities, Net, Current Depreciation and amortization Depreciation, Depletion and Amortization RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Director - David Lieberman [Member] Director [Member] SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION [Abstract] Dividends Payable [Table] Accrued preferred stock dividends Dividends Payable Dividends Payable [Line Items] Dividends recorded Due from employees Weighted average common shares outstanding - basic and diluted (in dollars per share) LOSS PER COMMON SHARE Loss per common share LOSS PER COMMON SHARE [Abstract] Effect of exchange rate differences on cash Unrecognized expense related to existing share-based arrangements Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Percentage of revenue (in hundredths) Entity-Wide Revenue, Major Customer, Percentage Revenue, Major Customer [Line Items] STOCKHOLDERS' EQUITY [Abstract] Equity Interest Type [Axis] Equity Component [Domain] Equity Interest Issued or Issuable, Type [Domain] Fair Value, Hierarchy [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair value of assets acquired Assets and liabilities measured at fair value Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE MEASUREMENTS [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] Other Intangibles, net [Abstract] Other Intangibles, net GOODWILL Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill, Translation Adjustments Foreign currency translation GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] Goodwill [Roll Forward] GOODWILL AND OTHER INTANGIBLES [Abstract] Gross profit Gross Profit (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) [Abstract] Income tax (expense) benefit Income Tax Expense (Benefit) Income taxes paid Deferred commission expense Increase (Decrease) in Deferred Charges Income taxes payable Accrued expenses and other liabilities Trade payable due to related party Receivables due from related parties Increase (Decrease) in Due from Related Parties, Current Other current assets Increase (Decrease) in Other Current Assets Accounts payable Other long-term liabilities Deferred revenue Accounts and other receivables Increase (Decrease) in Accounts and Other Receivables Other assets Increase (Decrease) in Other Noncurrent Assets Changes in operating assets and liabilities: Inventories, net Increase (Decrease) in Inventories Finance receivables Increase (Decrease) in Finance Receivables Sales tax payable Accrued commissions Interest and financing costs Interest and Debt Expense Interest and other income, net Interest paid Reserves for excess and obsolete inventory Finished goods Inventory, Finished Goods, Net of Reserves Raw materials INVENTORIES, NET Inventory Disclosure [Text Block] Inventories, net Inventories, net Inventory, Net INVENTORIES, NET [Abstract] Work in process Investment in certificates of deposit (included in short-term investments) Fees for legal services Total current liabilities Liabilities, Current Liabilities assumed through acquisition Total long-term liabilities Liabilities, Noncurrent CURRENT LIABILITIES LONG-TERM LIABILITIES LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders' equity Liabilities and Equity ACCOUNTS AND OTHER RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Major Customers [Axis] Movements in deferred revenue [Roll Forward] Name of Major Customer [Domain] ORGANIZATION AND PLAN OF OPERATIONS Nature of Operations [Text Block] Cash flows from financing activities Net (loss) income applicable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities Cash flows from operating activities Net loss Net loss Net (loss) income Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract] SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Total other income (expenses), net Nonoperating Income (Expense) Other income (expenses) FINANCING RECEIVABLES, net Financing receivables, net Notes payable due to related party Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products Number of segments Officer [Member] Operating expenses Total operating expenses Operating Expenses Operating (loss) income Operating income/(loss) ORGANIZATION AND PLAN OF OPERATIONS [Abstract] Other current assets Other Assets, Current Amortization of deferred distributor costs Other Amortization of Deferred Charges OTHER ASSETS, NET Foreign currency translation gain Other comprehensive income (loss) Deferred commission expense Other long-term liabilities Other Liabilities, Noncurrent Patents, Net [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of Fast Growth Enterprises Payments to Acquire Businesses, Gross Purchases of short-term investments Payments to Acquire Short-term Investments Plan Name [Domain] Plan Name [Axis] Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2012, and December 31, 2011 Preferred Stock, Value, Issued Preferred stock, shares authorized (in shares) Preferred stock authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock dividends Preferred Stock Dividends, Income Statement Impact Preferred stock, shares outstanding (in shares) Preferred Stock [Member] Proceeds from exercise of warrant Proceeds from issuance of preferred stock Consulting services Professional Fees PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,564 at September 30, 2012 and $1,774 at December 31, 2011 Property, Plant and Equipment, Net Provision for doubtful accounts and commission adjustments Provision for Doubtful Accounts ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party Transaction [Line Items] Related Party [Domain] RELATED-PARTY TRANSACTIONS [Abstract] Related Party [Axis] Repayment of notes payable due to related party Debt repaid Repayments of Related Party Debt Repayment of note payable Repayments of Notes Payable Research and development Restricted Stock [Member] Accumulated deficit Revenues from external customers Option price as a percentage of fair market value (in hundredths) Aggregate value of shares sold Sale of Stock, Consideration Received Per Transaction Amortization of deferred gain on sale-leaseback of building Amortization of deferred gain on sale-leaseback of building Equipment sales Revenue Total revenues Revenues Revenue, Net [Abstract] Sales tax payable Sales and Excise Tax Payable, Current Equipment rentals and services Acquisition date fair value of total consideration transferred Inventories, net of reserves Antidilutive common stock equivalents excluded from computation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Fair values of assets acquired and liabilities assumed Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of other intangible assets Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of components of change in goodwill Schedule of Segment Reporting Information, by Segment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Related Party Transactions, by Related Party [Table] Summary financial information for segments Schedule of Stock by Class [Table] Accounts and other receivables Segment Reporting Information [Line Items] SEGMENT REPORTING AND CONCENTRATIONS [Abstract] SEGMENT REPORTING AND CONCENTRATIONS Segment Reporting Disclosure [Text Block] Segment [Domain] Selling, general and administrative Series E Convertible Preferred Stock [Member] Series E Preferred Stock [Member] Share-based compensation Share-based compensation expense Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Remainder of vesting period Vesting Period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Unvested shares (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share Price Share Price (dollar per share) Granted during period (in shares) Number of shares authorized (in shares) Shares sold (in shares) Issued (in shares) Terms of award (in years) Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Award Type [Domain] Short-term investments CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) [Abstract] Business Segments [Axis] Equity Components [Axis] CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) [Abstract] Class of Stock [Axis] Restricted shares issued for consulting agreement (in shares) Value of stock granted Stock Compensation Plan [Member] Stock Options [Member] Restricted shares issued for consulting agreement Common shares, warrants and contingent shares issued for aquisition STOCKHOLDERS' EQUITY Total stockholders' equity Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Fast Growth Enterprises Limited (FGE) [Member] Subsidiary of Common Parent [Member] SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION Income taxes payable Taxes Payable, Current Title of Individual with Relationship to Entity [Domain] Warrant [Member] - basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which will be charged against earnings within one year or the normal operating cycle, if longer. Deferred Charges Related Party Current Deferred related party consulting expense - current portion The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. Deferred Charges Related Party Noncurrent DEFERRED RELATED PARTY CONSULTING EXPENSE The amount of the gain recorded in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller to be recognized within one year or the normal operating cycle, if longer. Sale Leaseback Transaction Deferred Gain Gross Current Deferred gain on sale-leaseback of building - current portion Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare. Commissions Revenue Net Commissions Total costs related to commissions earned under the sales representative agreement with GE Healthcare. Cost Of Commissions Revenue Cost of commissions The increase (decrease) during the reporting period in deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Increase Decrease Deferred Charges Related Party Amortization of deferred consulting expense The value of inventories transferred to property and equipment, attributable to operating leases in noncash financing and investing activities. Inventories transferred to property and equipment, attributable to operating leases, net Inventories transferred to property and equipment, attributable to operating leases, net Proceeds from issuance of preferred stock in satisfaction of accrued dividend. Issuance of preferred stock in satisfaction of accrued dividend Value of common stock issued for consulting services. Common Stock Issued for Consulting Agreements Common shares issued for consulting agreements Document and Entity Information [Abstract] The number of companies acquired through business combination. Number of Chinese operating companies acquired Number of Chinese operating companies acquired The number of wholly-owned subsidiaries owned by the entity Number of wholly-owned subsidiaries Information about asset acquired and liabilities assumed in a business combination. Assets Acquired/Liabilities Assumed [Axis] Information about asset acquired and liabilities assumed in a business combination. Assets Acquired/Liabilities Assumed [Domain] Adjustment to asset acquired and liabilities assumed in a business combination. Measurement Period Adjustments [Member] Assets acquired and liabilities assumed as initially assumed. As Initially Reported [Member] Assets acquired and liabilities assumed as adjusted. As Adjusted [Member] Cash liability related to the Company incentive plan as of the report date. Company Incentive Plan, Cash Liability Unvested incentive plan, cash Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Equipment Segment [Member] Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Sales Representation Segment [Member] GE Healthcare is the entity's largest customer. GE Healthcare [Member] The acquisition of a privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. Fast Growth Enterprises Limited (FGE) [Member] The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted Basic and diluted loss per share (in dollars per share) A type of deferred revenue by arrangement relating to extended service contracts. Extended Service Contracts [Member] A type of deferred revenue by arrangement relating to in-service and training. In-Service and Training [Member] A type of deferred revenue by arrangement relating to service arrangements. Service Arrangements [Member] A type of deferred revenue by arrangement relating to commission revenues. Commission Revenues [Member] The aggregate amount of goodwill acquired and allocated to additional pre-acquisition liabilities which was recorded during the period. Additional pre-acquisition liabilities recorded Additional pre-acquisition liabilities recorded Gross carrying amount before accumulated amortization as of the balance sheet date of an asset comprised of customer information recorded during the period. Customer lists recorded Customer Lists, net David Lieberman who serves on the board of directors (who collectively have responsibility for governing the entity). Director David Lieberman [Member] Director - Edgar Rios [Member] The engagement of consultant to assist the Company. Consultant [Member] Consultant Managed by Director - Edgar Rios [Member] Refers to the president of an entity under the control of the same parent as another entity (that is, a sister company) and his/her spouse. President of Subsidiary of Common Parent and Spouse [Member] President of LET and His Spouse [Member] A period over which the holder of the warrant has the right to buy more shares of the same security at a certain price. Warrant, Term Term of warrant Number of shares issued on exercise of warrants. Shares issued on exercise of warrant Stock issued (in shares) Represents the term of an agreement the Company entered into. Term of agreement Term of agreement The percentage of the Company's outstanding capital stock, which the Company agreed to issue to the consultant or its designees. Outstanding Capital Stock Issuable to Consultant, Percentage Percentage of outstanding capital stock issuable to Consultant (in hundredths) The threshold percentage of the performance based stock to be issued to consultants as consideration. Performance based stock issuable, threshold, percentage Percentage of performance based stock threshold (in hundredths) The 2010 Plan was approved by the Board of Directors for officers, directors, employees and consultants of the Company. Plan 2010 [Member] 2010 Plan [Member] An employee of the entity who is neither and officer or a member of the board of directors. Non-officer Employee [Member] The number of equity programs in an equity-based payment arrangement. Number of equity programs Purchase price of common stock expressed as a percentage of its fair market value. Sharebased Compensation Arrangement by Sharebased Payment Award, Purchase Price of Common Stock, Threshold, Percent Threshold for paying more than 100 percent of fair value (in hundredths) Purchase price of common stock expressed as a percentage of its fair market value. Sharebased Compensation Arrangement by Sharebased Payment Award, Purchase Price of Common Stock For Ten Percent Shareholder, Percent Option price for ten percent shareholders as a percentage of fair market value (in hundredths) The number of grants made over the life of the plan on other than stock (or unit) options plans. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted to Date Granted to date Number of months for FGE to attain certain operating targets Number of months for FGE to attain certain operating targets Number of months for FGE to attain certain operating targets Description of the conversion terms of a debt instrument, including preferred stock, which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. Preferred Stock, Terms of Conversion Feature Terms of conversion Non-cash dividends declared and paid in preferred stock. Preferred Stock, Paid in Kind Dividends Beneficial conversion feature Sales Representation Agreement [Abstract] Sales Representation Agreement [Abstract] Initial term of Sales Representation Agreement. Initial Term of Sales Representation Agreement Initial term of sales representation agreement (in years) The amended terms of the Sales Representation Agreement. Term of Amended Sales Representation Agreement Amended term of sales representation agreement The maximum cash payout under the extended employee performance incentive plan. Maximum Cash Payout Extended Employee Performance Incentive Plan Maximum cash payment under extended performance incentive plan The maximum number of share issuable under the extended share-based employee incentive plan. Maximum Shares Issuable Under Extended Employee Incentive Maximum shares of issuable under extended performance incentive program (in shares) EX-101.PRE 10 vaso-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
RELATED-PARTY TRANSACTIONS (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended
Sep. 30, 2012
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Director - David Lieberman [Member]
Sep. 30, 2011
Director - David Lieberman [Member]
Sep. 30, 2012
Director - David Lieberman [Member]
Sep. 30, 2011
Director - David Lieberman [Member]
Sep. 30, 2012
Director - Edgar Rios [Member]
Sep. 30, 2012
Consultant Managed by Director - Edgar Rios [Member]
Mar. 31, 2012
Fast Growth Enterprises Limited (FGE) [Member]
Dec. 31, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Related Party Transaction [Line Items]                        
Term of warrant 5 years                      
Number of shares of common stock called by warrants (in shares) 4,285,714 4,285,714                    
Exercise price of warrants (in dollars per share) $ 0.08 $ 0.08                    
Stock issued (in shares)   4,285,714                    
Fees for legal services       $ 60,000 $ 30,000 $ 194,000 $ 102,000          
Term of agreement               2 years        
Percentage of outstanding capital stock issuable to Consultant (in hundredths)                 10.00%      
Percentage of performance based stock threshold (in hundredths)                 82.00%      
Restricted shares issued for consulting agreement (in shares)           600,000     3,000,000      
Restricted shares issued for consulting agreement                 1,020,000      
Consulting services                 10,000      
Unsecured notes payable assumed                       288,000
Debt repaid   190,000 0             190,000 95,000  
Interest rate (in hundredths)                   6.00%    
Receivables due from related parties   $ 159,000 $ 0                  
XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) $ 8,604 $ 1,313
Investment in certificates of deposit (included in short-term investments) 110 110
Assets 8,714 1,423
Fair Value, Inputs, Level 1 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 8,604 1,313
Investment in certificates of deposit (included in short-term investments) 110 110
Assets 8,714 1,423
Fair Value, Inputs, Level 2 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Assets 0 0
Fair Value, Inputs, Level 3 [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Assets $ 0 $ 0
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET (Tables)
 9 Months Ended
Sep. 30, 2012
INVENTORIES, NET [Abstract]  
Inventories, net of reserves
Inventories, net of reserves, consist of the following: 
 
  (in thousands) 
   
September 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Raw materials
 $1,087  $842 
Work in process
  521   528 
Finished goods
  853   1,051 
   $2,461  $2,421 
          
XML 15 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Goodwill [Roll Forward]          
Goodwill, Beginning Balance     $ 3,168,000 [1]    
Goodwill, Translation Adjustments     32,000    
Foreign currency translation     32,000    
Goodwill, Ending Balance 3,200,000   3,200,000    
Other Intangibles, net [Abstract]          
Other Intangibles, net 713,000   713,000   856,000 [2]
Customer Lists, Net [Member]
          
Other Intangibles, net [Abstract]          
Other Intangibles, net 676,000   676,000   800,000 [2]
Amortization expense 130,000 9,000 143,000 28,000  
Patents, Net [Member]
          
Other Intangibles, net [Abstract]          
Other Intangibles, net $ 37,000   $ 37,000   $ 56,000 [2]
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
[2] Retroactively adjusted to give effect to measurement period adjustment.
XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
SHARE-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2012
SHARE-BASED COMPENSATION [Abstract]  
SHARE-BASED COMPENSATION
NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 "Compensation – Stock Compensation" ("ASC 718"), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the three and nine-month periods ended September 30, 2012, the Company granted 0 and 500,000 restricted shares of common stock, valued at $120,000 to an officer, of which half vested immediately and the remainder one year thereafter. During the three months ended September 30, 2011, 100,000 shares of restricted common stock valued at $35,000 were granted to officers and directors, and 466,279 shares of restricted common stock valued at $170,500 were granted to officers and directors during the nine months ended September 30, 2011.

During the nine-month periods ended September 30, 2012 and 2011, the Company did not grant any stock options.

For the three and nine months ended September 30, 2012, the Company granted 500,000 and 2,690,000 shares of restricted common stock valued at $130,000 and $678,000 to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC Agreement in June 2012. For the three and nine months ended September 30, 2011, the Company granted 0 and 10,000 shares of restricted common stock, respectively, valued at $6,800 to other non-officer employees.
 
Share-based compensation expense recognized for the three and nine months ended September 30, 2012 was $328,000 and $559,000, respectively, and $92,000 and $295,000 for the three and nine months ended September 30, 2011, respectively. These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations. Expense for share-based arrangements was $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively, and $159,000 and $367,000 for the three and nine months ended September 30, 2011, respectively. Unrecognized expense related to existing share-based compensation and arrangements is approximately $806,000 at September 30, 2012 and will be recognized through July 2013.
 
EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C M,C%C-#4U-3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]#3TY$14Y3141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)%0T5.5$Q97TE34U5%1%]! M0T-/54Y424Y'7U!23SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%1TU%3E1?4D503U)424Y'7T%.1%]#3TY#14Y44C$\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]224537TY%5%]486)L97,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-(05)%0D%3141?0T]-4$5.4T%424].7T1E=&%I;#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ/4U-?4$527T-/34U/ M3E]32$%215]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]224537TY%5%]$971A:6QS/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=/3T1724Q,7T%.1%]/5$A%4E])3E1!3D=)0DQ%4S(\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R M:W-H965T&-E;"!8 M4"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U M-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C M,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2!);F9O2!296=I2!#96YT3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,#`P,#@S.3`X-SQS<&%N/CPO'0^ M+2TQ,BTS,3QS<&%N/CPO2!&:6QE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^9F%L'0^4V5P(#,P+`T*"0DR,#$R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T M85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q M8S0U-34W+U=O'0O:'1M;#L@8VAA'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR+#4W-SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA"!P87EA8FQE M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-34\&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2P@;F5T/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,3(\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYBF5D M.R!N:6P@3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A9&IU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@R+#4V,BD\"`H97AP96YS92D@8F5N969I=#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O<&5R871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT M,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA&5S('!A>6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@S-#0L,#`P*3QS<&%N/CPO&5R8VES92!O9B!W87)R86YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#,L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@ M;V8@;F]T97,@<&%Y86)L92!D=64@=&\@3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2`H=7-E9"!I;BD@9FEN86YC:6YG(&%C=&EV M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!A9&IU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M M=&]P.R<^)B,Q-S0[/"]F;VYT/B!E;FAA;F-E9"!E>'1E2!T96-H;F]L;V=Y(&-U2!I;F1I8V%T960@9F]R('5S92!I M;B!C87-E2`R,#$P M+"!T:&4@0V]M<&%N>2P@=&AR;W5G:"!I=',@=VAO;&QY+6]W;F5D('-U8G-I M9&EA2`H3EE313H@1T4I+"!T;R!B92!'14A# M)W,@97AC;'5S:79E('-A;&5S(')E<')E2`Q+"`R,#$P('1O(&9I=F4@ M>65A3H@ M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!A8W%U:7)E9"!&87-T($=R;W=T M:"!%;G1E2!W:&EC:"P@=&AR;W5G:"!I=',@2P@86YD('!R;V1U8W0@<&]R=&9O M;&EO+B!!;'-O(&EN(%-E<'1E;6)E2!R97-T M2!F M;W(@=&AE('-A;&5S(')E<')E2UA8W%U M:7)E9"!#:&EN97-E(&-O;7!A;FEE6QE/3-$)V1I2!B=7-I;F5S3L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6EN9R!C;VYS;VQI9&%T960@8V]N9&5N2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2=S(%1R86YS:71I;VX@4F5P;W)T(&]N($9O2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!I;G1E3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM6EN M9R!N;W1E'!E;G-E3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&UA6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!R96-O9VYI>F5S(&-O;6UI&5D(&]R(&1E=&5R;6EN86)L92!A;F0@8V]L;&5C=&%B M:6QI='D@:7,@2!A6%B;&4@=&\@ M;W5R('-A;&5S(&9O'!E;G-E('=H96X@ M=&AE(&%S'!E;G-E(&ES(')E8V]G;FEZ960@=VAE;B!T:&4@8V]R M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE.B!I=&%L:6,[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C M-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%? M-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO M8VL[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#'0M=&]P.R<^)B,Q-S0[/"]F;VYT M/B!E;FAA;F-E9"!E>'1E2P@87,@=V5L M;"!A2!A;F0@:7,@8W5R M&5C=71I;VX@;V8@=&AE M($-O;7!A;GDG2!E=F%L=6%T97,@2!C87-H(&)A;&%N8V5S("8C.#(Q,3L@87)E(')E<&]R=&5D(&EN('1H92!# M;W)P;W)A=&4@96YT:71Y(&)E;&]W+B!4:&5R92!A6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE.B!I M=&%L:6,[)SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P M.B!M961I=6T@;F]N93LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P M.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0Q-"!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SY!F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXH-#8S/"]T9#X\=&0@;F]W6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH,BPV-3D\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/"]T6QE/3-$)W=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L M;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`U.3PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW+#,R.3PO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXM/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,3,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N M=&5R.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY! MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)V)O M"!S;VQI9#LG/CQD:78@6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA'1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXX,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXV+#4S,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-C0P M/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`T-SPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,S@Q/"]T9#X\=&0@;F]W M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#,Q.#PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-2PU,S,\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXS+#$R-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PQ.3$I M/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXH,RPX.#4I/"]T9#X\=&0@;F]W6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`U.3PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW+#,R.3PO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W M6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$-R!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH,2PS.#(I/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-C8S M*3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PT,36QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXW-C,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,"PP,C,\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@ M;F]W6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`U M,B4[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T M86)L93X\+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Q M.'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I M3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SY&;W(@=&AE('1H3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W M7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`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`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM2!A;F0@=&AE(')E;6%I;F1E65A3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE65E2!I;B!C;VYJ M=6YC=&EO;B!W:71H('1H92!E>'1E;G-I;VX@;V8@=&AE($=%2$,@06=R965M M96YT(&EN($IU;F4@,C`Q,BX@1F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!G2P@=F%L=65D(&%T("0V+#@P,"!T;R!O=&AE M3H@8FQO8VL[(&UA3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UEF5D(&9O2X@ M5&AE'!E M;G-E'!E;G-E&EM871E;'D@)#@P-BPP,#`@870@4V5P=&5M8F5R M(#,P+"`R,#$R(&%N9"!W:6QL(&)E(')E8V]G;FEZ960@=&AR;W5G:"!*=6QY M(#(P,3,N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M.R!T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE'1087)T7V4X-V4R-C1A7S8R8S-?-#-E-U\X9#8X7S@P-V,R,6,T-34U-PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E.#=E,C8T85\V,F,S7S0S M93=?.&0V.%\X,#=C,C%C-#4U-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE&-L=61E9"!F6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H.B`Q M,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^)B,Q-C`[ M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U M,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXQ+#@Q M,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT2!I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#`P,#PO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#`P,#PO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T M:#H@-3(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`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`],T1N;W=R87`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`W8S(Q8S0U-34W+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1I2`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`P<'0[(&1I'0M:6YD96YT.B`P<'0[(&1I#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE'0M:6YD96YT.B`P<'0[(&1I#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXM/"]T9#X\=&0@;F]W6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@ M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T M9#X\=&0@;F]W6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE M.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX+##L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@ M8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SYN($%C=&EV M93PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D M(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R<'@@'0M M:6YD96YT.B`P<'0[(&1I'0M:6YD96YT.B`P<'0[(&1I'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&1IF4Z(#$P<'0[(&)O6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M8V5N=&5R.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/CQF;VYT('-T>6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY5;F]B6QE/3-$)V1I#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`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`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-3(E.R<^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#,Q,SPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXQ,3`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`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`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W!A9&1I M;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ+#0R,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2=S(&-A M'1087)T7V4X M-V4R-C1A7S8R8S-?-#-E-U\X9#8X7S@P-V,R,6,T-34U-PT*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X M,#=C,C%C-#4U-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H.B`Q,#`E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM65E6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,"PV.34\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SY43H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M M87)G:6XM6UE;G1S+"!A;F0@ M861J=7-T;65N=',@87)I2!R96-E:79E('5N9&5R M('1H92!'14A#($%G2!C;VUM:7-S:6]N(&%D=F%N8V5S(&UA9&4@=&\@3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C M-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%? M-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^ M/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV/CQD:78@3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@8F=C;VQO6QE.B!I M=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`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`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXU,C$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXU,C@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXR+#0R,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^ M/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE2!H860@3L@=&5X M="UI;F1E;G0Z(#,V<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD M-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X M="UI;F1E;G0Z(#,V<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA2!T:&%T(&]W;G,@2P@87,@<&5R('1H92!S=&]C:R!P=7)C:&%S92!A9W)E96UE M;G0@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`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`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@.#@E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`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`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\='(@8F=C;VQO6QE/3-$)V9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE.B!I=&%L:6,[(&9O;G0M=V5I9VAT.B!N;W)M M86P[)SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S M;VQI9#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!M87)G:6XM6QE/3-$)V9O;G0M=V5I M9VAT.B!N;W)M86P[)SY!3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O6QE/3-$ M)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M M961I=6T@;F]N93L@9F]N="UW96EG:'0Z(&YO3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI M9#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX] M,T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/"]T9#X\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR.#,\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXT-S8\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`V-"4[)SX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`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`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F'0M:6YD96YT M.B`Y<'0[('=I9'1H.B`V-"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`Y<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM'!E8W1E9"!T;R!A2=S(&%C<75I'!E8W1E9"!F=71U3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2=S($-O;G-O;&ED871E9"!#;VYD96YS960@4W1A M=&5M96YT(&]F($]P97)A=&EO;G,@86YD($-O;7!R96AE;G-I=F4@3&]S2P@9F]R('1H M92!N:6YE(&UO;G1H6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE.B!I=&%L:6,[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N M93LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N M93LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F#L@8F]R9&5R+71O<#H@ M;65D:75M(&YO;F4[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$-B!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SY.:6YE(&UO;G1H#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/"]T#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@8V]L6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU M+#3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV+#8P M-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ.2PT-C(\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,"XP,BD\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W M7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY. M3U1%($H@)B,X,C$Q.R!'3T]$5TE,3"!!3D0@3U1(15(@24Y404Y'24),15,\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2P@<'5R6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@ M8F=C;VQO3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@ M8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6EN9R!!;6]U;G0\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT#L@=&5X="UI M;F1E;G0Z(#EP=#L@=VED=&@Z(#@X)3LG/CQD:78@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#@X)3LG M/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#(P,#PO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UAF5D M(&-U6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[)SX\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[ M('=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`Y<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX M,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE3L@=&5X="UI M;F1E;G0Z(#,V<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`R.7!X.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH82D@/"]D:78^/"]T9#X\=&0@#LG/CQD:78@3L@=&5X M="UI;F1E;G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E(&%M;W5N M=&5D('1O("0Q,S`L,#`P(&%N9"`D.2PP,#`@9F]R('1H92!T:')E92!M;VYT M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T M:79E;'DL(&%N9"`D,30S+#`P,"!A;F0@)#(X+#`P,"!F;W(@=&AE(&YI;F4@ M;6]N=&AS(&5N9&5D(%-E<'1E;6)E7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE2=S(&1E9F5R3H@ M8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M M961I=6T@;F]N93LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0V('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D M(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E M>'0M:6YD96YT.B`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`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-2PQ M.3@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPV,S<\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE'1E;F1E9"!S97)V:6-E(&-O;G1R86-T6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,#PO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXR,#PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXV+#$Q-CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`Y<'0[('=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Y<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D(&%L:6=N/3-$6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH.#0P/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[('=I9'1H.B`U,B4[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Y<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXH M.#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C4\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L M:6=N/3-$6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[('=I9'1H.B`U,B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Y M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXH M,C$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D(&%L:6=N/3-$6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`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`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W!A9&1I;F'0M:6YD96YT M.B`Y<'0[('=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M,"PQ,#(\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L M;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#@Y-CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#0S,SPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=? M.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY.3U1%($P@)B,X,C$Q.R!214Q!5$5$+5!!4E19(%1204Y304-4 M24].4SPO9&EV/CQD:78@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE&5R8VES92!P2!W:71H(&]U2!I;G1O('1H M92!396-U2!A8W%U:7)E9"!,:69E($5N:&%N8V5M96YT(%1E8VAN M;VQO9WD@*$Q%5"D@*'-E92!.;W1E($DI+"!T:&4@;6%N=69A8W1U3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P M.R<^)B,Q-S0[/"]F;VYT/B!S>7-T96TN($-O;G-E<75E;G1L>2P@=&AE($1I MF5D(&)A;&%N8V4@;V8@1&5F97)R960@1&ES=')I8G5T;W(@0V]S=',@ M9'5R:6YG('1H92!S979E;B!M;VYT:',@96YD960@1&5C96UB97(@,S$L(#(P M,3$N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SLG/CQB3H@8FQO8VL[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2`D,S`L,#`P(&%N9"`D,3`R+#`P,"!W97)E(&)I M;&QE9"!B>2!T:&4@9FER;2!T:')O=6=H('1H92!T:')E92!A;F0@;FEN92!M M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q+"!R97-P96-T:79E;'DL M(&%N9"!A<'!R;WAI;6%T96QY("0V,"PP,#`@86YD("0Q.30L,#`P('=E2P@870@=VAI8V@@9&%T92!N;R!A;6]U;G1S('=E3H@8FQO8VL[(&UA2=S(&-O;G-U;'1I M;F<@86=R965M96YT("AT:&4@(D%G6QE/3-$)V1I2P@0V]N2!I M;B!T:&4@9F]L;&]W:6YG(&%R96%S.CPO9&EV/CQD:78@3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&9O;G0M M9F%M:6QY.B!4:6UE2!P87EE6QE/3-$)W=I9'1H.B`Q M,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT('-T M>6QE/3-$)W=I9'1H.B`S-G!T.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I3L@=&5X="UI;F1E M;G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM65R('1O(&9O2!F;W(@3EE(02!#;&%S6QE/3-$)W=I M9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$)W=I9'1H.B`S-G!T.R<^/&1I=B!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I3L@=&5X M="UI;F1E;G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!A6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W=I M9'1H.B`S-G!T.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I3L@=&5X="UI;F1E;G0Z(#!P=#L@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q,#`E M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT('-T>6QE M/3-$)W=I9'1H.B`S-G!T.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I3L@=&5X="UI;F1E;G0Z M(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM2!#;VYS=6QT M86YT('5N9&5R('1H92!!9W)E96UE;G0L('1H92!#;VUP86YY(&AA2P@;V8@=VAI8V@@=&AE('-U8G-T86YT:6%L M('!O2!H87,@FEN9R!T M:&4@8V]S="!R871A8FQY(&]V97(@=&AE('1W;R!Y96%R(&%GF5D('9A;'5E(&ES(')E<&]R=&5D(&%S($1E9F5R3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!A9V=R96=A=&EN9R!A<'!R;WAI;6%T96QY("0Q M,"PP,#`N/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D M:7-P;&%Y.B!B;&]C:SLG/CQB3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2=S(&%C<75I'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3L@=&5X="UI;F1E;G0Z(#!P=#L@ M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA65E2=S(&%U=&AO6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!B92!G2!B92!I2P@96ET:&5R('1H3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM2!I M;F1I=FED=6%L('-T;V-K:&]L9&5R('!OF5D(&-O;6UI='1E92P@8G5T(&EN(&YO(&5V96YT('-H86QL(&ET(&5X M8V5E9"!F:79E('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@9W)A;G0N($]P=&EO M;G,@87)E(&5X97)C:7-A8FQE('5P;VX@<&%Y;65N="!I;B!F=6QL(&]F('1H M92!E>&5R8VES92!P&5R8VES92!O9B!T:&4@;W!T:6]N+CPO9&EV/CQD:78@3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM65A2`R,#$R+"`U,#`L,#`P('-H87)E6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!F:6QE9"!A($-E MF5D(&)Y('1H92!";V%R9"!O9B!$:7)E8W1O2!T:6UE(&]N(&]R M(&%F=&5R($IA;G5A&5R8VES M92!P2!T7,@97AC965D M6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I2`Q+"`R,#$Q+B!!6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE6UE;G0@86YD(&-E87-E9"!O;B!C;VYV97)S:6]N(&]F('1H92!397)I97,@ M12!07!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!S:6=N960@;VX@36%Y(#$Y+"`R,#$P+B!4 M:&4@86UE;F1M96YT+"!E9F9E8W1I=F4@2G5L>2`Q+"`R,#$R+"!E>'1E;F1S M('1H92!I;FET:6%L('1E65A2!A8VAI979I;F<@8V5R=&%I;B!S86QE2!T;R!T:&5I3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM65A'1087)T7V4X M-V4R-C1A7S8R8S-?-#-E-U\X9#8X7S@P-V,R,6,T-34U-PT*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X M,#=C,C%C-#4U-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3L@9F]N M="US='EL93H@:71A;&EC.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2=S(&-O;G-O M;&ED871E9"!F:6YA;F-I86P@<&]S:71I;VXL(')E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T M85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q M8S0U-34W+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#'0M=&]P.R<^ M)B,Q-S0[/"]F;VYT/B!E;FAA;F-E9"!E>'1E2P@87,@=V5L;"!A2!A;F0@:7,@8W5R&5C M=71I;VX@;V8@=&AE($-O;7!A;GDG2!E=F%L=6%T M97,@2!C87-H(&)A;&%N8V5S("8C.#(Q,3L@87)E(')E<&]R M=&5D(&EN('1H92!#;W)P;W)A=&4@96YT:71Y(&)E;&]W+B!4:&5R92!A6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE.B!I=&%L:6,[)SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.R`\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S M;VQI9#LG/CQD:78@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#8S/"]T9#X\=&0@;F]W M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,BPV-3D\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`U M.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW+#,R.3PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@ M;F]W6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX,#`\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXV+#4S,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH-C0P/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M+#`T-SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,S@Q M/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXT+#,Q.#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXR-2PU,S,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#$R-#PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/"]D:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@ M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!I=&%L M:6,[)SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N M=&5R.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY!#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQTF4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXH,2PQ.3$I/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RPX.#4I/"]T9#X\=&0@ M;F]W6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ+#`U.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXW+#,R.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM M/"]T9#X\=&0@;F]W6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$-R!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W M6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PS.#(I/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH-C8S*3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH M,2PT,36QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-C,\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ,"PP,C,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXM/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE M/3-$)W=I9'1H.B`U,B4[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA&-L=61E9"!F3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI M9#LG/CQD:78@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#@Q,#PO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4P,#PO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W M6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W M6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B M;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T M86)L93X\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE M.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8V5L;'!A9&1I;F<] M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([(&9O;G0M6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S M;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&1I'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@'0M:6YD M96YT.B`P<'0[(&1I'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA2!M87)K970@9G5N9',@*&EN8VQU9&5D M(&EN(&-A6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A M9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3`\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SY3:6=N:69I8V%N="`\+V9O;G0^/&1I=B!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY);G!U=',\+V1I M=CX\9&EV('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`U,B4[(&1I6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!M87)K970@ M9G5N9',@*&EN8VQU9&5D(&EN(&-A6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@ M;F]W6QE/3-$)W=I9'1H.B`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`\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`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`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CPO=&%B;&4^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C M,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V M-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE2=S(&%C8V]U;G1S(&%N9"!O=&AE3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W!A9&1I;F3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG M/CQD:78@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M,"PS-#D\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,C4\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,C$\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R!M87)G:6XM'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H M.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\='(@8F=C;VQO6QE.B!I=&%L:6,[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`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`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXU,C$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXU,C@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXR+#0R,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L M;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3L@=&5X="UI M;F1E;G0Z(#,V<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6EN9R!#;VYS M;VQI9&%T960@0V]N9&5N3L@=&5X M="UI;F1E;G0Z(#,V<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.#@E.R<^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X="UI;F1E;G0Z(#EP=#L@ M=VED=&@Z(#@X)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#DW.3PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\'0^/&1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM2!A9&IU2!E65AF5S('1H M92!E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R(&)G8V]L;W(],T1W:&ET M93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&)O#L@8F]R9&5R+71O<#H@;65D:75M M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XMF4Z(#$P<'0[(&)O'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!M87)G:6XM#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93L@9F]N="UW M96EG:'0Z(&YO3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O M"!S;VQI9#L@8F]R9&5R+71O<#H@;65D M:75M(&YO;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93L@9F]N M="UW96EG:'0Z(&YO'0M:6YD96YT.B`P<'0[ M(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W=I9'1H.B`V-"4[)SX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`V-"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`V-"4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXS,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXS,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C0E.R<^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#$W-3PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-C0E.R<^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`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`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O6QE.B!I=&%L:6,[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.R`\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO M=&0^/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.:6YE(&UO;G1H M#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I M=6T@;F]N93LG/B8C,38P.SPO=&0^/"]T#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV+#8P-3PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ.2PT-C(\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/CQT9"!A;&EG;CTS1')I9VAT M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,"XP,BD\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V M86QI9VX],T1B;W1T;VT@7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE2P@<'5R6QE M/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@8F=C;VQO3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@;65D:75M(&YO M;F4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6EN9R!!;6]U;G0\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#L@=&5X="UI;F1E;G0Z(#EP=#L@=VED=&@Z(#@X M)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M#L@=VED=&@Z(#@X)3LG/CQD:78@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXS+#(P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L M93X\+V1I=CX\+V1I=CX\3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF5D(&-U6QE.B!I=&%L:6,[ M('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE.B!I=&%L M:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;3X\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[('=I9'1H.B`W-B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Y M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX,#`\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#L@=&5X="UI;F1E;G0Z M(#EP=#L@=VED=&@Z(#3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#$E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@ M,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`R.7!X.R<^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH82D@/"]D:78^/"]T9#X\=&0@#LG/CQD:78@3L@=&5X="UI;F1E;G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T85\V M,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U M-34W+U=O'0O:'1M;#L@8VAA'0^/&1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M M87)G:6XM3H@8FQO8VL[)SX\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@ M,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B M;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P.SPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O M6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M M=&]P.B!M961I=6T@;F]N93LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/B8C,38P M.SPO=&0^/"]T#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S M;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,2PS-C`\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET M93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6EN9&5N=#H@.7!T.R!W:61T:#H@-3(E.R<^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XMF4Z(#$P<'0[)SXR.#@\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXR-#`\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXY.#<\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXY-C@\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R!M87)G:6XM3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,#PO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-3PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[('=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`Y<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXT+#DT,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE'1E;F1E9"!S97)V:6-E(&-O;G1R86-T6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C8Y/"]T9#X\=&0@ M;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C,\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-C0\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$ M6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S M;VQI9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@6QE/3-$)W=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXQ-"PY.3@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ,RPT-S4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXQ-"PY.3@\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,RPT-S4\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT#L@=&5X="UI;F1E;G0Z(#EP=#L@ M=VED=&@Z(#4R)3LG/CQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,"PP-#(\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A9&IU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C@L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,2!Y96%R M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT M($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA&-L=61E9"!F&-L=61E9"!F2!)&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U M-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C M,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C M-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%? M-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!2 M97!O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A M;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I;G1E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T M85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q M8S0U-34W+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!A9&IU3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S M93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA?.#`W8S(Q8S0U-34W+U=O M'0O:'1M M;#L@8VAA'1E;F1E M9"!397)V:6-E($-O;G1R86-T'1E;F1E9"!397)V:6-E($-O M;G1R86-T'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!A9&IU7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!$:7)E8W1O2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E M.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C,C%C-#4U-3<-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93@W93(V-&%?-C)C,U\T,V4W7SAD-CA? M.#`W8S(Q8S0U-34W+U=O'0O:'1M;#L@8VAA2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE M($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`Q+"`R,#$Q+"!A M="!T:&4@=&AE;B!E9F9E8W1I=F4@87!P;&EC86)L92!C;VYV97)S:6]N(')A M=&EO+"!I9BP@870@86YY('1I;64@9F]L;&]W:6YG('1H92!)'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M65A&EM=6T@&UL/@T* M+2TM+2TM/5].97AT4&%R=%]E.#=E,C8T85\V,F,S7S0S93=?.&0V.%\X,#=C ,,C%C-#4U-3 XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PLAN OF OPERATIONS (Details)
Sep. 30, 2012
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products 48
Number of Chinese operating companies acquired 2
Number of wholly-owned subsidiaries 3
XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE (Tables)
 9 Months Ended
Sep. 30, 2012
DEFERRED REVENUE [Abstract]  
Changes in deferred revenues
The changes in the Company's deferred revenues are as follows:
 
  (in thousands) 
   For the three months ended September 30,   For the nine months ended September 30, 
   
2012
  
2011
  
2012
  
2011
 
   
(unaudited)
  
(unaudited)
  
(unaudited)
  
(unaudited)
 
Deferred revenue at the beginning of the period
 $15,198  $11,360  $15,228  $12,637 
Additions:
                
Deferred extended service contracts
  288   240   987   968 
Deferred in-service and training
  13   10   33   28 
Deferred service arrangements
  20   20   75   65 
Deferred commission revenues
  2,037   4,941   6,116   9,085 
Recognized as revenue:
                
Deferred extended service contracts
  (283)  (269)  (840)  (872)
Deferred in-service and training
  (10)  (8)  (25)  (23)
Deferred service arrangements
  (22)  (21)  (64)  (55)
Deferred commission revenues
  (2,243)  (2,798)  (6,512)  (8,358)
Deferred revenue at end of period
  14,998   13,475   14,998   13,475 
Less: current portion
  10,102   10,042   10,102   10,042 
Long-term deferred revenue at end of period
 $4,896  $3,433  $4,896  $3,433 
 
XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Sep. 30, 2012
GE Healthcare [Member]
Sep. 30, 2011
GE Healthcare [Member]
Sep. 30, 2012
GE Healthcare [Member]
Sep. 30, 2011
GE Healthcare [Member]
Sep. 30, 2012
GE Healthcare [Member]
Accounts and Other Receivables [Member]
Customer Concentration Risk [Member]
Dec. 31, 2011
GE Healthcare [Member]
Accounts and Other Receivables [Member]
Customer Concentration Risk [Member]
Sep. 30, 2012
Equipment Segment [Member]
Sep. 30, 2011
Equipment Segment [Member]
Sep. 30, 2012
Equipment Segment [Member]
Sep. 30, 2011
Equipment Segment [Member]
Sep. 30, 2012
Corporate [Member]
Sep. 30, 2011
Corporate [Member]
Sep. 30, 2012
Corporate [Member]
Sep. 30, 2011
Corporate [Member]
Sep. 30, 2012
Sales Representation Segment [Member]
Sep. 30, 2011
Sales Representation Segment [Member]
Sep. 30, 2012
Sales Representation Segment [Member]
Sep. 30, 2011
Sales Representation Segment [Member]
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]                                              
Number of segments     2                                        
Segment Reporting Information [Line Items]                                              
Revenues from external customers $ 5,722 $ 6,530 $ 19,462 $ 16,550               $ 1,063 $ 800 $ 4,604 $ 3,005 $ 0 $ 0 $ 0 $ 0 $ 4,659 $ 5,730 $ 14,858 $ 13,545
Operating income/(loss) (2,659) 26 (3,885) (1,417)               (838) (640) (1,191) (1,382) (463) (381) (1,221) (663) (1,358) 1,047 (1,473) 628
Total assets 29,509 25,533 29,509 25,533 34,335 [1]             8,595 8,810 8,595 8,810 9,595 4,318 9,595 4,318 11,319 12,405 11,319 12,405
Accounts and other receivables, net 8,388 10,023 8,388 10,023 20,695 [1]         7,200 19,700 1,059 763 1,059 763 0 0 0 0 7,329 9,260 7,329 9,260
Deferred commission expense 3,635 3,124 3,635 3,124               0 0 0 0 0 0 0 0 3,635 3,124 3,635 3,124
Revenue, Major Customer [Line Items]                                              
Percentage of revenue (in hundredths)           81.00% 88.00% 76.00% 82.00%                            
Concentration Risk [Line Items]                                              
Accounts and other receivables $ 8,388 $ 10,023 $ 8,388 $ 10,023 $ 20,695 [1]         $ 7,200 $ 19,700 $ 1,059 $ 763 $ 1,059 $ 763 $ 0 $ 0 $ 0 $ 0 $ 7,329 $ 9,260 $ 7,329 $ 9,260
Percentage of accounts and other receivables (in hundredths)                   86.00% 95.00%                        
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
SHARE-BASED COMPENSATION (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Remainder of vesting period     1 year  
Share-based compensation expense     $ 559,000 $ 295,000
Unrecognized expense related to existing share-based arrangements 806,000   806,000  
Restricted Stock [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 500,000 0 2,690,000 10,000
Value of stock granted 130,000   678,000 6,800
Share-based compensation expense 328,000 92,000 559,000 295,000
Restricted Stock [Member] | Officer [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 0   500,000  
Value of stock granted     120,000  
Restricted Stock [Member] | Director [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)   100,000   466,279
Value of stock granted   35,000   170,500
Remainder of vesting period     1 year  
Stock Compensation Plan [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated share-based arrangements $ 128,000 $ 159,000 $ 416,000 $ 367,000
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS
 9 Months Ended
Sep. 30, 2012
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
SEGMENT REPORTING AND CONCENTRATIONS
NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:
 
  (in thousands) 
    As of or for the three months ended September 30, 2012 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,063  $4,659  $-  $5,722 
Operating loss
 $(838) $(1,358) $(463) $(2,659)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $7,329  $-  $8,388 
Deferred commission expense
 $-  $3,635  $-  $3,635 
                  
                 
     As of or for the three months ended September 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $800  $5,730  $-  $6,530 
Operating income/(loss)
 $(640) $1,047  $(381) $26 
Total assets
 $8,810  $12,405  $4,318  $25,533 
Accounts and other receivables, net
 $763  $9,260  $-  $10,023 
Deferred commission expense
 $-  $3,124  $-  $3,124 
                  

 
  (in thousands) 
   As of or for the nine months ended September 30, 2012 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,604  $14,858  $-  $19,462 
Operating loss
 $(1,191) $(1,473) $(1,221) $(3,885)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $7,329  $-  $8,388 
Deferred commission expense
 $-  $3,635  $-  $3,635 
                  
           
   As of or for the nine months ended September 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $3,005  $13,545  $-  $16,550 
Operating income/(loss)
 $(1,382) $628  $(663) $(1,417)
Total assets
 $8,810  $12,405  $4,318  $25,533 
Accounts and other receivables, net
 $763  $9,260  $-  $10,023 
Deferred commission expense
 $-  $3,124  $-  $3,124 
                  
 
For the three months ended September 30, 2012 and 2011, GE Healthcare accounted for 81% and 88% of revenue, respectively. For the nine months ended September 30, 2012 and 2011, GE Healthcare accounted for 76% and 82% of revenue, respectively. Also, GE Healthcare accounted for $7.2 million, or 86%, and $19.7 million, or 95%, of accounts and other receivables at September 30, 2012 and December 31, 2011, respectively.
XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
LOSS PER COMMON SHARE (Details)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 6,570 12,499 6,570 12,499
Stock Options [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 1,810 1,810 1,810 1,810
Warrant [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 1,500 5,786 1,500 5,786
Contingently Issuable Shares [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 0 2,000 0 2,000
Common Stock Grants [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 3,260 2,903 3,260 2,903
XML 24 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Sep. 30, 2012
Series E Convertible Preferred Stock [Member]
Sep. 30, 2011
Series E Convertible Preferred Stock [Member]
Sep. 30, 2012
Series E Convertible Preferred Stock [Member]
Sep. 30, 2011
Series E Convertible Preferred Stock [Member]
Jun. 30, 2010
Series E Convertible Preferred Stock [Member]
Sep. 30, 2012
Preferred Stock [Member]
Sep. 30, 2011
Preferred Stock [Member]
Jun. 30, 2010
Preferred Stock [Member]
Sep. 30, 2012
Restricted Stock [Member]
Sep. 30, 2012
Warrant [Member]
Sep. 30, 2012
Non-officer Employee [Member]
Restricted Stock [Member]
Sep. 30, 2012
2010 Plan [Member]
Jun. 30, 2010
2010 Plan [Member]
Sep. 30, 2012
2010 Plan [Member]
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                    
Number of shares authorized (in shares)                                 5,000,000  
Number of equity programs                               2    
Option price as a percentage of fair market value (in hundredths)                               100.00%    
Threshold for paying more than 100 percent of fair value (in hundredths)                               10.00%    
Option price for ten percent shareholders as a percentage of fair market value (in hundredths)                               110.00%    
Terms of award (in years)                               5Y    
Granted to date                                   3,790,000
Granted during period (in shares)                             2,190,000     500,000
Forfeited (in shares)                         840,000     185,500    
Vested (in shares)                         250,000          
Issued (in shares)         0 0   9,375   9,375     5,000,000 1,500,000        
Share Price (dollar per share)   $ 0.50             $ 0.16                  
Vesting Period   1 year                                
Number of shares of common stock contingently issuable (in shares)   2,400,000                                
Aggregate value relative to the acquisition   $ 2,979,000                                
Number of months for FGE to attain certain operating targets   12 months                                
Class of Stock [Line Items]                                    
Preferred stock authorized (in shares)   1,000,000   1,000,000         350,000     1,000,000            
Shares Issued upon conversion (in shares)                 100                  
Share Price   $ 0.50             $ 0.16                  
Shares sold (in shares)         0 0   9,375   9,375     5,000,000 1,500,000        
Aggregate value of shares sold               150,000                    
Dividends recorded           1,180,000         1,459,000              
Common stock issued upon conversion of Series E preferred shares (in shares)   162,917,996   153,186,295 30,668,500   30,668,500                      
Shares issued (in shares)             306,685                      
Terms of conversion   Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.                                
Beneficial conversion feature $ 1,180,000   $ 1,336,000                              
XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 9,691 $ 2,294 [1]
Short-term investments 110 110 [1]
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,086 at September 30, 2012 and $2,163 at December 31, 2011 8,388 20,695 [1]
Receivables due from related parties 41 196 [1]
Inventories, net 2,461 2,421 [1]
Financing receivables, net 21 19 [1]
Deferred commission expense 2,577 2,053 [1]
Deferred related party consulting expense - current portion 213 510 [1]
Other current assets 354 202 [1]
Total current assets 23,856 28,500 [1]
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,564 at September 30, 2012 and $1,774 at December 31, 2011 628 429 [1]
GOODWILL 3,200 3,168 [1]
FINANCING RECEIVABLES, net 0 16 [1]
DEFERRED RELATED PARTY CONSULTING EXPENSE 0 85 [1]
OTHER ASSETS, NET 1,825 2,137 [1]
Total Assets 29,509 34,335 [1]
CURRENT LIABILITIES    
Accounts payable 312 273 [1]
Accrued commissions 1,944 3,889 [1]
Accrued expenses and other liabilities 3,334 2,560 [1]
Sales tax payable 355 355 [1]
Income taxes payable (37) 278 [1]
Deferred revenue - current portion 10,102 9,484 [1]
Deferred gain on sale-leaseback of building - current portion 0 31 [1]
Deferred tax liability, net 112 112 [1]
Notes payable due to related party 3 193 [1]
Total current liabilities 16,125 17,175 [1]
LONG-TERM LIABILITIES    
Deferred revenue 4,896 5,743 [1]
Other long-term liabilities 127 141 [1]
Total long-term liabilities 5,023 5,884 [1]
COMMITMENTS AND CONTINGENCIES (NOTE N)       [1]
STOCKHOLDERS' EQUITY    
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2012, and December 31, 2011 0 0 [1]
Common stock, $.001 par value; 250,000,000 shares authorized; 162,917,996 and 153,186,295 shares issued and outstanding at September 30, 2012 and December 31, 2011 163 153 [1]
Additional paid-in capital 60,993 60,188 [1]
Accumulated deficit (52,823) (49,065) [1]
Accumulated other comprehensive income (loss) 28 0 [1]
Total stockholders' equity 8,361 11,276 [1]
Total liabilities and stockholders' equity $ 29,509 $ 34,335 [1]
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PLAN OF OPERATIONS
 9 Months Ended
Sep. 30, 2012
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS
 
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to "we", "our", "us", "Company", "registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure ("CHF"), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC's exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement ("GEHC Agreement") extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which, through its subsidiaries, owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. and Biox Instruments Co. Ltd., respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company's recently-acquired Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment. VasoHealthcare activities are included under our Sales Representation reportable segment (See Note C).
 
XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET (Details) (USD $)
Sep. 30, 2012
Dec. 31, 2011
INVENTORIES, NET [Abstract]    
Raw materials $ 1,087,000 $ 842,000
Work in process 521,000 528,000
Finished goods 853,000 1,051,000
Inventories, net 2,461,000 2,421,000 [1]
Reserves for excess and obsolete inventory $ 540,000 $ 606,000
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
LOSS PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2012
LOSS PER COMMON SHARE [Abstract]  
Antidilutive common stock equivalents excluded from computation of diluted earnings per share
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
 
  (in thousands) 
   For the three months ended  For the nine months ended 
   
September 30, 2012
  
September 30, 2011
  
September 30, 2012
  
September 30, 2011
 
Stock options
  1,810   1,810   1,810   1,810 
Warrants
  1,500   5,786   1,500   5,786 
Contingently issuable shares
  -   2,000   -   2,000 
Common stock grants
  3,260   2,903   3,260   2,903 
    6,570   12,499   6,570   12,499 
XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Sep. 02, 2011
Business Acquisition [Line Items]          
Number of shares of common stock issued relating to acquisition (in shares)     2.4    
Fair values of assets acquired and liabilities assumed [Abstract]          
Cash and cash equivalents         $ 442,000
Accounts receivable and other current assets         283,000
Inventories         476,000
Property and equipment         32,000
Customer lists         800,000
Accounts payable and other current liabilities         (1,222,000)
Net assets acquired         3,979,000
Revenue 5,722,000 6,530,000 19,462,000 16,549,000  
Net loss (2,518,000) 64,000 (3,806,000) (1,358,000)  
As Initially Reported [Member]
          
Fair values of assets acquired and liabilities assumed [Abstract]          
Cash and cash equivalents         442,000
Accounts receivable and other current assets         591,000
Inventories         670,000
Property and equipment         32,000
Goodwill         3,175,000
Customer lists         0
Accounts payable and other current liabilities         (931,000)
Net assets acquired         3,979,000
Measurement Period Adjustments [Member]
          
Fair values of assets acquired and liabilities assumed [Abstract]          
Cash and cash equivalents         0
Accounts receivable and other current assets         (308,000)
Inventories         (194,000)
Property and equipment         0
Goodwill         (7,000)
Customer lists         800,000
Accounts payable and other current liabilities         (291,000)
Net assets acquired         0
As Adjusted [Member]
          
Fair values of assets acquired and liabilities assumed [Abstract]          
Cash and cash equivalents         442,000
Accounts receivable and other current assets         283,000
Inventories         476,000
Property and equipment         32,000
Goodwill         3,168,000
Customer lists         800,000
Accounts payable and other current liabilities         (1,222,000)
Net assets acquired         3,979,000
Restricted Stock [Member]
          
Business Acquisition [Line Items]          
Number of shares of common stock issued relating to acquisition (in shares)     5.0    
Common Stock [Member]
          
Acquisition date fair value of total consideration transferred [Abstract]          
Share price (in dollars per share) $ 0.42   $ 0.42    
Warrant [Member]
          
Business Acquisition [Line Items]          
Number of shares of common stock issued relating to acquisition (in shares)     1.5    
Contingent Issuance of Common Stock [Member]
          
Business Acquisition [Line Items]          
Common stock contingently issuable     2.4    
Acquisition date fair value of total consideration transferred [Abstract]          
Share price (in dollars per share) $ 0.42   $ 0.42    
Fast Growth Enterprises Limited (FGE) [Member]
          
Acquisition date fair value of total consideration transferred [Abstract]          
Cash 1,000,000   1,000,000    
Total purchase price 3,979,000   3,979,000    
Fair values of assets acquired and liabilities assumed [Abstract]          
Revenue 271,000 96,000 1,181,000    
Net loss 189,000   299,000 24,000  
Supplemental pro forma information [Abstract]          
Revenue 5,722,000 6,605,000 19,462,000 17,225,000  
Net (loss) income (2,515,000) 19,000 (3,620,000) (937,000)  
Basic and diluted loss per share (in dollars per share) $ (0.02) $ (0.01) $ (0.02) $ (0.02)  
Fast Growth Enterprises Limited (FGE) [Member] | Common Stock [Member]
          
Acquisition date fair value of total consideration transferred [Abstract]          
Equity interests issued and issuable 2,100,000   2,100,000    
Fast Growth Enterprises Limited (FGE) [Member] | Warrant [Member]
          
Acquisition date fair value of total consideration transferred [Abstract]          
Equity interests issued and issuable 304,000   304,000    
Fast Growth Enterprises Limited (FGE) [Member] | Contingent Issuance of Common Stock [Member]
          
Acquisition date fair value of total consideration transferred [Abstract]          
Equity interests issued and issuable $ 575,000   $ 575,000    
XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET (Tables)
 9 Months Ended
Sep. 30, 2012
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
Accounts and other receivables
The following table presents information regarding the Company's accounts and other receivables as of September 30, 2012 and December 31, 2011:
 
  (in thousands) 
   
September 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Trade receivables
 $10,349  $22,737 
Due from employees
  125   121 
Allowance for doubtful accounts and
        
commission adjustments
  (2,086)  (2,163)
Accounts and other receivables, net
 $8,388  $20,695 
XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2012
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Transition Report on Form 10-K for the transition period ended December 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Transition Report on Form 10-K for the seven months ended December 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.
 
Revenue and Expense Recognition for VasoHealthcare

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the Consolidated Balance Sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.
 
XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
CURRENT ASSETS    
Accounts and other receivables, allowance for doubtful accounts and commission adjustments $ 2,086 $ 2,163
PROPERTY AND EQUIPMENT, accumulated depreciation $ 1,564 $ 1,774
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 162,917,996 153,186,295
Common stock, shares outstanding (in shares) 162,917,996 153,186,295
XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
RELATED-PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2012
RELATED-PARTY TRANSACTIONS [Abstract]  
RELATED-PARTY TRANSACTIONS
NOTE L – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. ("Kerns"). Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns. In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock. Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation ("Living Data"), an affiliate of Kerns. Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012. Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note I), the manufacturer of the AngioNew EECP® system. Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs during the seven months ended December 31, 2011.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company. Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board. He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company. Fees of approximately $30,000 and $102,000 were billed by the firm through the three and nine months ended September 30, 2011, respectively, and approximately $60,000 and $194,000 were billed by the firm through the three and nine months ended September 30, 2012, respectively, at which date no amounts were outstanding.
 
Mr. Rios is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement (the "Agreement") with Edgary Consultants, LLC ("Consultant"). The Agreement commenced on March 1, 2011 and runs for a two year term. The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy. More specifically, Consultant will be assisting the Company in the following areas:
 
1.  
Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2.  
Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3.  
Engaging final approval from the Centers for Medicare and Medicaid Services ("CMS") of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011. In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares. The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement. The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of September 30, 2012 and December 31, 2011.

During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company's acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012. In addition, receivables due from FGE management aggregating $159,000 were collected during the nine months ended September 30, 2012.
XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
 9 Months Ended
Sep. 30, 2012
Nov. 15, 2012
Document and Entity Information [Abstract]    
Entity Registrant Name VASOMEDICAL, INC  
Entity Central Index Key 0000839087  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   162,917,996
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q3  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2012  
XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2012
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
NOTE M – STOCKHOLDERS' EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the "2010 Plan") for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

As of September 30, 2012, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of September 30, 2012, 840,000 shares have been forfeited. In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 vested immediately with the remainder vesting over a one year period. In June 2012, 2,190,000 additional shares, vesting at various times through July 1, 2013, of restricted common stock were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 185,500 shares had been forfeited as of September 30, 2012. In July 2012, 500,000 shares of restricted common stock were granted to non-officer employees, of which 250,000 vest in June 2013 and the remainder in June 2014.
 
No options were issued under the 2010 Plan during the nine months ended September 30, 2012 and 2011.
 
In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE. In addition, 2,400,000 shares of common stock were issued, under the terms of the purchase agreement, in September 2012 to former owners of FGE for attaining certain operating targets for the twelve months ending December 31, 2011. The aggregate value of the aforementioned noncash consideration relative to the FGE acquisition, recorded as of the September 2, 2011 acquisition date, was $2,979,000 (see Note I).
 
Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock ("Certificate of Designations"), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock ("Series E Preferred"). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the "Conversion Price"), subject to anti-dilution adjustment as set forth below. Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.

Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011. As of September 30, 2012, 30,668,500 shares of common stock had been issued for 306,685 shares of Series E Preferred.

For the three and nine months ended September 30, 2011, the Company sold 0 and 9,375 shares of Series E Preferred aggregating $150,000, and recorded dividends totaling $1,180,000 and $1,459,000, respectively. Included in such dividends is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,180,000 and $1,336,000 for the three and nine months ended September 30, 2011, respectively. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.
XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenues        
Equipment sales $ 688 $ 410 $ 3,197 $ 1,495
Equipment rentals and services 375 390 1,407 1,509
Commissions 4,659 5,730 14,858 13,545
Total revenues 5,722 6,530 19,462 16,549
Cost of revenues        
Cost of sales, equipment 282 200 1,304 949
Cost of equipment rentals and services 148 157 699 635
Cost of commissions 1,229 1,454 3,685 3,503
Total cost of revenues 1,659 1,811 5,688 5,087
Gross profit 4,063 4,719 13,774 11,462
Operating expenses        
Selling, general and administrative 6,591 4,553 17,256 12,497
Research and development 131 140 403 382
Total operating expenses 6,722 4,693 17,659 12,879
Operating (loss) income (2,659) 26 (3,885) (1,417)
Other income (expenses)        
Interest and financing costs 0 (3) (3) (28)
Interest and other income, net 93 33 123 51
Amortization of deferred gain on sale-leaseback of building 4 13 31 40
Total other income (expenses), net 97 43 151 63
(Loss) income before income taxes (2,562) 69 (3,734) (1,354)
Income tax (expense) benefit 44 (5) (72) (4)
Net (loss) income (2,518) 64 (3,806) (1,358)
Preferred stock dividends 0 (1,180) 0 (1,459)
Net (loss) income applicable to common stockholders (2,518) (1,116) (3,806) (2,817)
Other comprehensive income (loss)        
Foreign currency translation gain 30 2 29 2
Comprehensive loss $ (2,488) $ (1,114) $ (3,777) $ (2,815)
Loss per common share        
- basic and diluted (in dollars per share) $ (0.02) $ (0.01) $ (0.02) $ (0.02)
Weighted average common shares outstanding        
- basic and diluted (in shares) 159,018 149,524 157,162 126,023
XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET
 9 Months Ended
Sep. 30, 2012
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
ACCOUNTS AND OTHER RECEIVABLES, NET
NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company's accounts and other receivables as of September 30, 2012 and December 31, 2011:
 
  (in thousands) 
   
September 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Trade receivables
 $10,349  $22,737 
Due from employees
  125   121 
Allowance for doubtful accounts and
        
commission adjustments
  (2,086)  (2,163)
Accounts and other receivables, net
 $8,388  $20,695 
 
Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
 
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.

 
XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2012
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS

NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 "Fair Value Measurements and Disclosures" ("ASC 820"). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.
 
The following tables present information about the Company's assets and liabilities measured at fair value as of September 30, 2012 and December 31, 2011:
  (in thousands) 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
  
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
  
Balance
as of
September 30, 2012
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $8,604  $-  $-  $8,604 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $8,714  $-  $-  $8,714 
                  
                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
 
Significant
Other
Observable
Inputs
(Level 2)
 Significant
Unobservable
Inputs
(Level 3)
  
Balance
as of
December 31,
2011
 
Assets                
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $1,313  $-  $-  $1,313 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $1,423  $-  $-  $1,423 
                  

The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2012
FAIR VALUE MEASUREMENTS [Abstract]  
Assets and liabilities measured at fair value
The following tables present information about the Company's assets and liabilities measured at fair value as of September 30, 2012 and December 31, 2011:
  (in thousands) 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
  
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
  
Balance
as of
September 30, 2012
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $8,604  $-  $-  $8,604 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $8,714  $-  $-  $8,714 
                  
                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
 
Significant
Other
Observable
Inputs
(Level 2)
 Significant
Unobservable
Inputs
(Level 3)
  
Balance
as of
December 31,
2011
 
Assets                
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $1,313  $-  $-  $1,313 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $1,423  $-  $-  $1,423 
                  
XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2012
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

In conjunction with the extension of the GEHC Agreement, the Company granted VasoHealthcare employees both stock and cash-based performance incentives for the ensuing year. The incentives provide for cash payments of up to $2.2 million and 2.2 million shares of restricted common stock grants and vest at various times through July 1, 2013. A condition of the incentives is that the employees remain continuously employed through the vesting dates. As of September 30, 2012, approximately $1.3 million and 1.3 million shares remain unvested.
XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES
 9 Months Ended
Sep. 30, 2012
GOODWILL AND OTHER INTANGIBLES [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE J – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,200,000 and $3,168,000 (retroactively adjusted to give effect to measurement period adjustment) was recorded on the Company's Consolidated Condensed Balance Sheets at September 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company's Equipment segment. The components of the change in goodwill are as follows:
 
   
Carrying Amount
 
     
Balance at December 31, 2011
 $3,168 
Foreign currency translation
  32 
Balance at September 30, 2012
 $3,200 
 
The Company's other intangible assets consist of capitalized customer lists and patent costs, as follows:
  (in thousands) 
   
September 30, 2012
  
December 31, 2011 (a)
 
Other intangibles, net
 
(unaudited)
    
Customer lists, net
 $676  $800 
Patents, net
  37   56 
   $713  $856 
(a)
Retroactively adjusted to give effect to measurement period adjustment.

Patents and customer lists are included in other assets in the accompanying Consolidated Condensed Balance Sheets and customer lists are amortized on a straight line basis over their estimated useful life of seven years. The useful life was estimated based on the length of time the customer is expected to remain active. Amortization expense amounted to $130,000 and $9,000 for the three months ended September 30, 2012 and 2011, respectively, and $143,000 and $28,000 for the nine months ended September 30, 2012 and 2011, respectively.
XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORIES, NET
 9 Months Ended
Sep. 30, 2012
INVENTORIES, NET [Abstract]  
INVENTORIES, NET
NOTE H – INVENTORIES, NET

Inventories, net of reserves, consist of the following: 
 
  (in thousands) 
   
September 30, 2012
  
December 31, 2011
 
   
(unaudited)
    
Raw materials
 $1,087  $842 
Work in process
  521   528 
Finished goods
  853   1,051 
   $2,461  $2,421 
          

At September 30, 2012 and December 31, 2011, the Company had reserves for excess and obsolete inventory of $540,000 and $606,000, respectively.
 
XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION
 9 Months Ended
Sep. 30, 2012
BUSINESS COMBINATION [Abstract]  
BUSINESS COMBINATION
NOTE I– BUSINESS COMBINATION

On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited ("FGE"), a British Virgin Islands company that owns subsidiaries which own and control Life Enhancement Technology Ltd ("LET") and Biox Instruments Co. Ltd. ("Biox"), respectively, as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition included a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock. The Company completed its evaluation of FGE's calendar year 2011 performance targets and determined that the targets were met, resulting in the issuance of 2.4 million shares to the prior owners in September 2012.

LET, based in Foshan, Guangdong, China, is Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a developer and manufacturer of ambulatory monitoring devices, is located in Wuxi, Jiangsu, China, and is Vasomedical's supplier of the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States. The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which has significantly increased gross margins and will enable the Company to meet anticipated increasing demand for its EECP systems. The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, has improved performance and profitability of Vasomedical's equipment segment.

The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the three and nine months ended September 30, 2012. The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
  (in thousands) 
Cash
 $1,000 
Vasomedical, Inc. common stock ($0.42 per share)
  2,100 
Vasomedical, Inc. warrants to purchase common stock
  304 
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
  575 
Total purchase price
 $3,979 

In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date). The purchase price was allocated based on the information available as of the acquisition date, and subsequently adjusted (measurement period adjustments) after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The measurement period adjustments were completed during the quarter ended September 30, 2012 (within a year of the acquisition date). The accompanying Consolidated Condensed Balance Sheet as of December 31, 2011 has been retroactively adjusted to include the effect of the measurement period adjustment. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
 
   (in thousands) 
 
 
As initially reported
  
Measurement period adjustments
  
 
As adjusted
 
Cash and cash equivalents
 $442  $-  $442 
Accounts receivable and other current assets
  591   (308)  283 
Inventories
  670   (194)  476 
Property and equipment
  32   -   32 
Goodwill
  3,175   (7)  3,168 
Customer lists
  -   800   800 
Accounts payable and other current liabilites
  (931)  (291)  (1,222)
Net assets acquired
 $3,979  $-  $3,979 
 
The goodwill is attributable to the synergies expected to arise after the Company's acquisition of FGE as well as FGE's projected growth and profitability. The goodwill is not expected to be deductible for tax purposes. Customer lists were valued based on sales history of certain recurring customers and the timing of expected future revenues.

After elimination of intercompany transactions, which reduce the income from FGE, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2012 was $271,000 and $189,000, respectively, and $1,181,000 and $299,000, respectively, for the nine months ended September 30, 2012. For the three and nine months ended September 30, 2011, the amounts of revenue and net loss of FGE included in the Company's Consolidated Condensed Statement of Operations and Comprehensive Income (Loss) were $96,000 and $24,000, respectively. The effect of FGE's loss on earnings per share for the three and nine months ended September 30, 2012 and September 30, 2011 was $0.00.

The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):
 
  (in thousands except per share data) 
   
Three months ended September 30,
   Nine months ended September 30, 
   
2012
  
2011
  
2012
  
2011
 
Revenue
 $5,722  $6,605  $19,462  $17,225 
                  
Net (loss) income
  (2,515)  19   (3,620)  (937)
                  
Basic and diluted (loss) earnings per share
 $(0.02) $(0.01) $(0.02) $(0.02)
 
XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE
 9 Months Ended
Sep. 30, 2012
DEFERRED REVENUE [Abstract]  
DEFERRED REVENUE
NOTE K - DEFERRED REVENUE

The changes in the Company's deferred revenues are as follows:
 
  (in thousands) 
   For the three months ended September 30,   For the nine months ended September 30, 
   
2012
  
2011
  
2012
  
2011
 
   
(unaudited)
  
(unaudited)
  
(unaudited)
  
(unaudited)
 
Deferred revenue at the beginning of the period
 $15,198  $11,360  $15,228  $12,637 
Additions:
                
Deferred extended service contracts
  288   240   987   968 
Deferred in-service and training
  13   10   33   28 
Deferred service arrangements
  20   20   75   65 
Deferred commission revenues
  2,037   4,941   6,116   9,085 
Recognized as revenue:
                
Deferred extended service contracts
  (283)  (269)  (840)  (872)
Deferred in-service and training
  (10)  (8)  (25)  (23)
Deferred service arrangements
  (22)  (21)  (64)  (55)
Deferred commission revenues
  (2,243)  (2,798)  (6,512)  (8,358)
Deferred revenue at end of period
  14,998   13,475   14,998   13,475 
Less: current portion
  10,102   10,042   10,102   10,042 
Long-term deferred revenue at end of period
 $4,896  $3,433  $4,896  $3,433 
 
XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACCOUNTS AND OTHER RECEIVABLES, NET (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]      
Trade receivables $ 10,349 $ 22,737  
Due from employees 125 121  
Allowance for doubtful accounts and commission adjustments (2,086) (2,163)  
Accounts and other receivables, net $ 8,388 $ 20,695 [1] $ 10,023
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS (Tables)
 9 Months Ended
Sep. 30, 2012
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
Summary financial information for segments
The Company views its business in two segments – the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:
 
  (in thousands) 
    As of or for the three months ended September 30, 2012 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,063  $4,659  $-  $5,722 
Operating loss
 $(838) $(1,358) $(463) $(2,659)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $7,329  $-  $8,388 
Deferred commission expense
 $-  $3,635  $-  $3,635 
                  
                 
     As of or for the three months ended September 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $800  $5,730  $-  $6,530 
Operating income/(loss)
 $(640) $1,047  $(381) $26 
Total assets
 $8,810  $12,405  $4,318  $25,533 
Accounts and other receivables, net
 $763  $9,260  $-  $10,023 
Deferred commission expense
 $-  $3,124  $-  $3,124 
                  

 
  (in thousands) 
   As of or for the nine months ended September 30, 2012 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,604  $14,858  $-  $19,462 
Operating loss
 $(1,191) $(1,473) $(1,221) $(3,885)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $7,329  $-  $8,388 
Deferred commission expense
 $-  $3,635  $-  $3,635 
                  
           
   As of or for the nine months ended September 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $3,005  $13,545  $-  $16,550 
Operating income/(loss)
 $(1,382) $628  $(663) $(1,417)
Total assets
 $8,810  $12,405  $4,318  $25,533 
Accounts and other receivables, net
 $763  $9,260  $-  $10,023 
Deferred commission expense
 $-  $3,124  $-  $3,124 
                  
XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATION (Tables)
 9 Months Ended
Sep. 30, 2012
BUSINESS COMBINATION [Abstract]  
Acquisition date fair value of total consideration transferred
The operating results of FGE are included in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) and Cash Flows for the three and nine months ended September 30, 2012. The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:
  (in thousands) 
Cash
 $1,000 
Vasomedical, Inc. common stock ($0.42 per share)
  2,100 
Vasomedical, Inc. warrants to purchase common stock
  304 
Contingent issuance of Vasomedical, Inc. common stock ($0.42 per share)
  575 
Total purchase price
 $3,979 
Fair values of assets acquired and liabilities assumed
In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date). The purchase price was allocated based on the information available as of the acquisition date, and subsequently adjusted (measurement period adjustments) after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The measurement period adjustments were completed during the quarter ended September 30, 2012 (within a year of the acquisition date). The accompanying Consolidated Condensed Balance Sheet as of December 31, 2011 has been retroactively adjusted to include the effect of the measurement period adjustment. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
 
   (in thousands) 
 
 
As initially reported
  
Measurement period adjustments
  
 
As adjusted
 
Cash and cash equivalents
 $442  $-  $442 
Accounts receivable and other current assets
  591   (308)  283 
Inventories
  670   (194)  476 
Property and equipment
  32   -   32 
Goodwill
  3,175   (7)  3,168 
Customer lists
  -   800   800 
Accounts payable and other current liabilites
  (931)  (291)  (1,222)
Net assets acquired
 $3,979  $-  $3,979 
Supplemental pro forma information
The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2009 (amounts in thousands, except per share amounts):
 
  (in thousands except per share data) 
   
Three months ended September 30,
   Nine months ended September 30, 
   
2012
  
2011
  
2012
  
2011
 
Revenue
 $5,722  $6,605  $19,462  $17,225 
                  
Net (loss) income
  (2,515)  19   (3,620)  (937)
                  
Basic and diluted (loss) earnings per share
 $(0.02) $(0.01) $(0.02) $(0.02)
XML 49 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES (Details) (USD $)
In Millions, unless otherwise specified
 9 Months Ended
Sep. 30, 2012
Sales Representation Agreement [Abstract]  
Initial term of sales representation agreement (in years) 3 years
Amended term of sales representation agreement 5 years
Maximum cash payment under extended performance incentive plan $ 2.2
Maximum shares of issuable under extended performance incentive program (in shares) 2.2
Unvested incentive plan, cash $ 1.3
Unvested shares (in shares) 1.3
XML 50 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $)
 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities    
Net loss $ (3,806,000) $ (1,358,000)
Adjustments to reconcile net loss to net cash provided by operating activities    
Depreciation and amortization 296,000 118,000
Amortization of deferred gain on sale-leaseback of building (31,000) (40,000)
Provision for doubtful accounts and commission adjustments (7,000) 15,000
Amortization of deferred distributor costs 0 177,000
Share-based compensation 559,000 295,000
Amortization of deferred consulting expense 416,000 367,000
Changes in operating assets and liabilities:    
Accounts and other receivables 12,212,000 3,516,000
Receivables due from related parties 159,000 0
Inventories, net (47,000) (804,000)
Finance receivables 14,000 13,000
Deferred commission expense (525,000) (719,000)
Other current assets (170,000) 55,000
Other assets 172,000 96,000
Accounts payable 39,000 (368,000)
Accrued commissions (1,945,000) 840,000
Accrued expenses and other liabilities 813,000 (73,000)
Sales tax payable (1,000) 45,000
Income taxes payable (315,000) 4,000
Deferred revenue (229,000) 838,000
Trade payable due to related party 0 (243,000)
Other long-term liabilities (26,000) (589,000)
Net cash provided by operating activities 7,578,000 2,185,000
Cash flows from investing activities    
Purchases of property and equipment (344,000) (21,000)
Purchases of short-term investments 0 (41,000)
Acquisition of Fast Growth Enterprises 0 (1,000,000)
Cash acquired through purchase of Fast Growth Enterprises 0 442,000
Net cash used in investing activities (344,000) (620,000)
Cash flows from financing activities    
Proceeds from exercise of warrant 343,000 0
Repayment of note payable 0 (294,000)
Repayment of notes payable due to related party (190,000) 0
Proceeds from issuance of preferred stock 0 150,000
Net cash provided by (used in) financing activities 153,000 (144,000)
Effect of exchange rate differences on cash 10,000 0
NET INCREASE IN CASH AND CASH EQUIVALENTS 7,397,000 1,421,000
Cash and cash equivalents - beginning of period 2,294,000 [1] 3,101,000
Cash and cash equivalents - end of period 9,691,000 4,522,000
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION    
Interest paid 5,000 30,000
Income taxes paid 411,000 9,000
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Inventories transferred to property and equipment, attributable to operating leases, net 8,000 93,000
Dividends Payable [Line Items]    
Common shares, warrants and contingent shares issued for aquisition 0 2,979,000
Fair value of assets acquired 291,000 4,469,000
Liabilities assumed through acquisition (291,000) (931,000)
Issuance of preferred stock in satisfaction of accrued dividend 0 224,000
Conversion of preferred stock to common stock 0 32,000
Common shares issued for consulting agreements 0 1,070,000
Preferred Stock [Member]
    
Dividends Payable [Line Items]    
Accrued preferred stock dividends $ 0 $ 1,459,000
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)
XML 51 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
LOSS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2012
LOSS PER COMMON SHARE [Abstract]  
LOSS PER COMMON SHARE
NOTE E – LOSS PER COMMON SHARE

Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2012 and 2011, because the effect of their inclusion would be anti-dilutive.
 
  (in thousands) 
   For the three months ended  For the nine months ended 
   
September 30, 2012
  
September 30, 2011
  
September 30, 2012
  
September 30, 2011
 
Stock options
  1,810   1,810   1,810   1,810 
Warrants
  1,500   5,786   1,500   5,786 
Contingently issuable shares
  -   2,000   -   2,000 
Common stock grants
  3,260   2,903   3,260   2,903 
    6,570   12,499   6,570   12,499 
XML 52 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES (Tables)
 9 Months Ended
Sep. 30, 2012
GOODWILL AND OTHER INTANGIBLES [Abstract]  
Schedule of components of change in goodwill
Goodwill aggregating $3,200,000 and $3,168,000 (retroactively adjusted to give effect to measurement period adjustment) was recorded on the Company's Consolidated Condensed Balance Sheets at September 30, 2012 and December 31, 2011, respectively, pursuant to the acquisition of FGE in September 2011. All of the goodwill was allocated to the Company's Equipment segment. The components of the change in goodwill are as follows:
 
   
Carrying Amount
 
     
Balance at December 31, 2011
 $3,168 
Foreign currency translation
  32 
Balance at September 30, 2012
 $3,200 
Schedule of other intangible assets
The Company's other intangible assets consist of capitalized customer lists and patent costs, as follows:
  (in thousands) 
   
September 30, 2012
  
December 31, 2011 (a)
 
Other intangibles, net
 
(unaudited)
    
Customer lists, net
 $676  $800 
Patents, net
  37   56 
   $713  $856 
(a)
Retroactively adjusted to give effect to measurement period adjustment.
ZIP 53 0001201800-12-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-12-000026-xbrl.zip M4$L#!!0````(``I*=$%3SHO)[+H```>O#``1`!P`=F%S;RTR,#$R,#DS,"YX M;6Q55`D``[20JU"TD*M0=7@+``$$)0X```0Y`0``[%WK<^(XMO]^J_9_T/)A M;T]52##D1::[MP@A/=2D`Q/2,SMUZU:78HN@:6.SDIV$_>OW2'YBFW<`&]3] MA5A'TGG\CLZ19,D?__DV--$+89S:UJ>2=EPI(6+IMD&MYT\EEY/`'G+;0@_$=:!OU-!U8KK\,$TERCACAA+T0 MX[A<%KV_/3$3`;,6OQ(_Z:?2P'%&5R3ZJ52NV$6MS!EDY* M/KU)K1\SR$7Q$^8A^5N*_K4FJ4&"^HDL#4DYS2*$9K63?WV]Z^D#,L3E)#^B M>R.J&.?F_,0K#$@IMT^KVL4L83V*L(+U0K@SV38G^O&S_7+BE9T("Y0K6KFF M!97`SL\8C\):?:5>J_C$B[@= MN"M"'X6?7''I`0^DCZ3?7`FS?2IQ.AR9PAWDLP$C_4\ET6\YZ.SXC1LE=.(U M)-T=#&LYY,U!U/A4TB6=5M$<.V1/TH;4Q'*H,_:?A4^I(9[W*6%(,D8FI`FT MU&S_6OI<@7^7M7KE\N+C2;)RT-5)1E]^3R/`I&TD^P?],.<&QL_/@1$J6M!* M5):H1"PC5J5>KE6BCHU8A>!IK.O@D:^[F>K4-.VL$$KT8.9X^@#L:V=AXW[) MN^BC,*":T,<$/MY3'YI6A0&C8/H`<%1AG-L,/BX*/_QEB(-?97.#7W%`-1$,-A8<90CXWG,`;T/@K6EBSCO] MGF/K/QIOE'_O0H9+8`IAR$=?R?")L!VH+W(U\BSX#!_[!0:P\38RJ4X=CT=D M4*#SE@;\J>#55"E+GP.2+'$_GF3V$'%VDL5:;K,A9?`<&GRC'CZ1[D6FOW8Y MM0CG/4\,+LW?^K=+1^)/_^F>`"!+UM)G,7&_RI9X6QC(<6*[''!ZV"3\@8S$ MVJ<%E&"'@X'0/-D5F)8$4]-F(UNLUN\U=@*RA+0*+5L]6`8X M*F;E+&85&4PJ9ATV6A*[>BIFY3=FY6S_6`HV)6SF)6D<&D8M9AHT7-KO(7J;:S=:VF1\4(-?E!@XH5>V-N M-4')];"_P1=8U`RC<,/^CM&@AOV],7?RO9&O^"^;-5WNV$/"/&M_(;\0;#H# M';."&SPMG._B:1'52R*I[5D%#;47.V471$%#;7E,66Q4T%`KBQ,K"DW;TD$< M)A/I!\I_7(^OB:4/AIAY)R0:NCR,#RFW3N@+?C)]#6;5?!R/B)>2^D9(T?AU M]QJ&\U0:Y;+3=#L/G6MR$Y@IEE3/MM=[\I-#)]WBP6SE;\K?E+]MZ>#_9%:L M/$]YWJ%[7C%F*BI0*G=5[OHNL\>)Z+K)A87&*V9&Z&8/A#N,ZLY>G*N?$"V" M9J:,Q4'&UA:J%3+4.G7V[M8"R/A^XU]8T;2'(U"_'/\;C&'K6>X5_D&=0=LR MZ`LU7&SV!C!$7V-.C"X>R[U#B"G4,4FG'Q')SCK]/M4)4_!;I=_-V"028,(X M:NLO-9-5?J/\)K=^DZLIY=*9R*;\YH8RHCNV(GN&I"KRSAE? M%4K46#)_M4BA1*V,S%\942A1JP"9>0D(95#QZ<47TB.ZRZA#"6^]Z:9K$..6 MV4.A2M<[SMKIMS"SJ/7,NX1Y6>(XNX$(,WUW$)3XZO"J\I?,_#Z!Q8KI`6_N68K4)W0E,I:MYJU M*I06!Z6'FZLJE!8'I8>;H2J4%@>EAYN7-J%O(`:]F>,VYZXX!2EKJ5G5?.#. M4Y[*7K>:O2HL[QN6#S?'55C>-RP?;B:LL+QO6#[D?'DXM*U]>'M].^!-:$ME MQ%O.B!5:BX;60\YY%5J+AM9#SFH56HN&UKSEK0*CMYBRW['I@B+#G[^`B3'3 M!^,[\D*\,VMA6=L"6W!9H!4;>(M)'F%HA@JVA:9M?@9M#6!4%3"J"A@96JDI M8-3V$1C>;;(JE!0SE&SP?O"U@:%"R0Y#29Z!H4+)#D/)%K\H(#Y'ZHS;0,0( M=\06!#$Z+-B*B-\Z'NY4P"\.5O/NL6Z:F'-A/J/!O;:*#9Q%]9&UA;.08M0Z MSNH8W*L+AI9'FKI[Z)WQM!B@4$[EO4=>=L2= M+\Q^=08MH>,1HYSP.SJDX(>WSP7_G,84H?VO1BPD^GY-M=\!"\OD5'NRR;`% M&&TZB=O1!L8>HGHOHFKA$;V3(+^':%;SWNW,>W/FG$7TB,/+.U2@7Q<(:G`K MTJ+>EK8;*_5*]7N#<^)X0RPCQAW%3]3T7OT!O0U!`_(#EKQMP4-LFN,',K(9 M#+'%A(J,'(N([`>9J8+O9+L`H%"I[A@*7PGF+I.71'=E7PWC+Y<[\E;HP\#$ M?`T<+#@:W-/%X0P/D_+NH>%W8,*\ZB-Y1$DM)>=[4I;C\T/)O2P%I6)!*4?; M6LFC:`I*!8)2OLZ))4_>*"@5"TKY.Q9#8?9,[N@+,=H6Y&'/],DD7GY]/?Z* M_[*97&KQ%JD@C[:'A-U17M299/B:X>)BQ]:BTO+OV7J3][*J@D3!(+'1UU27 M'26Z,$`5=J5I+3!,2'[H(X."P5Z.!I/K*RI4%")4Y'B9)3DW5H@J'J+R-45. M+MPI1!4/47E;O]/4&%5P1.5M[>6\5BG:OAUXV/G&7G0IH#ZTS>DCF6<'WP)_ M("_$FV)8+_J8,U]P?]5WMO@JT4XEV@I2 M!814OC-M!:D"0BK?J;:"5`$AE;=<>^E4"UOX1(>"HVF"JPQIE0Q)P2@/,"I\ M?J1@E`<8%3X[4C#*`XSRE1LE@]H#,:%IHPM,C1]!GQSKXM0FOQ['2R2<;B@C MNF.S8H-H<8&C5R4G)55.).5==T"G])_-)`2@J^+?!L MZ_+AE8<9A0CU.9[8[9++@:?G/G%J4,S&G;YWOS>4D4."4E!GMB9V,-IHF[P; MI!),T^4M(0HPA05,8AJO59:>QD]J]Q$@$V*O^:WJ0@)S-T/-(F@+7BF!M&@$ZI-?L(J] M5_('=09MRZ`OU'"QV1M`VG2-N4BRQO*5V^OQ(W5,TNE'1+*S>]LJ=_I]JA/6 M&HY,>TP*?K'W9O3D@W*JMM[3&=[3"0]BP%[>F=30O7]#=V$ANA>?6)X"OYU\ MN#C'2$B^U-ASH&4AK+SVL-.73AH<&**$M[K,CV=[\('7J<+&%H"F2[VC]>L\ MO\RHT)-[].3H)49OP5%A)G>8V6E>?GSO,+]+*R&CAR M,'#D>F:S:&ZJ\**R4163-!64Q9L7;4UKNSJE;/>'1*& M'3NU'K\P/W$%9[<8Z^Z&6/:06K,[G*?<9(_I1H/2F-R+J.UTIK5'\',Q@_R] M7&Z`-QC"(]"MB9_+9:_`(/0J+!$%R,??`^EG#E6ESWULDR)ONA M7,"0+,Q+W\ZG-A(RTY."#_B"F6?YAV:\6ZH'5;(L8J,VY2UB<(X]8T/XJ2`-* MCW`^9_>VQ]',9I*<_6Z;K@5CVQAL9Q+&T_R$%![!LGPDJB?[#Y#S0$8V>UTR2+$VO?- M.">3;:5,1L1M^29J6P9Y0[^2#/7X))("".9S$T]$IC:38D2^,(MDIG"$Y*L- M''5<1R1M!B@Y@R]90U;PR&/4:28U33LK(3&DRF#Z_0ZU2_FVR2U$OBHNZ;L.8Q!'8!-G.`!R3$9W0%_QD M$GZ$+.($?8>[O7Z5AF5T1(6'B/Z>.,$@EF9,L#.!H&H<067(D2YKEY<`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`"9FSU#KU2_2PH>-!(;NJ#`'1+#FZCP MD*&`G^67*19C3WPD]R>[>X^M$VH9_:^<5:^IFSM@UYE?V*+9V@ MOLV08;M/3M\UQ:PGJJ:',W>$H_0B2VVRI5N;W?CMI)=@UIFM5RN7:5]:N,O" MJ62A)5TMN96[FDIB=Z20YOFY4)_4B:"09D3>+DM-:$722 MC#(;U4DRM5M0)99##6JZCE@OX41WF9R=@79TTS4@.O>9/93+*J[_8HC=1[(" ME!',+&H]%CM=IS$.>B$#+;__6^B^&?7> MZ;?\/F$&+8/JE+E8*H%>KY?K<78#4;K@BYEE*2VU`GBI)4:Y]]#!WMLTE=0J MFQ;>IJF)G+)IX6V:FEPIF[Z+3?T[V/8XDD[>H#?'D&?)I51ER-R$SV4,>7:1 M7"E0ALQ-S%0>N2>!\D`\L@DJAF)B.>98'D46*VC!&D#YDWX[N/-CK.!W>H;"016NIPXS*HGD+ MQ\M9M%JOU)1%\QUOE8_N6U@]&!_=1<2M?@E"^O'*%;3!GZ'9LN03>4ZZ8MSE64HZ='J&U!HT!Y1UZ(B;3I MP4VV*&K*BE%K4^Y=""FOQ^'/7RAAF.F#L>Q,1IRPS.-#%FB+'6ZXT!*GPZ9Q MN+96JGG02G7I`T(;TTUT^1U-KGV\;6U MLF<^OK8^BN/C"YUG7AW-TX[BR^*U3A_4+L_.,YA*O4N_#B-+'4B[%&_HIC;( M,YEZM,7Q-RS+LCE:32?ULTH]H_MU^EU*!?72Y]IIK7:V,`]+W-DW0RV;N)3O M\BQY">@,,5:[7V]UB=:\0$_3:MKB.%G@+KS5)5GNLKOZ,D99&UL;N_#Q,O6& MXI:PM87+&6&"6%G<1BMCZ_TO4CRM:9?O/78N,F:?G=6R@FO8[S7FE(M%@VX< M`.+46X\^6[1/=?%:DW^H3-P&WK7%IT;$+NJC^(S+M6GK/U)JE:UV^O$V&Y81 M:S%J,&A/M"8;FW^-]3],YV>#OOSCV?G9_XFX,S;)IY*H5\8F]'.%3-)W?D;R M";7$UUNN4&4$3PS*1R8>7Z$GT=O/J`_=E?MX2$UX]DB'(-H]>44/]A!;/Z,A M9L_4*HO&_/J2GM/_D"NDR0<^"://`Y^F)%B[[SRVT#4JH^M&K]U#G5O4?6CU M6O>/C<=VYU[>/--\:#^*B^91H]GL?+M_;-]_0=W.7;O9;O6$9"B)$`M!P!AA!G34DLTQ0Q[:?:7.(#BL*QH?,0J-C$1,>R863*;$U3903D:. M5]19W\\B#$]"XJ!:M7$J*UIL^$$?68Y>XH0^"KM1K-4L_ M':,F80X&;JG5M]DPPGS4'T>6*!'B@<3>6K`OWC(*GJ764!V:!O`!K6+),52PB"ZU(SF6%G(- MZC<6M9S9GL>?=_N390LHB./A!(1(:K3IH?=_.7IDV.+R#A#_PB0$OV[!$N`$ MY5_E&7)1P8G(O.]:(6*)]FZ([GT+K*8=(1'"CR#D`W/2ZO&9 MCL,TQ)_G?@)^]@OT_CJ@8*57@L@;83KU[S=@MGF,VI[$]HA:_FX"^#_V;ER9D9Z9M@+7'D/GZ.'GT0C5`NG0KZ\W`M3NG#M%8Z6D3[D^R0&D1`%DP/ M.9GX1(]0.T9]L70QD<=":Q1R"4:'T!QW3>@LL)!O4JGHL!#HQ=5HON_*5JUQ MV(1O2;&-`G`)NZ?2!0T8/^0F#;01-`=(>B+RG+`N0>BWY]U"D&C59ZOO@G+& M!+/C0PUGPA[>J!3:<`K9,8L!B1MR+Q&'B%-8;X!]@C2!CD`(#% M-5+^*3=G@`&=_;X`J2-AX5^)AH>A-WD9NJQJ1I=1"2_V74VX0N1V"WN'YUNQ M>`)-Z.';?-.Z76'$%TVDW%@.?T=A69;@C+P0RQ54_L%W_VX,S`>H;]JO'!FN M=%?1@`=J'G@C,<3@[[ABAC.,[M4(_$27X[I!0?/,V]!T!C:/6Y0?(9()Y%RA(C_;>_MF]O& MD;W1_T_5^0XX?K*U3A7EB-1[=B=5CN-DO$]BY]J>F;MWZ]0434$69RA2RQ<[ MVD]_NP'P591$2J1$V3BU9V)))-!H_+K1:#2Z79/B4HA?_1&,^898S&N\'L3X MXC2&5-`GW0H8K28,<#7E;%V'_SXZR+H'-'8/(OD-M/PW[#]?JWZ\!E&%;:5` MXC6W6QS,0!^K@,^1X-\E%$S6JBEHRW@H^&0&Y$V]U6:,:!P0#B;@;(:KLB#1 M2\QCTE(/_0B!%Y.44?PE==M&R=EB&I?1YM!$&/ZJ>TY<6>"U2GYR?7$YA_[# M,JE'>TBQ1J,TX;*3Z]L5Q8#)J4>Y^B`7;V%#0-E.!;9Q+/$MQ=*LN/JAQ6,G M,ZS!TLC3W'C4?3+AB2F8/FQKZ*)N`+M<$9*,/YJXN?G!=XMC"@8OEH+%FQ@\ MK9:%^P%NS2SP69>5Y(0'%FR1=-%NB#9"//4B7]K'%(@9"P-[1GT^`.PW0"(L M9M30R$,?T1AY`G1NX1EA[A[0@S1O#\P4&-COJ,`(TA_9>1YCKO[H4K'\HP:& M+MG="R6R\W@'. M@A.X@B$@K@:-MM6A0P"YP"+1LG1&]"10+.S+>$X!"P[FM*9Y]'M1>V=)=TK8 MB/B=R`*&8.V&%RV412KZWM+`<3/TT37<;F&^*K>Y,.%^K:@[]=6Z6 M(0G7V0PKP(!`@&8$;1@Z$X2:@._%;C;6.^$613R:U.)U6#JU^:=7&D9Y?\<' M5;N<(<7'6^+DCK`\R=S:5S+-=;JXS"&2JX\ZZ<(Q%0ZG[GG:,IE[0R9LYWSOVNAH9ZY( M:OF&3%/)[/.JIFG'.BO[GH#FLC*^:)J^C\.V&_%[HZ MES.>N+E4O[S7Z*;[ION/&%CD+Z[P#()Z/KY&QS=N^'JR"F!^=Q?"S`$1\'A; MFR_&826C;B:`<=L!QJ48=&_:^JQ[/OGB.L]@.5WBF,#&0@?U5]BXH`(Y_?SE M\FTY)GO^S224^TM>OAYZPK3_*P+1STE+4"8(^_Q8+'A(S=[++TER MQ*TOCC-^AKU8;09,V,'A2L%TU$%O2YV0)GZ9:;5;$]5Q;V?3H36HB8G5+NQ5 MXJW4*MY1^\-J.;1BR78=YI/7B7"45J_L/.B#=1&Z8C;&\CZT)?(H^A-Y,=*CB!I]MC%B^" MYQ:)2^CBL;?OC^J\-B=$HH+#6I]OUZAES?4Q'D9@+0;VV9OK1OA9D/-LCOTI M8J']EPR8?`8F&\#D77W^TPG_MQ`+N!#L98+> M)9#JDH='F"W'_>GD_Q@&I9/)R688"8%J\:_?$VW^HR[226%L[Y&H-8#OKYQL MT79(WH.EPU()1!)V/%P`S"NT9R@[)0\KEYBQRR+I4IJ.8[K#8``>R-16EDZD MJI&5@TYX&1`>$E5Y2"FE-K,J'$3%&O0VX?#X@IE_CR% M'<5^5/DA-79Q$=*V%:'FZU_<6#57QU:J2B4ZMD&'*M$AT2%UAT3':](=Q7>Y M@F2D:^4`A(.HI_UEX[1M=>.GPDD3#M_U\R9&R=[=-&CU+\N>DCT)\C)?$S1M M0<*;K7IF7(JZ'FW7=4\9:%J%`K0;(];-A<3&OK'15_KMGL2&Q$9.U^I(Z?:E MXI#@R`7'0-&T(]`<.WJI$M97Q:`I[JUZ>;C=D81*`+R.AJ:!6&)#8D-B0V)# M8D-B0WJI=LVV0GUR:CF>]Q8SG#@SZ:]JJCB=:DI/[;UMCBQ)<#0''.JH.;B0 MGHDF(N2TH_2UME0?$AQYX!AU!HV%AG1:2=0>_09#8D-B0V)#8D-B0V)#.JUV M=%IAYC1#U(O@E8"%"VNY(+!T9S7KI/RT?=;6&KO5D)`X$"14"0D)":DE)"2. M%!()4^P=RW@0?5J?`K9<2H_MLQ^*"HMABBARFD@21426J+<*N:9^;9G3-B6I MPI/(0Z13&PU&6^:Y*C"BO8 MKZ'"%2;8C2K&8^$LW*.S/S"'*BS-"+^ZDXN+FO'0Z[D]QG\2?1]BA>EV=\SA MNVY`^YBO?249KVOB#J,+&S)YM>09KT_$2JG"HY>L_<]#(SBZ%'188Z9(Z.N* M]?$5^CMHYM>6UE.+YXM,T=U`SNTSX:NZT>`Y&K;M,\EKJ\-RO+X0SNTSM6MK MU-F8'GP#X_)7#9;DGR\9K6T+)+`V^*J3GZF_1.T#I(`1D,>63I(M&IA!9UUM M+4MBRDJQH=+R$55R9X?*$%7P[CI@^=*`&1XON<%*)C.V>'Z8X9=3B"6ZP](8 MF#B3O_"V=0M#A#91+DMS,LTH+\LI3MW-)*Y;0?-*1VQ9EB,F?"4\T\4W^B@6J2&PQJ"KGXS=6:=(_FFD0]!:J?:+V&L_^@W"[@I(QS6`;-'9E/\%SC@O[ MMOVX<<(.%X?PW/0'&V>FU!ARV;A?[THE_-R]^(HZZM;/V1I='Q7!LIRW8]"O MGV=[8<^A!IIOC'+E2D+M2H16=]RHQ)E"?M6M@*)#QWRTZ;CT.I)5V*RYL+5\ M.W4-C]I8^'#S(4`)$B(."5Z8X4K#U@.L9&R/HZ6A[`YP^T)PRP6_W*GFWB0JW3N84)>WPSN<;N73Z0:V]_NQRV\C0@YRIMK;M?#O MTBBVX_5^C?>*F+Z[^=YI;UL;L%KVUVCA5P;P4C:^-NPT@K%[XN'AN''OL.)A MX2'NG+FB][(NIB@^0*W=(O%#&^G>_G#\VO%I5&^;`?"K8S^V8#0S\HD^^*V[ MX`'68U.'S6-LP'S7&3IWEW'6O>@=5EKL^QZZQI[S(`IS<4LM'=@+%/B+>S`* M/=U@QS\?%\E?V/3$I-],..&<[HWS@CNZX;8J=SNNP5&--!T&?9XD`C?;4,:5HYB$UMKMPIJX>]APJ2V9G*U:W]-B"T7 MV;EWH.Z+78<;>+0^@3Y^,&U>'?23Z1F6@V`G_\++%83=KEB)GL2K\9O1I8RJ MZJQN=:FVPAJKUS?WE^2*7S(::JKZ-_+QE[NKZ\N[.W)Q\^WCU?7Y_=7-=?9. M2W8PZTB/+LX\N.1=W@69!E>@;3AY-W:BP)J&Y6I5%;W6GH,ES`PP=;]8S@/\ MXP6&`9">!+CB&\YL;E%4H%@*-S*&P>R"199]YP2^YX/.P+*[AC['@IWBU!`> M`O/S"0P@:]&:4FM,-EK/)V`^G[Q5B$X^NB#5WI3\:N)HR)5GL2*?2(]N+Z!G MW2?.L^T!N<*BPAC_YZEI3/%[IL50[%S'@N8G%/J;HLN+::![:DQMQW(>%^2K MC]U^O;P_>^6@Z/\#B\7PWX$OQA7.&#YW!4_@;4N=2;T[!Q'N"@2E8*1CO MDB,O^+@C+NF/+N4="C<^*);SX!'`0-01GX$S@H6+C:2#"?GF3TTO57C8M`TK MP")Y.C`9V#+7%ZQA>/:-2@`L%CX%I#Q3F!>=5S4V$VZ^7O20&P=\Q,>]^/@% MY^U?O=3AKT*".?$=HIUUHR9*'1,'<\<6A92G)GVB(=T&J&4=IA;ULX[O(1O9 MC38DV0<4L]!8G)1G[FM%PI[`[H!'U;/>!FHX9\68$C@VH1GZI%M!Q&S`'(X9 M(U#'NDL6%/Z#(78.CC&+8S M"KF8P@*L`).3.NVO'B\%;@+[8"K9Y,_!(@!EX>/V42B%,;G\`5-J@^JZ0`\( M**;`\CA`3B\O+[XC=\9YZZISOH\AG`E_'K MM\1;@"DX`]1S>6VFPI5ATBCY["&`_C8?&(.8FGD<#@^`=L/@\-O7, MZN,0^2WX82KD'R8`Q`LB>/`3D540$8KPX]7-_TL\RE:4RXLOY&?'`DB@5XR5 M">.<4I^L4T>Q`<<\+CVRY2N!QG"MYY@ MJ4FQ@#R;L"#C(H35SA@#?5PAV6_IB1"K/-_+X(D3$RD4$?(0VM%\$<:1X+)G M3J`9OB+8ADN9!#^Z&+[+)9T#^1ET(0%\XX*16(O8H"D,&5HP#7,N)I>UP^=^ MAF^'HLWHB/B:PP&VNL.JK",]E`M_%@V`:%@?'P+VCDW]9\>%1="/30;L43"? MH)-A`EQSQ$+%&8F;`3H.IPM_\'3T<-()4.I'"RXT+0P:$_&+'#-G.$'P;G+M M$1U.P+82?(<&TD1'&S;`[2/^6_M"<01K!@(@MB[X>NR)%9^@R$96E1E:*,*^ MQ.=L]%@%-HABA!<]@[SF8BF`-]`,;#D_1'9"ZLR*VPM"@6WYW%.+7Z"#2N" M**"(/ESVV9OK1O@YDP>DW=X^UT0BU5>Q=%[E^MF^.'JA3"C[(J9`,="\RIZ< M`/P=+!V0+-,H.T_K23YE&L@)/-SE5IG#9"]\K27-W'#8_#1SJ,]E_KAFI0%2 ME7:[W9PL0+L66GMA$I,P6Q4TD,[2+J33-W@-*D[.^%9*5T/3H&J*>L1B]O*7 MIF5!B[RHL*F.?-1)Z9.RUE!9Z[2[1RMI6RUHN37GCTCX$K'62:__`1:_=9S< MGT2(;45(Q(.EPW"!%,(\+&*F#BNT94BLILS\H,IRP/N+/#H9$?#T>+MQAR(SNCC&^9,R.R/AA\\GY MW<7)6S)L]Q22%YCF\4?P`8Q$B3W]"8,^Z?+',!(K/!45$08V'B'J]J,9AE>; MR!\@@GFL33O^C:?3U,-TFOBLEA@J>CI+!.?.>7"N'@>ZOB7Z!(^#^3$M3N;,<=,4N/01YM;$L`0=S+M' M<8/"GV+E"87SE40Q*/!-#E^Z^@BVBJ>),"R.+UC](#=00T_I&XM-SBET:$6X0 MH:]04`5K5L']V]H=E41PTP@]"@37MU-KJ!3!6A!NV8]>9+8W=G<)ZNEWC^"X M,RQ?P.ZF82RZR.SSH-P<83 M1,@A$2*]U!(@1Z]"7NEF^(OCC#'-FUQ^FRH[BEKIE52I8%\@2$X',N>%WR MFV-8FZ,PKGFBZ%TZABN\7U[)2;),"E4#B=5LKT8=M2=@= M+>RJ=(U)R$G(O7!-5SJ_9\65G5Y*(L\,@X^C_!6F.'P4`1175N>O\P9MZY&5^ MEVK7\?2+2=ILQT]1\$#)F&)U/9:$E-5)TW]@+M"YXV&^R_1)%L]MR1(T)G*" M\GI[4W@`BS`FJLVZ%#UJK(RA:(97;F.95#&YYB,^'9$S";#Z)*;AI'8`G6^" MP$LMOWK.\"#2CX8(,#'E2%21&8O+89Y.EM"4EY)S<1JI2-#*:N%-0)4A5'CJ M6GW&W9[0EN`P+X0'&PD+*T0*E&7+],60W%2C;V.)/BS-1]*E^#94X..5\[0! M*S/$6GRC#D?X8:DP-/M-48>)1[51[J,A!<5*`'[>IG2@VA26IZLB,NE],^HG M6-1=YA!7&G&25ZYL.,$VH;J+>7B]N'("V:ZZ(GMPF7-\RMMG[?:2_,L*FR3. MI,OJZ#(08$)JUR$L(W(J,S(6PF49B5EA2=`EMF'"PV%M3JR`NIQ@6&!RJH-J M-]B!R)C\(X#I9,F"VR-R&J(ZF4E3`2UNP%PF4"$>>UM'(4N9A'=C$M[-%GZY MIK>O`GG@[N,,NMWR52BKHL_*2>?(_HY3UF;/Y+GK-BEDRS(&"X/>]"2V586( M'2`Y7H9T4AC;>R1J#>#[#4[.5Y=?_'Z#6;G>2=[(Q'C;*M@MTC?7BZI#YRG/ M&V-2;U;=U?5Z*[@NO7TX+!8-,ZI/:QY28Q<7H:VSIC9?_^+.KKDZME)5*M&Q M#3I4B0Z)#JD[)#I>D^ZHY2)43VM^L/4M=WM7$)KT\FXO'##1;$\9:$=P>5]B MXP#8Z"O]MKR9+K&1U[4Z4KI]J3@D.'+!,5`T[0@TQXY>JH3U53%HBGNK7AYN MFW"5>`8=9J;;U,ZK21JCWZ#(;$AL2&Q M(;$AL2&Q(9U6.SJM/NJ>:;!+M&/3"O""L'!A+=_0E>ZL9IV4G[;/VI7F8Y.[ MT)<`B4H30TI(O`1(2"TA(7$TD"B=!*M\$H^5Z1QJRPT2_OWW=X'7>M3U^?N/ M@0?H];P+9_8@$O1\,CT#C*_`I??0X4=L^<-__Q*#Y_88_[F,GSKW+W3778!!]RNF72(&3`3T<4LG/YT8>&.F M/>JT3TA@F_R[7]IM[82,J6'.=,O[Z:35.?DPZH_4=KL=#Z%05_L:@:IJ'77] M"(@Y_NGDRJ>SEMH^^:!IHVYSA]/>/)P/'7BJN2-0"T"JV].TG4<@$M=BXB`G M>)QBVC%CJGN4):'1/9]\X7G-+O'NT1QSI>6/4+3S&735>2*5S;*H`-M]IZ#0 M9,>6W\EA1Z1&(RHT9]V<*2LT+,PKA7\D9E8AWZEK.F-,,>52'.+I)\K_>EL, MAOS]\/7PY1UG;=`9#0K@,K_O!HVZW,RJ7:V(/BDRZH0V`3OMB7H^3TPVO%CG"[V@\I)VL#R8;]= M9!'*H?B`_-::R&^M$+^/C-.=)G*Z<[RJ';5S=/RN M0Y?NS&^I2_?%::E+"^WH9-I8XR=#=Q MW+4\0DOWO)O);_RM&_<6?7%AJ]^QT>A'3_SJ%5DX.LG!:C#;9^UA8J!;]!K/ M/;Z,0Q5/$,A"]XT1O+.\P\PGBK M-Y.X3=[DQ\4VG%&3G&G#UE,;]@9J=P-SBM,0\\F9S4Q_QL2#IS^V?=-^I+:! M7$E@]U_HF2/,-;>L1N)&$)G))G(\>QMWJ!^$$W+#`7)^PMO-9\@5IA2^OKF_ M)->$NU6'FJK^C5S2WKM4)%GF&9?U1Y>RG,Q[952AQAJ08DLB`?C MY?4*OND+HHY8NO$V3W8>-:V(O.>8._T?`;RE*H(L8`_%19;GUP?EI%O`,W?& MB<&DHPN*JY`!N@15A_V8;*"-M18FV"I_*O0/LG&+U.<]A7C!`U9TP(?A,D5_8B%CR>!BG%\YL)$=I.)A>^#JK76$Q MSQF@PS18@GRLCA"PT@GPS)QA@I5`8-UCDGJ`D\TFU_07HC`'V)PV]9\=]\]7 M6V[BBOF5_PAL5D^"BQ%RG2'>$SGAE^4M/36/N#S#'/RJ>TXL@(3.YI:SH$#J M@P/->CZNGZ%5VN(51,!N8SGK`;$(6&@:L43"J@)`0X`H1,'ATIIX:.XZ3^:8 MER!@ANY<7W!C`&@.YCC);[0S#0!L64Q!0]?)S\Q>%`4:/!]L,H&C&?[&B'WD MQA0#-CQ"=#\".#\DC44YDO;.&3E'GHZCE/I^FFP37X.6V/@B%H%4,+EF]D<` M/4"#XM?X1`%?04*0)5@7`H3HW./&8+;"`HCC'!CTPT31A[;>J&>=%">2GP4G M!`V!V&DL"47Q8])R1E5LT*VS/\@IMUB6+?S5G17T`/WPS/>V:8%XN@$](>_V M2%#^-BI#4'P"JJ:HXUB]0ZPJY(Y-HD)N8)<*2P!+:I=#F&.SY_G3B6>WL>S5 MOC92!Z-1/SWSJ[K8$^$Y+%TBO-=1AT!\;R?"0X>%YP5TO(;D[0_OU7YF_YQI MM!;"RIW):XR;I:CT.)5"ZYB,2K:;Y]_DRE-J:OC`ZD(L;WU?1%>$UBV)O@.S M$'ZY)-]=.J&LX`MK=+77K6ZU+#,Z[7Y_ MV%L!MP*\F.LN+V)6U'\4M_Y==V]<-J0QP_5WZK(.2[N+KJX_,X=16\T=Q:I^ M#CBB')36."*!5SWPI[")^T])03N/7]M"0VB`+?9_:P`6][#O`130%ML/8%7M M,(5@D@PP,^_U'PHYSU0XA+D%`<\95-P<;PT:N9E`$SFS,B@1Y='2NL-A=GBK M^FK"\-1H>$7".<#&4[O'-+QR,3JMSF`P.*;AE0O&:6E#M5=Z>*`.<7NH/[(# M#MTP>)$UW*;!SAD4N4L-:C[AH/BQQS2PQ[!H^E/0)N?)QV_8X[>)QZ.%/*KF M"1L2[(T7#B2WII=8[5,NM#5&0*(%;"`>@+H)'[\OO?QQ\1$V1U,\SF*F03B@ M>!2>R5+S0>:I[ET5TZX1FFS,;5/'@= M$YN0#':@>L03FS:M"TSL7946M?T$E$-GPCY.&K&;Q:DV$SO%D344)I1T^!B" M?1X-G_O20!DG?6L;N7#.2DCRK_T"C"AQ&+^IJT.-J-Q2T\D$])8<%2_ZG`%I MZ(P1K@,2S&%T<!<7>9?*4H3'/7\Z&!$ MB8\@EKGAP2X$Q/>Z"]'%#5 MH:HVA_9R,.[UE[;"!^5[&8SWVL/L1K`P[?$A+V[OH$DV#D^\DC^$:)0[0KV; MQ_&P\7HI+0GL7AY_]T-I.1CW1WG:8U\\+0/:?B>[N\^E]!-]\,F5[?ENP(_+ MK_#.%QXAWX(5`U86&?1N@L>/'-LZNX"1RB\B=Q[L=*XPE[B3L(NL`?> M?F+WN3P_'=BQW5*+/:>[_N+>U6U/9V$`WL=%\A=N9$7TW4PX=9RX8ONK=F+C M7)SJ!#N%L8GLAE7X`DO3+Z_!X6/L*?',5L=N6B_CH\IKN1;JRIV],3,K<_A6 MC%11FVL5C>+G'.;U"Z@==33,)4FT6ADU:A%JU$Z_O1]JB@1$]S1M/[PIVKZTQVC@G7=5^P\PP M<88Q=MY@4,L2Y231O\`^>W/="#]GLJ*TV]MGWM@F#VRYKBHO2;^O[J-ZJ&JW M4#*4L+II7HAYE32?,N`[@0?&JE=E'I>],+9XJKT5=.^Q,OU>*[]7`-3^MH5[ MR4H<5T3^9Q&'RX/

CWIQZA-@;EIT).*T3S0:?D%<%D/3W0-8X@[*"&[%WX M3%U=A;"UH8%-J$W2JBF6I]$=6*EU;G_.UN:72)3KV@`Y5 MHD.B0^H.B8[7I#MVWKX>JG!.W7ESUP"W\8`\#6P]&(-I.WY;$R[WHZ#D',LY MEG,LYUC.<5/FN*@?Y865E?F4.8DC(DW!`X6G63H0DIH6*%(R3JX+P@F2KK09X M/N;)II8CI60=S8-)S3H:FB8Y$AL2&Q(;$AL2&Q(;372AI4RKT3PF>DOK;'00 MIQK/(DRCFVHLNM_5#=^3CK2&"IPVE)MB"9'U$.E*IYJ$R%H:1L,C\)Y(B!P4 M(OTC6&BJ=;"]#*,.?@O-.4Q"`/8*D%R2)!TE5%7E2"1(%F[ M6BNJVI<@D2!9>]2JM(?':]6]]"NHM]1P'FT3:Q_J7FB[R7L-S1&?8XI!E=B0 MV)#8D-B0V)#8D-XV>;-!BEQ$PZDV;$X42TXV?`F-`T*C/Y+0D-#(@\:P0;== M)#2:!8V!UEAHR%@W>6_AR,6K06'I4O$V"AG-B366P&@4,+3F''-)9#0+&T;I4;K!JF>ELE+U'78-0-*BW^(5$G M45?`<%5Z:I7[78DZB;H"1QY*IW=DNN[55J?(*RI&[3&6$I-EQ!J]]U2[RDC6 M$Y,HV8"2CM*5B30D2J0ND2AY+;I$>C[767Q?J>>])T8`5I_MD[GC8G$RZ?)L M)HD5YUG81=,V%WS-HN82^_\W7@3_0I80MFK=MU MMFQ>=TFS4OS]]W>!UWK4]?G[\#S_EANF'Q?G\:VD3Z9G6(X7N/0>^OV('7SX M[_\BY.__TVI%<0#B11(_3/Z%CQ/V_/^V6OR5%?WE=,'2#<&'6SKYZ<30VBK\ MKZWZ#OMKU&F??!!,J0WS>;NK]7]]7O%L!EIW:+<[,3G^?W+R?4F),$9D>,6WBP\<+9S;7[<5? MO:7ME4=T@*'N0>N6Y3Q[2QE'*Q2IW=`7;XE1^HE!+4OHGY].VB?LLS?7C?!S MYKBRW=Y2'VTZZ5JA+,MU1<1:X#OS]V1&QV8P`ZULTZV7O7UU#UP!ID/_:K?0 MNF'`]%(WI`!_?T],'WXTRL[.>II/&?"=P-/ML9<3![GUDK<7QA;W#97Q6=9# M.BF,R3T2M0:H_9637<9_F<)Q1>1_=ERFK/VI2RF9P;M3C_#T@G=T[M/9`W5) MIZW4[?`\L.IZB3!93P]TC2,(.Z@AK`:?J:NK$+8V-+`)M4DZCA["16-AZL/Y M(55Q<5'2MA6E399V*%V'.[;`C=;Z\XA#XOJ`&EBB@Z-#E>B0Z)"Z0Z+C->F. MG;>OU5K`QGTFY.W M7H*C4>#H*9HF-8<$1RXX-*7?&30?'*\VJ\_Y&`QKT[&7(Z4*`>;E"69GY>`5.&\I-L83(>H@TJ`JOA$@C(3(: M'H'W1$+DH!#I'\%"(\L!+AMULG;S<0F:VIQJFU(5-Q,ATIZ3"%F?LT+J$(F0 M#7Z#YB-$.NBRMIPL[7Q,(B:7:8D0B1")D!T0<@SE+21"#HF0_A$@1+KEEDVY M>NH\2QFK99U6VL<07BI!4L-YM.&Y,6:`%;:;O-?0'/$YIAA4B0V)#8D-B0V)#8D-Z6V3-QND MR$4TG&K#YD2QY&3#E]`X(#3Z(PD-"8T\:`P;=-M%0J-9T!A46?>V6FC(6#=Y M;^'(Q:M!8>E2\38*&M=P*4"_#>JOG+D(NP_:.]S*5 M9P\DDF5(K&B95[1NE1NL&J9Z6R4O4==@U`TJ+?XA42=15\!P57IJE?M=B3J) MN@)''DJG=V2Z[M56I\@K*D;M,982DV7$&KWW5+O*2-83DRC9@)*.TI6)-"1* MI"Z1*'DMND1Z/M=9?%^IY[TG1@!6G^V3N>-B<3+I\FPFB17ES%74=L/=`#NK M?`F_!L.OW97P:]KW7O+E]1?`[7NU7K5LT2WDW0?DQ^$J_.D"\3]T9 M&>_!:[J.6P>6%R"%C)W@P:+5RW3Q4MJE2*LHS=UP5&4&LSU/L83=<<*NHW0K M+6HA82=A)[6=A%TS87?,VBYA+[_S=>!/]"EA"V:MVW6V;%YWB:8>7/(NKXN\ MO__^+O!:C[H^?Q^>^=]RX_63Z1F6XP4NO0=R/F*_'_[[OPCY^_^T6N?`._0/ M>^];EV$:H3MQW^G"$6F$R+^^T=D#=?^WU>(OKN@H:HQE((*^;NGDIQ-#:ZM: M>]!6?8?]->JT?\^^&-^LNE_,Z?D/T_L])$=0$Q'#23DA@6WR]G]IM[43L-@- MY&SXB#*(:;EW!Z'E!3B@-II'@.VT`H[,&![C5`C M`DJK@^T9T&DD`DKK@>T9H&VO`\+1)P@ZC'40#CU!1[&Q;X_^>L:^A>R_F+%O M(?;;CGW0:]C8MY#X;WW[L%_'E.?'X8<0]IB,DHR#B.]O;?;6,?0MQWW+L MW5%7;=;8MQ#W+5V$SW:BQ;R'N6XY]U!Z6E/?HBH!X0B'7CBWBQS8,.'XP M9[9AG)LP.ARMG:>X^9J)556MHZXGEICCGTZN?#IKJ=V3#[U!=ZT9N3_*"["Y MTUUO\ZXC-CP`;64C"C>0?+$#+%!8M'4$7^R+VG*XZ('T=8?=9E!>B,_M;BD^ MYY>'JN->STJD7,?C;B M^PWE:6G#:O7-?C;B^XWS:6G]T79,BAQ0]_H/\M74'TS+]$WJ*>2:^@JY6.^? MA)<2[^SD\UNA(W)[V"OUY7R`_>V',G>A31U]?@J!3Q;%/]EV[7R&OL#_Z/G^ MP/B]Z"W84"7?V:3]-QVC+7GI-W=YF'%EE/=&S&75;ZEQ>89KSAD9S@3P]DS. M#<,);!_WU=]=QX:_#6$`7SL^65"?G(^=N0]P_1=&8A(6BIFC;**&;R;0;-QJ MNE%H\Y_4#UO<-,,?1&3J-D&JZ1#:>Q9"B^.]71-">WUS?TEN2(O<7EY<7M]_ M_2>YNKO[Y?(3.;^XN/GE^O[J^@OY?GMS#7]?7'Z#)^YV#Z-=$S"[XL;9'X'G MFY-%.`9\X#TQ??C5*'T1;8DOVU]$N_&GU(5U:09XG%+;,Y\HN;(-9P8O?G>I M!Q3I(?#RGCHH*U,]=/K[Y-N53?X1V)2@_"LLROLQ,,Q;WP$D MX1SEM:SPON$7QV8Z`IZS046$O[*Z8$M/.`P9N912D_UF@FHE'F@+"\ARF5XP M[<`)/)@TW6>J8Q5)^#R\[C\[Q*-SW87'R4/`5D2/&H&/3T:->)PCC(]&K M4],CP7R,;XX=8H/:,Z9HZK"AF/"FQ]D_`[20!PI6&1YSL8IHZ\8&A#W#5\`4 MUL@&3L2-&Y8.=OG$Q%EW$NS-F4T@'!Z!M_3YW#+9B9SO.MZ<&CAN:\$F!!ZB MDPG_"E#IDHGI&3#'"ZJ['I\S$_2P:\[$/5'X\H$"5)FS59_`3[`$&LRD(VI/ M$4A]AJDCT`3V,A98@O=GI@^L$7P.OX>A,RY'A(_-,6/T5`>:=!`-[!]H,F=S ML!\)PG)*F9K0[<5?66@"NPNMBV4#!-6#OR:F#=WTA_*3KS,*HZ9M)LF'1+FN6-?H1VPR;C&[\[&P@[G)'OT+)9';E)\*O M3`TU5?T;N?OY_/:R]?'\#JS+BYMOWR^O[\[OKVZN7ZOR:CAY]['N8$(*BZW' M5\#SNPMR[\Q-@PS4(3E)B4]JPGT$=/+G$W)Z@F_#>R=O83V=FL8TH49`CWD) M>=.?=7?,EGL*W3L+B@X#T!!6@!<)R:.K"VLK_!E8B3UR90G/H$E$PVQ&QR9,IK`:D1:7 MSG3DI0M33IF]B%^[E-F$9V1IP&R<*P<(!HDJAA'3GAA0W9;K^O:(-1N7[405OI%>Z(C./1XR1O&KP4"UI&&!BS M8RLVE(IPW\"FA^`W*2WW:IG\V7%S%,\&3*[0.*&N83.@]$=;B*S:B9MXTQ\, M0RUD.W9+B%.\C.%"9,+B\JON.3]3W?*G!G1%O.#!,T$CN0M\`!:F/\".9*2NT\IJ0=:PS42T*4^I MZ+XRY*SA&X!`5LL MCDQ^R/LWXE'+`H6LD$=JP[;6XA3JXYEIFX!>[AL(V_L;^Q'WJKH+!@-;`:$E MRYDS`8NZ76]+)BS(U&[ZC%R*^4!>I*S=9"0.8[6:9'57[6_/0BUWAE0^>_Q# MIS^H<(I^L1-PBQ'(M]9HT/\`QN,:Z:V"+9NA)$M,#UU^KO.#V=]@LKT9MCE+ M0*FL6$V9:R2]!8!Q.<'C%+0D-`$/=NI0-;5M&5=JI@W>DMV<$@F_R9,Y9@YY M>`;SJK2^N^'1+M_MK3R:#]\4+XICU7-[O.ENTN]WH2A=H%/M9L(Z8F?Q4>?L MJT(G\,ECQ`(D'6KD:O4C5[N]3.S!=N-'67)!"V`((;H$+DEY3J2HWQB5L9H- MG(3+DMQHAT?*N*O<+"KC_!;NV1$CM@.XJ$NUEX/0(?MG&@:AL+"T-A)=X9$YM"E/ZAKF.SX@KT"PQ+;KR0W:G<@'@&^[MFA-<8) M,;\M`XU+Q8&UE_;YX6G5DVZQ']A\"5X+!P0S2\*`H"`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`# ME8?%0T`(\::C_DA;7RY)(E__JHROO%5L5+3)6@P;C)O;6+0Y]9['9E?NYE106(]U@1;&6]#4^_"L^>S,Y9T^>BP=W7+ZZW4QE\I4=U4UW MV9K7:DFRSP6A]IA8<9EO,J,ZYL=G)4KBTEXKAR$:M\>)4N'?1!,W]BWF[,0: M0#R9NAM^Q#RFWCW:MOM(6WOP')I>5&;7M'E-2%;9X0%+8*9+4^IE)@73O`+B MD!E(7+'<3-F1KD@UP4B(:HIV5)Y4X#VSTK&]TON0`\Y(U70>?U+-"K(X["_3 M9F;SNB\R7V?VS4,P^Z@S\N;'"7POAVIKJPR@;A.F?5 MFPY'PC?=_1.-`+`4#D?$%39B8JUX;N$=CI+3KUAUC%R]71_;V=R,1@W1'9V7 MJSON@`Y69![LTH/A]`8K$ARP^P>/ND_LN.!P2L.>!PU0%=H&5=$$:=QZ)5^; M<7@#J[<8S-:BQ=[^Q7:VA.76>$H"H2/7C->!TH^ZI=O&-A!C+I0MWGLYR3GK MOE'4F%M$[`M>W`@:=:SQRG4DW^0M))YUW\@K()IUD["G\A[;*D@Y`W(&Y`P< M;`8:OUD\#6P]&,/B-J[+.CS,[85MU^>CNO&K>]-4X3DSC``R;:P31Q?XYI_4 M)Y,`:Q2?LJIO8_X[!D:Q8RTCT\H&'!2*!GUYE_+?;-5S)>&;0Z7?[E8HD#)A MP\O!ADSD(7$A<2%Q\<+6$IG7)7F,@$;=C,=+P8[!]9D'VJ2F]J9?2U4HSHS=CGIM!A43;GKQ!S9CN9E`A0?4Z0XD[/;L\I*0DY"3D).0 M:Q[DCGEQ+>K577\0P&S-:D\"BM]O>GF'$3N2T-R-_=[9(K$AL2&Q(;$AL2&Q ML6??7'VFD42Q1+'$AL2&Q(;$AL2&Q$8S+*.B+J,]9G;::XZ<"O(X;9T`8T/? MUCY3'%32VWK6'WT.'^P-2:[R-IS)AH,_U=5#*O%0LJ-*F5C7U->9M*@NFFO/ M<507X:M3(AT@YXG4S$>@F66&))DA*:$Y*H\1^ZK%+J7D"XJF4E[B]:E7>O:V($DB12)%(D4B12)%(J6AYTHE;:VFYY*0&<-> M19875>FHG>8+H<3&`;`A,T-)7$A<2%R\L+5$9H:5.>+_SV2VV M\%/./<:_OPN\UJ.NS]]_UDWW5]T**+^^<6Z/OYKZ@VF9ODF];U3W`I>.;^Q; M:@2N"V8>/'#MV&[X\:/NF=X]=G>; MDT5F3CK]C1$22^S;/D+B?DK)A3.;Z_8"<#:;6P!_$%5_2GSX9>XZ3Z9G.C:+ MESB_NR!#K4U.$@@7HL*")%A0;`+!)^3T1+QS\O:,_`(#=,-&%#+!1IY8(Z9' MQG0",('=M278":TP>*`'AH^83/.,[Q*.6!=W!XR"]Q'%A-V:R M'WQ7M[T)]*,32PCT@IR:9_1,80V?T!^FSYL_>8OQ'M`(VXI:"_ZN;O@P7NC/ M?Z;4#L.`Y[KKFX8);,)A^JRI63QT,M9]>K8)*UM,>W%93.O'K;3!_I$W<2S+ M>09]2ICJ]F!BJ,>C=2:..]/95.@/3L`Y+H#Z5X_/.P><%>OM<$K&.$4)?+'[ MF60W%<5O9M.Y+VYL`H)1`7/,)^YQXK?J^U(*J2DS4C6=I182!@!B@%P+Q\I/ M)^T3]MF;ZT;X.6/VM=M;6A/,D;)E/$.Y_BJ_[;WRMC/['=#LPX_&_LB,+H"K MW4+6X+YH/@7E[D^=P`,)%?%[U1BR!V-VY:6KMH#SUMZ_ZOM>`\6M\KH2IR\GTU3AHKS2I45$*W&,S6HL7>+IB%:]7KV^`I"80F9\LZBC7C6%"Z M_Q17RQZ38X5:E:D2\HAMS%TZ]D4JS]6J=23?Y"TDGG6?UA40S;I)V,W!4+N" ME#,@9T#.P,%FH/&;Q=/`UH,Q+&[CNJS#PT1(;KL^'].]=YG?Z%7DI!@J_7:5 M19!EOI*7@PV9QT;B0N)"XN*%K25U>V&.R5K3RL5.8WDBD85NPQ!VJ5>TR9^4/"3B:;D9"3 MD).0>_60.^;%=<<$FS*[D\V14T$>IZT38&SHV]IGBH-*>EO/^J// MX8.](2G94*1/KFOHZDQ;517/M.8[J(GQU2J0#Y#R1 MFOD(-+/,D"0S)"4T1TZ&I./4')4FJ-FL3:I>\Q-B29;6_00JJNBK8"ZF*KK: MB/(J.CF"'$^5Y\A]E4+W$M)%)3-I;_$ZYMY^<3"O-K5%A0="_(M4IBA&36*7 M("_U2L_>%B1)I$BD2*1(I$BD2*0T]%RII*W5]%P2,F/8J\CRHBH=M+RK;,71]S)CF$QJLF*/V=6JW&/*7#H2=C)]DX2+XY662.NSO]C>?=]XP!U\"`VUW/N^^GE$QTT\59"?@AMP]? M73BSN6XO_NHMA2QN"GS474K&%$_#0:3&T)CK!(]3\8Q"XKN#/"#2<5T'+'L= M&_2`F#R6QCY\=PUC^M><_3._WD!A&"R?BA`3P/FOSEW9;.P$V&^9,M[R?3EJ=DP_]0;_= M;B=XL9;$`S)#5;6.6B\SB#G^Z>3*I[.6.CCY,&RW*^3,=\"J?7!\""H*(:,S M:/CPRR.BQ/`36!B>?.A5*2053/J&J1NHG<;0RV:I,*]'('?;,?O+SW]Q?DG\0;H,.-57]&PGQ M1KCU\O[^JV/W=JM\'V:XRVQT>7/@(J[4?RIJ,` M=!5`+P,A?`3)8Q]/7>J[CLX29%D+HC/\HIGJD$?XBM#)A!H^?IQ1'2'&(D'G MU#6=L7@:OWE+GG6/N-1`G_28@(RFC>8+QV8Q$\\=OX;]@RM8QMGY!SX)`S\QY!O.!#=@DG2!1_2([F$=N>,"1Y]Q'_/"&X9 M#'@`;'_4,:)!8PI"2K'7J&G<"NB8R@N:?_;>9U&)4QS"RJ(^;!E:WEPW8`)A M&[K*;8POE=AB%0PGCOWA;&=B4,L2SOJ?3D!+XF=!&ON<<26TVUON4+=VSLOL MC#4D%:D_!UA=0>L7NNLN4/&=SYQ@.3/72\WPL<=+X>=HYBQ$UOG M3FS#L3W3\]'W9>ASTP?J_T-A,Q8>FEIX4,D\>7-V4`4OL%/4-=ZP33Y6/@!\ M``QP[-`X[,R^&/_;9H6U+Q]6`?VS7;+:"MQJ_4+J,45>!JQ5DGQJHL?="3P0 M,9%IX1`NB=H3UC;0H55]WW4XQ[2;5OIY7Z)E=)867+LD5.]P>GJ MZ_9,Q&WGXS?H):][Y0>/%XC2P]6`,L!G7)0S[49/RC.@8SXA6.K$' M_>8[L2]2.]4"ZDD>%NW[L*@_Z#?_J$@BXP#(&%;JS'QQAXC'H'^C*/IJ%*\\ M-&SLH>'@2`\-)?2.'7J]*NV'9IY7;W$$BZM#Y;Y2>3!\G`?#@TH3=,NT0A)T M1"Q M,2(@QK3%-32#Q\[@992"E^#R>])GCNNSH!K')CJPR]615((N(_*@>Z9'G"=X M`WHU74*!?:(V65#=]?C%M>3O>/4M?A,:C:_R6=1^ M]*?L;ALPEU]P"XF$KND/O(O'<0B8TV'X'*-G>`4'">@H=ZTWOE/L.IY'OKO.Q%RZQE+COW&WWT[?M$TWO3(H: MD:(6(66@CFHCI=PM<+4S&'1K9(M:@BVJVNUK&VFYLD$+47+Z%7YZ2R:PB*/Z M\4T[0+5T`ZL#DTZ//%"0#$K$\_?Z#SRIO?P!N@:,0M/6W07!R_N8[,*QD7+7 ML2QLXPJ//D%U9$?*6\)^/T.O<:=QGQ]9E_PYUF&J.]9;NJ^PJQVQW=)Z&<[5 M2.LKFXERHMT?R6FH22#*J+569]#IRIFH22#**/66VND=;";@96`KM])./U*; MPD+R-I]W\*AX4CRWJTKNYHUZJ9=:*2ZGNGH'I[>'5GE>):WG.82Y5(=9_03Y7^]Q4WK)SJA MKHO[TRELB.E2?J7PM?"E*SM\0[RP(T][VI),K>]O_P,J-QO9?4NI`25ALT!7 MS&;JSPW##>A83/B".P!W-`S437.2T^D>AK&C*BDQ!O%;Z+[@3AKN[[%,_<&T M3-\L`BW1SM?XG1WG9IA)AU>DRT.,JJ0!--AA5/>N/J8AT,@XH-PG93&?UEQW M_44!%1#0>^>6O_,=7H'V+]CM]ET7X/6*8&6OAQI6VIO8UJ?DWO31M\N7FO;=C\VD!()/>*;AXI>TN\ M=!Y=3]W%X3=H;YC;Y2X/-K22(MO;M+2O&1HH8?3BEUO5V1MB?>7:;,>!5F[7>Q]: M6:D9;D)=@;%%.Q,7S^2"`M@+W[CE+^P\05K1K8GHL$;2RTW`L+-)8%91OD(= M1WH`36`.NEMJ4),EYB]F`K/WS^TQ>SOQ\LZ6A::I2VZ;XMTW:>1EU6)/W:1" M=A@X'VLLHN46X?B]2DR,EKKLFBO2[8$'67)"1R57A&)CO+)!Q'W'+;0F)![> MU?LWV#"81%=[&T))-=K>Y!0I,8;/ILW"6$II#_%2E>IRTY"6NSS4R$J?"FT_ MLCL="?#U'\4-W>^N,Z>NOPA5:Y4>Q26_>8F^]S:FDN[%31NI0F,*77*&,YN9 MGHP5U]>5L;CD+2L5&NT([7AUM'-L&"O8[O)(ZL%MH$J36Q4GT1@3!7&@LQM<1RN9F^BC7H)+XO;P!)?T6FJ'I[@[5.70%;AO:%KK'?VV=7UKY?7]S>W5Y=W($>7]W5?J=K^ M[MJ^F)3P+C$K`S6+*^"E)',*XUT=GB<8BV'AH+"+5#K:3'+5]4EUBET:W+'4 M5@D&%[_?64'^Z!TI.-"UTM)%CF228IFD6"8IEHEG99)BF:2X&4F*CQ4J.U8; MK#:_X5%4&FP\-F6F8)DI^'"9@G?+2[E704GY8M:+BLS[NN^\KZK2'E:93E+F M!'XYV!AVJZQ.>`0Y@8](J?[FN']B8-7<=?"01ZK5ZDFH)F&JIC9?AB1$#@N1 MXZW?7%&]5RV33+?IVC-W4C-?#7IWI?&6V=8F]M9NS7I7F M0P,2KA?U>,ITZS+S=2':-*7;KU-&9,)U";M\V%6ZLSM0RO7MCN&3>OA01U-R M+UK'7K264Y2]LT5BX[5C0R;@3W@KSGVR(B?[4GR%PN)$+WC"?3+5QU$P*=EX MHP"C3-_TNHE$]/UV'S]LR/K>8,ZMCA5=GY)^77AVWA6!Z[SK0>)7O"ZP3?B\ M!G9Q?CPZM%@%$05BXHDY_ND$,^>V-!4IT@I0E#G96$D2/L>N!.-3N]\VZ*VB M;74_=9)QP0)-Z@+LF8:N@^D@!B/Z=SQ3)^0\B,WO;>MC[KIDOP7@]5R)4]#[`$Y5<*HDY4\J]O3+_DWE\0#>#K[.W$ MU8?<"?P]>O+C(OKS9Y.ZNFM,%ZS'\Q^F%S_&B6$_J)R.C:4`EB]&'2(_%2B$WUC/$S%2:#11]UBZ#V,4$;M3Z9+A@"\/VJF?Z*S[.W M-UPV_CV1#W%Q[^JVA^5R,(_[(OD+F^*PUXVSVEZZ(1K14^_0U'T,36UK^Q]; MYE)[76/K'V#:,A?K:INV47?#V!*Y-%;F,TT\LSIA:X'UHZ]F\HLO-UPU7>4L M30W3C:J#;8C$TF/!#&MJ35TG>)P2W?AW8((VAEE<0_BU[E9@ZPYUEA.*L:7?L_[2^J>]_G%Q7EQ>_7K^\6LSKG[G,&V_KJG[Y'UNPJ\3S]%99[/2F6#HS'B] M2!>L!:QA])AT[?W58W4UHZRE/%N-FT"NSC8C1?V&[W>?CIJN91_RQG7Y,([N')$=U2X M6R*QI5LO+J_T`M@AKUZWE4YWU/Q8*@F.`X!#TY1!YP@NYK_2Z]=1-4$JDMI+ M[=K4L%55ZS5?C"1$#@N1([BD_VH-V7,\Y@S!Z`V_T^)/`2IU?K%>^4I;D M+0%Y@T1BXV"&;:Z?,Z501_-X)%OJY-$^=7)\K?1'5;K\#I2:H\I[ZX5C*W>)96K`6 M`OR91;A^N?SY@IP_NI2R&W:Z2XD7//Q!#9_X3F*WPJ[5!0\>_7>`G^;4-9VQ MAS?M`FO,6F)M6@L,G?58H62&94&X0H(Y['Y@/VA,V=/Q&(GID0?=HV.%&%/= M?J0OX\I[@XDNX"(D^5O6"(X41H%9RL?$U&P"@1PK'L/E$MR@ MAZGN0Q\+Z`+D@S*"^&^IG`W/IF41)!P'8RT$+%<+R!E9/LM"`,]=:,&%B4HS M[@FY[`$=P#(8,R<49,=S;)M:1P5T*Q'_OV6>AZWN;4372*YU'R^&`)9N@(,L M6M];>TV$OW`S23S^DNZ`G),6N;G];N@67M$WSLBSSC2EX\X=ERE)4%*? MJ*4_X_(*?_\C`$6ACH:#,_*+;6&.&-0T`IRA4O3X]N_9]"AH15!3+IW`FLX4 M"NB2DV=ZHI`3T*OX3^#A?X56PS]=^FAZOJO;/GY*D'@"BI*^:8U/'PHE(LV]:&.G:5L@SA?^Y-*$`J?T(3;,QCZD'LP3: M6P'>V<%$-T`BQ4?W3\J6"V:W!'/@%/MX>7GQ'><;F;\^\H[/S`"OG#QA4@"@ M.D0%`X/OS%-(''0Y$O%E_!H(G:)Z'A-XFKJV;A&V_E%W'E@>OPWD+3R?SH1] M0N`+7,8"VX0E""TOU=7D/W>.(" MC]^PP5]L\3Z*[[$9UV")_4_=]V%4HY/3;U=NW?*W'-YQ' M:IL&&G3&GV;CF.,+!B0R"=3?[0= MH-GP!)K&[Q[>Z>S'GZEN^5/H%Z!-?T##/'$#8!#[XLND2\4%+3X5#P&8`2@J M3Z;..MP3I.X56`+KMO(%VQP&O\0-8-7'W$>OE`;E@>+7%I@\[K` M@=`T.+W^Y]WE>V@7&W'(`S<%_NIA6B<+6GG*(_2)VU3A*-A$4VR9VQ'CB"<$ MQ.41`1\9\&C(S*F!R2V$>,"KCZ'9Q9KL#IF2,!\#)_`002()!O[VBXU1ON2. M?XG3BM]^0B5@&FRD%XX5S!Y,G&*6WJ85D1'\31= M(Y@!9U'-;K3/7FH*-,!'?`%F.=$9NS"/*/FL@X;ZXCK/('^73'."L0Y$?#5G M#(RGGYGTZ.2C"Y/K3%:=627'$`8\]VN"VQ?=>Q M8+*?'7(Q15$&(>,&'J"#-XAWI5M`Q(0"54S',PC>ATH:?__JC_GR]M%T?H!` M@)@$7-8NG#/V:SH/6^K"+4*):2U&*E/^N/RP]E(+':C6>?K^-K[*:6+OCIE\ M/@0,BC:%4;F@FN/EA.^'A(X@N$A.',L$"L\M4+'F^GD"^F%42`IE'4\"ESF4 M&=)8]Y$VC.T!$KW#NK9@X>&9=![Y/*-1X5-8Z/!7VWD6W*>Q_'')S5\;F/V0 M71YR%P:NZ>R`7Z[%8<73G%AJDMIV:X)\+,.'. MDB-,7@G&O2(N]*U('D)`1C#\&^-2LN$[4,)L+R+61,[X$-P.7CWF6AT,C5IM MH72%:<2%/E_$@`">/U,P.G5AAI)P`&B<'L.4]"T;!MALB'%3=WQV3D-BTCRRV3 MTSN07]RGDXNW1^6C6+GE7`6M91_%LM,@=D"`1083!/-&3K\ZGO>6G#^!%KS=K"5J(U[A[>0;("]OBE'U,8\.3TUG?FP M9/_-8T`FM]DF!JBJVG]9#"B9*:DS;+\P!I1,NJ0-U4%E#+C0P9+][CI/)JK7 M!]@I_N*Q+=-;PM/]H5EQ'FGCG*%C"V$#'Q?X]I4=O1J_N?.T=[O901?LN2'C M+3G+?:U=\W@_@W7&]Z&EQQN]6MG\JKU.D>'F=-R0X9:<7K48G#>-%P^LUJJC M>M?;'6DIM_3UESA6&2&5+D$[,Z4HBPK^&NU_$_E;2FO_ MZ-7*%KM!;[`DLP5[;LAXRRDI31WV=AZO8\<^L]!LO_PQI[9'EY)A)Q_FSXHG M=UP.1QG#>U4W=5-=;N'L=II!=5F+4&T&V>6PWB_+[,]7U^?7%U?77])Y+NWE MDAPLVN3<'K/0DSC0!(1IQTRY*7HW][$OTLOE=>UA@NH,[\N,)=H>9$/4BX]E ME^3:6A;M&SK9"^'E9J"/^\R(5DY+MS;@<94;JX&.%<5##%@QW7.).F6.J@4N)*VD[]C)342UQ)$VG0[XWVRKHR MEI"J#0?EJ3.9D?3N%#>P2T;;3=J4JL1_TLUXTW/ZJ(/,TBZGS!9J3V26DQ:M M?QA6EG-IKA2:$F3&I]E"@ZYTHVPQ@M_9!1WT6&V>WOV+M.AC0LX6\Z@`Z M.R=H*M#+,6!'H*OM[NYK6S4X+S?NDCCO#-6&X3Q[)E`'SE5UM/NP:]3H93BP MLT;O#G97=55I]#(#+XET5=.:!O7L05`M4.\,5VP1FP#UI]K2FF2[EA MEP1ZOXSIPF)ZSSV/^JMK#;*'^#,[>05[Z`Z^YCCJ>`-9AXZ682OB+>V'&[NT3\NK[V/YB2?I#!(&ES];`9\V9VW35E)7#]@B/23IYW%Q%YF?'I7@_ MA']O+`C>(O4L#HY'W5PJDLF:NW!FH)ZGU$:7=*QP1&,7HJU$F==S>WP?-WP> MW?AG!=CO]1\[NBPR=8GKH;'Q/"OIBI(L*ZMUM9'D6>G0EGVR+%K*C#@O!^6N M]#)&/1(9K3B.!XJ3KE@SZC#FL^S*4E)HM-O9\I4-?$<;OM/OY*RU6S&B@"E? MV:C+F?"5#&_[L>QO"JJ6O-JVT4V7O#WLGCNJEK-_.ZCD5;]Y/ISD%5DQ2TX! MW]05+,[.'JZN@KRJY>PUUA=FKXO<4ALE3/ZD=M6RM'\7>QML.(=-V.T9>.G MZQALJ&D0HU_W@K\5*-\Y/7W<&&56ZZNAN$:?W0W'#)9-=J%?*K;@54(5>> M%]#QTG#"I]G#[-%=X[-SFJR1N'*KCKH%I1ZGU)OJF"1.#WS@OOD?O)N$*:38 MMTLQ0>F6[]A#Y_&;!3BL9F^3+8GPVBX.,XZY9L`UO]ENM4\TSC+'[;GJYT]!^)*>794#1>3*9JRD.?J M:1NQW4`Y;WB_5!<0TAVIGNLN)C`';8T4CQW+PGQQ8/]QZC<0_UUW;UR&H3%3 MR=^IR[HMPOY.C#_" MP9;+5ZE>Z1.N'&L3N"U_^(!R#TK$G MLM3_H*YA>BP3[;/N8D+H9;+Y"Y_A^=_X(Y?BK5WWPYW,/>IU7>UI`.6$8S?: MT4QBJ3Z!]GD:6^O&<"5>NYFDY_S<'O,O,`DXURP5ZKEM^F_,N$NJO*4]S:Z# MGU!V%*!;Y#.E7NO"L;$1+N?5PD?Q%G'V'WA?+" M+#$C15ARF$E/;]K1JY#KY=O3*YVLVQY!9B,YUW6P+[K+.7RTDP]=+;O>%AO$ MD\E.F_!^[Z>P9DM8+BYG!/SQSXX;/AR5EMOQ7MT@2_W*GO9"_1:B7Y)Z(5^$ M"1A)RAZ)"Y:L+46R2G9SZIWL7*-DAXHDN36I6+&1KZG\U[>77\_O+S^UOI_? MWO^3W-^>7]^=7Q2J-E)I(N!C+QQR$Z;A9_GLVP-638.F,O"3.VH$+D\H]#UP MC:D.EM!YNO+!_Z4N(/%;*N\XSS1\>L)^.WE[AB_CNL;2X/M3,U$^`?.S8Q;] M%F;1#TTL?&P>]M=5M&%/&:C=R!X6]9QXND^VKA,=%6N4Q3^RVN:NR>V`-^VS M]C#V3/`:*=PA!'TQ.D79">A5E!;@(PO;XMG60P)97G1!X3B7Q"1Y9\"1\/#6 M6G"^X1#@H[N(*T^LY3:;'AWSKF?FZ%,RB7NBEAI6LB)WP7S.B@YD9NTK[*M@ MHC[IOAYGIE^0,&R!E>TX23S$:GS81)],3,O$$`H8H>!:>F[I"GH4S.7-ZCE@ MJ348R@,UX"-[(TXF\>RXUO@9=GQQ:GK'#6L\G-N/IH/0WV.5EK`$2YQ7'Q$C M4LTG^'-&[E<.G4SU<1*=[$PM67Z"MX853SJBKL493%Q4:PP/Y8)'T!CASVI^ M/835)0<6Y/3KY?U;L>F8[K#X`$!X5 M!U&BTB,A=YY=&&[+F4Q$W;^9;F))(%BF=1[0CWG8="O<+T0!-I\2^&,A+F3, M=1M+]T^?J$U`O/TI*`A6/N83-7@AA'".]IN5_@4L1I_I@QM@405MJ(AR$I_T M)Q-Q38&Q,U0_:#N/'V&AN#4=CY=^BG/2/"S8Y'QT='?,YA*DPH#Y8^4$QM$' M@7(!D#/RS3V+N\#E:.ZB?<02-.D^O&+315@"A_F?L`4<]#]9M0Q<26(:L,P> M=;'V#*_7\"NN/Q=3W63TBZX9A6?D9U9\,EX6='C5-@%OF&G(QDH9/+&_I3_# M$LGKTGRDQI^,S)@I3*3P_\E'W<5:1A[\^O6[(G+YL#=AX0/3%_186&G&HH^@ MB:**G6$=BX@I;$\(_<'(7.='6)_P3:>M@`'+YN&-VM;8!S8+#Z9EQ5/`^HP+ M!8;S M"PZ/M!3JD;BSHF>._4=@\UIDS/A)%U(Q>(-,W.."4?C,2;)>%'MS!0U8!RWZ M"NU=-`;BM@ZIO1/'.B#Z^AC5MS=G#V`_1;2"8LWM,BXO;>UOTPO M*ZLR9RK)@%9WL):PJ&BF6RB]"0:QPJL/5'`I7-83C&+*P\%*M0P7+M6]]T39,/E#*N1>V`Y]ZEJY?M$;I)LN:;P6<>-YKP,DE:I`0_OK8F8=W M<)GXQ]6:P@)-J&5Q407-@NPAX@542)\_G1/#`MW%=J:L]B3S4>%&VQ=)%%F` MX<7%'6&A,.3JZNK=U:]AX4FF8'6@]`^';^YQWPU&2J)\HC\UW7&+)6+$+(W4 M75IGMRC/+L5A5W'07IPXK(G,Q,3#R`9/NT)X0W'L4RJXKY*[G5^HUA7Q1WY!], MW'B);2B8T=_NP-8NO@#Y8)FQB&_6_(JE12*^"8COO@K$`X!Y@59T[\8[*E%' M%?=OD>)/;[Y68SZ+;(%J5MU3(KL!R.Y)9&^/[#U8*Z^B&.P51GR>JSR0\(KQ.JS]-G3@FG2*8!)[YQYB3FYV=\J*+41/H;<-S$NH! M4RBZH=-.6[7]E]!Z388T&OK<]-$9S0YRT]YY5M^=NUS94(('?(V=HF'=6'9, M:>(5:$.8QD/M+V_1I8,ED$4,&G!\`O._'-]0XF>-!!WS+S M+\=GNZRTM6GXXB)V=`K-8N''Z"9^HRIMK1V[I<59LYDX85;#[FVZNO?4X82H M%P'M]`5)G%L>35+$R>3.P^3DP`RD*PS=%QQ/WZU(SRRSNN8NG:.U M)NZ;,\''DWQ^C!8Z$=B.!1`(XK@@J".XVSWT:T8>5DY?\A2.4V-ZHB8PG[+H M/"X=!7,1^VS#(C#`6CQ2UPV#CUF$O'J.98YU/E,HEU[BO,^;4NHS#P7P8-G[ MST9XX'.]!BF83_'Y9[&SDX077H@CGX5PYE:=/@%(`"6//`]BYMQ'9;A_M7-P MGSC*BD\P]+B"&R+Y\Y=+E(9X2OB9FHER[`4SH0$LD5F`K\)OM.&0:11X,0`A M,5B@@YVJAR+B.U*',E\O[YF88$R/-W<"CR94]IM1CVM`IGV8\H#F(XGB9(DC M/#:O"BQ0NLO37V*,"Z@2T*7]O[#`'=VV@QD_;PV;BJ-UF"Y%LQ69H"0+Z[`R M+LR`0;[P@O<\0":!LC=J;Q0K:_3F4*9+Q^4POX3+XI6_2\3H)2(#Y^'%;>!Y M6D-^H@]+@:7Q\S>39'_X[*Z%+4;I,-YU7>V'_JTC[:LA'>-WS+&)IX7L;(Y9 M"?#[NJ0[Y<8'>R\Q/@P!+A.@'=-V,^&4<<**A&N/>C7,<^W,2H*YLS]F52`5 MO"25*/*TC@?)8E#57>& M$YR%V58 M,991NY]=[0H/XA9#1`,:72,$SVS^RA;_VDEZ@ M#K.;H6.1_KV6^U([O6XMC*I^Z:^O&EC#I+]DDH9^K[?-VG_#@^'YG7-^9$Y= M`S'$K]2P,_>9[OY)_436O&E@CUTZ]J>8A]+2;3Q(:J^<8I9XB04TX/$?M3U> M@00OI?-CK8^+^!&1*??\67?'X87R[TA=Z,GFR?$XD1M7!R3N6I]1GKH2/N`# M>6C(5K-/I.6KC_QH%E!\V7D^SZ%UD8J)N0T#*."M9"J-\@E2L1N1RS/51=@# M=)!HO[CP;9\Z=>GP(0/B3S[&CZ8Z$O4N`,"3&?\!9H%DIQ'>T5NX#(;^.X2!TKVWU0VE/39=UXJ M'THFA%-?*A]*9E1?U@S;\B&V:''`2^NT,*;8\OG%<<8KRO^4D>G^<+A$?;:+ M2LDK)VM==9FYM9)75@1&@WVSKUP^T$R$P5KZQ/?KZ-H=<$M>X$SSNU*SHV.J M8FIVW2E7SIR2IGMW5(J1^PQ(P^IX$0D:!`D?'[M1K'/FH7VC::O83I(-DK\(9X8;=2W#FJ?74? M^QU`N?B`[O:CB==4_!K:9B,+@Z'7P2V\)[G[DM89K%YD$[W43'.YA:\S6KWN M[8_FDLMCM[W:VMHGHTLF*5V]AN81G5!M/#-2YG:)@]=[TI>36.E@OF-:&I0Q MI>,`?17Q=N,*X\W-B4G'O'"XJ/PT!G%+5,@[Y^'M]RAUU64T;53X/Z;<8#RT M'_'.3V#QN$L,;<=KU:9M6,&87S1B*3V2MV$NDK=A+J+;,)'KB;5T,Q=3Q)%W MD2R-')8/.,7JR&_Y[[HW)9\MYSF^Q5$NQ1:_!Z1O0!`VNQY%[%[`F\[9:#`B MP'>+70/@UQ#8.QX.6C05)?8YJI0^)3**Q7=I]W^G=_D:+Y)T$EWU?7!\WYE% MG9;KASS@%387""\WMMELFWGV=7G/YWP?PN1SA/<[86O MB=O`ODL>'H')COO3R?\Q#$HGDYSKY6MQ*81A./S+QOR9.4G\-F>_7N+"]IH! M=?#:B^;%P!^*_U\2E.=>I2^H#=;@OS!P$C1M0<*;K7IF7(JZ'FW7M8JWR2J4 MH-T8459F8-WTZ0N6F$0:)E83Z2Q]C?OT3?NLJR7JF$GIJIZ$2L1,4]0C%K.7 MOS0M"YI(H.^E4OPGI4_*6D-EK=/N'JVD;;6@B2U3BW_]GFCS'Q'=QR!\L,5' M/P%EV?+CDE@'6/S6<7)_$B&V%2$1#Q:>RP,IA'E%Q$P=5FC+D%B)4/<&O0J% M>I_S7.V:FJ6\BY2G1'5_M$^I?^>^)?2SYWO9DUD5\_R8E61OC%"6 MR<>XBY<_E\$5E./8T6@L3L%AC@'6V-X'=KZ7=;CO\SR@+\\##G`>4&;7LM/B M1PJCL?J^MSJ%VK`?V60#AT`]W!YX^M_HSP63!KJE;GCQ+:EQ4Q'#0_$,DB8T#8&/8U9J/C!KB98Y!J?[F MN']B2/'<=;#0@E2K#3VB[VEJ\V5(0N2P$!DV'R+UGNTF3Z6/0?M^-FW3FV)J M`;S^7,,9K@S':$HXQK#7J=O1=&"M+K'75.S!YJQ7I?G0@&"@HA[/=1$/N$)4 M[@&5H3;'&6JC*=U^G3)2\Q1+V!TM["K=V1THPFN[8_BD'C[4T93.W8V#F(=7T`:9P'1[R`$9;GMF^.32OP,2_#'=9K9.&MF"&'9X#@ M-9N=V3SPHR2%8=T:EOZ4)5HE_V)]$>R,L-Z6$QY%9";[C+L,>\3DN(G^;B9A M;]`9Z^O%IN2((ET)#[1TP^317OIJ#?UW8`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`,G;Q6> MJBE=EYD53059YPV:``4^N0`2WV$O8)U5Z/[1Q,@+!(XI"MVR4`S3CG\K!C+R M`/V.B6.+-$\4F#]C'4X2H-49;N-+'$VR5Z!ZXK@S/F;]23`J65#=7<5/,6&(^-E'NY&`X'7U`N=#^75^^S"TGQL[T&Y#BK0&LW MJWIPD6/:VJ`[($5Q3K1VJ9QHZW.%695FMRDX+GRJ MMMY96YGT;R%%-JX5%J1^VGMP])H0H,;W%EMW&TI[4D2OUV;D':A/,'3#5%YBZU@$#,R>[6",3 M8Q1$?W*X6RS>S2/T%0JJ8,TJN'];NZ.2"&X:H4>!X/IV:@V5(E@+PBW[T8O, M]L;N+I?P^]TCB`+6O2GS@ACX1R(K_?HY?Z6A]@>LB=P]AIK($AD'0(:\G"-Q M<;0:HY;;U,>P\(H310^VV0:%13<\T>/G308O_B/.*^1:7#T)U:0L&,DBZQ(B M:VDX[;2'559YV9$C$AK-@88VK/)6P!%O-=G8,:R_WUUG3EU_P?;$Z):>X^&=7(H;*DR=(W`U M283(%%(2((T%R#&HD%>Z&?[B..-GT[+D\MM4V5'40:_YXB-!3`4MGEC)!1G-_5RMFM$\KYIKZV=0X-=@JKR3' M7_$K'_M/[==11H-CS>PG87>TL*O2-28A)R'WPC5=J1RFR;_S\ID62A<:)2L- MW\.$>=R-L915,'S M)O[56\4PGMC38SD.#7W.LHK]AXZ)D3K789ZCN>ZCR\APX`O,-DEXLD.O:.+! M*'TJ'P`^$*X6=>5:WI#ZI+=?-)A:I%]D11EHS'Q5G7O7E_$G0V%.V96]];T&=5OG#]JT/]]CBIX5"G0Y MO>_Z#?HAD_)LJ[DD5JK!RG)*YE/][;'"I8K#QH:?(=YDS$:P_&RZX:[+B@FJ M^RA^C?@T7BQ.`UL/Q@";<5W"L!\U><`YWA<)C9B!:@\-5IX/#/K-/Q](1R`6 M4$^O-(3H@-F>^L=PG54BXP#(D#%E:\]GCT'_?F=NP^UZJ8#Q[& MD/CS$,7E0L;YSCRY4FS:_F@CX%NQ7M%:`GO[9J MO!&IX=S_=F4)R$?X*JS]"!_7UWUVU<;S;3DZ&U@+),\>#W& M@U>AV8?#YE\F#VT*,":6K`9YWMJL4[7C3IJTAW.U+05NK^=JGQV7`B$B58.Q M(+ZKVY[%+DC(<[9FDMB\9*/-/.S81J*3WL`C6S#+!DA+=_AQNL.9.^@E.\37 M^2J7?(:Q3S*8@8PLR,2T02),W0++;H(%?ID;"?X*?3YKKN_=\2=N6=UWX,E5 MW,+'A?BQ\BM\37`\)F[QD2>3/GO$]#WR$'A@&GL>^L'\9R=B(.'S.]14]6_, M7;;D5V-^/_SE3K>`1F"H2SWXGD]&ROFV_*[I$6H_ZH]TC!V/J0=L@LE0@'@[ MF.B&'[CBH_LG92Y2[,T+YF+6R.7EQ?>L3R[?WN>L&:#+ZXG"RX9NA=/"9@.V M]BE$#[I_2SGN@-`IZM\Q@:>I:P/J6#8LZLX#RQ.C77B@EX&;CC\%K0!SQOJQ M>&4'TV;OX9/X';OR^$S1W^@Q!L:#C.ZCHJL!&@#./)D&]3@;US&:8"4)W:?8 MHNL$CU/6\J^ZY_Q,=^6J0:JD&D`C2&10)"!MPWX3,3JPJ?&U`;#XG'!_+[H%'-U?F<5'W6IQ1S, M],<$9GS/5H;L(X_QN`[O/"CK:!Y%VJ8%,U7W?-1\"[J2%U^(!A7*F1)2S ML'T%%/:C;BFB"=!H$XK$F_838`H^,K)PQ$J):;E*.YZX) M6`/%P@MA/W##(OT,\L)ERI'+)I]T%[Z`L0-*?--?D`=J.<]L2M%C#O]O.QSE MX72Z](G:`0)WL\[&'B*U8R(D?/P>@,.Z*7TKN(".K:'._2[G4FR1EO=]FW[? M5^V6O_!;%7V9I8Z_G;I,O.H2<.H`2MX(EF=.ZY%W2S73GM;\H(%;X8`G$V@J<7(E+7>KW.#7:'SXCM,F)N,FD]ZPF,W:^>I:PQ"I&3?%K:"\/N#N24`F"U]'0-!A+ M;$AL2&Q(;$AL2&SLVU^U=\-(8EAB6&)#8D-B0V)#8D-BHQEVT5ZSB6[M*CI@ MQJ_R=54JIBO.6;IU+K^\G*71C"-!83NO(36IND1618)[J(1C,@-I1E!><,Y+ MF8&T2;,A,Y`V=&)D!E()D8T0D1E(Y3&PW)HV8&LJL2&Q(;$AL2&Q(;$AKRWL M9-7*K+=;D'#(2T"55KF5D<@O!QD]9="1V)#8R.M:WEZ0N,CKNJ_TCD%GO-JL M'S>99(D4QKV0!$J$J[.V@,).2BVR1LG':&:F.@ M(;5%`Q"A]1N#!^D?DYEPCT5LALI0;8[=)1?9)F%#U91N^P@NYDMP'``<7:6C M'D$F+8F-0]AB/:77:4Z1"ND3DYEPCUZF!@VJ^B*U;9.0,5*TOC3A)3;DH:7$ M1>&M75MI:T>PH+Q2CYE,A'LTDB0UK,1%7M<=1=6Z$AL2&U)G2%R\+)TA;T`V M$K@[DO#J;JM(;$AL2&Q(;$AL2&S48!J]\_$P+?J4<-D\N.1=WO=99]0ZUU,> M&6N:6NW74H([\S"/2OMLT)O[J50JNX$_3+>R9\KBU'7=0O)0)YE6.OT<;P3_!KWH M0_\&?^[4M(D_=0)/M\?B9@8^FN_BW%KD]SD/1YWX,0\=>\V`M`:Y6R1=W(;, MI22'-BSB&W(<:A5B5:8UW&??:Z#X@A/IR;2&39H-F=:PH1,CTQI*B&R$B$QK M6'$:Z^+F0-V>E@(`KIN$/6UYME4C<@;D#,@9D#.PCQEXI0&!,L7<<45R=)5^ M^P@B.20V#H`-M:L,>_+JI`1'7MD)B(HF)CC(<]AJ+ MB5?J$9-)Y9HK,4.E-Y)YPR0VRJM)11Q(<$APY78^DXI#86-&U!N!H'X'B M>+4>,)E4[NAD2E7:O2,0*8F-`V!CH'0TB0V)#7E**7%1?./?&1Y!9,,K=9G) MK')'(TA2P4ID,F56ND<#=D817EP%(8D-B0V)# M8D-B0V*C(/=]IARJ3^N73UN"D?E56 MF9=)_?;9]QHHON`TG_:H#_2V)# M8D-B0V)#8D-B0\8`[V35RD226Y!PT."M=OL(@K5W+ M:&")BURET5=ZO7;SP?%JK]''B21-VP";[-TI)I1\*PVS9LG1J:ITAEICLX)) M3!P`$WWM""Z_2F0<0EOT^S+3J$1$>OWHJH/&8N*5NL=D5LGF2LQ0&:I'L'&1 MV#C$KE93NM)/*L&1VW57Z:C2,)?8R.M:ZRF]3J?YX'BU[C"95?+H9&K0/P*! MDL@X`#)&BM:7)KS$ACRPE+@HO+5K*VWM"!:45^HQDTDECT:2I(:5N,CKNJ.H MFBQ6+;$A=8;$Q0O3&?("9".!NR,)K^ZRBL2&Q(;$AL2&Q(;$1@VFT3L?#].B M3TF7C?C[[^\"K_6HZ_/W=\:4C@.+WDQ$'IM;.G=_LB>..V,Y;CXNQ(_W M,)J/Z(#Z\-__1UVKQ!Y=["]^[=GSJ?75TVSNWQY]-6[<-Z/LV M:B+JD1C`#OAP2R<_G1A:6X7_M57?87^-.NV3#\*K5M[!UNEO]+#=L\FYALFY MW3DF;4KA62"S$=.!CX^Z.V8/P2L7SFRNVXN_`J?7LISH M+"W:4N8SC3W^"1[DWZH\']K[+$2R;%OGA_NXR<0FH\ZT/$3DU/&=^7LRHV,SF(%6`8U=A?[;+J_> M]B1%*83ZA51ABCSV.ZQ7/OQH5$ORJ6F#]#B!!^#WJHS.W0M?CSI#I4Q<599;W8X5*HU*D%]=Y=>^]UF"X\=@\#6P]&,/\C3=< M?FU$"H(;[M&)3KIX"*7&FSN>4LJ-2NC?6^JYJ\`2@AL@$B51;T.'C0 MR@O3M>=XR*';!IYWN&3L!`_^)+!2YQ?KE:^4)7G8*0_")38.9MCF^CE3"G4T MCT>RI4X>[5,G)ZYUZ.,_`L_'8_TJ;.!<5NT=^65*CQU(.,N06$UJ(DUI#_MU M>_]WXV/.T:Q$W;&C3JWTXO@>4%>MI9XEN)L@^"C,][VD:EC'I0.+!Y#"=BT6 MK5Z$BWLH2Y%646:NSK#*!#M[GF()N^.$G=96^J,J77[[G..=PV]+!\1&(;@B M-I=$D;ODD^D9EN,%+B7_PN<)>^%_EZ)Q,Q&_\6O[B+K=O)95&'1[?7-_22X( MG[ZAIJI_(W>77[Y=7M^3V\OO-[?W5]=?R/GU)W)QWU_=7-]E)[!\ M<"R\]."2=WEHV,PUW)^9DT6A<.5EWJQ@1?5=US5I]W'8,WDRZ;-'3+!&'@+/ MM*F'L=+$?W:(QU'LI287(Z;CVKGB$6;(X"^Y=5S%0V?D/O==$VM*/^J/=(P= MCZD';`*948!X.YCHAA^XXJ/[)V52B+UYP3P4RLO+B^_(?3&7`3 M##M0Z3!GK!]KP<@V;?8>/HG?*1A4_DPM3*7*&!@/$BMP,],0HUJA`>#,DVE0 MC[-Q':.)PS+C4VS1=8+'*6OY5]US?J:ZY4\-'=27%SQXYMC474&71XS`=>%M M(#2<#MC!4/C((GTI#)D:`>L'2$L'S@,1<\?VS`?3,GT3.@X`UBYQ`I?HCRZE MC*IG$QCRY?+G"SZ"$'\45IV`41N2#]2S6'WT;S_H'A""?6:R_9^1\_',M$W/ MQZ^?*)D$MH'403N!,45^3IB.IPJ9!M`8$@D$&6A@\YF(+P3XU)C:L"5Y!&:X ME(5TN8"+_T#7^*A++2QN&J;K`+O=`OED7_D.H3IT%V'\ALV9X7@@-[;C@TB# M:8],U7W?-1\"'G,/K\4#"N5,B2AGX5P*Z/9'W5)$$UB.G2+QIOT$F')<3A:. M6(DW$EX*40:`7(?IXWEZ4W(\=TW`&B@68NC>%/AL(:_2SR`O7+:&<=GDDRX* M`@-*?--?D`=J.<]L2N%I?,-V.,K#Z71%):TS>-_N&1KFF7^9E#+5;_C9&5?1EECK^ M=NJFQZH;&N$Z5N%68"^<;\)UC:*D[_4>1[U(+N/:#)%>"KHU'"0F(5YU5^?L M`B`NQ&*I`ON*@LT&ST[1B!W#,KGB4DD-DG2_>% MW3N^;HEX6&EI-4MBADJOTEM*<@_[;2G`T"1PCJ3@D-E9TK0$X MVD>@.%ZM]VL_R1"D3%5[0-F@G8W4MTW"QD#I:!(;$AOR@%+BXE!I<8X@_^$1 M&6B?Z(2Z+L4PPBC#H;@)+PVS9@F25+`2%WE==Y1^1SI()#:DSI"X>&$Z8^>K M9PE+K&+4%+^&]O*`NR,)KRZWNL2&Q(;$AL2&Q(;$QK[]57LWC"2&)88E-B0V M)#8D-B0V)#::81?M-9OHUJZB`V;\*E^,J6*ZXIRE6^?RR\M9<X$A2V\QI2 MDZI+9%4DN(=*."8SD&8$Y07GO)092)LT&S(#:4,G1F8@E1#9"!&9@50>`\NM M:0.VIA(;$AL2&Q(;$AL2&_+:PDY6K;=:/FTPYYW>GF/OVK33*FB5&I_UNTNLTITB%](G)3+A'+U.# M!E5]D=JV2<@8*5I?FO`2&_+04N*B\-:NK;2U(UA07JG'3";"/1I)DAI6XB*O MZXZB:EV)#8D-J3,D+EZ6SI`W(!L)W!U)>'6W520V)#8D-B0V)#8D-FHPC=[Y M>)@6?4JX;!Y<\B[O^ZPS:IWK*8^,-4VM]FNIPY6M(XMQ#,2@EB7R:OQTTCYA MG[VY;H2?,_!OM[?D*C,H-R.L@A0?1*12\9UYF$>E?3;HS?U4*I7=P!^F6]DS M97'JNFXA>:B33"N=?HXW@G^#7O2A?X,_=VK:Q)\Z@:?;8W$S`Q_-=W%N+?+[ MG(>C3OR8AXZ]9D!:@]PMDBYN0^92DD,;%O$-.0ZU"K$JTQKNL^\U4'S!B?1D M6L,FS89,:]C0B9%I#25$-D)$IC6L.(UU<7.@;D]+`0#73<*>MCS;JA$Y`W(& MY`S(&=C'#+S2@$"98NZX(CFZ2K]]!)$<$AL'P(;:588]>752@B.O:QD:*'&1 MJS1&2K=?Y0G#P6,#7YB%%J>9P_1RTAYKEOB$8B4Q,8!L#%0.IK$ MAL2&/*64N"B^\>\,CR"RX96ZS&16N:,1)*E@)2[RNNXH_8YTD$AL2)TA[[1#E4G]\FEK<%*_*JO,RZ1^^^Q[#11?N_G@>+77Z.-$DJ9M@$WV M[A032KZ5AEFSY.A453I#K;%9P20F#H")OG8$EU\E,@ZA+?I]F6E4(B*]?G35 M06,Q\4K=8S*K9',E9J@,U2/8N$AL'&)7JRE=Z2>5X,CMNJMT5&F82VSD=:WU ME%ZGTWQPO%IWF,PJ>70R->@?@4!)9!P`&2-%ZTL37F)#'EA*7!3>VK65MG8$ M"\HK]9C)I))'(TE2PTID,>0&RD<#=D817=UE% M8D-B0V)#8D-B0V*C!M/HG8^':=&GI,LF\7?6`16ZF]1ACK\IK^\U;8D!_Q%X MOCE99/Q9VF"C0^N>\>(:>'&[AA>?1=XO?^K238F_-';@B!G`%/+EDOQ,=,:QHAT/ M^J)C;5W'YY;GK&_GS>!,(\!%RW1L!;.C#?M_45C+;]31V2#UTZ@'/T%G^MI# M6:+[JX;U"9[BWZJ*&&.*WG7XR_O[[^\"K_6HZ_/W(JO2+9T[+MZ>^&1ZAN5X M@4OO`4L?$3,?_ON_"/G[_[1:=Q2&9#\JY)':U,6`/R!-'\],V_1\O'SQ1%LM M_G3W=/+3B8&C;@_:JN^POT:=]@D);)/_ M^DN[K9V0,37,F6YY/YVT.B1?WUCBO9_M^9X2G'] M?OZLN^/[Q9R>_S"]W^/>6&>\JS4C;9]\Z&C#A@Y4K7:@5:&OZH%F5/;N`QUI M#1VG6NTX=Q#1%*'GKJO;CY0EYWQ8D.1SW_4%^YK1JA!,XNDOR)4-M`;X@T=N MF)'E3W6;W,RQ.4]!HW)"362<:9/OU#6=\:[<3-#X<1$_(NACY''B$K0QTNZ! M,D%81-:5S8FJ7N;4S!0-N^T"4U3+X!HR[]\M>`+Y>A03CM1>ZS,^W_@!'R@R MT>JPUSOT1-_2F8Y;4Q=W0D\`5KRK/=\D?I],V"'YL(>J?'[8?W[E='!2U2HD M[OC.)'V*=A8P0T_WAN_K/"N8S MAPF%)NR`D["/H7^!MQ&,IZ`I/'S;>[N')4*($.O<"^7GB^MX7O6K]9*&J&@E M6#V&8V+NCB9?EKF-9.S-9&(:M`;%6H+36VR7ZM*O@AUR.G>:SL8LER6F$[-8/8]5$Q['8K:>NUI_ MM#_V_F+CC@T8R7F;8O/>/!S7CJ#B.F"GE\LL7O+TIYC6ZH$>[U0%RK+D'L!% M]2N?LT;Y)3E-^W-*:KU]S7=Z9.GI)M^![.531/R)_5($RYWDR#38-YSULN-B M;>7V?`=$@=Q>PL?PJE`!!.33UF[W86;N?-UG#+NP=,^[F;#FV"SQOBZCGE;. MU?*(U/[:$85:?ARXL?\R`KQ;XG MY&0A@5.K6I=*\K($2E;CX)`>_!J@L;6+OS+;;=M)%&N\,PE-#CWPIXYK_B=C MY-4X89P$T&RLJ_.X_WR%N".OJV#V*HHCKEYY7K!W*YE3P[O>W\)?'5?SZ%_' MT=]T;--O)",%;85<'I7I@+(,W,Y8J8VC69=5!99/'3[@H^>R6C>71YU!3S(Z MZ^=Y(7!N"G/5@LQM)GPK<$[<4W?&:GRSSW4::*RGFPG[>Z=HEP^]*D(`DN0D M&.JX?LN'GXC)_$',"%YF`3R%[U_%SQ3Q"2S'#"^=O"\W7`=MJJIUU/6T$7/\ MT\D52$.KTRM):,)&%;L!DRL`O#H!I'B!Q<))]$>76ONA50ME%EZ\XC]SZ4V%?AK\)GD>R7 MM+(QM_WA$GNVH'-[1FT,0JB*O$U1, M$52#[:,(&UBZ;]%[13-T%"$`2T(T:/<..T7U*;6*+P_QL].7R:J*KQ_U!\-J M657:8-O!ZF5$'=#H7<)=.V^A*TIWQ$)@[LP)C5B%/'-/*+\]C6.#=M#076:O M_N_`],SC55,4CX%].76L,76]OX9!#.<^ M`/LA8,D/B.\00`G"-X]6\:IX<9OM\;#35Y?I3+6[)VK+;9C[N&'6!OV=:+]V M?$KB&_GD7W@GG[!+^?FJ(=4VOIUSG7_S_0J1:6*KI!.;DZ@NY9S8/HGJ]+Z,H::J?R-W]S<7__?GFZ^?+F_O@(__SR]7]_\LFI$CC_8HU]F#2]X5 M2>^1Y0X?"S[PGI@^_&H'R!5(C&\R@U/=)30&_B_XNVEA*<[%6$#PB[^RQG\`ZX:Z(3'R?P MV2$>G>LN&&N$\C4#X`=F^0P@A%P5(1N$6;+D._]-$6SG$T)AM":B9@X8Q&?% M#`GCGCBB"5@[YX%K3,'L73'#//T-=LLQC]:$;ANT7+\"&2M`Q$7$6H"$F"*` MTG6"QRGKUIS-Z-A$9D24(AP#Z"UL#LPK+W61GHF@%YK,+F870IS#:)-2)O&' M^$/59HZA;7^J^RLT($MXI/.TYKY/::AH\IY\-D$EA7E;8"Y-'[[RIV02X/=< M'P&D82[&%`\],`L4FV=D!?XBVH8&S;E)$]HQ!"W.K8A&$M",U=32,V>1N(38 MSU-/`J8"?B;@V\94+@*?B49M,.#_'%((&Z!YBK,7ER^*5AYYFS'(^H.ZANGQ%7F. M$RV.7:$/AG`Q>/$$HP7JT^.V<: M8CG+FD(Z"FR(F<>&,7-GDFPX+GWBEUZYR0/!?,1Z6RXXOXEJ/=R$NFT0+L+7@FIQKYS"/ M0)A$``QD7",W`$XD= M0WO@'P'0P+/E=12>Z2_BPNJQKYPX)H+V'X'-7&3QX`#*8$G@5V(JOUS^?$'. M0Z=>@E7JL*?TDA,XSLP?6B:YDR\8`^-)SVL\F3N-;<5TXI##V>A$RV<\F8F? MNQOUR18J8%G(5\AT1>DR]ZN(KIUHY663M&8_)*+B2^?!K$#)'R-G059BIF@L M5V9"Q8:,SNXPUTD1RR[(-EM,6Z5^BS8:PK_+MA.JDA%1T%*ZG5GHL<"4( MU1]_$#4`[.9\D]E0H%8`#/$F!4?!]N'<.8SO?_YRR91#J"!1:7:7QK6L$C@3 ME`3<_#`&##]$@])C/69FV*JA/@&R9FC9/=NPAQ,$<1^V[X.:0-B"JL$_`>UL M+`ADF#<*:U\X)O^96D])6.-#2QE/N>FG/P)%CVC;I,QA'=IB=`(/*.8,MIGI ME.:ABX<::,*)O1W2FN`GIE0U''<<*6*VD8V'S,E(S0`:6>C9]\@;31D-1HSO MIQYL>ICG]NKM(46P68['3+#G:[4_0S>BUN5NQ+1NFI@6HH]<@,S`KM$0-OPG MZL$`=+&QG(BH9&H;PJ"\Q4Z$[2`"ER_P*BLT@GN/;)SMZ*@C_I#-P M]6YJ'+X(`MOI9=4.;K34'#4[C^@1ZM4K2O=R7/:)V!(:[#UFA[D1-[@`+X5R MZWS?"MLZ/70,<4_$0]@.[Y\I[04S*W%7A5IM@EZ*?^AVH+NA<0G_%;X0OD7^ MJQ?N24T;%(VZ6A.?YB\)9VH_L2(LN=B8"_DB'BZ[;XFSY@4/?\#$<%/=-UMC MTPH8'?H8D<]VGL!JC[(U"LS7!VHYSV?D,N8".D4"WX.M"=/!*\/@^<88,`+B MX`.,+&N18!Z[P`Q4K!AVBI6QD1[S$?X?&#.9\.S6Z%$'W<5VTJ M6\RYPUT"GLB)'FX]*,G.3&0XPW[-U1]Q8PXZ)6KUR;$"1K:;\<8OD88_KR5- M$*3UI.,;AKWY_F-P.9J4DVAXF`@,Z[;[2'_82KRS3_VHG/%VD`*6NP&8ILS?P0(.3 M-GMYI'0&ZSD=V:(H@F]4+G;\""0R))D/%?KVN&.4/ZFH0^'68,4"E&YOQ%]U M4R4(KFS#"L8\&P1SA\:-F5[H]G8>[6@S@%^EK&(*`VA>5>;"M".9A0 MW0] M[RGU3I5LB>J)7TS1O>81$<)+6`QO5B4^Z9[S/HKEYV\D8WYW M4=R:R@=6L(\]CZ"<@A^>?.B):X\5#^<:3(1R(XK?V&I:"@PA[N$@HR@W-:.3 M#\->H9G)&=:=#I;C5S2]'G38;"6"WTDTXB_HM>:W#_*PATU$+20:"-_'U]G; MN\A2.+JRG35JH*7FM8MWL-1X7K<>.4:ZPMZ9^4QO>9$WV&BFAY9X1CP"3^Q8 MC*S;%X5L5O=0`XWE"HOU!IWV_FDL=[U"[0Y[PT,PLE3!KTZOVRM.I.>3FPG) M(39#J.??3);;VA&8JJ:E@)G?27W4EH.HVNUU#TEM.;!V^L/>87E;!K6=7KM3 M@MHKVW!1`^.9;/C'.JL@-83PY?#=->OTCG/0ZJK]>%0E^CW\0,M-7ZO3'^PZ M4(QO=)AWR<_448F?T;:*3^[B/ M>^>[Z`$V,9=A^\E+6O?.3=@V6_B]W=>289)=U5'U@OA9#H&C3MT,#0_N\D4^BC=UOA^[2>Z,Y M4?*FJ998R'=E1_+^&KF*C\8NX@O54>REMV3^.7;BENMGQXW?BE^J:-Z+=G?( MD96T==N#S*:AU/AB-]W%U+3QI"16>08[?T/M&=XS2PTP](6)%R.]<1&^=A[? M3MNXQ^YFLQ^+`17N)&=$SU/'LA8M#(,;8QR&9XY-'35B[C!^XT_?X--WB8>W MH;Z3H7Y5VTF8L:/.J^@:",:8*N0"SZN^FOJ#:9D9RT:\$KV!+^#CT=/E71O) MO/[%^H@&\#'P<((\8^*7/R\GM. MTRS[`E++B4W0*DC]_)B;Y#N;J;W5/FN'4-]^!"]R%K*9BFJ>!57.0H%S)2D+ M!Y(%=9^R4.$LB#S9/)MIBCWB%_Q^HPOMPW=,+)I]+9UL-4K6XMBIZW7B!D#: M>9Y(17AC7XJG89T6MP6V/UW%8EC:L#=0NZ&G?'U7<;!$>'LR2CP4I1S[I(.Y M#8BC,'DSW<[@=(H)A<5*>1@_I&"T'2-(5-'HA_K*#- M,-1)94G-V1=D4C*LR:R<,N)Y.)9(FK!B6U"\>,6F#4^ZM[2J*YA6.C>K]/?P M$M'W,.0ZN<4%/1T#2#!Q$W_RTZXMYWE^R.9Y#DEAE'!?M]B[9N=QIZ34!25S M#\/8URRBA0,+KAW.(&^(1Q4>H;:P;@"*;^O7/.FKC@+41^LWMQRW-CMKGOJO8MLR25 M:#^V6-)WE!)5#1)7+N=.YZ_S5"N\,X,;`W#G3#&F.'1_APF&FUYOE9&V^/T(2Q[E6]`V7OIUPIOBT'O M=?X9':$6;'1I#W\^$Y=3BH]`[)WYBSN.H)?9D&]N-!K!-Y$UD)T[P!H'^I)< M8BX5'$Y4!S2Y#4V?6*3&)!K#MGA384MA0XEV4D<,6YU<:%KRY&+KOI=8(9Q+ MD:OB%Y:<89DI42MY/(B]0-@&:R)+4,S(`J-?JL><._HRO7*:+=/^\_W$<7S; M\>E7^$!^L*]"*>]\%F M^^F$BLY.6./9YL6CEOY`K9]./HMO6RS>5#TIT7'88+IS&+D#-CM^.[.@%_L1 M"+);O]R=?+BEONOHXH:8N(C-S>5'Y#]?G/'CC.IXZ8K)G2A_FKBVG4PI\?=W MJ;&E!FPYAJ`,5E.8O_^3'J)@`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`EVHE,W*+JM&9"KZ-3F*3IU@Z);S8",6'R%#_#]W]\A'?#' M_P]02P,$%`````@`"DIT07Z'CK_]$0``I@$!`!4`'`!V87-O+3(P,3(P.3,P M7V-A;"YX;6Q55`D``[20JU"TD*M0=7@+``$$)0X```0Y`0``[5U9<]LX$G[? MJOT/6L^S?"0[1U*3G9*OE*NGP=G;/(\WF4A'1TS_TD%A*BT>W=S>75]<7H MY%#^=SPZX\O7D#W-X]')AP_?C\:C=\#"ZHTDLRAY-/(_Z270X MFOC^*"6/1B&-:+BBT\/Q6);NL^#;1_F_1Q+1D=`ZB#Z^1.S3P3R.EQ^/CIZ? MGP^?WQ_R\.GHW?'QR=&_OUS?>W.Z(&,61#$)/'HP$O0?H_3':^Z1.#6YQ/[R M&/JY@/='15E:"OFO<4XVEC^-3]Z-WY\^W"4 M?BU(A2!F$%V8+;PW&JW]%W*?WM'92/[YZ]U5P;TB$5_0*?.(?^CQQ9'\?G2: M1"R@473&%X\L2-UU3F/"_$BHD(J+7Y?TTT'$%DN?YK_-0SK[="`%CF6HCS^\ M/Y;^^,XD[:BMBE?!B@8Q#QF-OM)X"^TT@EHK)@#-DR".)L'T)I[3\(YZE*W( MH[^MHD#!K16_)"S\C?@)_4*)K-H+X99H"WW-\EJK>29R#??95.8B\?@UCW9L*;CL;LT_);Y,8O=S2N,=6*@37S9"*.DE?FK[M?AWI6CZ$E,AJE!( M&M*=E:D2N1H^]RI%^[()XV'5[*SDM"68D>@Q;0Y$,_Y$R/)(NN.(^G&4_Y(Z M:'Q\DK59WV4__^>:D4?FLUAD0Q'L^YA[W^;9D^>:3^IP,H M>6-R25]E"J$TR$V5FZ8BJII5J MRB2L6DE"+Q?A7QAC`0'&E52]^.H*6\4 M\Y%.#@\%7K/^\C.5'=;L'WW&.DQ$RB:B)R#2\X)%LDNO#;F==A-Y$RUB`(!- MA.'`)"Z#PSMT<+`F-"M=%0;V](8.`E;3X.%7BAVTQD5RDWOZ(H&B2:^9J+,)SHBK%$&&04(M$Y.%NL?NHAU'D`01\=8S9&N5/A,6?`[%.%N?P]NPEY*Z&SM6*&SI"&#:=RLA M@\^/^%*%R&S6_B&(MI8X-+180>-BHD,:T8C+X/`3'CA\Y7'1P-U17TY,W9(P M5=HG8IPS8W2J!D<+SLR/3IQ8@=/>?`",G(1GH/I@`55/KC-/"G+`K)K.7TK) MTGN&FH=HSJ:DY5<>>+89QR9-<]*Q3--[`Y/UI+2V6>G4/5*]C3T!7*%XLU^J MM4X'[@V#HG=:EH8/V.G2)`3==L+,229"Q!@`VP<#@4D<<`YR`&V`LY,@S4`+ M5^USSLZVQF9=54.UCG8;9MDJU2I=_Z_98Z#(#%)2](=E,WKMYE2PJT:K4@B^ MY"[7/WB@C:SN<^:'YF>L,;48`@AH4P*^S#.93IFT@?BWA$VO@C.R9#'QZ\M$ M9JI\D4A'A37$,+,`D=8*PK<\="D'"@`5/T<3SDD62#C!%'Y-YK-Y' M@S-D_H(P8$6$L[$`<$!DXELM*FF9=CLK>[ZN`H\OTIU?7VE\,WL@+\UUY3;< MF]5F-VZL<-K.#9#$XUH`<.4*ZS#!V@]V'B.H).++VI,HHG%4KV25'_.ZD_W8 MLZJ:[2:J;Q7%^]\U)_?TRCVNX@^)AQ7QY0[827Q&PO!5Y&]EI]>%)^\)PWCZ MJY?J8/%VUE;J945RVE.&2<0W&+J?\S!^H.%"GB"(XG2S='WH;B#)!^]*$H21 M!]AB#K1:`,)AD?&ANCF&5$=_^N72] M762>:TZ"$M"TR1Y,7][Q8*9'&&Y7*\T8`$CKU1FJ8F]`3E+0C&20H4T;;:88ZNBAWA]K+:U!";=_C,^?29^?7U MU_K/F=&;GS%%3:.L)D(;:GP#>WV'5;NCS87%.C3`L$61FJB#Y/4Y?#> MO?=HW;\*XK'W(;%&NXV9FG`#1>&;'BAUB\R;674TS4XDUG!#S-"$5\-J&=3_ M?%2W^EK\>[\WL+2YZJ;'#7CU-7[-+@P`Y69;GIZRO_:7QIL]#),58;YL'!YX M:6-=MG)_2B+FU9OB=MQYJ^S*C<-+)A^8+.QUJCQ7XE*D)%$E8Q8D+'C:U,-3 M.N-A!LOT//;%2QP2D5980,+7*U%STWPC.$4-%_H]704Q#6G4G'G?>4G%1/X. M2^JQ/QSPM0%2':GYQ(AA-ZO6VM M0E\1AV_:17>L/YL;O*4AX^G9?C%$Y4\!^W/3X;3=027@65(L(5*O1!UMOD$N>* ME"X;!LW:P.;&3WV.,=*4SKXJ:%!*/+68:&0C[7*KVC=L:CHKY)0EUN"+- M2'*#ULTLS9GR<%16I^ZY7Q_:V`D+?.L),9AIMLULD,J*?2(4$`1N,Z<"6+W` M==6M"<**WUQQ95SK'RMAW7P<1E0UQC@'=2-G+TVG+++9$"C#I2>K!$Y%-HP0 M6@UT#J9*XG#:5W#+8FIJ34)4"%=-,N_3%Z99`6X::E>,\GF M=;0S)O7O]?F2S??^1G0TG;]:OXGF"^A-I@L6L"B6&JXT*V-N3/EX#\B$`-.- MN/&6-JO!GHM/N]A`L?AZ+G&KZ::;[RY%B\^>LDU` MWFMI7Y`8(:3_R@(__6^ROH](LY=^MX64CX?LH!#T>-^+=UVJQ:X4L@Q`L9V% M43QPC>M>OO6V/A&;4&[].Z?K/^O+"RU8C;?TZ5A[2X$7LQGU!,8N7KPY"9[H MG0CA3:!6ON:<-JR9<]Q8>TQ";>+/MW)--=:./T/(VY+*# M-CU]_56DE:O@4HRS`T^,JRS:I]6!'C]`Y4/PLM?&F.3;81LKH!H):37\8HK,GA'SJH/6H!Z9-=/M"H? M7Y6^HTORFG4*RL>VY9F>QI*%G;18L3"1#@UM#H9O@2ES*=`Q;T_0*3]K9X"- MBDP!F2K9D.%B,+@CJ%1+4.T1Z1DFY5SY.PG%,"J^>*&A?%Z[WDV`D"I:NB;I MT"#C8'A'K5:S%.!E+$/HW[?N;F[5NW'. M!C8KHPYQ!L;!PP[JE"ZQ9R@386\^;>W6BD]E!R']>Y2^?J::=353EB=9=91# MPQ3<["U`9"P$WT6*#Q\M<=5'N"8]>74CFAL[-;JOJ>AY#FRG.GESP\Y\EC/$O\_)VNYFR]E70S M6V\@'1K0'`S?`E'F4O"]C+:^)+J4C&]FM6O!53LO00R52[;-#$/#DK,3MD`4 MI"Q\5[3?"]7HJDX)Q#PTI[MVP!(*="54_(]7YA<%7_J\#PAJT%AR!>#1(M MO$/'HHMK.D2CI5C5&W?H\'B>4+D\4'TO5_T`7CMF+2+-S,.'I(-S.L6DN5S5 M4WWH0)F_!=R<,@;1:B%7H1T^PO2F=PJH2C'YQ.LQ:@"MMTI1E\95SZ*%DXIE M^*BR.J)3<*E*RS&&:5N-(L\:YR3`]/KV<>@S$JXNZ+85U,Q'G&#:*M-4>WVJ M=-U85U]>T^)*SZ*%EHIE^.BR.J)3@*E*RS&&:1Y>H_GF^3T7F.FXS$AKF@7FD+/NOD$QZY$=+WD(R;3Y;)(+DW6>H\HT?+P!G+&3F8UJ>3G: M$,WJ:VK*Q6+I\U=*LV'P-2./S%=M0FK-;\YY)O[AH]'-1=WG05/1.48[65W8 M84(,$S=8ZEE,R;#!,GSP61W1=2)LE)9#[$?,$,M/#>1ST^F%ANJ3M>V8M;`S M,P\?@`[.Z12*YG)S4/Z$&919;7+"HH''EOG>&O+LKMA%[E/C[`-FG.73/^K7 M),#TULDY!.]+=#TY!WAXHJO)N?J+%.^.46,JH0^\]4*IA=6T3*IE?0.@@SJF MZR52;:DY%!$=+;!.!CF/;HVLT,F\-S:L`#MFE]-ZJF'&.TR/$71\L,Y^UFL7 M!^N4I5HV0N_YXLU+PL+?B)_0+\*6)%Q?MWE.8\+\J+<;-M>3SH5JYRSR?"ZU MJV4=*UT66P-=O\?7&Q"SV^S,9[P_%."3?=9Z>T!Y>P]4:KBVI.)0.ZR$K#:C MZE`6%X?8T00C+EIJ,S%RW#C9"@>+3:SE".F>\[UA)ZEHQ'I/_$;MU*,@)YZ\ M08#Q]%:'<_TV>EG--Y'6K%:3]EA[G2+(G6RNUF-(0;).FPM`>"A\O1NQNE/=T(NA>Y-J]"%T5'N/ZIU.W=?.JU7Y^J<4>>OY"8 MAHSX4?J>AWQJ,EPIYN2@#'5##0Q]/LJHB!!O86;M4<6-U+PW;Y.&K_TOM/Z= MA]_2!5R/1C!PV#GJZ#!Q((8'V%`8/DSB\/4$"K4OY( MB0,Q0,"&P@!B$F>Y7&W/C71^T]X97SRR@*SO*^JWI9N$WIQ$]#9D M'I6](F^-FW1N)K^"LK2N(3XDPM1F4[\3V1DT.I;=6[Z`VU$YF@!ZYVDGLIW] M#Y+=7[;:#4CY;KU?28R=6B`S:\>:XYNY;VF@_O1I=P*WJUY(3JYBJU/`HZ]8 M*I+R[.S@:T_17^NF[C3$;5=S2N+^JCZX_]'0I$MY+#S9(3`<_,]R<+.7G?NMZHQ3A7EKJ8_^L:8O0I MEFI15Q+?S9?%0R`L$&&^9BNY"3(FP1,3G<;4'TKLN[(5VQF@;&\0VRU]MELL MPY7"=QNP<_>N[(7J(?9M1Q)VR6T'%2;);["2[,[S6-H$@-ZVZTJUBPW9!_F_ M1U&R^.5_4$L#!!0````(``I*=$&>10F@GB,``(\W`@`5`!P`=F%S;RTR,#$R M,#DS,%]D968N>&UL550)``.TD*M0M)"K4'5X"P`!!"4.```$.0$``.U=69/; M.))^WXC]#[6>YW+YV)[9[IC>"=7EJ=BR55%5T[W[-,$2(8DS%*$!J;+5OWX! M7N*1.`F(H-K1$6U;3.2!_'!F`OCS7[YMXK-71-(()S^_>?_VW9LSE"QP&"6K MG]_LTO,@7431F[_\][__VY__X_S\$TH0"3(4GKWLSZZC=!'C=$?0V1..=QGE MD)X]/,YO[^YOSMZ_9?^].[O"VSV)5NOL[/V//_YP=G[VX=W[#V?/:[Q)<7+V MB'89E7TV6RQ0O$O?GLWB^"PG3\\(2A%Y1>';\W,F/8Z2?_[$_O<2I.B,:IVD M/WU+HY_?K+-L^]/%Q=>O7]]^_?@6D]7%AW?OWE_\[^?[I\4:;8+S*$FS(%F@ M-V>4_J+X(L-[E1_-L+B2L&'R]J65P*]J_SBNR<_73^_L/YQ_=OOZ7A MFU)%]EE!2$7^K4=?VD1K[\>+_&M-2AE%`M8-LW/Z['U-W"3\(?]7F+VAE7QV M5E0SP3%Z1,LS]N??'N_J4;)#`W3D<3)6[1/&X=)=0]&2:T+7Y!V0#M.(R,%:/# M"-X5/4;NF$>T0-%KP!PS3%%%QL:*WP81^26(=^@S"MB`FO=[`_05\S-6\QZG MZ0,BK&_&R=,Z($,:NX"9>G7>QNK/R2I(HM]R=I3]0QPD\^5\BX8KK\K9UFCUG#=B"X-5 MQ,6[^_2=(?"$FU4T@/!"?WKHG"AV=I$C;.QZH+5I.7%J=55 MJ9WEJ(-UJ,T%J+VQW,(H[F;\MCQRVQVS+8W6UL;IX2.TL['9_JAL>SRV-A); M'8/MC+[6UX7V%H0NIP1.)@-#NI`@C=+Y\H'MS],^J5RH79$H8W2-P1O'D>D` MJR_#U5+6P1IVT#PF2:G)(1M(Z=]#BC\4/M$**AKM?'D5I.O;&']-_Y8$NS"B M9&;S&P,Q[HPZ5%V.X\V6H#4EBEX1ZR3<6JHLVZ[YET',8C=/:X2R@Y0'VO M5X1%?4'N3:TI2*(D8NWMGOZS)1A]RQ#M2.KNB*D[I'MP)M:X[QM+"\&8XEZE MP:/Z<54$IEBY+I4V,5ZT5(A91@LF8'O)V\HR2%_R!K-+SU=!L+U@(](%BK.T M^B4?H\[?O2]36/Y0_OSWZ^@UH@J&Z4.P9PM7:CZZHXK6D^,X>$'QSV^D=+1I ML'H1T%WX8N/5CI"B17^A"Z?B'Q)S144XEL-%VI5P@-V,M*N#=J45_[)7-1P@ ME@1O5-R'C8P^&/#3&5?&689['V'>F(2(E*EJWL`EWUR7X*-%PP%$2>,2`8VI MX0"_0\88.[ID5GKV`_-L]OZG!4XRVK'>Q'F72"<$Q:;&B%ZO^^>K.$AI'YWO MM<^^1=V.4$I75IB`SB4"!%,O&!%M9V-U`T6(R)DR-`B8>='6FVI=MU8!I;OY M!&4U0`1..WG.JJ7PKMQY6,&FIFNY')E[(4Y3]>O?/_CCV?8*>I!K>V8-<"[C MU>S(1W/O`RE#>[ERGUL3GM+!(I*R)F"2D69H@D:)E:QI^K7/C#D49M)OKW^^ M`-9$KA9+6AOJ5B4/"T18544SIF-7MD+4RZI`6?3/JC"%`*A5>3HA8:N"16%R MN\U&EA]@59IRJH3=33]1YHA526J9,W8;O"2+R/)>F&(ZE>5:U4\Z.VZ'#F7L M.>YEG8M43OL\8H_K7+P\@=AU[^MV+D\DS,*Q^TY*A5&6UHWM7F, MTG_>Y6KL"H@5:9TGC%,F.M2N4^Q&9VMY:K7"ELV:K( MW8]]IZXE=`AF/P0K]%[6/`!27@-ID7H-#0TKU1$A9NK%#E5/12B*)";B.7^, M.)*ALV61)$TWMV-)'[V-)?44O]Q?TC7/>A,0**2D2LX#1(]\U`"3!`003,3V M"@%31YKD3/T<(&HEX3"%(CD7&EWR\4)3REX'$2(T6XB0CA@8*UWVIXB5?H#+ M%[1`X2Z;"8C*RS-NF3^3+GY/4+6-E&,13:[)NK MD3Y;3_N,_3.5J3;KZ%+R)QP'RNG--3A6&D\S#OR\Z`+ZNE.):@-&GY*[!FE0 M>C6EZ#D77);P[)2,"Q5S>''28.IG5V`"!/FD800H*,X7-+&@.TM01(,WT-_"H5W3XQ;&\_ZA8?;+WS^AOZ(@ MSM:+@,#+=CY!:19$,-+(*V][6,&@II^X')F[($Y>M,SBT.BO48C*%(:6`?>< MV+EFJ;*VE$MY6AN',)Y6=?2+*=5'L]A(C437S=BX*IH-25$J:U;JTKQH;.Q6 M^'`7TVZBI_CEOMW/7^[K%)LRY2:%0K06.58'PVQP/&KPUP"E]JO-$,!6%#$[ MO'CD%8_-*M=='EF0+5E+C=RO=)+R&G=`\$9PG2)5SZ!49+1**!V:WE*XW7S+ M$$F"N'96QWHEVM)L">U(0[.6_[">Q:VFHR"'M0T)?R^:29DGRXQ84+U8"GH' M%P**LFY`BHE@0&Z=B>=!KE[L*,_2%&5=%[=_K"+)Y8\3<21H@XGO*D;\'4%_ MZV!@4J]R%6FE]_[GN!T<4[`ZDG"%TZQYK'GU\8/UJ@%>[BJ+;5V&`XOS8@I?J@0&C\!O[;7K M^!%!-9]BL37@'2D0P]RM;4;3>K M;[X3JR]T6J^HF_;T%-#5(AV$&U?YB%J6*GG5)4K)??.8IH%"%\IY]3K&2%!LBJ&H/V!Y"'8LY]F7P,2]A9*%6BM,:Q@;8'A>!,< M4^7G6T:8?J*$67J7/"`2X?`3Z6]5.Y0PU`$B"6-U1?;0B8]1]ZTN;[#N>3_I M0FBB\WA%VCU*N8W[7#]S[@@UJ()MZ/\*4S6DT#3NUZ`#_QHIY M$G'N`#9)J4DH@?ND M83H2X#P)K\[BG#D*82UOOK&_=N-J>H6J?`3%0B;+8Q MWB/TA,AKM$"PRE]P\DJ[8%3TQNDSSH*X^9W%L+_@[/]0]H@6>)5$OQWV-:I- M7M=RJGUB=W).HHTYH@4RL+WP8#?JNE2^YLO.1^6D(7%QG,R/X8)SR=$ M;:%^[/49FW6PIK@VF1W7A/,/'(I0W18Q$C%>4@L,3Y7-CN%UV81_2P^E_0LC M^=];@KF(?D+/E-L"E!=TU,8@3"*-;4:^<8B!-J MXT6/]GMY\]7)DLGDG5BKRR?YV[(CW[?W_6W9[V_+?G];=FIORY8OIG&GN-SO M=3IW[[N73\K*[&A=?PB^)PMP\**!'HZ0@B/+KU&VODM"]F3Y+HA[@PP=>)Y9 M#;LR<_-U3EO:ZCK;/^":_ M-0@<3`U+EQ[3+CW>],HQ@O'0JFR"WXVNK"5HZ^C%B'-4B/=F7;Z"')II>H=R MX1S6&YQ[,SN>+Y?1`A%P9@Q^JVX\:7\;:49LV@-BL7%-R&B*R.\]:;/VHD>[ MC@A:4-Z@H^&/U9RU\W%ZKA::-]#77=[]1GW4LY/]5\+'/CM(VVRHQQAK; M\7*"AIDPV[#;N^S6=INGG:JN>([4'5G''W93RZWPMB6=\UPG.[IZ,38>EOX# MK1*GI=IDWLM-M#V+KW7,D)[VXC>8!1,H?4#I.+DVG%AZLV.:QY?+^^(X>=$@@3-5,@. M@5?+8$$VH\@N.5J`A,0.0R_ZHE\#%E.`[ZH#OY45T/DV`9^*K-%U9X>7%XWU MBJZ=:"]$ETOQ_BY-=VS&EW='<--5):]3BV3D$X"`ILVZJ)"S]R(IXG2RS/1\ MKYYSIN9L7@;:?XX44+D-(I+?>/49!>F.%/D_8\=4:J6*YTAF27@?!2]1G-=H MJ6@X3QY9+;.+NRC!%YR0ZI^701JEO,"*$]XE'"SS'J^Q!^F:ZL;^8+<8OP8Q M0T5MW764+F+,C.EV`KKEJLY!O=Q(G88;U&#S*FOV/%:5R[LI=:6\F(_>Y9>% M;-1`JD9<5K.,^-3@J%4Y3C$HT\2+Z7-AK!QS4KK6LV._"Z2I5HE3D`F4\&+6 M;<-@*&AKG:_%"=`8H5IG*'=5T4Y;A46EFZL;+T.UM:V7^_JO?XT0H5!9[^_1 M*X+.TN@5ZK8-2:%18Z'V\8H-J\LVPNM@IJHV7LQLP>5Y7VTP!&14M@M6M;+C MA2\UL86'50L(2J'D%N+4)/Z^@->+J?D)/2@JZ1A[PFBC(_1Y$T6L%;Q+MKLL MS2UZ#^X\*U!VD051CKV^TNJ-L([9(&Q4Q+70`XGQJZ=J:/A!&2D?E)'RX920 M`IMM'2D?O`IV0AI^5$;*1V6D?#PEI,!F6T?*1WZT\ZCQ,/'K[E5@K-+,OGRV M[9E0_$='DE<]+'J%-R]1DN%U-Q#0 M1@IX,1<$6V>:S9?Y#P2%Q4'HAQV=N@0I>B#1`LU>THP$B^[A41NL1/VO,JOI M`=BTG@;WP\IBO0@#`B:TU2U>*F*N+C;(2\L:N^3TPXY._NB<4AW%]F3PX6U# MQO1P;[UF!S8(&_IX\2);^?@W74/M$-6N@W'.U^K80?>KY[@26Z.#B!XG+YXT MHYK<)72ABN[[;_."WTK+.]\\]Z+($AT?=OAX\106U-,0?(O))KA+ENR/W!'J M`Y*\L&"D$17V'"2#ZF+HV"`2U'Q!RB>8I9769:\FQQ:O!!]0_1+30Y'$ZH'0 MZ7,O\?)?WN)%-.AHEU/`SK0&*],:L(4C>)#[T1!-;$,\Q\B['S^^RQ'"?A&- M6KU#NT$:+69)>,W._:CL=FDRDH]F4D;30Y19'5D:Y:1"J\W9=[YU89PUW-6. M$'9_<[Z4@P]V&.\$:/#6W@%0XCU!<-NJ238GB:".?7V1%@W1)>8=F[:(2*)56RP-X.DGOLAN&XP>XT48&S0+I%:#' MC22HF_()X_!K%,?@S<)#V6A#M\OF9/`JK!\W(.V*K)`Y;ERDBL?=,HO1??2* MPKLD"Y)51*PY9=[7H=(HJTJ("OG<1(_,4")>)-"X3:$X(_OHU.5K" MS*$)>!<$@]+BV.;?0Q`IA#942NNE.1Y*3P^H&K7A()GQ(*D"FVF,[*A@`].) MZ>)0Y]"#.5<]<,JYG@9H-6O/`9CE&E09Y=[%Y*2)QA92R2VDD)\*5D7UXCIE M_(!"[\)B>2!;$6Y]6CZNFK33`Q#7TH%(:?*M(#'RC>SU@R!0;LWEOO$O\0M/ M>L5[;SBI%C_JU5_*V=;#:D$K'5M;5(6SC][>LP58`ERL):'B=T4>7)UE#!"X M>U)^Y$=-&J>S\NBJ*TB[8KB%7SA1IA>@ID,_WC56,@!P,"*R5]+C5-<#*;`] M37CTKE?R!R#095,V$"*\46H(1BQ<&\5)QKT-TNP3P5^S]0U;`&Y)E*+T/MI$ M&0IO5XAS>XM&F?H>%Z4R_DQS.6T?FYDO`T)+6'&'BY(0+[J.]@9"]Y#ZY?Z9 M*@!,1G2+E56I7FRRTQ7#FADZ?U$7Z\45`V)UF;+@P*5;3`EVS6+CS7*T<2/% M&K]3Q+OSHX]AO^8'7T%W%09I&RPB%L[0P4?(&I%;IWI.0BJ4G MA)]A-6/>?VA*'7A1#V>C1I;Z!"RP=8JT'DB2%9GLPMJ@1H8NJM5$#NRW##$# MOVRN54@1-^.OC;58AX.ZF,VA< M,/^`2(3#6?B/7?E().AK]0)E1:@4F(SWM:TW@X&*&%=-OA#%;>GPY[J!=S]/ MQK,2RTR;++)?=@+$Z@K3G=7 M+=A+=)<7/.[KUIH`,JX!$S#I"//_-6F^"9?[S\$_,,FWY:$GI?5+RGNM?DE/ M=L:5<27NSB0U`V^-RV1+>KB^3"\F3P*-#_I^"39P/I!A:3D"X=(C/A=M`"8Q M!A7J1[%;["H@`2(L^/<'QOX#TI["$7Q"^BAX%+\D[121WJ2O7>W2#&\0N8]2 MSF:Q@*)*7H`H_%L5"+LDK&*H(CX@07E*`B3`BY[I([K#NM_:C;AI?HR4B!(7EDQ-C;Q1WU)FQ;+!5OE[A[1-KE"C]IU1BM";W M&;_FNMPE'3T?<1S?8O(U(-W;A72*5($[I2(CM5L=EV(C\YM-6$%:'K93DN)% MK]U1L+QF3MQN.D1P4ZF)I@$,)1,-H,#CZ\7$K:/<%YPL5/S?IX,AT*2;)`JX MA@X'0I.U%YNZ'?W$"!#[?:+>MNYC3Q[N["H?AD72JF1RU"7CS(@.9)-T.L_, MX=YOF.&P) MQ?>TRDA76*TR1XWJ#>Q25,RVT+]PQ#3?#?4RDL>W@W-;A'H!*:8\N2%"#S%" MB"E<"*$D38RPWOT/7JU:.XJ"H0^=(DHP&C_BI@$**82DT36Y,#F"O(JD.<)0 M+R#D%8J@0)E]&`F#8O:`Y.[`RTVY-_Z$R&NT0.P<*,OFA(,;:L35+1\28N]F MR?!Y7"V;U;U_B'S(!+@Y!7.7G)<"9TGX3*@N4;("G:Y`65HOI)R(N]6M-?&U MD+N;!E[).Z@$MVTI796@R*>;B(M5+35QL("WF]//[.*/*&5#7JD:)RU!0M:X M7`4FFXAO%>TT<2V?=7_O\ZC!ZD<4!QD*MP')]K1/25(Z>K#=N+&CUJ5>#QV] M>AL+];5/:N3U#5`R;S)>E8G/R&*W6V9<=J[#Y\@DM=B0_S'@5Q#$*+_R/EJTCSI%*BEM]=*ZA15RL&&?4$X*%GL2X2I-R]B*[?HU40 MWR+4[59ZOY>UT/A]`A[F6:'KRP:?@<%P3E-E\ZKY5[F%VSMXLI";ON9$$U M"5;=&/,@'F7U&/*8`"QLU(XN>`QE-N/4]B!&)2PQV03)`ET&:7G5;ZT*+9JN M<1QRT65:O#K+H%U\`I@:6">Z<-(75R)IW$=_:S51>$W73LFJN+"I.8FYQ:3< M">U.%LP*5S-)S<(3@-R@^M">9VH**^$V[K._'*5_">(=,D2;N*P8;+RRT\6: M4FU8@AI/5K5-..[CNP\$+U&^Q0\N='B?JR&Q]WD"F)#8I#VD]=A5GO7NX;?6 MP[NS.!=.?_Z",Y0^!'LV!L^2\!XG*[9FN$8OW:6659[\Y^-,>$X`>"YJ3Q>M MEG2H(#[VTRK;8)]'G.?+IO$`H4G@+-!]:&+-5UA%=[&/==UN'Z+ M8V-ZN6]]$5[,9\"C=T>?%H^C'NS16A=:J!/M]:&9S`J(?_3VS(^:.<#9'_V" MXDPHL*`G5_>9X`P/J*(F.HVT**9[ZM*]2'MJS4FA4QY\`@!:XY\",G`_5C!2 MH>L"1'01X=6)'P//]TZRC.A[Z.R.+><+3^P,=;\W%]5=1P0M*&\P&1S^6"W? M.A\]F#KWT[R%%O`<>DCE[A9W<\2FDG(=O$;A?82HJ$V0"#TB(NWX!R;UVEL* MUJG[#F;FY@S-(:S/>\P2_'QXK;+SV4LO2:R0>Z;/P$VNX@-![(7*))LOGW8O M]*]10/;S9?$$+M6)?IDEX=,6[U($W]%HS*".].@S\-+G@VM"C@H3$5ZD._*T MA4_/*1%7^P<28B^AHF6A'!8R=EY<))1OO++]A.+M6ZKG%B=LOQ]8OBO1UJD% M0MII+])U*L+*NEPBT(OY>$ZG1%RZ_S7SNS:*[/*X!3A#`;^VCHEX\5L]KH%AL0M.+ M(*/&P5#^JONHQZ;S##668(M(^;;]V`>FRP-AN6+WG%/20IKV(;TNS8AI=>41 M^URC(MMTMLO6F`"W,:H1'Q9B0N*1FI+825C3R&;;`CF7RRPA1R^&Q2N;);VXD+N7*'\!`R;--"Y9U!4:0GVWS;D+%'F^OT>:H"M4!:T\!/W87`[;3D=O*]LTCJE)NU2-: M(/9N#E6VL?71!;51X0JUFH6]A>602E##G:8$+_8LKZ-7MMT>INV1NA=P%%+5 ML48.E:^84#-+R?E<5E[<65YLF??F8+W9LI"J<>D;2.6KE]7,4IS9IQ(Z,-MDSXG`>>@E9"P$,0T1GJ_T1)6(\[0N<+ MZ$&_@_33<+G<5`-O@TS].(1\B(/FFE[N%%[%IGD[T\35!'Q)H&BK(/>'3=S(,^G2=9!WRO8W4SX;R"'NM6]D"?I1][ MY@VUP#@RGP`(!WF4,,!U(5:P"8P:=SDV+EEL<9JJ7WNQ\Q$]*\P,T'.M6DJ` MFG.]R05X0B1"Z4U[UL&[>%]&>;AZGT_IP60.O&I?T3;>8-ZZ6I_/RXLFK>!L MA9J8D'NM^%7H4`^BAR:!A][,=F@TJC]5'AB"NO<@+\18^?KR;G$JB3/^0RN? MSW^D9FX1ET,"AHKUWIH?#-9\4(21K[&;,V65O")A[8'@%0EZO8R8J*Q$'M%) M(%"I!NS#B"?6G\'L16[B2]?$UI58U6F-8A>MN)(&ZG:="FKVOXX$G40S.)HG M'/7(CE1W^(2"78V[=P"[;V@\B>Y:7%_B]Z9GY)M)M,&^#0.SL8[7&&\Q>49) MJ7=>N#@\<+2VJ:B`NZ8J5>![R[7AN4DT9*E)7B3#&5=?F0V0_]W6K@+$<^A. M0IOGZ;0_R_7KT8Y!6TLWK\_DDL\5M#OOJ51>SI-;`0_.6J&Q['$BXQ0XUI3LS:U?8K&4.S0 M85%;[.DTZ^-[R:/!5=L0/QY4D>CBXG9(&G@NWRY3_=*$1TY-H-TYJV'Z+ ML:6F'^^12:WI&I._1CM+TVB5Z+<1)6:J;4/"[/?1)G1J=(2V(%%OZ!MIDHS? MSSC)UFQ[XW:%GO$LRZC3KA!A?\RW^<4TR>HY("N4\=*!#3AT`+CX);X=O_]S\4+Y'/65O>1'@J'8=K`#L:5HU MF#]Y>S?`0QPD7X(-`JX#@#Y5QPM;GWPY]&\)5UAH.N=6@&&R\R.,+9E^G$4M M50*/EL,?.P`9_ZH`T)58HG[3R4T&33]Y=1&`AJ=Z)^5'\A5T^%_-6<*S_F)W M63C:S[N*B^2D%WIM`OB7J]->_)G9OI\>2`"1D^W0JJ[-1T).;T1_2CN<#8W<*6] M%V=*>[HQ<_)'FEC,=AUMG_%-DD6<1V@-2Y<>TRX]WD3&,8+QT*IL@M^-KJPE M:.OHQ8AS5(CWID>^@AR:`7J'W-EU7RYC!8(?C(:_%;6:N?;2'-@ MTQX0BXUK0D93!,-"A[6C2T%HBRP%W6RV,=XC^-U;*5VUW<^GFYYS58T>Z&B! M&"\:=S$II5*`]0[XK:R6SK?36UV(C'>V*.@(G<8K/%RS#M8DH7`WRZ4(U1PN M(Q'C+1U@>*ID9@VORR;\6WHH)5L9R?=BRC_1EM";[DZZ+4`KC*,V!N'JX2C- MP9N5P2-*,Q(M,M'-ID*:L@8Y-+YFB@SI0;%:C6B%P`WT8=#DZ.%%5_LK]*;P M9)Y,=HT@40T<`SD=^?R^Z!06`@/?%AB^*)"_1-!(KSWJ4]GLWI\HRZV@.+G" M"4LM0\DB0FGU9G:N5JD4^]\+-9/^\O]02P,$%`````@`"DIT02W!Z3R)B0`` MFIL'`!4`'`!V87-O+3(P,3(P.3,P7VQA8BYX;6Q55`D``[20JU"TD*M0=7@+ M``$$)0X```0Y`0``[;UK<^,XFB[X?2/V/V#K3$1G1=A59=>9GE,],SHAVW*6 MHIV6QU)6G=Z,C0E:A&QV482:I)QV__H%P#N)*PF0<&;&1$\YR?<"$<_SXL7] M/_[WRSX$SS!.`A3]YW=G/_ST'8#1%OE!]/B?WQV34R_9!L%W_WOV?_]?__'_ MG)Z^AQ&,O13ZX.$57`7)-D3),89@C<)CBBTDX.Y^=;V\68"S'\C__00NT>$U M#AZ?4G#VRR__"D[!^4]GYV#SA/8)BL`]/*;8-YAOMS`\)C^`>1@"*IZ`&"8P M?H;^#Z>GQ'L81'_\A?R_!R^!`)'."P, M_/QCZ8LK0?YU6HB=DD>G9^>G/Y_]\)+XW^5%)*\5G!3B+QWY_#?AK_?+C_1M M*8H-!0+3Y<_&7P^`[/O%*(3W<`?(?S_>+[G:O_Q()'Z,8'KC/<`0NZ3JZ>L! M_N=W2;`_A+!X]A3#'=M.&,>E&?)U?B%?Y^S/Y.O\C\KRCT.*]TBPN$&I%YHI M)[77+6O'S?!"WYKZM*(BWYK\RIBG<(2O7',SO-!W,`Z0OXA\^P5ONS)5^'7J MQ2-`I>ML^`^P7VI&44/RZ`;_U?`+7U(8^=`O/!/;@MA)7=-@2RV7MM&V834D MK0B*F3^'&DS@]H=']/RC#X,?2<-'_C@E?YS^=)8W%/\#/_KO^1Z7#O\OO0Z] MQ\(<_27_^1WS71JDY`>TWOW8+"W1;Y07-ZGH&&]ART.G!/\=/H1:7ZI1T5G1 M>$;W(79+D@L8G7Y4A/6W\GEV,]KQ:0)*/EW\+:N\OH"$&4@0XNC^.`[K+8QP3OSB-\\*_ M02_&P>L*LZJ%#IE8_AOY8@-0R3-J"J`2^SRL"M5F^5N0O0;D/<`"@$A,"V)I M52+US]Z$-D^C0+G8XDB`OT+;(V%:V50ST"Z4R7\S1V8`SID638%<9)R'<+[. MK'@%LG>.0%M<;TCQ,S=!S10O$"VP-1*<%Q$N[NOO,`S_&J'/T1IZN$L-_662 M'&'<`IF2;/[K);(#8"ZT;`KN*DYXL)?KSC(10&1._R!"H)`"F=BT/%"K:*19 M'TU>"-4*?BC8'I4GOZ'P&.'NS>MU$.(^)I,?')D&+SHR@_G0LFB6!VSC8ORS M=`K2&/@9)&GM1>NOMVU`2B320VQ89#-VF0;/89=H6@Y>A4J"W M>@7(.Q?@RZDPI/:!60!N2C<1S+(T;EJ"&X#8"Y>1#U_^"MG!ER/33$3:,L,S MD*9%PZD'T[@DYV#HE,E&]@[0EP"_=0'*O'I#BI^9F543*J3U1%L;"LH-($N5!B.>H%YPQ20>Y+P06:@)`<5!%3R M!&2RH";L!%=4<(#ZU!2310+=%J6D7D8>BJ\F!*[QDW8'5B+5&H[O2!D8D&_9 M-#TDSS8O&Y1G:57#\O5I)_K>C8%Y7ATBY0_.'IQO*;2'YYGV)@%Y-E$@ASE# MC@GTAIPQJ->LV@%[UX$:W-MZ'<#GTU'.09Y5GTS0MXA@QL,TZ1XTL9=_OB_YY^]V"?EF+\$[5#+?%(N59Q?S]7(-5M?@ M[GZQ7MQNYIOEZA;,;Z_`Y?URL[R7JX^UF>?L>W*UNEI?+Q1KS(KG02&)Y:GYE,PC?Y4^P?@>;F'P[#V$,+F%:3XIQ::6FDZ3 M93(=,X03>]'E7MK=(,$DH))7!2XJV)D5HL"+?("(,(@KZ1,0P=0)XBEBI,M! M]2IDTE&LSF"FBK^QP'FF@\YG&#^@]M:2GO@\,P70,R6$`K3#;X$7AN@SV6H% M=B@&/CH^I+MC"+RZ@2W:[X.$[+(#GO_W8Y*29#DA!O[E_.2G__5GX*5@C:$( M]P_8T<\_G60;Y8@J%CC[\\]$X`K[S]Z?T?=G7SI%SL;FR-EX)#DWG#ZI>33" MCO-O\;M>@6.!\WP\H"B=- M_46BK8R?+6J(B2SC%OK6(C\JA..JSS:QYT/WF"6L7P:A9/7`IA%+B\4>OO7) M.7/GO9)RB=G"%FKQI"UDB"%-L[K1D!?,8CM,*H![,/V6R M;DR]\FM8R)UN;<@HDVF(J5*W.B5#XB/TUQZNJ\MR7H/;@Y3+5EP1R0XG#-^Z MG31(ZD_"((G^+!>I32Y-W^PHU#;J42D=\O#56@R2V;<-*Y,)CMS3($2=59"B M0J"2#:AA@_(S&$,(FSF5(X6X"[R$(`Y)=":,T7ZX9H5ER9FC4M6PO,G-] M*7"(HUO2![X<8)3`^N136*DXP2%!97?Y(ZX7)G6Z*@S:\.S:1)/I@,SWTAM( MM4!<$W`K!AO`CSCV#@#0Q#'WN#_2'NT5/,1P&]"3IO'?(21_S"-_OB='9/R3 M/K^+T0'&Z>L=1DJ*WRW^<0P.>V:(-FJVBNB&S`ZGK)&"&.[_FBR3)!R8XW?Z/KG!?_]7%Y]V%QNSDA2](*+\"ON9D\H)B%-K(+JTZT,N*A%=P, MEMJ%4$@'>7!^C'_,$\Z,@F>XC'"W%=Z@A"PD6>TVW@L_XNEH=P.;FK:Y^*7B MSU*8TG"M&(V4+F8BC!2UV8-&M;V[\4#'$"1/J M99@P&N"P%$/_.HB"%-[@(OK+*,40#!Y".$\2F.*8=F0D/GIJ)?]5U0837\V1 M6<9K^1137;I)/W8S6!@8956INV:A::?-7Q.AU1?3\@:847 MWGD!+N&E=PA2+VSS4BQ5T)`G-91U;+M&229T(>240'-6O00'_/8TB,`V>S\Q MG23UB;0^?HLL;(4&-T0V)Z1"N5=G@^XA^7P!7<19M:X;=.DE3S@%?PY\Z%^\ M?DP(JU<'/M\+;HH26C#Q6`&FR^46?I;*Y\X=EAR.ZM9 M)L2+"]MT)QM)RLE3\O<66P>'W#RYZ0T5IH%7VIXZ6%DD#1H/I.TP:=Y;,\;: M^C73!>B0&H<^/<_LPL/%);T@W`6B(R.+;!ZF'7*UE(H@JJ@T-"PJN3$:Z'0\ M"D.7NJ%9*0L2(GQ*+D'T@1?'V#BD")TXP.A!!`VIP%804-)OT%K#XZ1$I9ND MKU%\E6^1[JYOXDQ/]]&MT59#UP![E;TIDUATK5Z7R[K^9936LS>;]]X-/SWC M]4&&#-1]E__*9MIA0-/_V&@W-_7>Q[-1H"N<$-'_7(BOC0F\A0"C46'2!0.U MF;S5KC4@V-E?I"1!+26VY@5IFH4F6C/E72 M8II0KT$M!0_342E*`S\@=]$_PS7<'F/:55V\;,,C[LU>XX]*$N-CFI=^X<41 M[M0F=S"FJ3-[_LFDS8*89FP.Y:^)4ABEN<$"":.!,3^SNBF0E+9P_,B,99L2 MMY4Y!-$<)G"?2<9,6S63'2LF9TV0)8%<2A&MLMD,4PV734C964.+!J1\K(9*0N; MY'3W[*X/\(G8!=3PU!L$3-BU>V`=8%`/8]F9=UP)3]+7^))&'&$NK/L]<1Q05J52/.KMSC)4VDP2FS7)E;,S6#* MO/0&REF!E!-`)``5`97,EP(@WJ3A8`1-.AE("Y;/3/)6#(MD&J&T(V.$&BVK M1C,^@0,Y(5AZL\N/]_>+VPV8K]>+S=H%\/-JK@-\P8=F8;XEWL4[T][$4!=B M7`ANPZBV!V=M'+?6;3L#7#EB5:'*QZA3X.0L1V2]8\5=L_'64JJJL1BP(S_; M$!]@FZ_`\9Q)4$6+DWC?5!!2N:'48,)I99D223<.G]&N7F&:J%*_ MTZ>#S/C###R&L&@IU"C'F'IP<:?7RX>;+(QT\64P<%B(&.JA(H\1656Y$__% M524,">RZFC((7'A)D*QV=Q@-."1Y^0$PZ^`Q"G;!EASYTKF<0ONM$PV@E5D'C/-H#'$:CW4#"_= MQ)0RU@29*(A--N'FCIH@ZY/J1NA^CIJ9VLW*H#`$/A%3@-J:>(;/-7IQ&F57 M^#5I`G!,@@@F"3T_)J''9-QA)C]Y";R+@RW,-X!6YP[73L5LW:K3S@?,6R[2 M`Y.6AX8VD$1]- ME]TMSIK+3LR7:T2ZDMPEMPAJ)D]`8110JZ`R6X[[-4^B+EE_Y\+]AF^+U[Q, MYTT0V[$\Z!+1E`T7&_^5!#X]IP9%=.54LDR2HUK2HV6&G^$HFC$?&I4<:X_J MRN[U'E@0S;BG;GI&+N+`';(D)9V`;:D7OH(@EW,N7NDA4!RH\]1D+#%@;7Q3`XGZ6I7'`*] MP(1.7^EIBU[@JZ2H\OU9YIJ":^VV56)Q1O[E'`F5$"-K#=6J M4:$-Y!N2-GVR,KA$\KL87:-X[RVC'?D/C4;L):[]E`7#ZR)E"Z-Q?'>6"2[W MK#NB)C$X6Q\/AY`>2TI.;8\1H'(@J.1Q0YQKN-<8JZ!*,MJE5M?R\2R^'=F0 ME:P$3L4`]OC:>X3\ST$8,H^9&FI&>]JM;6:T\?JF8]NQ0J,,9L;A&:9GQ3/W M0H,6Q'H-B?.KN^_P=]-BO[%N5JG>0`C)]TCDN5!]I#Y)CGOHWT+>IC&K/K2# MCY:/T2*31JFF"5OZ!303TW3]SNC&TV>RM9(ND\H6!@,O-T"7"-06!9#WQ(S3 M290YLO0*HSVQV3?&:KCK%X"U?X]+T3DITM%[^`RCH\($(T^#'SF[&N;C8-O' M&#.$')^:@8II99;_P[G@P:U]<2@058^4V&UE"4W9OL:!G,TY-YX_`WCC+Z:) M$:#"X"L`I/H\F`%$NC:[E35?[&,!E>4%,UXM>0MS7PT/MF?!6,YTY\.Z-C@L M+"0=.1Q0'0Z2^3)NC:%FCFFLH=86U3>O-L'%/C3+HQ MG4\P`RTVF,>4%`ZEV(58_:"NT.WG[;6M*#!?;AZ_L:?&-3:9MO#HL+4 MH'-A0PE/VA."*GME]0SI3PF*=\2^T0%]FP/Y-@?PW1JX-WZDB8W2C39:G\4N M_$=[:-Z]8#4%>S M#G+SWY\`[.$;U7L"\ZURW;'!4_$NQ/P8-B]YFD<^^<\"*^)..[D>M7=&I&&[ M[S$&8MMC;XH6E6:,R;[!I3.Z-UKJCZ[CSN[E)7_`ZO5;"98Z"!^RPUD56`.W M.(O<#-KD+"^_:U2=[@0#E9*-RM,AIQB4IYD63*=_++XQ?3`NWRK5'4N+RFEO MG+4MHRW:PQN4**0\8CV%=48M/8M+/QJ>+(\)"YWV7032M47'4MZ%^)_?@X"^ M@ MXTV3?BW]678?[($V]>3>;!^%H1?7;M.>^`IMM:H7\XY=0U*N56H2?K7MV\:8 MS2RVZVD0P+A99H8[*O>E`4P]F>N),,>2+9(*IJ_+"(S[`U9<)1DI^G@ MO[;U8ZH"*@QB&'KTR&#,*J^VZW:$,"+H]-`N$FC6`_[DG#7N\3. M<-5F$SV@2.,0]4R!J;M8K\'EZL/%\C:[.<.U1<'"VF8P6%8K;%JR MM%ADXUN?G$&:H\;+Z!G_C>)7,U/.'7/#9IEKYJ:9K2H+,,UV>&%9+,Q(-5W, MBG^^O6/M>6@RDG9S0VZKQ;P@>(_V1""5C MJB,0$F.V>S-"]^./.*@49U`'1NY@-G]\C.EM(_G>IFPDX9F.SZ5/L#Z:X%RX MZ@-4G8Z),EPT^R-"NUK]$(423LZI\48&E(IBEU#+R@.P3 M0*V!PMPWNG&1Y"[?7.COUTK/VOW(',F81[[.O1?]K>IM@I9;'6<_M*P<$VR- M5BR2@5W22IYF>8`+"K%B:H*LEG/X_HP!2-;?%JT#HUX[I&4.>FR65BNS2T%/ MI2]W#[

";E-[0O@&%PV#!-P^`T`S6U(C@P5-,MC87!FK:3ZJ+"N'S#N*O0 MA3O,#0)W^(@.!SI&QG1JM@V,ZG1*ZE(HN\$/EBG<*P2ICB@__-1$S0>6TKCE MD-'VHQD,FNJ<:U*($*!2CLS8".M;S%IFO4CY6&I)F-:R[A*'I"?`].OP,$T, M..)IDJ.=IC[2R=)13AFG-_2,ID.QN^?@Y-)+=6@-/(7)[.E+0T]=W4A%.'3MQTV@&BW=O)9#) M<=HKC"D!I6\,XQKO%\$D99T\?-66[UX%R39$"4YT9>?5JBGQ5YXSEX MT0TESS!^0&H=&B7'FLO3>8:8"]7=B`J*V!"O4Y?4G'3%.D-?LG:=ZW$T6!I/ M]M5;0#V8_XTA'+:4OL0;;; MDEC#[+D^9A>1;P2QYZ80>RY&+"3KCKX6K)Z/C=7SJ;.>?+;T&G_@VG``*]<1 M2]8S')ZD"5:R;1O/9H1NI+03:.=P M($M@#W&03+UQ4P4";<;)ZXI!,[92AUPBVX[U(^YHZ%Q&VQCB&KZ"V7^5NA-B M56&O@J=JI6ED.].>?9==9-+#N7X3*3`WNUULP/+V\GXQ7R_P'^!ROOX5S&^O MLC\6__5Q^=O\9G&[63M`5ETP2=M+>26KM)IL*_+&4^1]9$P;&^OJX]@DH.N= ME?;ATB<@TP.%(GA7J$Y\:M#8Z-;JP)B'MWL#8]=>$-,,MAK*4VK-!'K"IHRI M9X7S#$_V!\KX3O6YSK.5\;S>LPNB9YBD.`4-(K!'$7P%>R_^`Z9@=XS\A)P1 MM@V/?O9^R^L?.AD)1#"3A@$)`E1"`,.$G/]_ M>W'L1>DJO@\>G]+%"XRW0;X^HGR9Y&\YM.AEHLD:31-F2*7EU`+G^OA7H*2^ MV5DAE!_=CJG[.9=S\ACW0;CKTKPW#IA10,L:(TCT*,W4,83&M2NT]X+.B"I7 M@-%J%@(&F\S,I*WVLF%=M;&L*75:RNR=0ZUDJ\XX363W*_/;QTR6USC6+4V- MZB81RT-HR2:3@%SE>.F%(?0O7OLTDOK61.VECC4;3:>Z?^,;EKH6(_,OB M&IZTW%E8UM^K`,((I&]P=KGZ\&&Y^4#F0[-)TM7M M9GG[?G%[N5Q,/4/:#TS(1!6WHH.6G48PZ%&"T7%MKI7MY=HLI$D;6BEETZ9U M-3B]-+5:>:,79RBY_(Q2V"LJI37)W0-ND[$EF'45.%B.]N5YL%N)UZH$BA MOM5(UXMBBH1R@#XHHJ/='R#IT3)(PWQ?HTKKO0&"-"R:I@7+N(P,79U9]KB8 M*\G>.-#PL"L+*7[?+KH;HFU,,^S8J'VM[HQ\D)[G0AL$9RT4O,^&Z]XZ&`3= M"#TT3-T9R`N4W=2X.J9)BCN/./+R8QQ7M!ON&*+FL-\Q;FFT2N).D1%L]8(; M=$KII)QJJJ0Z9:`9'3Z2.1J"L58`/@&9U`FH MR7U9R)+'YD'0?Z/^*(.P=TR<4!_^$_K^#LS^?G_QR]F\GO_SR9SJV M>O:O/Y^<_:\_GYS_\J^%>.U^EWKX]E*PQK#/!J=,*Q?3-27[[V=NL?WFP50*`(T&5 M=7L[+P-NW?'.27X+*=/I2'6INK5$I.%"*P6I:;(SW#Q:NIO\BQ-F;`DD,X'7F"41(\PV6T17MX"]/5;N.]=#DDDZPXQ)<;?.'YDA]28@D MU)XU!$"(DJF7ABM4,-*NB0Y?>$HMOHAMVT61R8$9F9\!$#IK8R@3`>]N,):^ M/P%8EO0[L/0)F*=I'#P\#?\$HC>D9T/=! M\L<&>V3OC95+EB%:(#F87%S;9M,]'BS$WKE)8N91PZJ45>QR+" M,&M#PI<;YL$M$LONL.4"1MLG#D3L$M25A&,M32'3F%[1PQ:S>%JWG0 MR]Y*168K1%^[1I1F50JSM?:'ER5J12]/Q:([!+AX+1DZ?PFD21I'G-O@M,6- M-SA-!W8;'*8OO0:'84+2X!`YUUC$0X&PN>'7E*RY:6J*FQN6%Y?81CIJ:D1K M2_(Y5DF:IU=AVS*S6FXT2=70YH\BN$FE3CV+6<2J$"F!"B4)=YJVW:'-'8S) M`^\1GLEXPQ#E$:-6J=/UH\6=MOJL>D"&L;WM%AV+PP-0^@1C$,,M M#)Y)*I.MH7DZ1GX,_?1I^JE'!2B(N,6I,@FY:EI"=G6L3TFO;!MEBO]*`A]F MA:2G]02[`/KSA!SUG+YR-C;VTJY(J*<]G)#C3!.8-\TSN2<(RF8'9VM4]!THUCOK42X=3`KT6HZ0> MW.'3?$]Z+-GC5(%2/'D>J[KRIHG5]F"56QQG6O1BVIA=-C9BU/9?I/EA:=O: MHE;'6,<%A8AXHGJ3<*^M*J0?V\_$#$P#W,[>%97<"1,?#S@#+G\(DY.]+#18 MJFG!"&^U?%K8"MVW#'*"ZULM&M4E>SN68XUL/[QU`D!O`+!"@I:Q;I#H499I M2&!PL6]O_Q88<%:T>E03E*K-4S8:_*@,?,V* MH&&J%#89DA`+)YU`LSS">YK`MP[U17!^*LC\Q"=E0;!_9U%6J>IJ/;,4G1'L8W M09)RUJ/P)0I"L22&,JAKTRAEN.:%'.%HS8H7@+[)CBAP9+Q$4'M(^7.W*-`5 M;F">9VMRD'=6C`H!+Y%N@9\K;8@('/LV2"%VI4(0D86*+`VI?$N;4Z21(8!! M((5J8I.)H\@BEM#'9"2[@@_I,L*-VI&DTLLHA1C9Z;V7PNR(M6IU=@OI^HKY M%]11',A"=5?&)Z"U78L(JFEL5D@`.@7@U&:$'K!!0RNT25UU&W46ZWH>%;G& MAJCTW9J#[=EW,Z(`*HT34`*9*)V`3`U4>E\/ECF#7F.`>-^1SK7:5$&./ MJ5TG9;-GQ\G@0&.C6";S6ZLE%(.K$-US(5T)C`:T=*&_Z: M4=7>+W(@`"=I3.5-AB]C&[&IQO;B_ M7UR!^\5OB]N/"V'`(-*2K7$IA57E<4QB1]7^"9FEYA+IIFCRY,#C`/D MXPYVG*JD&TTO&@1I)1GYC"^Y6R]]@N`!/@911"[;PYT/\B`KEE,442"$,OP% M8#>:9-1L:N47V>=?1+XF)E1SC(8*$Q60G&"S>\,XD*07:D`8OEV58?3<4CM: MV-8$P'D-`/GCMUC?YR;J^]R=1NWBM39*4+7`&_B27N!2_"%N]%2UV8VB7-LL M*V3^+":?BJXU.*5D<7;Y1$020"[^:H7?B9=A]442GYXZU2MDK\R0@-UJ97"% M_-I\UZ;X"*PV0&2-@3BITUZ]R19KV]U)IYC:CYQ#^*A'0576V8&=\?$]N;OA MB#OKYF:@$@6?B#"@TJX.9QB`HEHF;P2+#@TBUIJK[*19UMG[6CKLAH"G8Y:4 M;"\6\SJA0PUB"NQTJ5D3/@$/K_DYRBZ<[*\'%#Y%Y?4H)"E;7TU5QU^_EJIE1MA0N71EH!9` ME!HI=@6JME&5MEH3U?;F(#EO./<+:FA(J7EC[,9!!1_C$+/MKA\OFU;$M'3G M6D(=:"B1DEEWJIR\8=U8J.S+%4;>XL\M7#;'E6.SKRYGEG.59?N#=QU?&C1K MZ78F-9WB$*-:^?`"FU$;8>H#*^/QYT[RMF?2NE]Z`8LRNGX!*Y$M!D-KL>P\$.30C MWTKT!5N&Y`I*W5NC6WGX+L;KVFINL9$84>G6.K1Y1@$4REU:M4TM?%WU[JQ# MFTWR`HJWF["%V'0SO>6D:=8BK?3WFS`4N\O^3D$1G0\H3B<_8UE2I7RR*&\^ M:!Q=C*\Z5!&+:)6?5OX"5%T'5K>HM?\7P2"2M'R*:.IH!7 M'"^3$VSCO=P$WD,0!FD`)5MAA;(M:G%D#?&*:=WB^)[(GPJQ^/I5%I-Z+R#, MA5Y/0`0=Z5R+:YW!*VGEL$G%5&,Q2F#?-KR,+\(3>AJ$K/K2.RP$:E+T3$#' M=N&:0YDD$QH.LVGSHD,,MP$]A0'_'4)Z'$/DS_IBS5Q.9FGP:T$#]JZ[-1+EVDY"JWD9"I,%60-VA M"3">-=%X`DIA"LSY5P-,;AMA!YG3MAC)-@X.*;U0\A9^GF^WY#[)('J\BU&$ M_]S2L=+D%J5_@^G<1X>4T;T>8*-L4WK9&$SI'EZMM#K]RR%F?E^[L_O%Y>)V M<_,WL%RO/RZNP/SRW^._+Q0[LET6+V7HYE/4-<[IMG'RZAF5>2-6NPJQX!D[!E?<< M^.`F@/CEWHL<.8V=4V%(Y3.WV-"0:\"<8<%XW9L+Y4S3>A5_5JOYMUO/O+"G M4='3!JIB2^EJ5S_L\QZ&Y/1D>EY=]WQ/[OY^,];*4#C0VF#^#/)OHT-AI$1B MF@[W,%O_.K]?G%[,U[B#<;GZ<+>X7<\WR]7MU.PV`TYD!2'M\#'(<#/>&"CC M]$PRV'09*8ME$M'&L3PR`7=,ZG9`;J@X697:.GT@QD!AS:6^B9/$XS;<+C'O M3:0&#_7B\PZ/-6),-S'@&!LKFC'=&UT%9*(D1B(9WP$W&W#G5%LSV.P3GJ0( MZ1F,3,^!#R,_P>4B)VLP#YD1R91QA"DS.#PPK)IE/=^!F,P\ MO5GY"N3O'#D`1EB)2..;MWG$$&_2@VO/&=3GBU/FD<_?EZNAPN$$6\4P15A. M+(Q5*CO581'7S&R^W<9'G)(?XF))5I*2%-$O++A%+B$X!%R359Z8>BQM$1/Y MWD;"I,&.J+I#$X`\8X3Y+QN!W"Z>'0A.VUEKEO&&=V**3([3#-R8.QV%9]EF MBM1VHL.GF];Y)]U4Z<:90T^DM2M@$;,BQ,RY81YK(K;K`$6*]GB=LJ8PA%(= M>K2DC)&C8=<.-5@NU(C1U:S1(H9;%/MPZG,F)/7()`+WH_-HT%!@DX!A< M/=!*_BU[6QE(L9Y^35)P6!%$%!UB>?8[#!Z?R,R:]PQCI&/[4]+[:'X0T;!T`P-/0W60\>@,KD:6O1"B%ZHL!T21J3^<(IG5#X% M#^0QW>/B9R_`.W)Q#0I#+T[(86@9K;]WFLH]*-N;FAH4=(QJO`5I4CD.O+>S)U^V%U"^ALKEN,$:X44?K^8I8P%W=([#K# M#,4$5C%#M9:"]LTQI;,^$DHKH%C%TTC[]O$XE<1-F9B8Q M8VQ61N:D+V#..*'4F54PIL##F709BIXI)U<6NQW[54AW)+PYG1S$7?KY"!NN9FF09980MS M'1!C)=QEP"]BB.F"N_T1V&+=B?G9!TEH>`VW:*QAI4%M;>_3L3T?L%S#^#G8 MPFJ%;GV=W"V*GF&".T+SSU[L)QN4>F']/5E`E^U(Y!Y?9]U/$4?L^1D:=&R5 MS'P6:;FDPIAFU??L8Q171]G!%Z*!0V"^P0`S&+X$"=T+G=1V&7C5>;L33W+8 M9Q$:&;"M@&O+92,ZV_U=+H<)?L62@R#^DN+)9/V`B/\-5]_#_SB6-ZS;G%KZ#VVHYBN6I&U*:L-C:Z*CLSG5'J.A>%/Q]2L^C?I]A7GR).YH:=C MY,?03Y^2J2>%=$&#AE5H*TXH6FC07LOKB)@UU\!K.C4%6-+\4O%3(E_=QT-5 M0*%S`BJMKP.[O$;.,GC=;8)N.&N^-;64&J`;8^O!%?T8'7348RJU&'MS>LE>9:/J5CFRX*"K9=#F=8P9Y10+,M" MWG059NO-ZO*OOZYNKA;WZS^!Q7]]7&[^YL[L&+N>D,K7;>&\(=>`,\/"Q*A= M1CB-QQVU99(78H^Y3S1M'4+),& MA;@[M\MIHZ3#,[T:9#%0;J'+356O$[.6C*2@"*>LSMRN0![B<5&B=Y^^40_S2PH]R"L>M5IP6K M+*BW8&VODW'YV@OBW[SPB-O4\L]?`QCC.GEZO<'=O)"1=>HIY=]256D@B]7< MF.2PED<1@S4,S8@`H!(GH)1Q(MG4!`<:4G5-FJKIUTFJXW%ZBLZ3!*;)//)K M5V9]@![9D^6OHGM(SL8(HL?LH(RX^"?929*PCNPR;K=-].%V3<6"H26Q$BX, M%4HIHACQ50LZ(%>F*Y).0&F`;O^JFW#C8#/S4&>%+9,HXT2VH2Z8P<],N:>/ MCZM=_DNV./>*.PM`I7+M^-65,Q6/VI:MQ!>.$Z5XP=3-^/],^8]VP*,2P,M% M'&$XMW)9C!75`X>!;14FH]AVIV?(4*;S]GW:_+2A+BRH;@\@?5,^1N MYY(Y0MI+MQTAU71-!3\5;U;BFH9CI9"E;*\Q]-+L!M7Z1[4Q&2<&4/M!BQ5R M=&N<$TU4S#`#A;K_Z6/`@*!VPUE=9L6VP2SKQMA*-:.E<2VW:A?,=EK5]->( M8;7LJF:W"&T^H!?@<,=WJ'6'UM39X8?AW(L)2_-IUPUK%9^%\D\?:.5'"*J( MML.@C<,`1<:M!*E^Q_I)U6?7\^4]^&U^\W$!/BSFZX_WV476SBPA5*IP%J^U M3M\3:3%9Y]XY>JRB20=Z1+("&ED8?F%9UR62PEV0*OYT"=4:YN`PRCT:J8U- MR"I&3B3QB`'?OFUH&=OCI.1I$*K.&K-V-2F'+BPT#S'.7B5S&)MR5U)9N&5T M.*8)7:;P,_/FVE82'ZT:)2!SM1H\IDSD!5`K\[,AUVBJU MS2*1N%HX#.HJ,?G#L^T4>OZ,DK&7:R%!>UB<94JG5`M4:OE@>[DGG:@"HNO*-&%/F"$C==]BO)ZA1A3H M4P87(T-G)D(>#KJ3%](8<&-NSD[!R4AL;_OK2?&;UL29D-*VB"6N;E+ZFG*M=37N4;?L:B;D+9+^%*6]J64M)3O&&DCUVU]R,1.RNQYZ< M;AN:T2O*:CS&&78$4W?FHO40HD9;3OTI,[:FKTC6CD='>:K%3RU>6N;C>#P< MS#\1[UPFFS[)^I)+G503D^D]0O[G(`Q;D&T_SG][]7@@%0I#)D'?LBF"=T-T M]GZUNOI]>7,S+70[GQR)/U<3CH5$'7A-+8,UIK4&X@#C`/GKU(M3T1J;MGW5 MZCO#]9?_\P12K5NFY M1I6>UZMT0:\`?EOU>=ZO/L\=:`\9-6VK"K3:#)VP( MPFSS-MH7H2<5C`L,U(!?DP(U,3<8(*EY!B_D]<,F"UN/12&1!^L@TVH2I>?U MJ_D;AC6R.A#%,'B,`%G>#Z/M*T@KZ2\/9Y)6U@30IEP:6)1N'G6Z&=5*1M[: M[G[*K0BOJFR(C&KN+"P'[U4`%;)J&"P[+6!^>P56FU\7]V!YNYG?OE]>W"PF M7C?>$TT,-NO7,9O<:G989-C`-K88O9]KLYBN]>3H5L/NS$REZ-`*]BG` M+FG*QD"["TW=/0I#G,.0>ZTX[1E#HM5H-20,$;AFTT8'I&M>A8AMK8ILG\@K MD+]SA$VLBF-0AO.EV;2H";.PW[$U.;Z%;.1,2/;2U4GDC$U/:GFSP2,=QX.; MNN:K8%A*J)3VC#\"!/IF8$8RJ0-)OV$)S)=3`:EO7;'V:ZRMT M[6I4YEE1FW=OKC9Y6;=2=4Z9+R^C+=K#&UR>:_RS+U&4!M$QB!Y7!QC38:SD M`NY0##.YC?<"D\4+#HDH]H/(BU_I4LQ;_!FQ)OZDN'R/Q>'V+>R-X"G_^%8] M#62>Q;(9C\SVRRH*#K:]S]X1V]^#@.J#!VJL^%=*S$T;@,;@"QH=F,WX:-%I M/=Y:_VUN!P5CS?L(Y9PP(N#T(],$>60@/`25&U#Y*:)%+D]=G8"&LVRWQPEH M^BMOUOD66RS@^TL,+M,GA^O42^FYFIQA)8E4(REC2!F)G1V[)@>%Q"[D$8NM M.;MH,?9&>FK:[!ZFYQ/]\LL2@=#[I_+<#-:KT&[XZ1=_2#%/K?.S,X)(-$)S8(ZX]%ZXY"EY(` MQ:@SGGEP?/0%3Y7SX-YQ/=?`F*$V5%?R$R?E=!$ZLX+VM.[G+?MN%F\-87\S)[YK*-M6@GG-8U: M0(0)..#'CF"Z53TL+'>_*0?"F2`3NG4;4R(VAEX"KV#VWV5T!73% MC["]B%I9OD*U3'XXSL4>[&0(2CXEE%"P,2L>`HR:?9`D9&%UGCU,3A=%)*"> ME=6AE%BU13(5/V-`SV2:H>9M,.JRU(.^!^\*23(<#4HTYM)?*@3YF8EA#$Z< MK;0*.-]NXR/T\\;IE7$%JY8.MPU@ZA@G(\.+X2Q(V:$>)7EVVAD3?>,:!45X M$-)04ETR)C+4Q6SD^G./D+7[+E3YR%"1T;&A8HN--2>CD+'KKQ<7VV9F^?,B M%\MNHT'T<(':C7^.DI,%#A5N-H=H M%%R;1;9@\*9`>:X+QAG>W1H#H\6AYZ;(=)]*&CJ_";=Y8 M*L99WW4R2E/&=:M'+^`#0C8H*:PNA6')CKYT8)+CT2%:TM!! M5FUGT4-G[D"N*D[I.*IV6E2F,[MTE?KMT;[RS>6Y7HBBQ],4QGN7)Q84D"-O M7J4UJM3*,JTHM+8"[PZQNUA#<`^?8724M[<<>>GRK%+>VAJ9W(/ER02FLWXK M9.HVJG5999!WG^](%<>H+&%&;%J)KLX(/T]+M4=H M=YR_[6>\H7Z.YT$]P>Z`O\,#_5Q@Z'3X>@[WMPUH=?/L#_JS?-D>]^?Y-`1( MV>A_I>/R!(!AS.I-`Q@"K6,M2W:F1/1XZ1V"U`OY)S)H*O+;%ZZB>3)S7%D> M;11[U22TR-CL\@E;PID.IC$J!/,VA^:1M9''OSA':!F`Q)Q6J%HIJSDV),06 M>G:(VLOH&0<>%*O,(#!DN01NR!KG;,WZ*,E@UY\>0=OZL]H#!^XH5*MJ(=4X M-2)C5TU-3*B.?=N8LIC*,3P-@A,_;:L)?FD(4T[+^D+,K13L.HC(;7,Z@]5\ M%6[49JD8)UK7R2@QG.M6CWL<,[/\N'BLU"4[EM,(--MUJ*NYCT\M+78LQ::\._BC*W]1`K&^>O MR)W=SKN"9SU&2PW.UAX%I_?BZE(_)>0(N:Q:GS)2B^R(Z2TO@4,\IR5<[`\A M>H4PWX&BO1Y0KB^>`A+IVQEVYWL<87F@U'F/@7B)S?(P@NJ,*.=:;U4HR0?@ MU6I7:22>;TIA3%Y6C@GC0'9&,PY15_`AS8]([)!=)%0RFBTTF+8LLU9Z>`)' M8AYR%6?E2=MD8'Q'LSTR6KY%R?237<(Z13HUT.8/2[Y)$KY%:W`QV!$3N>B' ME+,65,CKXAS7MX\3;O^I/U"F[2.5I:+!?4E/VN+'3(90-V8VA,R1H&;6;#XC M\*!(@;9BDP'9DLN`OG9B2D-8G6P:<#X^EP4U>0X+.A8G)P'S[.+NJQ;@#9U: M7!FS`6[E\XI;XA6073BHF%$7#+3*CBBNI%C(=.)PXFRVY?4W+SS2"TON80+C M9T;/52988I4O.!BY/--F<2SQ(D:U4'E6_`OL4`S@RQ8F^5+YAP27*R57D.4& MIB:`M+J1;L6TR<'3:5)%;'EZXEP'49`\09_<*)O8)=_\%@F$&WSBREJBED,X[J<>H;Q`U+,L?CN ME$C%4Y\M;W];W&Y6]\O%&K=GBXTCC!+5,HM+DMK@L(BAQ>0/U[IE,)E/F@2. MAN"HGB:!2@9\(E*`BDU^FZ599,GRH8'0#0NJI;;ARM6*-9E+6W*O:SNT=NEI<7LGB7$QE\RE729*(.;.]-"_9[RC^@RZG M)=-,2B-1T%,9BQA%1P8E),+U]@F$C9`-+YYTQR3>I+12V)@ M5LD0?FUAG`:[`-4!*DX%T0;<.C#WTBE#RA.,U.@`TJ#Y/?`*\$ M$=2G(KM4Y.NU62CS,!D!;^"C%U[#3O/6>9[_^MKS@0PJ+9DD2]NHB!=-V1GY MBRXQ"]:F\"^_HROD"!1H;`4%AV M3&JOY9"-FG!="-'*5IIMB+?RYA5GSN(65!U2_=@M*'=D&YCF6+*"!F-3!7SS M^E`X^VY6>^'([5E#8,`96^N#@RE'^&LEFB?)<0_],WZ8:TMTXUPE80[:A4VC M+3'7O"*T&UIU:),3P,@;D#[%Z/CX!+SM/XX!SD\#%#F#]DY%LN'.^O)]X481_2R]OYQV\=4-'/`_0Q(CEPJTC1#_>WR]N-^!F.;]8WBPWR\7:&3[PZE68&W[T\WB_H.3K!%4M*PU MT>).5TW:N+C'H'GDKU.T_>,)A3Z,DP7N**6O5??UW=7"WNUW\"B__ZN-S\S1E*JL&%TP-6K4I^ MMUAD@==7EGMUEKZ:M-6DJW6:VNQLBQP.X6:C"UX?B8I\D-2D_P0@E7>;F7T8 MV9^).@PTW7OG.K'1D1X@N&FKS/;P1KDXX$("_"N6,*$WIA M,^.B+OE&K4$VB@:AGXVA).WCU<+NA"'E$'*ZM]W9_/)R]?%VD^5]J\VOBWMP MO[A<+'^;7]PXL7%L&.J001"THD,?]\07RS\<2 M&,C\KDF3XQ=H_BS%[=/S=-1*8"OI#*4"@I.C))#W9^0+JIF9H4DO='.SX5! MG-]-_XG(@UQA:EKI0`3UK\(6]12T&V14]C89/6^]/5SM&E'C"NV](&IQ0"J7 M?RF!W$#V<2V;I)S,B8AG8MT9>4TV*S1;*?`IDYF83_+J19HUT60.5Z5.%XG= M"3F2XC1QM["@YZVL,C@XX_X\L)^OF7!`9MBS-RP,R[$"M\GU]-`;S#(0RV MQ5UP6ZK<6'TP>9#HA3)DI.H[X4''4"LVZ)=A?,B;2S?[^3:,][,,\/F-).]N M*.Y+55(_F3*H:Y\`JO\UPIZ7^HZ*>P>3YNRLA483KI8L"Q3%23)3T4YRS'!E MH_73<]TC(^89HR%@2[+A8Y*=,1(4DJZGPB+XR%-@2<4JI;X,&PHI+]?SJ`@V MV9AINC4'W[P)H[VY0@4\O()W'S,P?P]*13#_"M',;[*LP]G!AHK1U^P]JM-[ M-&?$49RQ&BJ^:S-#-ZV&ZE`G^K$@^EL>P1DVI(2"`>W^ENU)"8'+$28EY-[-Y+#B M28FWW!/K,2FA6.5]4UF-20EI25P+$?G$:O\0H6!`'"*$!NR$"('+$4*$W'N/ M$"$SV@D1J%!P/42H`$P>(A2K7"E$"&PIA`AI2=R8MQ3-2HKF',U.KVAW1&4W ML[*L*\^.5-U),M4W.5L8%<*;IU"E6971)6 M[/#3*3LFM2ZVT9OD+\QK5>\Y8XK^K=4SYY(;]7J>\IH;]<:P=]K9.]T<,6PA-)$(MDO@;0YG,IQ9WLX5>#6'(3EPZFEHNO#J5;0 MK#><:A3.TPZG?IYOM^@8D6+A\D;XSVVV%W`>^9=/&'PP649U&9Q2!(=0,'AB MS&+9O!FP.#AB#"Z#V?$64\411Q@S7F;DF)#;SL-#4>JGHP&'4VGPM"B96NV_GAW=T-#Q/P&K"]_75Q]O%F0 M+82WJ]O3R_GZ5T"NN5S3B$)V&%XO;^>WE_1?EYOE;PX<%*N/*32PNEO!0=5$ M(P3H^9V2Z&5?+!L(6+P<8)2TZ2.5JXC,DQM.7+9E\]UEB2<).P6Z^7F3B)YU ME.\!>01[!R[+EEYH[7VYP2(7 MF?BV1G,`XG4K!R-HTDXCKV#\?$I-7A9^3>9/8@^&\R8E9[W(U,R35NR8["B; M)"F/>@TIDHN3XJCXF9!K*3TGEAYL5QUC=PM3[B56.BHEXU14!I-.[L0L[Y3] MB:FG:&96]3H:YZ(ZD`]I``+UK[`V#>7:32:J>G.0C.Q[8I7EI30T=8NLU,,X M!%2_7E;-QJQ:"QY71WTZ33W!M:-:E:1*.L:=I(I^IJ7;G?=*"G4/0R^%_IT7 MDVF3R]!+DF`70%]`/#W-.@55-4V04#RB8P(2JD5V MP7\F>N`W+T&_0B],G[9>#,&3EX`'""-R+`P*(D)J^+(-CTGP##'-#_B#8OCA M_A;^YP[%X/T"U+2O`N\Q0DD:;,%R[SV2!OT0(_^X3:=>BZ`!/]0;'ZTH(%=N ML%_5U^2L+Q="K.$CG5#D<)TKUV(X0\X0KSN6;;"9YT2%PVS=&G.3_+D;].'7 M*(,TPH_/IDI'A440CMW):+':[8(MC#]`4KP6()GO\M_>>C<0\@UK)F'.,BR" M=E=^EC\"G[*'$R\.8=<)4OB43=`VQ.I`9>A/!\Z"+/FX*&_1A%2N`"U?;BB` M>9:-@EGB1`ALH>ZL6H!9#-Q/#'-IC2+-C]^"/T^E006Q77=H(:.#C`;FX6]\ M20'/@Q;F&TL(7$>\$M(U$"Y$MI&%`4RKQA8$<*UK0^"L'N\6;[SV.;/\^M4_ MY:Q^62#NSEB!1#NJ&=PER[!I+[)I[9CE:=60[=`V/%'ML0"NLJ66(N7")H@2%@4__ M,8_\NW*T$D6K73[)Z(5TA"U;"<_I#)FT6<16,S:'4L]$*8QVR`P62$AN8WY4 M+L1Q9B.,620CBT!JQ2$3YAN1RUQYIPMU9'G@/$E@FK#GS?D"11!B"`R-*!V3 MNN%!X4(KKA,AY=E*^2K+8@F31P4F9BF_WI#JEV[QIR/;(`/'DA4HF$OKN.;U M47!6P"![\;#:_+JX!_/U>K%9GX#;Q<8%CO`JCYT!J6QE M8(ISTB!G-BO0,EVB_2&&3S`BR^^J,;=K%,/@,:DSC<+3DP0UGBQC#/>5@FE(<..XUFNG_>_ MMZ\@K73`HQ=$#L0@>XQH!S&K^&-$0>/^.F'4TB]R,@X71;R#<8!\_#R&7@*O M8/9?WN2",8,*\575H,58JE:$L>*F5FGZQD@-)\5H9-U0N0/%&/9;HR)@)'VZKQ6,!Q(*4W4V]6 M#BQ@'.R#)"&)2[X`S@&N(0G;WK2XOPF\AR"D1W6*APR$ M@G4&<`1-T(!IVM9`L)K">`_"2M0!U=^EC\Z(0=4.[(KBETQ2.%[-L';$*OCE:$_(4)? MZ<*>#9IO_W$,8G@7D\T,Z>L=KL5T'OD+_/2P[R8+^HHEMM45!P-?U94R*W[) M6!'!1W(H@2BYT'8N9HZ6L=D=_BI/'EFICW9DXSF5!5[D`U@(3DTR;?B@H17; MIJ>JC29W]3R/BF!C28V^6W/@/2.-PFNYYSE7`87.":!:)Q3,BZ\/S)Q,:0PT M3YM)M4IZ<4R"""8XQ+V/NSM\5,5Y;5)'W#2/6P[&:'_8+K6(RS(QH^^2H%AM M,!Q$O!74F(6-+4TA!II<1X&>O\>`X&XH\ M3D-129X`*OME(D^U'1@(/:=B_OH)Q>D&QOOL('_6B3M:.KSHS]8QS4&6ES': M`8%?+4IR[31['PD1RX9`@TK0,5(*42)BIJP2)>QDJ0LIRO"Y]?;P"NV](&JW&/0>CF49@US1@=C M69:%M.DJS,@S0!Z"3]GCJ<=BV56#5#YH"]<-N0:`&18F!^K\)>BD-HQ7+9!F MKPQ!E!BS`=":715XEN)U<)*'CD"S41T,8+8_(QN61(H%RDI[.DC&^7J&=8JV M?_SFA<"E88[AF,TX__W0"2)5F0Z57<)L_/J./SR9FCP`R2+F.6USJ"C,"UY.VPL8D^:KC2*M*>GG92@0 MAE^>,#,2=X6-DJ%MWF@ZH>))G2!,`]V`W0G+X!W.)K.G$R]05H0!ET6BRA+Q MJ:W'IQ;;@W7$:45BS92`YV\8\,XZR/MJ$*<4PH=!SK7`GK6["D&]*2@(Z(6@ M!6IEIFT'\H8772[5E+D!/$^@G:92J[HE-.I6C)Q!F8Z,/77+CA#GSHM7,3V6 MRJ?YVAV,:5F%))(I,0G%5S)*+IX;>T23>%0GG=!0EX!E;Y>2ST=AZ,4).."> M*26B4SR4(H;+297Z%/&3I\_GJMBC([R]"IX#'T9^DNT=*P^66^X/W?VA?529 M'):I&F6RV)F-"5Y]]^KD5C#7257]0L\CH]C2 M^)::8Y,`[HZ(@5+II+C0O=0#F>+7!6VE3ID];+O685M50^X*O3:&M*#KUI"V MT'^KV;?=B>NZTNW)M2UPNW/U21"G^W0L,$@Z=IP:D_?N:HJR+E['AR-\8^^< M$X@PF65J'QW#J#T.J>^JXZEUFC5']M>)JH_+!>EN.X8T'_5N[+V+T19"/[G& MG^5W+XZ]*%V\P'@;=&]A4A$MH2\2'4P!OG&S5)#Z$5-"HCXK)`#!)(#Y2[)> M]7,F/S5'%.H;Z==+FS-\K29W9-:=X!`9I_3P)UWMFF3/#K;'#R!^29\(V*5O MA,$['2,&&:GNUA97M4N@RF)-PRU^![EVMANVD4*ZP_,>R.-$@'XXX,<&=7N\ MJ*%;HBGCR0[2DXR\\!JRVF'FZRH&M%X/9W?#H(4%;DP'$EIV56;D*I%C2*^& M2F#\'&PGW_+'JRJD]GD[=&A(MH#.L&*AY@T.N;&-ZU8['3JK'@/R_&W6.G>$ M2Z_:IQVIXNS=[AYSIR):A32!Z'"0(K='Q(=\=POMVB(V.'M()H%?L%HL.9Q#6N&_L5 MSGI4<">ADUA]5DJ`'8J!G\N0J$^%*+MJYZ1ZY?'>TV=,YS2!<_>0PAY]_`*)/+/ MP908R!6&39,#AWSS(E[PM&;SR\O5Q]O-FJ;?V84^]XO+Q?*W^<7-(KO5QYG; M:$7UB90KH,D$AG"=`%Q;$\*>=H;N/)Q4U:[!2*Z"9!NBY!C##7Q)+\+N@'T/ MS9(F&IJ#Z:/LRT+"H^]=S#H]:[/[Q56N`:@*J.N`2@E\(FJ`ZDW>FHR) M:4XB-@ZHITW3F$6]"2*X3.&^W=%6%1>W3#5Q.W0N'9A-[91\]:!MTP2?JN`3 MD014U$UZ=H$@YR2SLI1X6&HJD*_EQ0G",4]NX@LP2&7H!*>N25O$43[)B:/4 M(H<;)SH)JHP#?]G)3EU9'L2=..&)U^!Q>_YJXI+^C<$Q`;&#$5H1O=$"!1." MSHI#(P:*.%!([%3&$L2:*AFNW# M4(ZQ=J/FP$EP/8"B0%)Q%:K1M6M#A;@\SQ-2^)`?,KK:-=IS^-!M+N6B)4U% MHH.)R3=N80^P@CLQ!R7JLU*"K%:)4`H3@!^0T63@9Z=IQ3DO#T1Q:D(J@`#I M5U:;='RM)LUDUBUCS>SY1RK>AF#MC-PKBK]@C.6"B4^C,PTD[M"9&21U!\=, M0^G<7`HA=S0$1>>UD$6/H6^F#43LRX+6N5UHG3O2_-^2IN9+UIY=\C"K%H.47C5P.=(78/'CZY5B\@Q.*LF M=M(7-&?M2$L%P-V7A!N%=KL/<*:=S$H@_H)/\\B_@L\P1'0IZR*[O;T3615D MR_`JE!W,%(%ULT,<J89)P'4C(P=&;5:^<.K-"7(E(XYMW6-`5;Z&? M9V]"U*=>$$%_X<51$#TF\VICTQ7Y3K'_6MH3:O9+I-DJEYFI!QSS`Z0KJ5?O&2PCCRPLMCDJ(] MC+O35@JR)<^$LH,I)K!NEEUR1V)BR?1GA4AQ7DPF!+:%U-0$4ZESU*-JVK02 MJ#49);4_&9GHB6?4=Y[=AT-#`&V"N:R0!BO92BZ&/9^6QUH.LA M#T0*>`GPR&';Y+7W2`_$V7E!#/9>_`=,:P=S/QTC/X9^^C3U*8HCL`B-C==F M5+7GLQZ2;?^RZ>*Y%^)BT0*10V@"'\;TIV4;GO!O@7%M=4,[1O=2+N*NIO+0 M6*KESOCY&;W<"P.?OL'9_/$QIO,C>:BB%TS3(V`3%$X\6]P32\A$#;8QCW`KCP@;(?^\%I/CH,6)<%#C`0JW%T[9@(#YH M^K0PY=Z_%+)PT/;EW&5J38K3T>CI)MX?%Q8:TC]*W<)TI9N M,X!MS0F$B\$MQK5I2%M$LSZ02PSG_W8'NPJP54:L`*RF#LMDV-3;BX!2+Y0E MY0P'FA6-,X<-\03B?-;J+5:XH!%7KW%7&E]<',YV:(D4.U09V_S,L6OA]":Q M)PV`MS8ZNXAPT19FA2\N!#QKP[+0ICV$&.UW"7ST!,=9B0YZ]*\S&]_-@$4M M/&JB9?)P24XA?B'7\&R\EWQ=>=Z]8H5-N70]?(JD39"$;]]6.)5ZE#)'8H$. MY"<@]5[8$Y+)?(N1$T=L8YB:/YGDCL\ZOSQ'WSQE2C.2W(64PM:G9M=5O[[I036S: MFK6Q*%+77IAQR(UKBF1URDEO.!7`SVYJ"KSLIF-S.CILGZ!_)).SU>#PTL=U M%^P"Z,^3!*;)?(MK-<;_BOR;P'L(PB`-,,63Y+B'_H9PFW=ZL"7K!?U,6Q]* M6[/E,4IW*T43A@D+'F=4(0GHK)-/EB;1%97E^B0ZB@6VC44=*9D/R2:G)@X_ MEKB`1@%@*]R9==0(DS9^@P/A=1GAR(^]O.9YD&+<5%/K!$29FK%()W9D)X0I M^52+30JF9H4,AEAYPQC^/K@)GSRCT84),U:H5R$O"(@ML-FMXM4!VLYQX/&# M\)@&SSAKVQYC&FIPWR8\^M`GFV[(&N]C2AN;U:[8UW8'8[K$6TYPTPXZH<"< M`V-!PU21S"^\ME5$M6ADU.FL;HW>AT66Y="=WA`WGSAIHL>(P-QZMMUN6]FG MRWJ(.GX'&`KH^G+L`GVFP#9^[G>,N!@3?T^@8CPZ0# MO.4ON@ZB((4W9'_!,DHQWP*,U:P'N6&<:J>OV,FUY(K&(J;,E9VNEZ)7M?BF M9*P1MC*-4ZH"*AV0*>71R)D0I`PC9FC1J6!>Q)#98$<"-<\.$+RQ7W8>4I\X M."D.K6AI=ZBNJ&V,[TK^[)!>Q[4:\]4MSJ[+$5YZY*&7,=W+1P#I]%)8C0&2 M]V00T)40H(,%`RQ(X(&F5P("P,S62$N8%)X\;':@SG&":*8R8PFUIC!0K_^>9%"S1([3.B4PH$8L<#)4?KZ>^##?,'DQ>L'[^\H+@^V M)!>G'<@1!-'C&C[20__%86.PQ4XD&6#16'#I708[\69H<=1"T#`OC:B4&R!A MB)H`I0T:FDHSH+#C6H0:#FMFT#*"*UX:\-RH10FV=H/]9+$+BF!^F<[VB1S/B3LOX#%7=87D_%IG MDE=8/3Q2=I389./8=H!$.;5+JB^C'8KW=/3DXC5_*4X1M"UT2*=AP1@9E7W: M(:FN>S7RZEEMD#I_6VN[:\JT52\D'&O*]>''9'\O//"B@K(Q=K30+(L+482, MK5X(CFY.\K.;+]IG-TMBBQF[W8@SU*ZY.#2L)):BDY%"*<8L`[Z:D8P(G])# MPD'=)*C;I`&M)IC;!=2PI6P#5W9MZ=EOC*_6KH.OJ^?A*_;5CP:H/%CE[,7M! M@[_C4MD<;U^E9GD<""Y*F:1T^*27E7Z]/`O#+EI^)^SM]1JNT;<\6Q_W>R]^ M!;L@\J)MX(4@J)0`_@LD^7"?*R&E'_[Z=_-T!H"T#`[H[KDW<$2VQ%V\7H9> M(IE#XDIV0T17TEP8:-NV1'6.&T4Z,[6;W1NZ%1%G`53(M=:?7]=L.HHJA4NY MMA*'5FS;#E!GOMVB(XZO]+;U&X13B7GD7V?A.'K,[O906_[5VU)W":V^)7/K M975]6UHUF?%6ITQ7ZV3BPN99UIH?OCD+U,=0@@N&M2=8UR%J#V M*]MT88>?7=P$$5RF<-^^H%='I0@D2BI#(X:"$Z.A0=V?,`:HFID))V'`)R(- MJ/C4[;T.0%#_"FQ164&[P5EE;\Z0DW>FN$2,0T)SIXIS#-LDF\Z!XB+5V7KQ M_L/B=@/N%W>K^\WR]CV8WUZ!R]7M)7YZ/]\L5[=K=\Z2EM6T@$T*1X]S-$2L M$1X^/AU3KH)D&Z+D*#@K2%V#PQ^FAF$J,7S8.%U:V:L.SWA6E"CG%L]$X!!0 M3E)[8O8QE$5$Y/H:!Y'FCH=1]V<`C&>LK*J2!9_<.8/%*B1YIZ18P>2DYYAD M1;Q">R_HW*7->M<,_L4[,Z3*K%E(DQJ&%6A2DR_Y\"E[Z`;L6W72!7CW4S*1 MG(DQ,%O7GQ"<(;;Y^!Y&,/;">>3/_7T0!23#(AM:%R]D(4-G)%U+J82SFM)@ MG*NX,4L`#8]B9B@;FN6R)^`QDZ:C<5Y#?FH6:6$$#:G!-N]4])N$5/A!SA*\[JBZ*WM;<3DT)< MD4CGL[>8P)1OD$!@T1I&]&ZAE3;80C_]H'+&QPJ`60KW]C'#"Y\#0.->T*RM MF>Z-'!%5B)LGKQH=:"+8*]1O(-!2DY3N<.-!O*5(K%5 MS\+P;LFSE7A@I:SF.P6CEUT_;MDKS:Q\#-X%47;6?_*]BP'0+N>D4=4ZF%4B MM95"R,._Q=_^M@*/N<[B^.5V*.JT4C#>9D?A7L<3D/D&->>`>@@ M"G`XOF5E^!;>)J#,UQC?WF3.3/_?;S`A\Z393SDSE10+3`_->IFFIVI=&(6Q M/X`RJ%Q66@>>N]D])'.:/H[5:`>>,P%RU]3;CW M](X1=(S1JV&E&Y.G.$W+'[[MO&DB;IK.?$8FYYO,7?)D[#T63),B$WL?HZ2S M5<2>AZ&9C,C#5/&27R8G\AII\:R$38G7&7WQ10RL*8#>1"!50YFA<,IW9B2J MRG[+VXNM-[Q==\8,#HV<-^9V[`TN@A-QL5T:*V'PIK47<.C(GDO[!Y$-%32MQ?LI.-]MV2-7X*;]]LC:VWEV'ZM3QIW_#H[<],JJ1.! MN&>AIYFS895E]C%_EF>R7T!2VYMJHTRF"%`\UDQ*JPCCS*,P?_<7V'[\1G_D MZ*N.V&ZMMQYMM\XV'LV"OJ'%1LR"3]-^,(HRRYY]#:T&AV&C-!I\]([59C1+ M,$Z3P?K5;RC`O(%%1>Q"NQ)=1EU.E`>R+WXMD5MA;/151&[$L/>];E4:P2KA+,0`^L`!SC>_?YN5G2_'H`V5Z0"[IFFT M"BVLK&C85J_)LT95@G<^"D,O)JN/LLS4A<14L79%45%2O9-'%BL1M#G;-EJG MFNW6>J>Z[=;9G+=9T+_ANXUAVNCY*5\'(^5 MEC9+,$Y:ROK5;Z_MR(:3\^N7DODQ?4)Q\$]HK)&0V1_:&O#M3Q7V>25R(KY+ M"F:Z,A%SQ[WA[L37['LTK@S`24HG95@RO67]=X3D*#P2PB<0GR;")HR6!D* MF"PW1H(EO_RN$77ZB1Q1R49EZ=EWL^SA-X8:P--;I>B;'&3\KE!N^K2#5:)1^&9FY4?)6?KO;T15A-M;8:K364@BW)6] MP>6;1_X=9M*MMX?LNR$LNE#-47JYL!T_>Q1JU*'K_N4;%%O[NIUE#"4"KMS` M81/Y.J%S(-(T`VD/;UIQM?>OF3#*HC@E87])]X[0']&)DGR1,LJQ1`9'J:Y1 MLU&&:U\<)3AJ,_KF%'?-]B"HWDU-=$'E(?6/W29:5[I)%)ZUZ8">>BGEZ&IW MZ25/UR'ZG/"NWE00+8`O%!U*`(%QHT20^Q$20J8^NUS=KEW=NZ50!!=*OO!:Q M!%H-@DFM3T^TBV,21#!)\LNXDOE+T&E:5&3;5&/+FN(:R[H5L@D<*;&-JS\K MWH#B%281?ND*@81US6*0K$HX%&*I,3G$MS\]B;(E9B3=1)&,1"+9-HG8LJ9( MQ+)NA40"1THDXNK/\CU-U2NW2"2L:Q:)9%7"(1%+C4DBOOWI2;3:70>1%VT# M+[Q#24`[;=+43ZK230$%*N920:X32RFAS)]B:B@VPTL1+^8W\]O+!5C_NEAL MG$\,Y9!A)XA*5"XU;-Q*95%']/TY?&FK,$G"MCLA,W`YLC4B5W33 M2K9.I+YVY!K%:Q@_!UO8I4L?Y9)#>LJ#B:7CSBS;>G@64U#;X.P>XD`<;&M' M10792K`=B@$F3W(,Z9'2WF,,L]E9=Y:(]4,9,E'W;:;KV&G27[\$T\:$?"M; MO;2_>>$1TB(_M".=^9`;,&[(==#,LN=;EI&U8 MSQZG6%?3IVNEOLKV-T-T4.N[1VQ38T^]L.L!(;5#)^Y?RNE;J7K+-*/0N M1?Y=8'_G`D/&JRYW#5P@6#-FB7E*%_BUQ69%R@:\\6V]6EW_]=75SM;A?_PDL_NOC*-P>R7.AA_]\XR+QEHVQY6__ M!"!][QKZU5"O@W8QRLWL]F.:-;=UCVM>'PMG>6^VA$'^D>8I3K4?CJGW$-*# M)>]P;N!$0MT3';R-;#W@,>D6LTZ);E$*KX)D&Z+D&,,-?$DOL/\_I$%1HL>- ME5P]XYSA>-*-K,\P?D"2K>>:OO5H)K+U)C(0&52$Y%.H11DE.2;$3!7Z'1.K M%L.^Q*LQF/(:":("*AWPB6@!JN;":.@H(%9N6$RC>-)FZ/B0!'[@Q:^K73:Z MD.4'[,D$)>&BP9$(#V6NT+SY,TU4W`EI*C?T"2PB7*9#'"0P M`3?!/J#7\%R_7WSORBR%&A90GQIK$5"HUV"=@@?KL#/72BBY&H8YTAZ40F2U M1C["F,E]P5#C!7N#6)LVK!\.(9TY\<)BD]XRVJ%X[XEV(.AIE8%>46LP]93\ M&!VRU'(IIJ*ZI=GZX]W=#=V=.K\!5\OUYY47=Y>K^X_S#?+U>W4 MS-0##!I4FVVJ*AEH4Q)D&EQ0B!1/Z-F!(#^<>P M::$'S_@T,F,"UG1)6'E+]VDPL,X3KNN;;L(,)8!B2P MWP,,.->A;T#^Z@3D+]\R'CAY3#]`3)FQ;$CY5[MEY`?/@7_TPM^#].D>AC0R M)T_!88-PEPAWI)FG:?74+J*EKO90WNCY,YG1]',M9%L/BS.J1/H;E1KXC/5` M79$@-E-UY.2JOBA#1JJ^Q7`]0PWV]RG#9('A]VR1"W-`BODN_TZM=P,IV[!F MDI`LPR*Z=>5G^2-'>NOL.D$*G[()\(98';X,_>G`"8/'IQ3ZH^P<4/( MZI@FJ8=)%CU>>$FPG4?^51`>T\[E1<.,%'#O:60H+WJYM=!O&%00(>'Z&YZ= M@@?RF*[/\[,7[FR;'`@[9!($+>KWLM>($0-*-!DCC/6;AA7!#AEP[ZM0!KDV MJ.[6RO:Y@IJ)$W!14BE'SIUV=\]A)$V]2??OGY)]JBDB?_?05W M$/=&_4OL]Q$F-"(=N$18J("A.&*(P0B5U]F!OX=O]V&1Y_N'MGM@C#`GI,3@#Y',$Z()82? M;LG?)+)@Q2`&P7X/?2((=MX>JQ`%LM>/[(A,XR/^=2=4.D%D,7WZA/^5$E6P M*XZS`4EQ?`?P\1\G^'<%VR?=XN_ MH6XJU]619W-U'4N$JUR,F=-UO/9A73'<(OQ3 MRJ^4)7W=G`_G>P>Z_18+[5+2_ZUE?P_P%66E?\M)((.P"E&/S2?EN%>IJX2^ MMK-18H3UG+#K;GATD&>&E?P7C4C]%'$().TEBDT_8^6*7:_#H4DRQL7UXOY^ M<07N%S?T`-^[^?WF;^08W_7'F\WR]CU8_)\[+%[55A]"2EUOQO/*G@7@,K67O5:V M27(=DB/1!"KV<:N"_\94BB`UE:T+(4*U]))<)EZTF.<0D6\JV M?C:2QR(E!"$I;.&U%">E)SK4%@S#;,*YF=.]T:&ZWOQ`!C#;6K&K::D,3/V* M,#91S21W?3T;I2C9%D(H5>J!FF+9J@"B"K(S*)T8')P$Z[R=)&."?6"NV,>E MT;2Q;P&,@KX^_$C;(W+2$K9S&I8LP.W&PS$(Z1B$8P.0DV"?DW:.BGVCR2C9 MR14D9'@(I[_/,#K"6]C..(4R^8?@R`PA*=.D\011Y(7+-K[2;/[X&,-',@`7 M9V^`3P^@R_(O.@P&"(!QPE?:H$-E,']>I'<)-G#`WRO%<.*<2XP0I%JA35(QQ4OF"(Q9`9V99$=H7A]N9]D)>06,\I<`OWW3 M>.!D&#T!,3!7X-HUFA`(O>@#X[P!C#<-!DZ3VQ,,AAO/),TV0S=]==I/L5C9 MA/+$AL&7;=5"0RIT),"P0"\_[BV;EBOFWG`E,QK/8^3#^(VVGA)\((VZ;+.$ MK5$CBLBD+>"9:DS%'GI!CC:I20I6.\!H6K\`H'`;UP%(&=S$\DT;;F7%CGHA MYCQ'#.XK;]UIENO[YC)'UQ2=*PER)?#.S]6^KW>C<=-.1J#PO_(.=1!]Q4MX)LY>^E`) M#<-X,QYI&"E#E+;C$9EL)CGJX=04A\_H*209@0N5:@Z%N:+FJX$P)_L:`<,# MODUA&2=W\SUI;/Z9W1?67"S:7J3]U<"8DQJ. M`&/#"21.3+$P;F/IY$OF>8/N\G42\\@GAYD>2+)4/U9\@U;%\@Y-T)TUL MF"Y34).FAP4%03"'"J7])"4$!8^ MR++NYBGXU7H=.KM+5V5'.)9XR5.Q]ILDJ9%/G279;50X+7X.4NQU\AS3`IF0 M91"W0Z,Y+[78:;KH+D4#4XFP^5*-%@=H*FV<^R<@FGJ&\$TQFINTOP%*#T[[ MS1;'Z'"NC<*-1NWS;]1V@-K[NSCO@66W"T9K[#G9 M94.DJ]U\NXW)K9KD)#T8M4_V&FBEZ.#TM3(HTO5S:K[;,J@<_/`UP.P,(W0+ MH9]D*]2"W%2V`:$8#:%7LI%>15*S1T2\S"+PMMCY;36WH6DD5+U96<6LX%BZH5+8S^ZT8G]OFUU1GW&;>[)[DEXU/ MOM9,$SYH0-5V5VRJ6&@LXE1W.19NS2T$U_%H!+%GY87J5!XL*Z16*J#2^0J@ M*EAJ;@VK!A:DJ[HROD9=Q[$1S)Z7F,W.$.:$5^]K`JU@2;PUT)H]+BMOS\F( M!SUX7WY5EXY*<5B6DLJ@,T<4/!@\!D?#&_^H$64CLT*4CD%FPJ`F#3X5\A,? MP*\%#=2WZEH'C2BH5^>,J/LRQ['B2./+IR"""2R'$#'I#UX4P&2^_<#E4B!]BM'Q\0D\'!-B M,"$R#T%$?\C$W0U],*$A]=SDJ+*)DJB:3D?#L9GV0]NE&03CEJ0Z]S[7J!\? MTP'T5P%93KMB&;,#NQY:OK3Z'MS[J/OY-8/<\V_(%=7KJ,@UVO\H//_^A,+P M]73U.8)^>;\Q=LQ)B63BK4R(+VZ"@SSKUO(>B4,IY83ZK2SGT:TZKF1<*:P,D-?$`ID=]USLS6H!"?6LZ"81 M5;1+,JJ[&@.Y9L*_CK?!F,7-0"8*"MD?:\(@EP:?B/S$@YY6LBLAO2E;U\K7UU)T[\ON6>%Z!*VNQM9V-PZ.QVDS MFOX,(%BUW7#B4G?KV.S9>O0&I]$6Y`/TDF-,Y[WOZ.$B<__OQR2E\^#,*]G5 M%?+/H:(PA&UR^\9;#&677*XI6IA5C^F1]V^[E="`#NI5N4T"RG5+\JFZL8]3 M,RV"NJ^!",4M04T09)*@)@H^9<(3-P+6H,<)_L:Q9[C;L(QPR/#"\/6>GBT% M?6:LE\J5G0.NW+`\BF/60A=`[$F0,XD4BRQ)&K$]2K&$MJ' MPBK+5WOJ9/(#]WF(S=O81:?D4;2Q0\'`C#PJ8]UK_5QWLJ@C-T*.3LVL@`,V M0^)@?HM==OPKO9UX^MUTBHA!?2JUL[U#K%K?UZ'BQ#HXC6V54W,U#);9YCB* MO%(0$,D30/%:"G^1D./O@S.)N>$[W^0^#"X[5?8W#'GGW\T^TC/WZ%!E/>B= M`'(^WQ<)./X>-I.`,[IJM#R<9PT?R7^871VQ4/YC>4)#R,&V:3Q'$+KA\D"@ M1:,NBF!V-RXY<#W;:48V>'Y^"K;T*MP8@H"'IVJ*47DA/:R]EE3';!?X`OE/9`D,(4/7GO%HSW7!A3U'8]:X"9$$[D:`#>DE##@$'Y,4[6$\ M<7`55"52^OA-4'=E2QCSS)C'A9FPR+>MB8BS-B3GD/U919PBHE5P8CW\Z7KD$4#=" MMZ?2J=HD*`_L!%CA&6>=X>OI$PQ]0,R!S!ZH&02Y1?#NN^OWB^^^/\&:%S$V MDSR!WX+X$>>TRP07T$_R'>6O6=:+/D=)<^]KEF'CYW2RN+B/[B;80>SOB1QJ M29.3#=P^12A$CZ_@)B5N;Q:;[[ZG.A@'+*$GC8[8:[1+]0(1^P%+D'2D= MKNP#)#=_X!]V0J9=#L6]NO30N`,&PA.YT:NZ49=N(F2\H]3+WO'6G*+,.2 MT^!9PJ719O$B7Z,]KR+M78RNR8#`PHNC('I,[F"\)@4?;XBA(83M[]=X4SNX*%R"#[1,&^5#3*]!W7O@@8C05L[/A,A5&&1" M#?=;:!M&#Y"D0U5><7$L66>:+2I@;0\`](S)\I\)>/)\\`!A1!OJ$!(?N*&F MZA"WXZ3$>69`S4_<_!D@`3(*QV9`ZF^SC%)#BS4=0\VTL\/+8(F;N$4N#(": MA1.`;0!J!!16R!X)0.V<@(N2PKFM;P02'18V.8,&KN<8YMS@0H_A!;'$HW/, MHTZS%J(DJ35H[\CMYR@,O;CV]/MOS!$=5C8Y<\PN3'E)8>1#?YW=,7!)!@:\ M+6>_JIIPL5!%(CQH'8#0MOF%*RKN^*L#Y-JS.2`_NG%%=`R?872$Y+PR+XZQ MY6S`A*YX)-AE:G M*/D9@$.R6J6`5"X%2C%'1D",0XNWC,44MHR.0QH(9JQ4D MRSO!!9+#+@#E&C8>HN6^!+=SBE5[!N<@.BW",LG`TMSPU%?8*<`"Z=5?^_I+ MKE+M-DN)88NH,W4SM-1)7[S1>YL+"0J=0L:1"&P00MS;D0=CR.QBPMQ1Q71V M?BR5*Y8/\N4&+:3BF36_8%#BB;^`2JC8,]*68;9F=>J5?%(D()U*:ZVGXJE4 M"ZG$1JV!S-`R/9F+?O`B"_-RI-0%'(FJAA##6X(W##+&;Z\,D@2'EON,V^Q@ M*A.KW4[)%AMZ41K+JHU]LR)'PGO0N'H]X^BVM%E(3QU&I1A`&O75O?&,I=&X MX8QOTA:XS%T1*?+0"U;Y%9`Y0HKWCH1/(T@1W.C8&RIFSTKQ?3I:[(5W,3RM M#1_7SCB\AUL4^YUE#7U4BS-6M%0'';BAXC:RE8)/C[&\)%L M:O'V9/<+">"/"/F?@S!LGO;BA10VV9R"5SHCEX6?UM<:UD^%R98`?O82'-TS MS\`_QC3V/T$WEAWT`BD:")[6F2,:5JKS2+1=C\D20T?6]/!JC!_DJ!LUE!?8 M_HJ`S#L]9PPD#YS&UW5G<.*^CVMC>#[_AF>%2IX`ST8GUR_SG4\W09+R\C*A M3-''9X`[%9(\%+LTQ M.P\*OXG3X)_YM0#E\4\/7DBV.H#D"<+L%*A\+W)V&C19FDE6*_OTMM2\&(UM MQ;U,4DZQ0500O+2D8`]$`^\GG`_ M0`P]NXEGU^1Y32(?^K`XK\&"OCPA*\K?-"1XIR[U@X31=O8*]XNW6/C*>P[\ MFP`^0!RO(^:HLHIH_@/%HD,`+;)LO`U6<,;%MU1W1M^`\A6Y`)'.QY'K-K,# M-QZ0%],&U<^-)>`=D=JB,"SV"H(G[QG2W8,H2H+\M"ZRV^(1/4.Z(+*VM?S[ MB9M:)0@AS:INDDJD57)+;MHF1LVTQBI>>J,3M\V%"&CCU(U1:Z-0XK391K`T ML`67F3?8D*NXZHVH\QJB3L'"?_1B/VZ^'3>TUK5F8+V8Z$$SH,>3I9`.,'KU\$ICT=DNY_'(DG+#5CU2> MNGO+JT2D\.';LWE-R=HL'LN$:328FN!E6];"`9W0+:O=C1#6JZ*Y\[8:-3WX M?.&N2:/'";/-:]7W>:.^/W@1YK]/%H2XW*;U`@3WA&`-0!AMH^XP=@(?Q]K5 MKKSB_'6U(PL'4'3GQ?C-//+7!W1,V"?X]#>0?X(^!H800M^?\;:R=Q&XK.II M<79/5F$EQ2T%A\)*\R#,8^3GI^44Q_/DH]:)1TXAH-;IE2X1(B=E%FKOZ(D_ M04+.!B*M-HR+LX"R@N1'(I[04DWPC"J"A2<.>1/3@!Y]F;JC]-X*U3@P.:V9EB;ZM,>M#F M0[%Q\_M^IU#C9PUET6XB0^8LX`O3KMN$%]&VW^25*QV\^(0]A8@.6_S MG]9Y.P3V+6/&VV^V?2ZJ6>*S\CZ:K->8YJDG631>GF)?OWL8DD.OZ76<*9JX ML>;5)))__B:06X(E<)D&#`/"3./*,:P#A;.JWU'6_)NK7TY+J%'!`ULZAD6# MW4J.=9UJ/O\2JIG3(&E4L]$&9W5,D]2+_"!ZO/0.0>J%-#4@+9[W$,(-JB;@ M[W#C1T+Z8QL]@VSDGZ&GC2%X[^72>$,XI!1<\O0WFAV_7SXK1ESS)O1/"4"5 M:;#-;&=WR)S4AG>+%I?2E.XYH*EF,6]*&8A#@]MN']+J9R8\U&09E9`I9 MS=C0RUP900849A)VF,O/10625719$#]VF@(&L'8#&^20_0*_"9D(6:Y)^!#V/Z MZZ=>>-D7EL@`5%H+<#0M5A5A;'X86F[9T[-19IS1-I,)_:*-/*F(3Z:N-$VPZ9:P48;I5L4G:ZRP+G(0R6S?9+*Y3]&(#<$E5RS MQALPF2Z-J5V2\G445-8 MLX,D0V%2:+\'AL[J>R1:`'KCP."%Q;[(,'OK'5F53#E)^MTP2FC4J%T0=?%: MB=QEK)U_QAG/'8;>$WYX1W9)%MMCZ1!.>^BFA<\1/=9W*]GV.'AC@-T"VMDU M-4J9Q?L31BC"K)#/M@1G)ZG1$RBR06+X0A:/DV:-C(VUIA;)DK2=%\1@[\5_ MP!23.SQ.O:MX3`JB:3#.V*-AUWESG\<8/_0-1!R#>^;&*>S4L:;8NY=ER757 M]>LLR;A[32QW!ZB_$U!&J[LB6N7GY:RSM;6;:BXW]_PM&MG&_Q.J@1#;+E//@9&(/]][)@DIZG$KZA/OV9S_]5*0])-[0?(8*F7FASMH^N6';'@IK] M'CS`I0"X&$7O'=0*\N5VZ=]&'!ROP^]V('1O.$"AT&Z/#BC^`,?"X?EWL]6! M1K\LQ2/#!RF.7<5H05)I):PLKY/A??$C"F\CT(TWWN!VH#,_&G%Z(?\-F4S] M1V3+!)91DL:T\YFLR-K%S9,79?1+WI-#QJ"_05=>VHZYH_NMCSV,XW=P:S1& M,>V,-(Q8#A9MAL&NVKK+UF\CINH[,H5.J*= M#4"\PZW5,0K2[P'*?%'1J1?XCD]7-"43&"W,&$5H-BSC_>@W$ZD,#AR,660W M8E0Q3'"J.$YPRAPHR/R"FF.PJF)8[OL$Y-X)HHG_;]%K3'9\5>'+1+]_K+*: M[NZ/66XW@ACNW-="B_\MM(P,W*\JM)C=99FOKO^`HO0IP?W\ZT>X0?.47/QS MF=W_LSK00WVBQXT7/\*4MTFHAX76#B(M"R8VA6@XM+;W2+\,TDTENB9K&T[V M5)4.3EZ_7]#+L:EZ>1<4*@R`-+/@QIZ4/N!K;UCIB0;V9A8-8YV=+MH%F8`+ M9G=/]7!NF@5GWV@P#`B3\V!@RMW3J\'D>4`)3+/A_!L;AJ%AKB=B6E@=?J*O@P?P"5CEO1_;FJ M5F97,-G&03;KG(_P;TM)>K<+/6S*`SY\2$%0]D%.\-_;\$@/"SX4_IHGTN^] MUUP(MNW2$T#)['1AP@M#<$`I-AQX84_),F]I$%^:"-^@<+0BY.ZJ;0Q.4(G MX).VO>JCM*S2*9'R5^%2U]\1(]^?M#_,@5[;>@+(*?[E#]X&Y`2P)$';P"/C M!Y^#](E94R?T_!5Z.LL+N?B>G-!'GGA[=,QV&WC@`49P%VQ;GWF786+J@\3T MP@'J3=;.!<@*^O5+CY7=C1.#C%UHK^'/0/3)+J[/0T>QX:Z(.)4&R%6^<&SR M+Z2W`\[A%\\K.C)[V;R&4P,0S>\^2K+E]H7`%XY$_CWQ=I!H,0^]\P)_&?TU MB/RKX)G<5.^WQR:5Y9G9)U/>'*T8YBWGG'R/BFSB&:!G>FV]Y`GXQ7.<96UQ MPD6VK$3DF*.`W!'8SB:=2DE$\&#S3%*#(H8Q5#GDXCJQCD0;F8?`U3`,LO*- MNQQU1!B4TE\DYI02C,&@,YI6<'Q8RR@$_H9!#^<1%Z*.UQ<).*4\8C#@S*XJ M]D*8E!?<9C.TQ260\P?VG5W)&BK%6EXEE4&+0Q0\&%R7IN&-OQI#V$=LINC'200<[(ARR`VFA=E M+N?8MH^[X.IYD;9>_HDT](8P5=F-\;Q(US.7JGJ&Z!9/+Q.NEG2090).)TCZ M,$)#:KC)4V43)4\UG8Z&8#,)DK9+,]@]R^9?"5YS#:<3I)$@RTF0+&-V8(*D MY8+T52"7DQ591J[1K.B#]Q+LC_M++WFZ\U[1,5V\ MI+04Q75,M;M:EQ$Y^R1XAN0BO!8I!MO)/^$`.T/HW-NM\:QJ:$FX?!]FF&9= M^\P$H`L?#M0(.&(3<;Y*,[-77:Y7OULY*$S2@S0F3L:&HQ69!$XS?/0V68:3 M@86:C$AFDKO!1;!#(9S\Y?J`&`"9!5"8J&X&K!D!I15Z)^DWTO#3Q8E9,S"= M'.3;8'HYN!QVN'-><:=H>VC^E#4^9?KD[,'!OI+#UZ(%DFR9%L MJOE(4-(N4ED.=B+;QT(SA=6S8"!XZ#BTE;;V*(,L8FB;;*2JK>U.(,CML/+6 MI';<4IG#NIBW]@(G,H,69NS0,=:.&OH%F8`K1C/3/LY-LZ26C6:JH-`%5)F1 MEY;Z7RT'Q*GGF"0PDV[J>C6?:/8I@6DJU)++?$LLN6.DV4[(4LSLDEXZ*YS9 MF'A:>$*2B+/,,4E29I;UNKC!?^&'Q2/\_TB#CY_\_U!+`P04````"``*2G1! MK^&[M$A#``"6=@0`%0`<`'9A`L``00E#@``!#D!``#M?5MSY#:2[ON)./]!Q_O<;K>]L[N>F#D; MNO8J5FY52!K[[-,$5862.&81-21+K?*O/P!X*1+$)0&"`E"MF(AIN9A(9"8^ M)&Z)Q%_^\W63G;R@HDQQ_M?O/GW_PW%R5Z"3>YSM*L*A/%G?/J> M_N^'DW.\W1?ITW-U\NGGG_]T\N'DQQ\^_7CR\(PW)I?GO?Z;_]YB4Z(1(G9=_?BW3OW[W7%7; M/W_\^/7KU^^__O0]+IX^_OC##Y\^_K]?;NZ7SVB3?$CSLDKR)?KNA-#_N60_ MWN!E4C&5>\5?'XNL9?#3QZXN*07]KP\MV0?ZTX=//W[XZ=/WK^7JNT9$^AE0 M24O^.J)O="+6^_DC^]J1$D:I@G6G-K'>R4EMOP)GZ`ZM3^B_?[N[EI;^^2.E M^)BCZB9Y1!FIDA6O]EOTU^_*=+/-4/O;4[]`$&66Q_V@8V@N*GFB;W*$M+NC(5H]Q2_)3D4SU M]'#>UN+?%D])GO[!V!'VBRS);]>W6S1=>"AG5Z/5`^O$#@:KEM$<8Y6]D`"F M+DT$5S!R-4_:RB?G,-$K9BPGCZW:,LI=6R<[A"&4OH9S7?&[?7EHPZPF+ M$LHMVU^7Y0ZM&K21FA8%SLF?R[H)[=8F,,YSK%$=+TZ=KDK=+$=G6(>Z7("Z M&\L=C.+SC-^.1VZW8[:CT=K9.#U]A)YM;'8_*KL>CYV-Q$['8#>CK_-UH;L% MX9Q3@EDF`U-<2%*FY>UZ0<\6B4]J%FKG15I1NM[@C;/4=H`UKV.NI>P,:]A) M\YB\)"JOZ$!*_EX1_"%ZX%#5G?9V?9Z4SU<9_EK^+4]VJY20V"[PA/PPJ0Z\5(BIW MAJ.R3E"$5=M6G.'EH*Z,1GO@0J<9_>7OJEI.'TLR""V[N51&CQ__^IU)$?*9 MZ@DK\M%W-!0?MZRG?U@^IUF' MI'6!-X:-@D$:]J7_\PFD@I,*GX@9XX(L.:AVGX&/$N0'(I]`!&&/+/R3#[A`OQY%=(,4`,1Q$94%3Z3<$'Q[>!Q;_% M`8MF?Y\>6K*M]?)V5]$[%_3RC-C!``H,W8RR0&08,M!^DLM15M,@[-]#1UBK M\V&F?T5^X<$IE7#+A9 MPL]0A-\:(W'?HFEWE4YV#<]Q;%L^^%W:5K_NEJ)@BU9)PSD`CB8:1$!TG.82 M.,XM0J;NR_[EX\BT-^2'^4Y;30ZGIV%XG92/3/5=^>$I2;8UD%%6E>TO/**; MG__>!3O"*=E21I#HJ[X8^O6N8^> M56CVBI2:2&@&"HUHO.E%0XUHZ`WYAX8SOR09HM&4U7E2%'NR'&61B_Q!F4F9 M]M0,5L:;EU:W';93>NBFA56P$S,8:]_G\1.T"UER+/<=DISV]T*4C:?2XA2;A(`:@$!(>8D_W! M_&0_(XO3;^5\3HHG5/;&P;VFU;4%>`PH"D2`"*BZIOA0\+4_9`]D5&*3]H$) M.##)"1IKB@C"!8M6'2`X1'SLC]$#`8,*!RJ;1=/Z#AI>W.86I^#5*,NJ-XMI M3279A1:93&JK`X]X=R`7!=XBXO_I96%V3O;/7;JE^VCC)1R$M#&CFC1`;!CH MIH.(FI7]WF0URJ[K`2YM=A`.&OS/C:D./P?8Y!*9=V#IBRMY<$(LMHX@L M++6BR&80U@=+'L-2["9-'M,LI6>!9*8PSJS@G541YB(N[0G2?RYA\`#8.!N@V]@YQQ_ZB=9VCO&P*9-Q'% MBAU:W2<9*EDRV)*^_25%C)[V`!P5;?CX`6MJ"",57_NMG+#0-#:"&$ERNB&* M1'1Q($BKH05Z1#RCCQUC78+N;;XNTQ(])*_*L0M(W4:SZJ@#QY*9MB:(TG*. M/H",Z(34\R`%16-1(47@F-%K98(3(;?H]XRXC.GJ0!$Q$;?GR!,%#A*0;B8X MD3'TL:$DV8:F+N\&)25Z3):_/QRR][>B?T[2_'.!2\G,Q;9X;R@R*QXXA";: MPW2P,JO*8YR:6P]%_*]V3@VBY?R5A#9PS)EH:N.])'RCCV-C1X;-*#Z\*7"> M)60END[12A%G;5:R?V0++1DX[NRM8()"HUI\9Z5QN16KW8+5;KT&CR"G[DKA MHV(-M3,^>1#:%'0:!*U*;.DC.QTZ'/[JST/DM.-^*:+U/IEJ%B?:H!,IG7C1 M%T2X`*R=QDL_8`2!DKU@`2@(*HCWJ(0%2P@M((HS41+V@TTDA.%#"*RF(894 M?*,_(8'@!V+3:%$S`V#46+$X$SF&N9!VF'8R'1+5$F^R#,#CJFU>'L`SK$TV M'OT+JY&`"ZZS/;24=<0;'@\.O0('6P497K5H&X5))\IGI:#H+OH(*#R&(T)Z MAEXK/A)1U0>$W.QGST'<\NFEX1:F.9-\[OG0X>?``:'1QP0-8U:17_@Z7:U8 MR&V2+9)T=9V?)]NT2OC[7QJJ-CY(1A4X/F#:F0?,.54F:H]5E4N1D M%E">+I>[S8YMB%^@=;I,^<$37J`Q,*1`X$@RUMD$5!#FOA^(FA2LV&K#MAP& M;^)>YTN\82_C?D'5[?HA>1V',-J4/@0VFI4.'(;3K&'DZ$QK\OU`EXN,"[QVJ]R\;)BR57Q6S*MG8P*QMP3K8)1H#F;#.KPG'8 M4T!Y%][3NPP.4X0%DZ71;,/"OV,'F`A7LA69E MQ("ND#"(0%XH\+U0*]WM0PWD%<3K:X8:UD^`G^ZJ9URD?QSV!(18DQ$+,38F MC@I;&EWM,35F'&]XH$BSZ[+<@7`T)%1@J"6,$#]"':=BIV4:;R"#2*O;7556 M2;Y*<_[I92"U`D$#Z@AA)-=V*I8&G.,]ENK%A`%G408EQC%WT9-@$HQZ"*;L($U](21-*I4H1Y>$=J">=)&BH9:"*9(<&TFP06 M;FYDD>@D.*#()T804AED8IH2&>@Y"3RBR9#CY":!1ZR$$1<5X1G:>X!*>`$J MG7G*V_7M%A6LLOH672]"EL;&=M$KW@)6ZCC=3F+);K>&JGOL5T+E-Y=IFP$! MR;334/5SEXJH@M"./EU4CM_U4I$(]#J0^'-HFL;`(*4X?R7FV>5='?&*=Y>] MK\\]*E[2)=+`0D`E0,:`*A9PR%6SPL>`G8_-5`JP`) M6X$%72RT`NE+]/GUVS6;*=`E33,BW)-5C61R"2_0>6%]@1#4IQ+)=>U_'2M6 M?_76(0S:!.NT&O8)/>=ZH.$XQCO?K%5I%17B@?\X@,/A8U1HD.AD#X8#PZ`F MEE2T\;1(V,QRLD&#B\BB:GJMGO8@$+&.?O8I-P!XI`2/D)%!":#KQ.%EQ/SX MI[+&$R[PK!;".=Z8.O9@PZ+`ZU$V%\&7]A'X_I>002%7`=SZ`Q9S9+1\RP2Z M]:E$_G3YNJ5'%K++FEJZ-GVNG,[?K@?*",^GSR@GLF7T:LQJD^8IE:M*7U`C M*;\98E2HW2,!%O+60?3-B"U5'_8>:3UL3P#(/]ZUT!VQ!6F,9Z+;!9F^99A= MMA(##43;)<=2TH8-*Q-%#="D81OO,#S26N>2=:XX=(#H%#(`A8!5Y*FG`5,; MZ!@-GN@H&,8;J-TI=4A,)NM88PJ^:_4IHH"&5"5S4/19S9'W%+2^]-]^N\0J3M*S9^/DHF*6JB+NI'3.2M8\";"0-5'/82+7_: M7V1\+6:W/]==)D=/-,K,=Z?I*<:R/M86D`-'0#0&SH`H.N#(59P&G`'?>&>T MLM="F]0L"U2DF#T9>H>6^"D77&N9P$'SVJN20QQ`G&X<"Y1:51KOO5&I3:`S M!.C,(!;0016U@):"]?$?7IA.,<'S=P#C>.^X'=8D5\30]5LU.Z+H(?C^#*UQ MT22E?DA>47GY2K0F&J=Y4NROB;W8`TJD)%$H8S:JA^'1Q&;VF@;!]#/5%'(7 M>#L3@SO/K"+9WQ@,8A'=Z=SXDS.4H_$1HH9J@'D!5?AXU:EFB#4!.XM[@6&M M'+^@2KKY)OS63I:&WT+&@DH-^%`]9&+_L'@0_F&8_.,B?4E7*%^5G/[7F^UX MO\VFJ#`9BZYHR)":8`0PXLSJL'C9/&!'=/J2I!E-J/N`>_>RFVNJ9TF9+E6N M"EY:Y,P@I4/&YC13V#E$2#7M7IG-&WTA^$S(H_E<6Q^., M8?^][(D,@S3O%9G&IT_-/M9RW]O:.LU7[+^RNO.M_K$KV?.HDE>IYJT$T`Q3 M*O$7,>`.J/B-VH"+3YBL0/?P^@R"QQM;)3"&I.,!*`_W7>641](%X-:8`\?* MVB>\GAK);J[S81<>KN&@YK9](CQR;)_);+/_2:9%.K+&ZG*R8!1D$U\::Y!F MNVIT?@JDEJ@[HO;6Y;3MA4UU'78H&7_:H[1\X\TA!?!DP)X"]D]R?JW7L8G8 M#.%1;0U.F&.^2,MEALM=(;UX,9$+K"?+N7BSWF]D:OM,1#M]047RA+[L-H^H MN%TSZ7M9\M3N;AJ3QG:V3()QCJ:0P8X,IW:I0*FHC["59IX<$V'[8SO_8.VN MP=6UWGQJQ'AXB?W.D_+Y*L-?`\CAUTO'V$DE2W4'(!T_,BD@];EY3\59%)B> M4JS.]G\C#7.==_'II\LJ?:E33DJBN*T9'+;PC1F$<=81X:'KA-8R.H\UKT=^ M5!OA]MIAL[!\P#1F,U^F&1JH]X"G];LYJVC?')RE"F^-`GGCCS.R29'&:+`B M_AYAG!,VV,IB0\\QAX#4M\`$BSZAVOOM@-!ZA.L+!7-UD"EW$$SVM,,*7F%& MHBFB!*]#C^*G]*1=O)2*]&BA;F"AM\&T6J#HP*!=KLOAM@K#X@,1H+IN9JHG8U(B(X6 MMB"KO-&<0B**C\?C)$DY^0-[KBO=(?8^_"(IJCV'/HN2AXL9\))'BU-[^[T- M>(WDL[CM%]9$F->V9Y[S9)M6229_S,:PH*07J`H&9)9V_MAF%""(0^D+#:'F M9UM69:7&49;U>;AFVOJ"KF]BF=$I&[!^49?6U'L$V45X?2]VB%ZZ[#DOXO6: M);X6OI#"4ORJ"T316+(39[+5$3H"Z]L0]0SCM"S1Z*3$I(A\,2@H$CT4M79P MBT91=<>X4T'5I`EAS#$I*Z6&Y;C4<2!38XT9P#FNT2*!3^CX;#<9%LF>7;4O MDM4XQ:=)(>TFT;!0].`$V&*>;:%AA18Y@P()2)3TOLO--L-[A)K-@]X#\S#O MJ2^O]J.J\M&#ULQ",_A65=WV:9#"@S+IK,7.#+WR(BK7.BH2/4:U=G#N5D?5 M6>0_"A:)BX)F!:WV[6D"RUW8C"%:3$(*2]&I+AP]3@ULXQ:QZHHG9$8*#[Q- MYS3"K**,SI$>&4+UEIC%E8KQ&&&."?E6FOB57#"]=J/3_[NYKCDFN*JH[(I47C!R?4+LZ/QZ75NKI.'01DN>TTX[6\ MLBAT._2X5D=@N\RZ,2I:+7UR%3I[Q/&DX$!$/^&D*O'LD]C[;N1I%\S?X%*S MBWOJ\X@9[Y-4<"MR0Y%Y0>.D$='V!6O;.,K$`*X\\C=A03E64]+0`!BH/8J2@;];R\F^&7U.E__717TL8*7O_C(OJ`16; MVDKLHPZYJC(RT(K+'`M>`1:9!:KB>J._>3#2\VQ7ICDJ2U1^+L;IOZ#D,FR. MR(\%EFH[S(+(49717TR@5FF46]'K/NSO,A5A9N/?N.%IG6MG$!5)/*[9,S',-Z'KYB=+*>5U9W=#N"]16M">MY M``.U1U$R\)F%;(G0BKV'^UM2%&3)=_F*BF5:CEPLA/20A4Q!&IH;A30M-M(? MY#@5U389Q!35Q;OA=H>VS:3Y=OT%5[*(+QU98VDY6:0H`^KM`F'RJJ)?0?=5 MZZ?+N4"/O+^'D`K`-B8]`L!I]'<-NG%UT:^6^U[[NBQW]%[X[7HQ>)?W-%_5 M/R#RD?VB&&G-F0C&8!,FD<+8BY'*]1DMBBLO7Y7.2/Z$[8IS;G.UQYBOZ#SV# M?$DRP>F<3='V536CHL$C=((ES+!I5E&\XYI8(_%KJZ*C$,.B_;,1<-'@43G! M$F:H-*MHCE'+.S1/R9A1%'LR//R:9*-[2T9EE&`,OY'VYY,E$LU)M$G]H*8\7LBI$@%(MDI1_44GTJ;M0U?_DKP,9-@I6*L5U&!CO M^HI,GV>\AROU-9#F:K8`#L*OARMVPZ]Q@4*EV@1<<&P='XP'.%39N4FSH0I< M1[QYK^@M2J+9(<"]W M21<]?EI51?JXJUA6,]S=)F$/OY5?T/AZNWO6G:-SR=K?_K(Q4O"L9N4VGJ'2 MU6[6I531/Z5YD=)-WWS5)0$4Q$;NNS\)>4WY/ M5TO'OVP^IO.W-NZ)`8''\^S^N>4O:/.("DXA%4EW%BTB M\>8Y%4V`0?H,7=V877T.+&+C>&GA8_XH[908`&[)/)'GR?8S!+SB-9_:7V.X MTQM:4,B63;'E[.)=WO+:WJ0Y8I,)S>`XHI,,D#VZ8'1LDZCGJT-B%HVZJB(2 MS<5%@NDMXP;$5FJK.T]7"WNV'<3=OB]5J)#,-$/R2M">!/1*"G;Q[JQ8+<0@ M\_<)*RH)^WCO=;#QB\;3H=6GT7)A_*E;(?0_Q840A5H3@#'D&F_(T%62%NQ$ MZW9=O]_0WH;DP*&E:TRJH(L+-E"%)V!(446\T3Z]9'=$J=UF[&<4%(U-A11Q MP4>OY`3@")F']"2W)%[[.K\GZI9KH@9[];Y)@=P.LOS6]30N[2ZU+9>X\.;& M6%/VGFT%L`_E\>WJSC&Q3%$RM>I]@0U]+/!>6].>84+(FJYRYBB3P5"HI1*IL4Z7$&+Q08O*W-,0AFT M1OL3>-5A6H!Q#[8'[X;W.N"U.'HHZ2\?1Q:_(3_4WX2?!JV!7BLRVAU6#X/V MH#Z`3.+299)]O\2;NO;;XBG)TS_JMLU7-(W<[;HYIR40^\[7J->7BV(=9^FJ M$[)G@MMUTR))UK6F+%K#*<\&4(YX^HM\2:I=@09-/C2:G*"-91$0>/,?;IL8 M`]0?>A0G]3/7(ZC7;:C$F[N:LZ1,2S9Q/Z`A7YT79(5)Z)JG%(EG71"C+>EM M15]]8BR*Q*'H"1N0J`B]=7UQ>]RG3WFZ)BV25V.I'TBKGV7C._`N6#6FFL;* MWZL%>BA@IW8:^AUY]=293*LVB4*5+6T143I8O?.-E4N1D%*+B,$$D7D]'UJ8$D9+YRXW"B23S05HZB8HA^`UM MZV"X?L.^+N/,\IC(.3H*D7WSCME%9OR"$NJ>ZDU\[S$Z!W\IFY5`2/E('2&I M_X"DGEBRO@JB5:@;0I\%M1@VTW78=U4U#,*0Q)PC'V.;#92R??_]#BU1^D+# M.-DM-W^953LQ)%U90='E4150^`O\PDE>LORW#T6R0@)[ZS<9)O%H@\?L>'AS M`*IVQFY,,O0'@@I94)E=19&[A]Z569_NH!5C?["QQ"T`*+G[V4)*CZDU1E+) MO`&$5*YK"'T;TEC82-%A5U;P[]\'%_.-O.>V3T21U?-CFOO=613((AO6(:3M M@9N2U-_IY%@L?5\V*R0W0%C]&]28V%+[85=75<5.$H%51-[K/V.\^IIF63L] MN2:L\Z>43D^\]?Z>3`=QZAL=VN'NY:"2^0V16M?.W5<_)H74Q8/KVW$Q/[^^\42:;]$@1 M7$"G?0AN`MZ4V$)U[GA/5Q<[P0/4$7FW;PXCM_1U'995J[[)Y&^ZT7_NIR^0 M=!\11MYM*NK(/;Y&)19-[P4L2FK,$99?`+2V-PTJJ.4&)AR#0F$^5>;SLH9-).^JW*]NZ' M&I3U>/\:(*?,4=@5-K%0""[##@9XHGFXO(XF,K2W:DWJCMSUT!/6O,KV]0WB MWH6/`N?DSZ7GZ*,OZ*M,)MHZ[.FJ\CKOTZ2DK;;RR`:''+N'#!UP]+BI42Z+ M=%O?/E2H0L;>_T'5Z0IOJU%^IDD\NJT/*QX>7X9TAR/LQH1<+H'I`M:;+%:" M1>X6M;?#6"Z^]SMB\RFX?$:K789NU[QPO3WS!PK/3./IK%@>(G9(1:I5FNRI]0?=HN2M8OKK+UV6V(VU( MG_6F5WYV;=8%Z/V,^2H8N1IW%01](V1VB\*ODLPABLO4TF%<1/'LP[[-ZRA- MAM9\U4N^V33*ZC:_HQ`MZEGJ%YP7[7^R_`ZLO;1W6)Q7P!O6807QW):9RZJ6 M5VPS;SN^:SF](;4Q/+OCP6Y[]+/F':0&S+QL.8VG6.:<0KVH MX\X\H.LZDZJ+U7<,;^MX]A7?SIV=`]8Z^9IG7)13&]-B(^^@*Q;ZO1Y+`QC= M\8'7$6NG%]QL\-SSOZGK/@>`D:$$/^7I'VAUO2+MFZY3M!H^7#&)!.LX?=Y4]P78X>+`OI^J?G.>'[)5#H"-A*K!_MI)2CD4U`&=]=3KCB$R]N M*BLZADG659JG%;I)7]#((L")EC&'$20-.,0,55M#.8.P@0".IF:^;QY['NG> M[Q]WLIWM3XN"1G'24W9T"C3[RSK*XQUXU3S@M0%JI(T M>W](ZN@?DMIM'E%!GT$D0I77^6_/Z?+Y,B?:[6LPH-'+4O`2[04,2(DC>GO* MV$!#/^7N,2J((#YF])*'+EMYSY_I?@5JG%'^1(/YB$50*7E^W+@-# MIZFQ9L8H0!S["?HX5M,E7'][QEFV_W#[-4>K^]UCF:[2A`8A2%"J(^?`*2<_ M/DP"33,S%.52Q+HQJKTMY7NV=_37I5IL=?ZMD5'F)*1TG'<0T`5]J0FJ'_S: MDH+C,6Q6@NYBT2T?Z6:E,0>[6W4U!X\I81J7WIYVM3`X?4WY3@:B[5*_*&E] MO]%W@3=)FHO=Y/#;T#>VW]S-AF@&F"UEW=3P"Z+]DI-,3=1+,R0B\NW8.'MB MH#I"5U;S8@_D2'C$Z[S.<4$DV0@A(OG:Y4[BOX36Z6@%-:X\*^P@(D?3@ M^R1#)7'R/0U4?1E*WCH>+7EX36VHHJ;M]=P M$ZFRDZ^27J.^?*U0D2?9^:ZL\`85O/8@VN[FFY+6M_>'M2`VTUF]C!755"=& M5=80;__JUNC7^9(H0Q-P\$=TL'$\;W[*=E=>]FZMJ/`Q,RK0H@96)!T06-K#$&*RF!H(_ MQ0=!IE4;]<,>%:=/_7&CDHJF'9?$--%`"J*CY=@DYMQ`YE^_O?6:^9+!S;(- M5*_C24-@YT_3CT5F2ZA7UQ7OG.V@[B4+,?HM7:$NBO*7Y!^XZ-8P9_O.%.W6 M@?H,:S+'T9G6!([>+#P44'"P)2=H]!<1^#L33S:D(08B"8^SM'3MF;B;1EG73EM&5&N\6W0C4PS4D^V"&Y9J#_JA MI0*UQ@(5-(8N>>(G+J;%0/;H%_.7,M:PH;&U,;B\L+!Z64`%N#Z7R5_C]YYV M?7@6EPH6Y5M9K+I:_]@L7B?4'>_&]"`\^BXM?Q>M3]5$7423F"@XYV:&O9"QUPG^T1&14R MH$E\[H2Q[,`QWJT"O2D--[[E%E3L91_#(EZV?:TGE(V)TDUJG_@0;L-.#QF3 MUV,>*.9TS]4GI`[[R9]TH!*0RF`U(`T<6`9ZFN!)S?:8O3G8&UF/B^,==%>! MFX'MH(-V:.&;XC)VCHSX]GE!Z&N(CTE)PS(W6Y27C+'O9""'-'NWZ[Y<=RA+ MJB:"]"#Y(MFK&=_DO22'Y=G^0-.HJ\DC1V29RH8L8J6B3-4H7' MRYG$EZ1+XFSN*[P4;WHI:;K+F$(:?X/YG$C`,)MP\X`9)*HO=PHEB7>7G:G1 MMQ'569PQ0D_99=U14!XM2.'V>1NH*N6)=P4F'GSQFPQ'PX8;2,(L/HL$\>XB MNY]?8O7D2WK1:EKU;(-L6&W,#K])_W&>)65)TPL3-Z%*LR:CXU.LC>G\[?/U M1!&?HTH)VCT]`8'';[=!.?KN;P--;GFLUX3;,QOQJK=Y1CPB M=J':7H@!:):D9N)Y,NL)>$5LOCE&(*AGG'$T4H@0[Q74PR5SH55^2ZOGZWR5 MOJ2K79*-#$2,]D#M3A]+;HD$P]J\E7#/N;BNQ%O3C.2A*K!]4Z)9^9QN'_`E M"S07CK:6I1MC&I?VEXQBO4Z7J!".T<)O;?*)X3=OWM*VG;!:O:$?-*R$I:`8 M,H]W[GV1%FA)>`L1(O[8G5T,/\:($:6"DT'"K,.,F=2_YX0^*T1I79]$:6_]090^B!'8!A?.:]W3*7])D0 M5N5UOD!%BE>?BW&"S!EKF-H`JAK"/;.!XQ-R0C#9^H8G.UKI0:<*-E+'.X=F M6QU,)[2ZV!5I_E0K]FN2[9`X)$K8$R>RZ1]U6K$YEC[EQHZS=!QKT>+=0[.V M'/N_7U%9=6;B(Z+G8#UUT!*R/I:>-9^]@QJFA.(>VQP=U)=`O>+(\>T-J5/B MP(.XW'*:,>9H)=;O\I7^R8<`FQ5J8UR!A8X$J%8VF@.X4$$_C%ZMJ<K)PS0,.!K/%>[G-T;0O/ M`23A&=8D>;EL\5/E=+0U]^;7$>FK10N:8H2%WU$-?5]%O$R*G"PJJ51,'LDE M0QU9.Y9+R0*X&'B:5^DJS795^D*&H^6N2*L4E9>ORVQ'&I$^14;1N*L;^W;- MZZ*^'>B2^>B*H!OF_E9=T\0_VXL9B&X=SE]3N[Z;LZ;`6DIZNQ%*KK19$+<. MV3YXG"AS+>$_3?DOHQ$3\1+3P M6V,W[EL48%#I8XX#CEN\1T;G.*=;[T3[;']=ECLZH#(_+G864/)#138 M,=3:'$[Z"N(]$CFF^TMFH#&YS01#B>QND]-3"^_V=#NKQ<:S.4C+.)&1;>MK M93N&P%:GBTAIB\ZQ'))M$[K02-[^CC2)=VHZT2RC35\WRVC97K([MK$:_'1# M,TBZM?:0IQM3MSQC'?*$QVASV-GI(#@X.',D[?NPZ'Q8-#TJ"V0,')^:17CO M2WL.@6?>E.<>;9.(,SSN5TE:L'#B7U!"CP_9^9[O8Z].J,.QIBR_ M)H2T`8>:U-NDI1/KM"P1RU]]DR:/:<9@V+3*ZC:_H]"D(>"$X`O.B_8_SY(R M%;Y>[9PO;\;I?/W;_&S?_?E?*2J(BWO>WZ`7)$J\8%:(MY:FD']3]!W`6%3A M"9-56=XPL++^[7.=DT&@9$WV2;@)"*#D=1=1>AN][5H3FR@^')^-*J2#MK*B M>/<)1&K]"(;8CV"(_7A<$!,K/@/$?HS_B$RDUD]@B/T$AMA/QP4QL>(S0.RG MF<[(?!@>-CW"TZ8/DC90UCTP/JS.>#=HW$__L>446-)44^4:M*9&GB.8&TPP ME^P@81;>#E>)(1PIG"?E,Y&-_G/YSUWZDF0#AW'82N`C`DS+M9$"\')1NQ;A M&8"MT=Q[F,%FOX%8\3J::W;)9P-#-XRX:1T=\?'AV,@\,X-7)TN\:YK:0GJP M:NG:4UDYW?%!%&J4F=&I$,-^)531&XJ^P\+FG7_/,&-[BVFZ&['C/2`%G58Y M:F?]^:A*&E?-%OGQJ/I56=_GI#UI),>C"HKN)2X!A;\QO;'W0:KQX\#ML`X@ M;4=V):DW;Z!J'&RDX+!?"_CV7T@6\XMWY7*Q0S1*H\UE4(KAHJ%JLU3+J$(% M"4PM$#ZDK")>(F09_IKD2W2%BPN\>ZS6NVS<#23^Q:9L+[^00=E0P37%!#"7 M9%:!Q9+@YQJ(.7JB>1"\9[B"/5(O'.=`9;@!3U,F6-Q9J&PT!&H83[B1-%IZ MOOF4E6[XY`2_:1!3U%::_6&-(9FJ`BA[&XI22J\;J$RJN^3K+\39%&F2T1:X M7=^1]BU>$'_\`B_`ZZTHX*U+0YH/6R@][->*6MK-3AWW>">ZG7:_X>+WZWQ1 MX"4J81#3E^`QIBH1#8QS1E7WTL<@4BR M[7@(:=/2:M(`$O:U`IXN_[E+RY0)>+;O_9@O=J4=A&OWP\T\_,'WH+W^_2LKJ8,R74PDJ(RWP0K>2-C.`,/12UM=?08-JB;> M.&V=!\#FG4=OYB88'L`X7L-:#S42B\/3ZL#JDS5`Y`'K-$*VVE_3SHK*BB:" M0ZO;HDT(=[9_(`((!D+38FU*8W"Q0`U"!12.F*;%0`;I%_-F$+((J8IT25\! MD2;44])TD2M"&G_9+TQ;#,/TY)):`&NA[D7"/5[GY@QYX3V`8:\-S`)K`0YPB.,H-KFYV6_%6F1(WZ[9HL*R[#>>%^C,9X<8^OYHTE['"IF;TF!*_PVUY26*YSI MBTQXQ3Y&?,F>7'/EH-Z-Z-\[(!]V&]*Y!<^+&!097/G2%7D[K<3O>!@5`FKF M?A?UM+S.20U)ENWOT!879-4A'$NU=)T&4CI_B4_-F@+#M>52E8+JJ2_02?G[ M6.9)L-%+ME$_D'RZ^L>NN94J!`F\0&,_2(&(8&.LORU^(!4%-2S4\DE]B_AS MYU+XSQ%!0J.;O0/AV<:;@LAH!H`M1U8S0W=/)`"K^C;GQA93M^GS8EBE\6YY M""QQ(\D$!"&5G\SW2$-25K)!4+])U"Y_](8P8B,W$I!-2.?08PB(CT9M+*0] MH^XJEYR3`BNU]Z=!Q,<*%!\NYTM^/?]E1T?QYA7?YJL>Y!.8RB%OQ33&#C#= M>I.[@Y4(]A/[4#L'?>CZ=MV.Z9?$153[Q:Y8/B\'LPK= MF#0)VB))`2X%4MK,9(?2(3D)`BR3='!5R1)O_`!05:$S/ZYFG4+/]5OI+(;V]=*)]#+&&W5A8T('P["#X??;Z2,JRWGI$)Q`1[7; MPB;;0)B/:>5X[M,>(W"EMI@=H?V:(W^6>-)^CMW*Q\&>#KCBHW(40QTS5CE% MB&:#^@NJX,M9=W7('9.+.B)HER9/4*V6.#FX=7L8\#9N!Q#OD!R60\R*/9VS M1M"ZONFJ2'SF%!6.;W,<8HU>TB\WW53`<%K?'#!\[Y!@U-_"6F%1X"TJR'(I2X@%\A4=Y['#]3B&XXSLW078]FI;M:YIEIQN:6]:ZOXG9&'SC5?`P0W M!@$4:+KHOT7[&(-3,\]Y`#/GPZ1O*DXXTW9^_#GY ML-N%1/$NK^^3#)5WZ`7E.S1VGY*O;198_FOP@%3K8P:E$:]XUX=$_.M\B3?H M!I?\69SP6V,P[EOPS:_2Q:SQ.4[VRZ1@#W`+?(6+37*=K^D_K!'A,2[ZPHHY ME*IP2"8J6TD;)Z"WBZR$W!CC$B%U,D@[BZEXF19[F3^4"%2R*E[X^O3S-5Q=I MMJL@5V`-&>D'$BVCXX"KG=UFP"]8D#G>3`IPUCEI@C1]>:NJRF+O\`BRG(`: M;L;4\KW*XLV%V>JE?$('3WYI1HQ_4:5L36Y!Z6-D7;F!"CHJ'B8H(!0-@QX^\M:XP$6>>[LB(#57&3EI4,0DJ: M-DV[F"944$!4`K6^A%'D+\NVRCX425YF=7L=4IM*1@PU,3>.R(A#!8R1DD9C MCHQCO,>3#M'S]Q^_"?R,U'2)((NSS:"I%[FXO@Q M#Y8R6S-BR#)+;$Q017TS#RJ(-VO787=%'CAQ.K/^\7/7LDI M1&LF[TGU;5N.7TT!$NP;5C5:9\7_%N,BJ9#L^0[AM\:.W+<8P:)2;S),..:. M3]_#,+!TE,%3W2_8_+P([+%QTZJ/X;4&\-1(W3::B8/L0%-7NZ99QK7&ZU`5 M:M[PQ\3ZJ"B2O]@=KE=\TKRAZ`@XO;8 M4T,<#=Z,M+;#F:Z*>"?@SN=XLCG%3).[FU&\6H2-8+U+;+UY.7'SV*1>1\WR MYE%L%XVHS9T,WY%KO#BZ:#4P?8,(`+VW09"3[;0H"-#8>Z3UR]2B?7VC,F(; MR,H$:`?^87"M$20OB4,*!*J^<)_>I`C(!.[?Q+YL/-,]*E[2):)OUM'N)MXT MA1$WFNB(O8UW1JV"#;4>#FV0JNB(IJLBH(>RK_,/C91DO'XHB`)I_B1$"X"R M,9J2,AJ

TP(6<>[\TJ@PDEMII]F9BZ/9*#51/O M!JS94D9K=^W)&Z@^O>%C/VN3:S?:X]*N-F2[8J`2WBSP"WYALESGG)SRZV$F M11H;P(J$`@-UDZN;UZ,/,6J7L0M1^@L(;X&[\'X+;1XWT=R3TOD&GDSB$`YD ML4)'IJD3#/68Q_M:"J]Q^\\2/^7I'Z-[:E!R,:($Y+$B2Z>Y$X0)*HGWK1"C ML6QT?>-H1C/-Q92IXYG%NBZ8"RLF4UAL-=V#KC5N^@?PL'J.9JW1I-96]T^. M2-Q).Z)8$`52T@I#,L[>[JK/`ITO.%]"T#.F$P.H3Q"Q^A:KQ$/;W:#22F( M#3(OJ`&1J&`09A%&!LD)!&IZOX=[D19H27@+SVO%']OI'/?1VR"G,#C6Z#`< MOL:,V'C%,?"605MR]M[*=Y&\I*N;%!$A-TFN;$\5*=>Z8M+`VQJ@GTG+B]D% MEXF,>,I=5B5Y)8F]$'_N8B[XSX&VL48/2+N.67A+-R9IRP71(ET1/6[7][M' M\F>:%/O;-0W\P/F"6>XT7]UO\:Y$XCOPU@S:B_(6#`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`H\8 MMONJL1XMG.U*HF!9]EXK7NR*Y7/2;,"=9JQR\O,77*%RD>SI9.,T7]W@_(DN MS"[0([^F=Z(RG:#A+KR<,=VB9[EJUP>*XNP#V$M#L[ M5I%&@5(#;8BK61[6I%M=Y616[.F$#$0J5U1W1DH5BR!?BY@6[&^OP M@E&@S]H2YE@TJ:I%9JR1\-?YLD#$PU^@^M_K_&*'KDCK]`Q%SYF%Z1/L"G?I ME'CUGR+:/!>K8X/N?WW MC_%]>^SF-CKLDH3X:1:C6F/-X\#V..C.,!E@Z@A/WQD<:BDD^1K$'P>!\D'E M8F#[F6P_G@;.(H*ANI,=TIR?[0\TBWI:>TJS<:GS,SCB.\K9,)FOOSVL+,GI ML[&"RR2B3^W>U>"3=^&%=T3$'SD%W+^K0CF37W\07[P5?NS)U/_H;;216`YK MY!\.&D,F;*./*SQ'`+$'*_$W.I2X$]NHO;G!%SV&*QNN7"Y6.B39'')B[?U& MB?T>89M92V*(W]+J^3I?I2_I:I=D(YL0.SU04]-G*%LBQT)-C7W#^H9'NAB1`54 M[.]XES; M1_RTK?!;TTC<-W_[:-:@.&B0KY2;*W-6T;^KY;P*CS$/956DRZH),1;.8Y0T M792#D,:?3YT3"1AF$\X[SB!1?<`DE"3>'8'8,]+,#3UX0INY("?.AQ/A9%L\ M;.(W&4B&3360I+OMZER"]TGR8)*LFC;-.+?EJHWW!:TNG5!SO9^-0*H$<#(Z M/OG;F,YW/@HFBG#2*2<8YI(8$/AK,E2DJ+Q0Q%NV`3 M[8:.8,RU>?%U(3M2?5$J(C@2[(!G/@3U9QO(=53.E'O5T>>;L,+IZV+TBP&45S^4KD MZ&>MJ._Q9ZKH2/K/F[7%;&/`3,*'EL?2K9I\/J+Y>ZBLQOFZZKC&]SYKV3J1 M=-ZQ%MZ>OGJ[KGR%BP>4-QJSPO5MLC?KV4`!YNOH6@'>^[V;MHO$#6B5FN,] MLQ@V8FC>E_)VS?YVM?DBXCEUPV7(\YAZKV,+![6Q,I0SM"S`3.8/`+T^C!2K ME_B')"/E;?6,BH?G)+_=LM#FSS2T!JT>\$52C:X,OW6]_<[W-O4>4P?UT%*S M=>*WT<5;-F7/@RG,3N5U7B>M=#7>6E8[=4@VKO:8G,+;MU-0`[NQ*O:)K8/8 M`Y_%1F11LD8I\9MO[A"D-<_N$P0UO[N%B:T5EV<0:&.?2/S(YPN_HM*'>Q!7 M.[MOX*M]=PQ3VBDNK\"K8I^X/6Z74(>@U)GL7?=[%>^IG5O,^UOOP0"+!]5- MQ?).2)D?Q.2='0>(.M'@0[\'-!^.";XB76?#7E-9[*GDK2W"_H\.:=T#)9]< M.7$%ZZD^7,CZF/K`//8.RH,+Q8T]_;[@98MV0EGG=F_?DRW:Q]6&$;WU5ZX' MNF4J?_7$BNF1]+I9;#Q'?W,EZ(3G!'Q/E;0FX"W`WMPZ+J8;EU=/Z`&?5E62YN>HH/_<;E&1 MT,'V(2F>4"6[CV'!@;NL8<3A2!`_W7IS7O,PDJK%MM/@E^AOO;I#R_S78QW( MZOB1^S=L?LD;#W@.8(B:W-<]4R"C'#T^, M*4/P/U+Y7=RCYYG#;L9'")V^+B-W*LB)(W.Y$II`\IS4JS/I_7(8L3#WR9@X MB"PHPGF4D9KRE"B#69".9^3IZ^P]!,C/>JT*MQ-AP\(!@WJ*&:"H M-:PC\@MW%S0=/8&J),W*[WS.]&6BI>4RPR49*?@F M[\W_C[RK+IOAMWUM=X&* M-2XV2;Y$USG-AI:^(/KB%`>^R7R:!IC`)QIPNK*5'5@GU&Y_LC`\[-G0> M^S>B2\'KU"DBAJT-AR%@S3C$!M4)]ID$4K-Z0\O=2@]HDWP_Z$2TV]VDR6.: MD979>,(/HS],\G7TT0#-5'<[6`%JB?SD<;X<#%_H!B=-PU!'N/.+N+>N=_9\ M(Z-ZH^E+OMK"KD^^H;2.3XS?^&UJB;,[)HBK)2:\O-S`)2>A1H`X`;:M_?1<@ M*9$BQ2\G#F_*R4,H8A?8W1\^=A<@_/&GEXVK/6'&B4>O.^=G_8Z&J>TYA*ZN M.S[O(FX3TOGIQS__Z>-?NMU;3#%#`CO:XTX;$FZ['O<9UN:>ZPNH@6O3F34R MQX9V?B;_];6!M]TQLEH+[?SR\H/6U=[WS]]KB[6WX1[59M@7T+:FVS9V?7ZF MZ:ZK*7*N,\+.6;XPW2!&(K+"9H@_D6V?BZLQ9B>]7K/2'N M;;!#;.2>V=ZF)UOJ7UY(C5R\P52,/+89XB7R77'=^=U'+ED2['0T,`'E5R]\ M7]/S\_/9\\69QU902?^\]Z_[\5RU'='*IDJT&Q"#%<5NBP_5+Q%_5)5')8JE MVS_O7IQ'3"ZAOR7D>7ED;B3114\6/R*.]\*GZ$/YP>J7/56Z)X6*2$[5A'*! MJ(WC]([8,\2)/_2"PHB4T"?,CT@YML]6WE,O*,O0E/J;;&DP:/EN#Q:/>(S\$D6S0HB,L%O4W39']#E'H"R7ZM7H4OMUM"EU[X!MY)VUY% M>,SP4E/6OI)27'@-4XFTQ$P1ZWZ$S];Z86G(P5%0+6&S?;;16#EY6 MU0I8""5-5LI%CU65`A;L?EU]9#T+T$"3#P\S\^1TJP0:>K8OIWB=.@851.Q, M&*-LHSI31R/.=2>78M]VU/H!M1_[L`+T^[!R137$'Q%UM*`Z+5;?Q]YQ)`;@&G@N<:3K`,\.IM#6 M#7+E.C-?8RSX`T6^0X1G&WVL3P:&-K\SC,5<>^='+?RMQ;,^GE/$P!AK+&0-E<%-N1ZSY5[ M109C;@>XJ-L!!OK\3AN-K<\MTGE(6VR%*/FODA3&Z11F\OC0#5`M(LI%\/O( M!SOD'+J:-;O5)^:_U0A5`W0*TWIRW+90'4%U@SB!$32-:2IG5D;4>J?;MN># M.TM74QB`-GCH`7:5N0K`?)\&\T:?FVK,P10[A_%W0'4P,Q?F0!]K^F!@/4P6 MYN16F\+0'9A&B^\QOG.\DA/<#&\])A%1RR;X550D!F,Q60&"%VD$Y\:MG#BU MF3&U9@JE8-$$3VNR:,?C";S6X&_*"%AY-[#2Q4+6$V4%R'R7@8@;DW'E7F#Y#(>%^`PH&/G^8!0Y?"\41 M%.&Z+D,O"R)B-L,V)D_HT<5\@D6`20%-`3C_2(,3+O)!Q&4M[F"\S(R!87[2 M;\;&_._:Q%BT0!T!9=(GT-!C)`;,T;L"('Y(`V%./L&HL&9F:_43KK3/"<6< MPZKP2&ALW3^-R:UE#3^;XW%LD!IB@8A;[IQ41)L+UV7-XU+:N[#Z%L+*$6X"Q-+4 M!3#6CG%;'"L=N$F"ETM2@%B%XS`40*B$G0%6%4];O1_`=K'WM'U/,&+Y"4^ M\@H?LI%9.8VF;I"*7\RT0FB;N*THN'UJ[-FJLN1-0IF,/>P*'KWI'JHZ>^%. M=-])KCAYEQ3EBG/,(Q]>+4#&!4YE9(BQA<^OED1%K&Q7690X7_3C]<+XX*Q0 MNX8T<<;]KU?+@U_L=659]DSJZ=4R4$1L=:G9>14A#ES!8_=003TQ.+$K"Q'Q MR(O@06\;OMRMA`LV@:BVZ.*7K8LH$A[;C>!W^=DB7HMQJ"3'9N&UG$K&0]P_6,O[ M/7D8;4YEM#E0BV/X8:-TO7\M0QSNN[S:>#"/(;8S!=Y(EQ'4\A^Y($)= M6WK+/'\;D1(@Z6B4N*[,@E]W!)-?+B&@9J#9=6>)7'7OIB+>0K?PG(5J*9@D M1%3T&%QH==UQ\",1M?2>>-2NHGJ<_@^B_1RY>(P1QX_(_BV658BTO$5$"LAY MN@]49VV*36R0+L\H*D#D\DI>'F;!]I_U*LU/E+^U>H[/PJ]>*^O'A;5,:Y%0 M\11)8[0LZ-DF!3-`[QSBZ/^3XS:F=R6NQIBB"/#8II4:J(%."V\:W`2ZDY=R M_NZ3K;J@4PA&'GTA95MXX<$GNE(CG2?'P9>M]H]C3M'K8;]RQ*D<>UAW=@FR^@>_`[3_53.D*$\(@9 M+!5KN0>+]P-;'MU"%&8&W88I@.%X]Z_`$]>64(%7F+V)QU"D[N>UY[J[KO5, M8>B"&,0AB.V_9$UH>9JT:*F*:AS4VY9(!AFP8E?[*3TRJ%IGCJ!S3.U."YJFO#!'`Y+ MESQL39ZP/#\O[XN-ALLNN>07T?Y10L:]GQN>/$\A=XJ@:?C)J!["G/C.XRF5 MBDF;IMPMOL/(%6L;,9Q2)ZNP:0J,$!?0U+-8@X>(V981B)[&9"/O11ZMTCJ5 MI&^:FM&)/K76[&9H:8 M-S_#ML>;#+ M%&?C*<5&$-/4P>QL[4OSIK MPU2'=?!]_[R?GBF/"IHV"TX\VK662W"`F;'9NMX.IV?[')K&J1,F^H/C_A!C MKAC:9.T$'!,T+?^?_>%]+$BYV1U(IFBG-JN>$7.F/K/7\'+*B-S4C&WE'0^C MX\7B:[?VIB.VY%+Z974>>6R!::BP8@Z^/GD3@QG-TGN/BC6'OC): M@5>A"P$S]@`S^=]^[W>A_JIXUJQ9B;MY7EKRA(=T*^5?T/-H^$??1Q@)G^%D MG%.*X:L\`SCO$V0-2^G<`6>YBE\CU[(QM_(?598:CQ?1%L&D9L= M"XL2.[/Q0P+UZ_AF&[H%]CBD+F0##Z`,.U9JKTG:$M6XO^$RK;[)##XI@%__ M`U!+`0(>`Q0````(``I*=$%3SHO)[+H```>O#``1`!@```````$```"D@0`` M``!V87-O+3(P,3(P.3,P+GAM;%54!0`#M)"K4'5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(``I*=$%^AXZ__1$``*8!`0`5`!@```````$```"D@3>[``!V M87-O+3(P,3(P.3,P7V-A;"YX;6Q55`4``[20JU!U>`L``00E#@``!#D!``!0 M2P$"'@,4````"``*2G1!GD4)H)XC``"/-P(`%0`8```````!````I(&#S0`` M=F%S;RTR,#$R,#DS,%]D968N>&UL550%``.TD*M0=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`"DIT02W!Z3R)B0``FIL'`!4`&````````0```*2!`Q0````(``I*=$&OX;NT2$,``)9V!``5`!@```````$```"D@4A[ M`0!V87-O+3(P,3(P.3,P7W!R92YX;6Q55`4``[20JU!U>`L``00E#@``!#D! M``!02P$"'@,4````"``*2G1!YRPO#.H-``!_A```$0`8```````!````I('? MO@$`=F%S;RTR,#$R,#DS,"YX`L``00E#@``!#D!``!0 52P4&``````8`!@`:`@``%,T!```` ` end XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 142 240 1 true 40 0 false 4 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnaudited CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) false false R3.htm 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) false false R4.htm 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) false false R5.htm 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) false false R6.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS false false R7.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES false false R8.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS false false R9.htm 060400 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vasomedical.com/role/SharebasedCompensation SHARE-BASED COMPENSATION false false R10.htm 060500 - Disclosure - LOSS PER COMMON SHARE Sheet http://vasomedical.com/role/LossPerCommonShare LOSS PER COMMON SHARE false false R11.htm 060600 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R12.htm 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET false false R13.htm 060800 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET false false R14.htm 060900 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION false false R15.htm 061000 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES false false R16.htm 061100 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE false false R17.htm 061200 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS false false R18.htm 061300 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://vasomedical.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R19.htm 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R20.htm 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS false false R21.htm 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsTables SEGMENT REPORTING AND CONCENTRATIONS (Tables) false false R22.htm 080500 - Disclosure - LOSS PER COMMON SHARE (Tables) Sheet http://vasomedical.com/role/LossPerCommonShareTables LOSS PER COMMON SHARE (Tables) false false R23.htm 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://vasomedical.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) false false R24.htm 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) false false R25.htm 080800 - Disclosure - INVENTORIES, NET (Tables) Sheet http://vasomedical.com/role/InventoriesNetTables INVENTORIES, NET (Tables) false false R26.htm 080900 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://vasomedical.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) false false R27.htm 081000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables GOODWILL AND OTHER INTANGIBLES (Tables) false false R28.htm 081100 - Disclosure - DEFERRED REVENUE (Tables) Sheet http://vasomedical.com/role/DeferredRevenueTables DEFERRED REVENUE (Tables) false false R29.htm 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperationsDetails ORGANIZATION AND PLAN OF OPERATIONS (Details) false false R30.htm 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsDetails SEGMENT REPORTING AND CONCENTRATIONS (Details) false false R31.htm 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) Sheet http://vasomedical.com/role/SharebasedCompensationDetails SHARE-BASED COMPENSATION (Details) false false R32.htm 090500 - Disclosure - LOSS PER COMMON SHARE (Details) Sheet http://vasomedical.com/role/LossPerCommonShareDetails LOSS PER COMMON SHARE (Details) false false R33.htm 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://vasomedical.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) false false R34.htm 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetDetails ACCOUNTS AND OTHER RECEIVABLES, NET (Details) false false R35.htm 090800 - Disclosure - INVENTORIES, NET (Details) Sheet http://vasomedical.com/role/InventoriesNetDetails INVENTORIES, NET (Details) false false R36.htm 090900 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://vasomedical.com/role/BusinessCombinationDetails BUSINESS COMBINATION (Details) false false R37.htm 091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLES (Details) false false R38.htm 091100 - Disclosure - DEFERRED REVENUE (Details) Sheet http://vasomedical.com/role/DeferredRevenueDetails DEFERRED REVENUE (Details) false false R39.htm 091200 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://vasomedical.com/role/RelatedpartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) false false R40.htm 091300 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://vasomedical.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) false false R41.htm 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://vasomedical.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) false false All Reports Book All Reports Element us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued had a mix of decimals attribute values: -6 -5. Element us-gaap_NetIncomeLoss had a mix of decimals attribute values: -3 0. Element us-gaap_RepaymentsOfRelatedPartyDebt had a mix of decimals attribute values: -3 0. Element us-gaap_SalesRevenueNet had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '090800 - Disclosure - INVENTORIES, NET (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090900 - Disclosure - BUSINESS COMBINATION (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '091000 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Process Flow-Through: 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) vaso-20120930.xml vaso-20120930.xsd vaso-20120930_cal.xml vaso-20120930_def.xml vaso-20120930_lab.xml vaso-20120930_pre.xml true true XML 55 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
Jun. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Dec. 31, 2010
Sep. 30, 2012
Extended Service Contracts [Member]
Sep. 30, 2011
Extended Service Contracts [Member]
Sep. 30, 2012
Extended Service Contracts [Member]
Sep. 30, 2011
Extended Service Contracts [Member]
Sep. 30, 2012
In-Service and Training [Member]
Sep. 30, 2011
In-Service and Training [Member]
Sep. 30, 2012
In-Service and Training [Member]
Sep. 30, 2011
In-Service and Training [Member]
Sep. 30, 2012
Service Arrangements [Member]
Sep. 30, 2011
Service Arrangements [Member]
Sep. 30, 2012
Service Arrangements [Member]
Sep. 30, 2011
Service Arrangements [Member]
Sep. 30, 2012
Commission Revenues [Member]
Sep. 30, 2011
Commission Revenues [Member]
Sep. 30, 2012
Commission Revenues [Member]
Sep. 30, 2011
Commission Revenues [Member]
Movements in deferred revenue [Roll Forward]                                            
Deferred revenue at the beginning of the period $ 14,998 $ 15,198 $ 15,228 $ 13,475 $ 11,360 $ 12,637                                
Additions:             288 240 987 968 13 10 33 28 20 20 75 65 2,037 4,941 6,116 9,085
Recognized as revenue:             (283) (269) (840) (872) (10) (8) (25) (23) (22) (21) (64) (55) (2,243) (2,798) (6,512) (8,358)
Deferred revenue at end of period 14,998 15,198 15,228 13,475 11,360 12,637                                
Less: current portion 10,102   9,484 [1] 10,042                                    
Long-term deferred revenue at end of period $ 4,896   $ 5,743 [1] $ 3,433                                    
[1] Retroactively adjusted to give effect to measurement period adjustment (see Note I)

XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2012
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]  
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The new guidance allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements. The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated condensed financial statements.

In December 2011, the FASB issued authoritative guidance to defer the effective date for those aspects of the guidance relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. The adoption of this new guidance will not have an impact on the Company's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation of other comprehensive income.